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Summary 
Hypertension is an increasing public health burden worldwide, it affects over 25% of the 
adult population and is a significant risk factor in a number of other cardiovascular 
diseases such as atherosclerosis, heart disease and stroke. Numerous family and population 
studies have identified candidate genes associated with essential hypertension in humans, 
though no major effect loci have been replicated. The experiments performed in this 
project employed a number of functional genomic techniques to investigate the genetic 
causes of high blood pressure in the stroke-prone spontaneously hypertensive rat (SHRSP), 
an inbred model of essential hypertension.  
A genome-wide scan previously performed in the Glasgow laboratory by cross-breeding 
the SHRSP and the Wistar Kyoto (WKY) normotensive control strain identified a 
quantitative trait locus (QTL) on rat chromosome 2 encoding genes involved in blood 
pressure regulation. This QTL was confirmed and further refined by congenic breeding: 
introgressing genomic regions from the WKY onto the background of the SHRSP, 
generating rats with reduced blood pressure compared to the SHRSP. Renal microarray 
gene expression profiling in the 16 week old SHRSP, WKY and congenic 2c* strain 
identified a positional and functional candidate gene, glutathione s-transferase   type 1 
(Gstm1) which is involved in defence against oxidative stress and is down-regulated in the 
SHRSP.  
One of the aims of these investigations was to assess differences in gene expression 
between normotensive and hypertensive rats prior to the onset of hypertension in the 
SHRSP. Microarray gene expression profiling measured renal expression in 5 week old 
SHRSP, WKY and 2c* rats, showing reduced expression of Gstm1 in the SHRSP. This 
verified Gstm1 as a robust candidate gene since its differential expression precedes the 
development of high blood pressure in the SHRSP. Gene expression data was also 
combined with the previous data from 16 week old rats to examine differences between 
strains at both timepoints; Ingenuity Pathway Analysis software was employed to assess 
the differential expression of groups of genes according to their role in well-described 
biological pathways. Several differentially expressed genes from within and outwith the 
congenic interval in addition to Gstm1 were identified that are involved in glutathione 
(GSH) metabolism, leading to the hypothesis that renal oxidative stress caused by impaired 
GSH metabolism may contribute hypertension in the SHRSP. Renal GSH levels were 
measured at 5 and 16 weeks of age, showing lower levels in the SHRSP at both timepoints 17 
   
compared to the WKY, while in the 2c*, GSH levels were similar to the SHRSP at 5 weeks 
of age and similar to the WKY at 16 weeks of age. This verified the likely effect of genes 
from the 2c* congenic interval on differential GSH metabolism, and renal superoxide 
levels were also shown to be increased in the SHRSP at 5 weeks of age, however 
quantitative real-time PCR did not verify the microarray results in some cases. 
Reduced kidney Gstm1 expression was also confirmed in the spontaneously hypertensive 
rat (SHR), while expression in the normotensive Brown Norway (BN) rat was equivalent 
to the WKY. 13 promoter single-nucleotide polymorphisms (SNPs), a missense mutation 
and a 3' untranslated region (UTR) SNP were identified in Gstm1 in SHRSP and SHR that 
were not carried by the WKY or BN. Rat and mouse Gstm1 promoter sequences were 
aligned, identifying a conserved antioxidant response element and regions of homology 
likely to encode functionally important regulatory elements. Luciferase reporter constructs 
compared transcriptional activities of SHRSP and WKY Gstm1 promoters of increasing 
length, encompassing progressively more SNPs. Following subcloning to isolate the 
transcriptional effects of two clusters of SNPs in reduced expression in the SHRSP, 
luciferase activities suggested that an interaction between one or more SNP in each cluster 
contributed to reduced transcription. Further novel constructs were generated by site-
directed mutagenesis to investigate this interaction but no consistent effects on expression 
were observed, implying complex regulation of Gstm1 expression. The Transfac database 
was used to identify several potential transcription factor binding sites affected by the 
SHRSP mutations, the strongest candidate being peroxisome proliferator-activated receptor 
gamma (PPARγ), with binding sites affected in both implicated clusters.  
Recombinant adenoviruses were employed in experiments to assess the functional effects 
of modulating Gstm expression in-vitro and in-vivo. Previous experiments had 
demonstrated effective Gstm1 knockdown in-vitro using a short-interfering RNA sequence 
designed to reduce expression of several Gstm family genes. This sequence was expressed 
as a short-hairpin RNA (shRNA) by an adenoviral vector. Consistent 32-58% knockdown 
of Gstm1, 2 and 3 was achieved in-vitro, though several mismatches in the target shRNA 
sequence prevented effective knockdown of Gstm5. Reduced expression was not measured 
for Gstm7, despite only a single mismatch that was also observed in the Gstm2 coding 
sequence, this was accounted for by low endogenous Gstm7 expression. Total cellular GST 
activity was not reduced by the anti-Gstm family shRNA adenovirus. Adenoviruses were 
generated to express SHRSP and WKY Gstm1 sequences. WKY Gstm1-overexpression 
adenovirus was infused into carotid arteries of Gstm1 rats and nitric-oxide (NO)-18 
   
bioavailability was compared to contralateral uninfused vessels by wire myography 48 
hours later. Overexpression of Gstm1 did not improve NO-bioavailability.  
Significant progress was made towards the generation of a transgenic SHRSP rat 
overexpressing Gstm1. A bacterial artificial chromosome (BAC) encoding Gstm1 was 
purified and a linear Gstm1 expression construct was cloned and purified in which Gstm1 
expression was driven by the ubiquitous human elongation factor 1 alpha subunit 
promoter. Eight rounds of microinjections were performed resulting in the birth of 78 pups, 
though none were transgenic when screened by PCR.  
In summary, a wide range of functional genomic techniques were applied in the analysis of 
a genetic model hypertension, involving genome-wide and candidate gene approaches. 
While the role of Gstm1 in hypertension in the SHRSP is yet to be fully understood, a 
number of tools have been developed that will aid in further investigations and guide the 
analysis of other candidates. James Polke, 2008    Chapter 1          19 
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1.1  Genetics of Human Hypertension 
1.1.1 Blood Pressure Control 
It is essential that the supply of blood from the heart to all organs of the body is well 
controlled in order to deliver oxygen, nutrients and hormones at the appropriate rate and to 
ensure removal of metabolic waste products such as carbon dioxide. Many physiological 
mechanisms exist to ensure that acute and long-term local and global blood flow is 
maintained at the appropriate level to individual organs in response to tissue needs. The 
most fundamental of these mechanisms is the control of mean arterial blood pressure, it is 
also one of the most complex physiological systems, involving the endocrine and nervous 
systems, the endothelium, kidneys and the maintenance of heart and blood vessel 
architecture. Grossly, arterial pressure is dictated by the following relationship: BP = 
Cardiac Output  X  Vascular Resistance. A number of the homeostatic systems involved in 
blood pressure control are summarised in table 1.1, these systems form a complex web of 
interaction and feedback to maintain appropriate blood pressure in response to changes in 
diet, activity, stress and other environmental factors. The organ principally responsible for 
long term blood pressure control is the kidney, it regulates blood volume by controlling 
salt and water levels. Its importance in blood pressure control was elegantly shown by 
experiments involving renal transplantation between hypertensive and normotensive rats, 
the blood pressure of hypertensive rats receiving kidneys from normotensive strains fell, 
while the blood pressure of normotensive rats receiving a hypertensive rat kidneys 
increased (Bianchi et al. 1974a). 
The major mechanism responsible for blood pressure control is the renin angiotensin 
aldosterone system (RAAS) (figure 1.1); the most studied aspects of the RAAS involve the 
vasoconstrictory mechanisms of angiotensin converting enzyme (ACE) and angiotensin II 
(Ang II), though in recent years there has been substantial progress in our understanding of 
the role played by ACE2 and angiotensin 1-7 peptide (Ang-(1-7)) in vasodilation, 
cardioprotection and salt and water homeostasis. Angiotensinogen (AGT), produced in the 
liver, is the inactive 485 amino-acid precursor to angiotensin I (Ang I), it circulates freely 
in the plasma. The conversion of AGT to Ang I is mediated by renin, which is released 
from the juxtaglomerular apparatus in response to decreased renal perfusion, or decreased James Polke, 2008    Chapter 1          21 
   
Physiological System  Relation to Blood Pressure  
The renin-angiotensin 
system, renal body fluid 
regulation. 
The major mechanisms of long-term blood pressure 
control involve salt and water homeostasis in the kidney. 
Arterial Baroreceptor 
Reflexes 
Increased BP stimulates baroreceptors, inhibiting the 
vasoconstrictor centre and exciting the vagal centre in 
the brain, causing vasodilation, decreased heart rate and 
strength of heart contraction. Converse response to 
reduced BP. 
Renin-Angiotensin 
Vasoconstrictor 
Mechanism 
The short-term effect of angiotensin II is to stimulate 
vasoconstriction of arterioles, causing an increase in 
peripheral resistance and an increase in BP. 
Stress-Relaxation 
Mechanism 
Increased blood pressure stretches the blood vessel 
walls, they stretch to accommodate this and 
consequently reduce blood pressure.  
Carotid and Aortic 
Chemoreceptors 
Chemoreceptors detect oxygen lack and carbon dioxide 
and hydrogen excess, exciting the vasomotor centre to 
increase heart rate and cause vasoconstriction. 
Endothelium-derived 
vasoactive substances 
Alter vascular tone. Examples include nitric oxide 
(vasodilatory) and endothelin (vasoconstrictive). 
Natriuretic Peptides  Released in response to increased BP. Cause cardiac 
and vascular vasodilation, inhibit renal and vascular 
effects of angiotensin II, inhibit cardiac  
Capillary Fluid Shift  Reduced capillary pressure results in increased osmosis 
from the tissue fluid to the vasculature, increasing blood 
volume. Increased capillary pressure has the opposite 
effect. 
Kidney Kinin-kallikrein 
system 
Responds to increased sodium by stimulating salt and 
water secretion, reducing BP.  
Central Nervous System 
Ischaemic Response 
Reduced nutrient flow in the brain vasomotor centre 
strongly excites it to activate parasympathetic 
responses, increasing heart rate and constricting blood 
vessels. Principally an emergency response to very low 
blood pressure to prevent brain injury. 
Table 1.1 - Physiological systems involved in the control of blood pressure 
  
   
 
Figure 1.1 - The renin angiotensin aldosterone system 
  
Renin 
ACE 
Aldosterone 
Tubular NaCl 
reabsorption, H2O 
retention 
Increased sympathetic 
nervous activity 
Increased H2O 
reabsorption 
Arteriolar vascoconstriction 
Decreased juxtaglomerular 
perfusion, decreased serum NaCl 
ACE2 
ACE, NEP  NEP 
PEP 
PEP, PCP 
Angiotensinogen 
Ang I 
Ang II  Ang-(1-7) 
ADH 
ACE2 
Vasodialtion 
Antidiuresis /  
Diuresis / Naturesis 
Ang-(1-9) 
The ACE/Ang II axis (blue arrows) mediates increased blood pressure in response to decreased glomerular bloodflow and plasma salt 
levels, while the ACE2/Ang-(1-7) axis (red arrows) has a blood-pressure lowering effect. See text for details. ACE: angiotensin 
converting enzyme, Ang: angiotensin, NEP: neutral endopeptidase 24.11, PEP: prolylendopeptidase PCP: prolylcarboxypeptidase. James Polke, 2008    Chapter 1          23 
serum sodium chloride (NaCl) concentration. Ang I, an inactive 10 amino acid peptide, is 
converted to Ang II by ACE, a membrane-bound enzyme that resides predominantly in the 
endothelial surfaces of the lungs. Ang II, an 8 amino acid peptide, is a potent effector of 
many downstream systems leading to increased blood pressure: it stimulates aldosterone 
secretion from the adrenal gland, leading to kidney tubular sodium and chloride 
reabsorption and water retention, it also acts directly on tubular receptors with the same 
result, it stimulates sympathetic nervous activity, causing increased heart rate and blood 
vessel constriction, it also stimulates arteriolar constriction directly. Finally, Ang II also 
stimulates the pituitary gland to secrete anti-diurectic hormone (ADH), resulting in 
increased water reabsorption in the kidney collecting ducts. A negative feedback loop 
exists whereby increased juxtaglomerular perfusion caused by the above effects reduces 
renin release. Ang I and Ang II are also substrates for the generation of Ang-(1-7), directly 
or via Ang-(1-9), in number of reactions catalysed by ACE2, ACE, neutral endopeptidase 
24.11 (NEP), prolylendopeptidase (PEP) and prolylcarboxypeptidase (PCP) (figure 1.1). 
Ang-(1-7) is a 7 amino acid peptide that was once considered an inactive metabolite of 
Ang II until it was demonstrated to mediate the release of vasopressin from in-vitro 
pituitary explants (Schiavone et al. 1988). The discovery of ACE2 (Tipnis et al. 
2000;Donoghue et al. 2000) was the catalyst for further elucidation of the role of Ang-(1-
7), and the ACE2/Ang-(1-7) system is now recognised as a major counter-regulatory 
mechanism of the ACE/Ang II system. Our understanding of the actions of Ang-(1-7) is far 
from complete but has been show to have endothelium-dependent vasodilatory effects in 
several tissue beds, a response recently shown to be mediated by nitric oxide (NO) 
(Sampaio et al. 2007). Ang-(1-7) also plays a role in cardioprotection, reducing cardiac 
Ang II levels in rats (Mendes et al. 2005), and mediating blood-pressure independent 
prevention of cardiac fibrosis and hypertrophy in experimental models (Tallant et al. 
2005;Grobe et al. 2006). The renal effects of ACE2 and Ang-(1-7) are not well understood 
at present, with conflicting reports suggesting that Ang-(1-7) can mediate the retention or 
secretion of salt and water depending on the experimental system or segment of nephron 
examined (DelliPizzi et al. 1994;Santos et al. 1996;Vallon et al. 1997). 
1.1.2 Epidemiology of Human Hypertension 
Blood pressure is a quantitative phenotype that shows continuous variation from high to 
low values throughout populations. It is clinically accepted that optimal adult blood James Polke, 2008    Chapter 1         24           
   
pressure is <120/80 mmHg (systolic/diastolic), whilst the normal range is typically 
<139/89 mmHg. High blood pressure, or hypertension, is defined as systolic pressure over 
140 mmHg and/or diastolic pressure over 90 mmHg (Guidelines Subcommittee WHO-ISH 
1999;Mancia et al. 2007). Hypertension is a health concern because is a major risk factor 
for a number of cardiovascular diseases including stroke, atherosclerosis, type II diabetes, 
coronary heart disease and renal disease. It affects 26% of adults worldwide, its prevalence 
is predicted to increase to 29% by 2025 (Kearney et al. 2005).  
In approximately 5% of hypertensives, increased blood pressure is secondary to a factor 
such as constriction of a blood vessel, an imbalance of hormones or monogenic disease, the 
remaining 95% have idiopathic or essential hypertension. Factors that contribute to 
essential hypertension are known to include environmental and genetic causes. 
Environmental factors include high dietary sodium intake, excess alcohol consumption, 
smoking, stress, and increased body weight. Of these, reducing alcohol consumption and 
restricting calorific intake have been shown to most effectively reduce blood pressure 
(Staessen et al. 1989;Beilin 1995). It is estimated that 13-31% and 41-46% of variance in 
systolic blood pressure are due to environmental and genetic factors, respectively (Annest 
et al. 1979;Annest et al. 1983;Cui et al. 2002). Evidence for a genetic component to 
hypertension includes results of twin studies that show a greater concordance of blood 
pressure between monozygotic twins than dizygotic twins (McIlhany et al. 1975;Feinleib et 
al. 1977;Havlik et al. 1979;Rose et al. 1979;Heiberg et al. 1981;Levine et al. 1982). 
Population studies show greater variation of blood pressure between families than within 
them (Longini, Jr. et al. 1984), and correlations in blood pressure are more significant 
between biological parent and child than parent and adopted child living in the same 
household (Biron et al. 1976;Mongeau et al. 1986). Identification of the specific genes that 
contribute to blood pressure regulation and how they interact in essential hypertension is a 
major challenge, the number of loci involved is unknown, as is the extent to which each 
contributes to the phenotype in given individuals, populations and environments. 
1.1.3 Monogenic Forms of Hypertension 
In an effort to understand the genetics of hypertension, much work has been performed to 
find the causes of the monogenic forms of the disease. These mutations are very rare but it 
is hoped identification of the genes responsible may not only provide candidates for 
essential hypertension, but also elucidate the mechanisms of blood pressure control and James Polke, 2008    Chapter 1         25           
   
identify novel therapeutic targets. A substantial contribution to this body of work has been 
made by Lifton and colleagues who have identified mutations in 10 genes responsible for 
hypertension and 7 causing hypotension (Lifton et al. 2001;Cowley, Jr. 2006). The known 
monogenic causes of hypertension are discussed in turn below. It is noteworthy that a 
majority of the monogenic causes of hypertension directly affect the function of the salt 
and water handling systems in the kidney, underlining the importance of renal involvement 
in blood pressure control and the likelihood that genes involved in essential hypertension 
may also predominantly affect salt and water homeostasis mechanisms. 
1.1.3.1 Glucocorticoid-Remediable Aldosteronism (GRA) 
GRA is an autosomal dominant condition characterised by early onset hypertension with 
normal or raised aldosterone levels and low renin activity (Sutherland et al. 1966). This is 
often associated with hypokalaemia and metabolic alkalosis (Rich et al. 1992). The 
distinguishing feature of the disease however is that glucocorticoid therapy completely 
reverses the hypertension. Genetically, it is caused by unequal crossover between the genes 
encoding steroid 11 β-hydroxylase (CYP11B1) and aldosterone synthase (CYP11B2), two 
closely related and closely linked genes involved in adrenal steroid biosynthesis (Lifton et 
al. 1992). This generates a chimeric gene whose expression is regulated at its 5' 
(CYP11B1) end by adrenocorticotropic hormone (ACTH), but whose protein product 
exhibits aldosterone synthase activity. Aldosterone synthase activity is therefore kept 
artificially high as the chimeric gene expression is stimulated in the adrenal fasciculata by 
ACTH rather than the normal regulating hormone, angiotensin II. This leads to expanded 
plasma volume due to increased Na
+ reabsorption via overactivation of ENaC by the 
mineralocorticoid receptor (MR). The increased plasma volume suppresses renin secretion, 
accounting for the low renin activity, whilst Na
+ reabsorption drives K
+ and H
+ secretion, 
leading to the hypokalaemia and alkalosis. Treatment with glucocorticoids (such as 
dexamethasone) suppresses ACTH activity, reducing the aldosterone synthase activity and 
restoring normotension.  
1.1.3.2  Apparent Mineralocorticoid Excess (AME) 
AME is an autosomal recessive disorder caused by mutations in the 11βHSD-2 (11 β-
hydroxysteroid dehydrogenase) gene featuring early onset hypertension with 
hypokalaemia, metabolic alkalosis, suppressed renin activity and near absence of James Polke, 2008    Chapter 1         26           
   
circulating aldosterone. Despite reduced aldosterone levels, antagonists of the MR were 
shown to lower blood pressure in AME patients (New et al. 1977), suggesting that an 
unknown mineralocorticoid activates the MR. Biochemical investigations in affected 
patients failed to identify a novel mineralocorticoid, but did show an absence of the 
enzyme 11βHSD (Ulick et al. 1979), resulting in impaired conversion of cortisol to 
cortisone. The significance of this was not clear until the cloning of the MR (Arriza et al. 
1987) and in-vitro studies showing that cortisol activates the MR to a similar level as 
aldosterone (Stewart et al. 1987;Funder et al. 1988), leading to the hypothesis that in-vivo 
(where circulating levels of cortisol are 1000-fold higher than aldosterone), 11βHSD 
normally 'protects' the MR from over-activation by cortisol by converting it to cortisone, 
which does not activate the MR. This was confirmed upon the cloning of the 11βHSD-2 
gene, which was shown to be expressed in the same cells of the nephron that express ENaC 
(Mune et al. 1995). As with GRA, overactivation of the MR causes the hypokalaemia and 
alkalosis. 
1.1.3.3 Liddle Syndrome 
Liddle syndrome is characterised by early onset hypertension, hypokalaemic alkalosis, 
suppressed renin activity and low plasma aldosterone. It is caused by deletions or missense 
mutations of the cytoplasmic C-terminal PPPXY (proline, proline, proline, any amino acid, 
tyrosine) domain of the ENaC β or γ subunits. The PPPXY domains bind Nedd4-1 and 
Nedd4-2 proteins as a first step in the ubiquitination and clearance of ENaC via clathrin-
coated pits (Staub et al, 1996; Kamynina et al, 2001). Disruption of the PPPXY domain 
therefore causes reduced clearance of ENaC from the tubule membrane, resulting in 
increased ENaC numbers and activity, leading to salt retention and hypertension (Schild et 
al. 1995;Shimkets et al. 1997). Directly converse to Liddle syndrome, mutations that 
impair ENaC function cause autosomal recessive Psuedohypoaldosternism type I, 
characterised by salt wasting and hypotension (Chang et al. 1996). 
1.1.3.4 Pseudohypoaldosteronism type II 
Pseudohypoaldosteronism type II (PHAII), also know as Gordon Syndrome, is an 
autosomal dominant condition caused by mutations in serine-threonine kinase genes, 
WNK1 and WNK4 (Wilson et al. 2001). WNK stands for 'with no K', the WNKs are 
characterised by the lack of a conserved lysine (K) found in all other serine-threonine James Polke, 2008    Chapter 1         27           
   
kinases. Along with hypertension, affected individuals also show hyperkalaemia, 
hyperchloraemia and metabolic acidosis. The pathogenic mutations described so far in 
WNK1 are all large deletions in the first intron that cause increased WNK1 expression, 
whilst all known WNK4 mutations are missense and cluster within few amino acids distal 
to the kinase domain of the protein. WNK1 and WNK4 expression have been localised to 
the distal convoluted tubules and cortical collecting ducts. WNK1 is also expressed in the 
medullary collecting ducts. WNK1 protein is cytoplasmic, WNK4 is present only in the 
intercellular junctions in the distal convoluted tubules and in the cytoplasm and 
intercellular junctions in the cortical collecting duct (Wilson et al 2001). Recent 
experimental studies have investigated the functional changes caused by WNK4 mutations 
and have provided novel insights into the mechanisms of renal chloride, sodium and 
potassium homeostasis. In-vitro studies have shown that WNK4 affects the activity of a 
number of ion channels and transporters. It has been demonstrated that wild-type WNK4 
protein inhibits the Na-Cl cotransporter (NCCT) ion channel, which mediates sodium and 
chloride reabsorption in the distal convoluted tubule. PHAII WNK4 mutations abolish the 
activation of NCCT, contributing to salt retention (Wilson et al. 2003). These findings are 
consistent with pathogenesis of Gitelman's syndrome, where loss-of-function NCCT 
mutations cause hypotension, hypokalaemia and metabolic alkalosis  (Simon et al. 1996).  
As stated, WNK4 expression extends beyond the convoluted tubules to the collecting duct, 
raising the possibility that it regulates ion transport in distal portions of the nephron; Kahle 
et al ( 2003) demonstrated that WNK4 inhibits the ROMK potassium channel, which 
reabsorbs potassium throughout distal nephron, they also showed that PHAII WNK4 
mutations increase this inhibition, decreasing potassium secretion. Furthermore, WNK4 
has been demonstrated to regulate paracellular chloride ion transport via gap junctions in 
in-vitro monolayer cultures of kidney epithelial cells, PHAII-mutant WNK4 increases 
chloride ion transport, equivalent to increased chloride reabsorption in the collecting duct 
in-vivo (Kahle et al. 2004;Yamauchi et al. 2004). 
An in-vivo study has further elucidated the mechanisms by which WNK4 affects sodium 
chloride and potassium regulation, and shown that it has a role in regulating the mass and 
activity of the distal convoluted tubule. Transgenic mice were generated to homozygously 
express two additional copies of either the wild-type or mutant (PHAII-causing equivalent) 
mouse Wnk4 gene, these mice were designated Tg(Wnk4
WT) and Tg(Wnk4
PHAII), 
respectively (Lalioti et al. 2006). The Tg(Wnk4
WT) mice exhibit reduced blood pressure James Polke, 2008    Chapter 1         28           
   
with normal serum K
+ levels. Tg(Wnk4
PHAII) mice have raised blood pressure and 
hyperkalaemia equivalent to that seen in human PHAII patients. Ultrastructural analysis of 
the distal convoluted tubules of the transgenic mice showed marked effects of increased 
mutant and wild-type Wnk4 expression: compared to wild-type mice, Tg(Wnk4
PHAII) 
showed increased lumen surface area and NCCT expression, whilst Tg(Wnk4
WT) had 
reduced lumen surface area and reduced NCCT expression. These findings correlate blood 
pressure and electrolyte balance with distal convoluted tubule morphology and distribution 
of NCCT. In order to confirm this association, Tg(Wnk4
PHAII) mice were cross-bred with a 
NCCT-knockout, generating mice with PHAII Wnk4 mutations, but no NCCT. These mice 
had blood pressure similar to Tg(Wnk4
WT), normal serum K
+ and normal distal convoluted 
tubule morphology (Lalioti et al 2006). 
1.1.3.5 PPARγ Mutations Causing Insulin Resistance, Diabetes 
Mellitus and Hypertension  
Peroxisome proliferator-activated receptor gamma (PPARγ) is a nuclear receptor family 
transcription factor involved in adipocyte differentiation (Tontonoz et al. 1994), it also 
promotes insulin-induced uptake of glucose and has high affinity for the anti-diabetic 
medications, thiazolidinediones (TZDs), which increase its activity (Lehmann et al. 1995). 
A cohort of insulin resistant patients was screened for mutations in the PPARγ genes, 
finding novel ligand binding domain mutations in two families displaying autosomal 
dominant early onset insulin resistance, type II diabetes and hypertension without obesity 
(Barroso et al. 1999). These mutations were shown to have dominant negative effect on 
PPARγ activity that the authors propose causes insulin insensitivity and diabetes whilst 
providing sufficient residual activity to control adipocity. Barosso et al propose that 
PPARγ may play a role in hypertension in these patients via increased vascular tone since 
TZDs lower blood pressure, block calcium channel activity in smooth muscle cells 
(Nakamura et al. 1998) and inhibit release of the potent vasoconstrictor endothelin-I from 
endothelial cells (Satoh et al. 1999). James Polke, 2008    Chapter 1         29           
   
1.1.3.6 Variably Penetrant Hypertension, Hypercholesterolaemia 
and Hypomagnesia 
Hypertension, hypercholesterolaemia and hypomagnesia are among the risk factors for 
metabolic syndrome, which has a genetic component. A family study was performed on a 
kindred of 142 relatives of a patient with hypomagnesia (Wilson et al. 2004). An increased 
incidence of hypertension, hypercholesterolaemia and hypomagnesia was observed among 
the maternal lineage related to the proband (100% of those with hypomagnesia, 87% of 
those with hypertension and 73% of those with hypercholesterolaemia were on the 
maternal lineage). This implicated mitochondrial transmission and complete sequencing of 
the mitochondrial genome identified a novel mutation in the gene encoding transfer RNA 
for isoleucine (tRNA
Ile) in the maternal lineage. Each of the three traits measured had a 
penetrance of approximately 50% in patients carrying the mutation, implying phenotypic 
modifying effects of nuclear genome and/or environmental factors (Wilson et al 2004). 
1.1.3.7 Hypertension with Brachydactyly 
Hypertension with brachydactyly (shortened finger bones) is an autosomal dominant 
condition featuring normal renin-angiotensin system function. The cause of hypertension 
in affected patients is not fully understood, though there is evidence from brain magnetic 
resonance imaging that it may be caused by neurovascular compression of the ventrolateral 
medulla (one of the brain structures responsible for setting basal sympathetic tone) 
(Naraghi et al. 1997). Autonomic nervous system function has been investigated in 
affected patients, they show normal sympathetic nerve activity during rest, but exaggerated 
blood pressure increases following sympathetic stimuli with the alpha agonist 
phenylephrine during baroreceptor reflex blockade (Jordan et al. 2000). This study implies 
that hypertension in these patients could be related to abnormal baroreceptor reflex 
function. Genetically, the locus responsible for hypertension with brachydactyly was 
mapped to chromosome 12p by a genome-wide scan, though the gene has yet to be 
identified (Schuster et al. 1996). James Polke, 2008    Chapter 1         30           
   
1.1.3.8 Mineralocorticoid Receptor Mutation Causing 
Hypertension Exacerbated in Pregnancy 
The MR mutation S810L was identified in a screen of early-onset hypertensive patients, to 
date it has been identified in eight individuals in one pedigree (Geller et al. 2000). S810L 
causes dominant hypertension before the age of 20 with marked exacerbation of 
hypertension during pregnancy. The S810L mutant receptor shows partial activation in the 
absence of steroids, but a normal response to aldosterone. However MR antagonists that 
usually bind but do not activate the wild-type MR have an agonist effect on the S810L 
receptor; this includes many steroids including progesterone, levels of which increase 100-
fold during pregnancy, accounting for the dramatic increase in blood pressure during 
pregnancy in affected individuals (Geller et al 2000). This antagonist-to-agonist response 
in the S810L receptor is caused by a structural change in the receptor protein. Recent work 
has shown that the S810L MR receptor binds with high affinity and is transactivated by 
cortisone and 11-dehydrocorticosterone, the main cortisol and corticosterone metabolites in 
the distal nephron, suggesting that these are among the endogenous steroids responsible for 
early onset hypertension in men and non-pregnant women carrying MR S810L (Rafestin-
Oblin et al. 2003). In contrast to hypertension exacerbated in pregnancy, loss-of-function 
frameshift or nonsense mutations in the MR gene cause autosomal dominant 
psuedohypoaldosteronism type I, typified by neonatal salt wasting and hypotension (Geller 
et al. 1998). 
1.1.3.9 Early Onset Coronary Artery Disease and Other 
Cardiovascular Symptoms, Including Hypertension 
A large kindred with a high prevalence of early coronary artery disease (CAD), 
hypertension, high low-density lipoprotein (LDL) cholesterol, high triglycerides, type II 
diabetes and osteoporosis was identified via an index case who presented with a 
myocardial infarction aged 48. Obesity was absent in the pedigree, despite the frequency of 
other symptoms associated with metabolic syndrome. Genome-wide microarray SNP 
genotyping of 19 members of 2 generations identified a 750,000 bp region on chromosome 
12p with strong linkage to early CAD and high LDL cholesterol (Mani et al. 2007). The 
exons and intron/exon boundaries of all six annotated genes in this region were sequenced 
in the index case and a single missense mutation was found in the LRP6 (LDL receptor-James Polke, 2008    Chapter 1         31           
   
related protein 6) gene causing an R611C amino acid change. LRP6 is one of a family of 
receptor proteins that interact with frizzled proteins in Wnt receptor pathways. Mice 
deficient in the mouse paralogue LRP5 develop hypercholesterolaemia and glucose 
intolerance when fed high fat diets (Fujino et al. 2003) and deficiency of LRP5 (in humans 
and mice) or LRP6 (in mice) causes early severe osteoporosis (Gong et al. 2001;Kokubu et 
al. 2004). No other mutations were found in any of the other genes in the implicated 
region, the remaining affected members of the kindered all carried the LRP6 R611C 
mutation, while it was absent from 4000 control chromosomes; in-vitro studies showed the 
R611C version of LRP6 is biochemically less active than the wild-type (Mani et al 2007). 
While the mechanism by which the mutation causes this collection of symptoms is unclear, 
Wnt signalling pathways have been implicated in cardiovascular disease and osteoporosis 
in other research (Yamagata et al. 1996;Horikawa et al. 1997;Grant et al. 2006). 
1.1.3.10 Monogenic Hypertension Genes in Essential 
Hypertension 
With the possible exception of WNK1, none of the genes found to cause monogenic 
hypertension have been conclusively implicated in essential hypertension, though several 
have been investigated in candidate gene linkage and association studies. Regions of the 
genome implicated in the continuous phenotypes such as blood pressure are known as 
quantitative trait loci (QTL). The 11 β-hydroxylase gene underlies a blood pressure QTL in 
the rat, WNK1 and LRP6 are located within a region of human chromosome 12 identified 
as a suggestive blood pressure QTL  (Rice et al. 2000), while WNK4 lies within a blood 
pressure QTL on chromosome 17 (Julier et al. 1997). An association study in Japanese 
essential hypertensives found no association between essential hypertension and WNK1 
(Kokubo et al. 2004). However, a family-based association study of 712 severely 
hypertensive families in the BRitish Genetics of HyperTension study (BRIGHT study, see 
section 1.1.4.2)  identified a promoter polymorphism 3kb upstream from the WNK1 gene 
associated with hypertension (Newhouse et al. 2005), while a second study associated 
WNK1 haplotypes and single nucleotide polymorphisms spanning the WNK1 coding region 
with variations in blood pressure in a study of 250 white European families (Tobin et al. 
2005).  James Polke, 2008    Chapter 1         32           
   
Alternative methods have also been applied to studies of human essential hypertension 
genetics, including1 analysis of candidate genes and genome-wide linkage and association 
studies. These approaches are discussed below.  
1.1.4 Identifying Essential Hypertension Genes 
Strategies to find genes involved in complex traits broadly fall into two categories, linkage 
and association studies. They can further be subdivided into candidate gene analysis and 
genome-wide scans. In candidate gene analysis, markers in physiologically relevant genes 
are tested for co-inheritance with the phenotype under study, while in genome-wide scans, 
no such assumptions are made and markers throughout the genome are analysed. Genetic 
markers used in linkage and association studies have advanced in recent years. 
Historically, restriction-fragment-length polymorphisms and satellite repeat markers were 
employed for genotyping, however, advances in the cataloguing of single-nucleotide 
polymorphisms (SNP) throughout the genome and automation of SNP genotyping have 
improved high-throughput genetic screening. 
In linkage analysis, family cohorts are collected and affected and unaffected family 
members are phenotyped and genotyped. The genetic relationship between family 
members is taken into account in statistical analysis to identify markers that segregate with 
the phenotype under study. A popular method for linkage studies analyses affected sibling 
pairs, the hypothesis being that since siblings have 50% genetic identity, they should share 
markers near loci responsible for hypertension more often than would be expected by 
chance. The loci responsible for hypertension may differ between families, but if a 
sufficient number of families are studied, the most common effect alleles may be 
identified. Several factors affect the statistical power of linkage analyses, including the 
proportion of the trait variance due to genetic factors, the family structure, the number of 
families, the number of markers employed and the genetic distance between them. 
In contrast, association studies involve genotyping and phenotyping unrelated affected and 
unaffected individuals to find candidate genes, thus the power of genetic relatedness is lost, 
but subject recruitment is significantly easier. Though association studies have been widely 
employed in candidate gene analysis, historically, genome-wide association studies were 
not feasible for the study of complex traits due to the number of subject required and the James Polke, 2008    Chapter 1         33           
   
subsequent cost of genotyping. However, the advent of cost-effective genome-wide SNP 
genotyping has recently led to the first publications in this field. 
1.1.4.1 Candidate Gene Analysis in Human Essential 
Hypertension 
Numerous studies have been carried out to investigate the involvement of genes that 
express proteins thought to be involved in blood pressure regulation in essential 
hypertension. Candidates include those from the renin-angiotensin system, cell signalling 
pathways, autonomic nervous system, and others. Notable examples are considered below. 
None of the candidate genes analysed so far have consistently been shown to affect blood 
pressure in all studies. Typically, as many negative associations are published for a 
candidate as positive; the apparent effect of a gene in one population is often not replicated 
in others. This exemplifies the extent of heterogeneity in essential hypertension aetiology, 
interactions between environmental and genetic factors in different populations lead to 
quantitatively different influences of genetic loci. This, coupled with differences in study 
design, size and methods, our incomplete understanding of the physiology blood pressure 
control, and the likely number of loci involved, reduces the likelihood of candidate gene 
studies in finding major effect loci. 
1.1.4.1.1  Renin-Angiotensin System 
Angiotensinogen (AGT), whose conversion to angiotensin I by renin is the first step in 
angiotensin II production, is an obvious functional candidate for investigation in blood 
pressure genetics. Jeunemaitre et al  ( 1992b) published data showing significant 
association of the common M235T variant with hypertension in two family studies in 
populations in Salt Lake City, USA and Paris, France. The M235T was associated with 
higher plasma concentrations of angiotensinogen in hypertensives. These results were 
supported by observations that transgenic mice with additional copies of the Agt gene have 
higher blood pressure than wild-type mice (Kim et al. 1995). The functional cause of 
increased plasma AGT with the M235T variant were explained by the observation that it is 
in complete linkage (i.e. is always co-inherited) with a promoter polymorphism (-6G>A) 
that causes increased expression of AGT (Inoue et al. 1997). Many further studies 
attempted to replicate the findings of Jeunemaitre et al, with conflicting results. Meta 
analyses of case-control studies were performed, they tentatively concluded that the James Polke, 2008    Chapter 1         34           
   
M235T allele is associated with hypertension, but only in Caucasians, and caveats were 
attached that the association found may be affected by publication bias: concerns were 
raised regarding selection and reporting of properly matched controls to cases in many 
studies (Kunz et al. 1997;Staessen et al. 1999). This example highlights the difficulties in 
finding minor effect alleles, it is unclear whether the difficulties in replicating initial results 
reflect differences between populations, diagnostic criteria, case-control ascertainment, or 
the small effect on phenotype. 
Angiotensin-I converting enzyme (ACE) is another central renin-angiotensin system 
component, catalysing the conversion angiotensin I to Angiotensin II. ACE-inhibitors are 
effective antihypertensive medication, and early genome-wide scans for causative genes in 
hypertensive rat models pointed to the region on rat chromosome 10 syntenic to human 
chromosome 17 that harbours the ACE gene (Hilbert et al. 1991;Jacob et al. 1991). A 
common insertion/deletion (I/D) polymorphism in humans has been shown to dictate the 
serum concentration of human ACE, homozygous I/I and D/D individuals have 
respectively 75% and 125% ACE levels of I/D individuals (Rigat et al. 1990). Linkage 
analysis in humans generated conflicting results, some studies have shown limited linkage 
to the ACE locus (O'Donnell et al. 1998;Higaki et al. 2000), however the prevailing view 
is that ACE genotype does not affect essential hypertension (Jeunemaitre et al. 
1992a;Kreutz et al. 1995). This is backed up experimentally by the observation that 
transgenic mice with additional Ace gene copies do not have increased blood pressure 
despite increased plasma ACE levels (Krege et al. 1997). It may seem paradoxical that 
ACE-inhibitors are effective in reducing blood pressure while increased ACE activity does 
not increase it, however, this is explained by the finding that conversion of 
angiotensinogen to angiotensin I by renin is the rate-limiting step in renin-angiotensin 
system activation (Sealey et al. 1990).  
1.1.4.1.2  Cell Signalling  
G-proteins mediate the signal transduction of many vasoactive stimuli. Immortalised 
lymphoblasts from hypertensive patients were found to have higher G-protein activities 
than those from normotensive patients (Siffert et al. 1995). Mutation screening in the α, β, 
and γ subunits of heteromeric G-proteins identified a C825T polymorphism in the G-
protein β3 subunit gene associated with hypertension in a Caucasian population, this 
mutation causes alternative splicing of the gene and the loss of a highly conserved 41 James Polke, 2008    Chapter 1         35           
   
amino acid region (Siffert et al. 1998). Other studies in Japanese and German cohorts 
failed to replicate this association (Kato et al. 1998;Beige et al. 1999).  
There is decreased responsiveness of the dopamine 1 G-protein-coupled-receptor in 
proximal tubules in essential hypertensives (Sanada et al. 1999), potentially disrupting the 
regulation of sodium excretion. Speirs et al (Speirs et al. 2004) performed an association 
study on variants of the G-protein-coupled-receptor protein 4 (GRK4) in a Caucasian 
population. The V allele of the A486V GRK4 variant showed an association with elevated 
blood pressure. Haplotypes of two other genes analysed in the same study (3β-
hydroxysteroid dehydrogenase/isomerase, involved in synthesis of steroid hormones and 
protein phosphotase 1, a negative regulator of insulin signalling) showed no association 
with hypertension. 
1.1.4.1.3  Adrenergic System 
Sympathetic nervous system adrenergic receptors are clear hypertension candidate genes 
since the adrenergic system influences many aspects of blood pressure control such as 
vascular tone, cardiac output, renal sodium absorption and renin release. In black 
populations, variants in the α2 adrenergic receptor genes ADRA2A and ADRA2C have been 
associated in with hypertension in a number of small studies (Lockette et al. 1995;Svetkey 
et al. 1996). However a large association study in 1767 blacks recently found no 
association of ADRA2A and ADRA2C variants with hypertension and showed that these 
polymorphisms are not predictors of blood pressure, heart rate cardiac output or vascular 
resistance (Li et al. 2006).  
Three common β2 adrenergic receptor (ADRB2) gene polymorphisms, Arg16Gly, 
Glu27Gln, and Thr64Ile have been linked to variations in receptor function but association 
studies have shown contrasting links to hypertension in various populations. The Gly16 
variant was linked to hypertension in Afro-Caribbeans (Kotanko et al. 1997), and white 
Americans (Hoit et al. 2000). Both the Gly16 and Gln27 alleles were associated with 
hypertension in Han Chinese (Ge et al. 2005), while two further studies in Chinese (Gu et 
al. 2006) and Japanese (Kato et al. 2001) populations showed association with Gln27, but 
not Gly16. However an American study reported association with Gly16 and Glu27 (Bray 
et al. 2000). In addition, there have been a number of negative studies in several European, 
black and white American and African populations. Linkage studies in a Polish cohort 
performed at the Glasgow laboratory confirmed a blood pressure QTL on chromosome 5 at James Polke, 2008    Chapter 1         36           
   
ADRB2, but association analysis did not support a role of the three polymorphisms 
individually or by haplotype (Tomaszewski et al. 2002). Subsequent analysis in the same 
population assessed the interaction between ADRB2 and neuropeptide Y (NPY) 
polymorphisms on cholesterol and triglyceride levels; the β2 adrenergic receptor and 
neuropeptide Y are co-expressed in several tissues and are involved in several aspects of 
lipid metabolism. There was a consistent interaction between the ADRB2 Arg16Gly and 
Glu27Gln and NPY Leu7Pro variants in hypertensive patients with elevated low-density 
lipoprotein (LDL), but not hypertensive subjects with normal LDL cholesterol 
(Tomaszewski et al. 2004). 
1.1.4.1.4 Fibroblast Growth Factor 1 
Fibroblast growth factor 1 (FGF1) is located on chromosome 5 under the same blood 
pressure QTL as ADRB2 (Tomaszewski et al 2002) and is functionally linked to blood 
pressure control by its role in stimulation of endothelin-1 release (Sugo et al. 2001), 
expression of the endothelin receptor (Li et al. 2003) and increased plasma catecholamines 
and corticosteroids (Matsumoto et al. 1998). Following improved QTL analysis tightening 
the blood pressure QTL to the region encoding FGF1, haplotype analysis showed that 
variation in the FGF1 haploblock was associated with hypertension in a Polish cohort and 
implicated a SNP in FGF1 intron 2 (Tomaszewski et al. 2007) furthermore, western blot 
analysis showed increased FGF1 expression in the kidneys of hypertensive patients 
compared to normotensives (Tomaszewski et al 2007). 
1.1.4.1.5  Other Candidate Genes 
Adducin is a dimeric cytoskeletal protein composed of α and β or γ subunits encoded by 
ADD1, ADD2 and ADD3 genes, respectively. It has been shown to activate the sodium-
potassium ATPase (NaK ATPase) ion pump, mediating tubular sodium reabsorption 
(Ferrandi et al. 1999). The Milan hypertensive rat strain (MHS) exhibits increased sodium 
reabsorption, and carries ADD1 and ADD2 mutations that increase adducin activity 
(Tripodi et al. 1996). A number of studies have analysed the effects of ADD1 
polymorphisms in human essential hypertension in several populations (Bianchi 2005), six 
out of a total of 14 linkage studies showed positive associations, while 19 out of 22 
association studies were positive.  James Polke, 2008    Chapter 1         37           
   
The endothelial nitric oxide synthase gene (eNOS) is a robust candidate for hypertension 
genetics given its role in defence against endothelial oxidative stress (see section 1.3). A 
number of studies have analysed eNOS polymorphisms and hypertension with conflicting 
results. A recent meta-analysis combined the results of 35 association studies and only 
found association of an intron 4 polymorphism with hypertension assuming a recessive 
model in whites, no association was found in studies of east Asian or black subjects 
(Zintzaras et al. 2006). 
Bradykinin receptors mediate the vasoactive and metabolic actions of bradykinin, a 
component of the kinin-kallikrein system (see table 1.1). SNPs within coding and 
regulatory regions of bradykinin receptor B1 and B2 (BDKRB1 and 2) were associated 
with hypertension in association studies in African American and American Caucasian 
populations (Cui et al. 2005). BDKRB2 promoter polymorphisms have also been associated 
with hypertension in Chinese (Wang et al. 2001) and Japanese (Mukae et al. 1999) 
populations. 
1.1.4.2 Genome-Wide Linkage Studies 
More than twenty genome-wide linkage studies have been performed to search for 
essential hypertension loci, resulting in over 100 hypertension QTL (table 1.2). Table 1.2 
illustrates the wide spread of hypertension QTL, every chromosome is represented, 
however, it also shows the clustering of QTL from different studies on several 
chromosomes, notably 1,2,3,17 and 18. It is possible that such overlapping QTL indicate 
the involvement of a small number of large-effect alleles responsible for a majority of 
essential hypertension, however, more evidence is required for this conclusion since many 
of the QTLs have only 'suggestive' genome-wide significance (Cowley, Jr. 2006). In 
general, there has been very little replication of QTL identification between populations, 
and no specific genes have yet been positively identified, this likely illustrates the genetic 
heterogeneity between different ethnic populations, and the possibility that a large number 
of genetic loci have small and interacting effects on blood pressure, rather than a few genes 
with large effects. However there has been recent progress with analysis of the BRitish 
Genetics of HyperTension (BRIGHT) study (Caulfield et al. 2003). This study initially 
recruited 2010 affected sibling pairs from 1599 families with severe hypertension (top 5% 
of blood pressure distribution) and included 3599 individuals in the genome-wide scan, it 
is the largest homogenous linkage study in hypertension genetics. Aside from exhibiting      
   
Study  Phenotype  No. of subjects  Chromosomes  Population 
(Bell et al. 2006)  Hypertension  3863  5,9,11,15,16,19  White  
(Caulfield et al 2003)  Hypertension  3599  2,5,6,8,9  White  
(Hunt et al. 2002)  Hypertension, SBP  2959  Hypertension: 1,7,12,15 
SBP: 6  White 
(Levy et al. 2000)  SBP  1585  17,18  White 
(Shmulewitz et al. 2006)  SBP  1546  20  Micronesian 
(Xu et al. 1999)  BP  1450  3,11,15,16,17  Chinese 
(Rao et al. 2003)  Hypertension  1300  2  African-American 
(Cooper et al. 2002)  DBP  792  2,3,5,7,10,19  Nigerian 
(Hsueh et al. 2000)  DBP  694  2  White 
(Rice et al 2000)  SBP  679  1,2,5,7,8,19  White 
(Pankow et al. 2000)  SBP  636  6,18  White 
(Harrap et al. 2002)  SBP  548  1,4,16,X  White 
Table 1.2 – Continued overleaf            
   
Study  Phenotype  No. of subjects  Chromosomes  Population 
(Rice et al. 2002)  SBP  519  3,11  White 
(Hamet et al. 2005)  DBP, Mean BP  500  DBP: 1,3,16.  
Mean BP: 16  French Canadian 
(Atwood et al. 2001)  SBP  495  2,8,18,21  Mexican 
(Kristjansson et al. 2002)  Hypertension  490  2,11,17,18  White 
(Benjafield et al. 2005)  Hypertension  481  1,4  White 
(Krushkal et al. 1999)  SBP  427  2,5,6,9,15,16,18,20,21  White 
(Zhu et al. 2001)  Hypertension  393  2,3,8,15  Chinese 
(Cheng et al. 2001)  SBP  390  1,2,7  White 
(Pausova et al. 2005)  Hypertension  389  1,8,11,13  White 
(Allayee et al. 2001)  SBP  388  4,6,8,19  White 
 
(Thiel et al. 2003)  DBP  320  1  White 
(Sharma et al. 2000)  Hypertension  288  11  White 
Table 1.2 – Continued overleaf            
   
Study  Phenotype  No. of subjects  Chromosomes  Population 
(Ciullo et al. 2006)  Hypertension  173  1,4,8  White 
(Gong et al. 2003)  Hypertension  158  12  Chinese 
 
(Perola et al. 2000)  Hypertension  113  1,2,3,22,X  White 
(Angius et al. 2002)  Hypertension  77  1,2,13,15,17,19  White 
 
Table 1.2 - Genome-wide linkage studies for essential hypertension loci in humans  
 
Numbers in bold represent chromosomes on which loci were found that surpassed genome-wide significance, otherwise, linkage is 
suggestive according to the criteria set by authors. Adapted from Cowley, Jr ( 2006) and Binder  ( 2007). James Polke, 2008    Chapter 1          41 
severe hypertension, the study population were also selected on the basis of heredity, all 
participants were of white British ancestry at least as far as grandparents. The initial 
publication identified a locus on chromosome 6q that achieved genome-wide significance, 
and three further loci with suggestive significance on chromosomes 2q, 5q and 9q 
(Caulfield et al 2003). The locus at 6q was received with caution in the literature since it 
was located near the telomere of the chromosome, where linkage evidence can be hard to 
interpret (Harrap 2003). A follow-up study included additional polymorphic markers in the 
regions of interest, and increased the study cohort to 2142 affected sibling pairs (Munroe et 
al. 2006). Support for the loci at 2q, 6q and 9q were diminished in this analysis, however, 
there was increased support for linkage to the locus at 15q, and two further regions at 1q 
and 11q achieved suggestive significance. The locus at 15q was further supported by a 
confirmatory linkage study on a second cohort of families, or trios, comprising an affected 
proband and either two parents or sibling and single parent (Munroe et al 2006).  
Novel statistical techniques have also been employed in analyses of the BRIGHT dataset, 
including a genome-wide association study specifically designed to identify pairs of 
interacting loci that contribute to hypertension, the first such study performed in humans 
(Bell et al 2006). Four pairs of loci that individually did not have effects in the single-locus 
scan attained suggestive or genome-wide significance in this analysis, highlighting the 
importance of considering gene interactions in complex disease genetics (Bell et al 2006). 
Wallace et al ( 2006) developed an analytical method to integrate blood pressure 
measurements and associated phenotypic data, or covariates, collected on all BRIGHT 
study participants (such as serum and urine metabolites and biometric measurements) to 
find genetic loci linked to hypertension and the covariates. Blood pressure loci associated 
with leaner body-mass index and renal function were identified on chromosomes 20q and 
5q, respectively. Meanwhile, analysis of the data on anti-hypertensive treatments in the 
BRIGHT population implicate a region on chromosome 2p with non-responsiveness to 
antidiuretics and beta-blockers (Padmanabhan et al. 2006).  
1.1.4.3 Genome-Wide Association Studies 
As mentioned above, the cost of genome-wide genetic analysis at sufficient marker density 
in large enough study populations historically precluded genome-wide association studies 
for complex diseases. However, low-cost genotyping technologies have recently led to the 
first publications of genome-wide association studies. The largest study to date, and the James Polke, 2008    Chapter 1         42 
   
only one so far to address essential hypertension, was a collaborative effort between over 
50 research groups comprising the Wellcome Trust Case Control Consortium. The study 
covered 7 complex diseases in the British population: bipolar disorder, coronary artery 
disease, Crohn's disease, hypertension, rheumatoid arthritis, type 1 and type 2 diabetes, and 
included approximately 2,000 affected individuals for each disease and 3,000 common 
controls (The Wellcome Trust Case Control Consortium 2007). Over 500,000 SNPs were 
genotyped per subject, using Affymetrix 500K Mapping Array chips.  
The study confirmed 13 out of 15 previously reported genetic loci with strong prior 
evidence of linkage from previous replication studies (none for hypertension), and reported 
21 loci that achieved genome-wide significance (p<5x10
-7) across 6 of the diseases, 
follow-up publications have replicated a number of these findings in other populations  
(Todd et al. 2007;Parkes et al. 2007;Zeggini et al. 2007). None were hypertension loci, 
though a similar number of loci achieved significance between p=10
-4 and p=10
-7 for 
hypertension as the other diseases. Explanations proposed include the possibility that 
essential hypertension may have fewer large-effect alleles than the other conditions 
studied, or that they may lie within regions poorly represented SNPs in the array, for 
example the authors reported that the WNK1 locus is poorly tagged. Another more likely 
explanation is that the control population contained a number of hypertensives; the controls 
were not phenotyped, they constituted 1500 individuals from the 1958 British Birth Cohort 
and 1500 blood donors. The authors state that an incidence of the disease under 
consideration of 5% in the control group would have the same effect on power in the final 
analysis as a reduction in sample size by 10%. Given a likely prevalence of hypertension in 
the control group of approximately 25% or more, the effect on the power would be 
substantial. It is important to emphasise that this study was in many ways a very successful 
proof-of-principle publication, testing the effectiveness of large inter-disciplinary 
collaborations, novel technologies and data analysis methods. Future genome-wide 
association scans for essential hypertension will include appropriately phenotyped non-
affected controls, so called 'hypercontrols' (The Wellcome Trust Case Control Consortium 
2007).  
1.2  Rat Models of Human Hypertension 
The rat is an invaluable tool in physiological and genetic hypertension research, being 
suitable for detailed physiological study and large breeding experiments (Rapp 2000). Rats James Polke, 2008    Chapter 1         43 
   
are also experimentally advantageous given the ability to closely control factors such as 
diet and medication that are not be possible in experiments with humans. In addition, the 
draft rat genome sequence (covering an estimated 90% of the 2.8 Gb Brown Norway rat 
genome) has recently become available to researchers (Gibbs et al. 2004). Several inbred 
rat strains have been selectively bred to display particular hypertensive and normotensive 
phenotypes. An understanding of the genetic factors that influence blood pressure in these 
rats will provide insights into blood pressure regulation in humans, however it is important 
to note that the same genes found to impact blood pressure in inbred rats may not be 
factors in human essential hypertension, rather that they will inform researchers as to 
which physiological processes and pathways are most significant. 
An inbred strain is derived by selecting for a particular trait over several generations from 
an outbred stock, followed by twenty generations of brother/sister mating to fix the strain, 
resulting in a genetically identical population. The selection procedure can include 
provocative dietary or environmental stimuli such as high-salt diet or stress induced by 
restraint. Divergent strains can also be derived simultaneously with opposing phenotypic 
responses to such stimuli, such as in the case of Dahl salt sensitive and Dahl salt resistant 
rats. Each of these strains was derived from outbred Sprague-Dawley rats fed a high salt 
(8% NaCl) diet; the salt sensitive rats develop high blood pressure when fed a high salt 
diet, while the salt resistant strain remains normotensive (Dahl et al. 1962a;Dahl et al. 
1962b). The original Dahl salt sensitive and resistant rats were maintained as outbred 
strains, but have subsequently been fixed by two groups (Rapp et al. 1985;Iwai et al. 
1986). Table 1.3 lists the common inbred hypertensive rat strains. 
1.2.1 The Stroke-Prone Spontaneously Hypertensive Rat (SHRSP) 
The Glasgow laboratory maintains a colony of stroke-prone spontaneously hypertensive 
(SHRSP) rats and a colony of inbred normotensive Wistar Kyoto (WKY) rats. The specific 
strains are known as SHRSPGla and WKYGla but are referred to in this text as WKY and 
SHRSP from here. The SHRSP was derived from the spontaneously hypertensive rat 
(SHR), which was in turn selectively bred for hypertension from the normotensive Wistar-
Kyoto (WKY) strain by phenotypic selection without dietary or environmental influences 
(Okamoto et al. 1963). The SHRSP was selectively bred on the basis of its increased 
incidence of stroke (Okamoto et al. 1974;Yamori 1994); it displays higher blood pressure 
than the SHR, but also has specific genetic factors that predispose it to cerebrovascular  
   
Strains  Origin  Lines  Original Stock  Reference 
Genetically hypertensive (GH)  New 
Zealand 
 
H,C  Wistar derived  (Smirk et al. 1958)  
Dahl salt sensitive (DSS) 
Dahl salt resistant (DSR) 
 
USA  H,L  Sprague-Dawley  (Dahl et al 1962a;Dahl et al 1962b) 
Spontaneously hypertensive rat (SHR) 
 
Japan  H  Wistar derived  (Okamoto et al 1963) 
DOCA salt sensitive Sabra (SBH) 
DOCA salt resistant Sabra (SBN) 
 
Israel  H,L  Unknown  (Ben Ishay et al. 1972) 
Lyon hypertensive (LH) 
Lyon Normotensive (LN)  
Lyon low blood pressure (LL) 
 
France  H,C,L  Sprague-Dawley  (Dupont et al. 1973) 
Stroke-prone spontaneously hypertensive rat (SHRSP) 
 
Japan  H  Wistar derived  (Okamoto et al 1974) 
Milan hypertensive strain (MHS) 
Milan normotensive strain (MNS) 
 
Italy  H,C  Wistar  (Bianchi et al. 1974b) 
Fawn hooded hypertensive (FHH) 
Fawn hooded low blood pressure (FHL) 
 
Netherlands  H,L  German brown x 
white Lashley 
(Kuijpers et al. 1984) 
Inherited stress-induced arterial hypertensive (ISIAH) 
 
Russia  H  Wistar derived  (Markel 1985) 
Prague hypertensive (PHR)  
Prague normotensive (PNR) 
 
Czech 
Republic 
H,L  Wistar  (Heller et al. 1993) 
 
Table 1.3 - Rat inbred models used in hypertension genetic research 
Modified from Rapp (2000) H: High blood pressure. L: Low blood pressure, C: Control strain James Polke, 2008    Chapter 1          45 
lesions. This was demonstrated by backcrosses with SHR rats to generate populations with 
respectively 25%, 50% and 75% SHRSP genetic composition, incidence of stroke was 
positively correlated with increasing percentage of SHRSP genotype after salt challenge to 
result in the same blood pressures in each group  (Nagaoka et al. 1976). A genome-wide 
scan for stroke susceptibility performed by cross-breeding SHRSP and SHR rats revealed 
hypertension-independent stroke susceptibility QTLs on chromosomes 1, 4 and 5 in the 
SHRSP, of which the chromosome 1 QTL was reported to account for 17% of phenotypic 
variance (Rubattu et al. 1996). Reciprocal congenic strains (see below for a discussion on 
congenic strains) between the SHRSP and SHR recently further confirmed the effect of the 
chromosome 1 stroke susceptibility QTL (Rubattu et al. 2006). A genome-wide scan 
performed at the Glasgow laboratory located blood a pressure-independent chromosome 5 
QTL for ischaemic stroke severity following permanent occlusion of the middle cerebral 
artery. The locus was identified following breeding between the SHRSP and WKY and 
accounted for 67% of phenotypic variance (Jeffs et al. 1997). Subsequent investigations of 
chromosome 5 QTL candidate genes, atrial natiuretic peptide (Anp) and brain natiuretic 
peptide (Bnp) by sequencing, expression and functional analysis excluded them as 
causative genes for this phenotype (Brosnan et al. 1999). 
Hypertension in the SHRSP, as in other hypertensive strains, is more pronounced in males, 
high blood pressure is fully established at approximately 180 mmHg in males and 150 
mmHg in females by 12 weeks of age, compared to 130 mmHg in WKY rats of the same 
age (both sexes) (Davidson et al. 1995), the genetic influence of the Y chromosome in this 
sexual dimorphism was proved by the generation of reciprocal Y chromosome consomic 
strains (rats selectively bred to be of one genotype throughout the genome except for one 
chromosome, which is derived from a different strain) between the SHRSP and WKY, 
transferring the SHRSP Y chromosome onto the background of the WKY increased blood 
pressure, while the WKY Y chromosome reduced blood pressure in the SHRSP (Negrin et 
al. 2001). SHRSP rats are very salt sensitive, replacing drinking water with a 1% salt 
solution results in a blood pressure increase to approximately 240 mmHg in males and 180 
mmHg in females while the blood pressure of WKY rats does not rise following the same 
treatment (Jeffs et al. 2000). In addition to high blood pressure and increased incidence of 
stroke, the SHRSP also displays many other symptoms related to human cardiovascular 
disease including left ventricular hypertrophy (Clark et al. 1996), and endothelial 
dysfunction (McIntyre et al. 1997;Kerr et al. 1999). It is also a model of the metabolic James Polke, 2008    Chapter 1         46 
   
syndrome, isolated SHRSP adipocytes display impaired glucose transport and abnormal 
non-esterified fatty acid (NEFA) metabolism (Collison et al. 2000). In experiments 
performed in Glasgow, fructose-fed SHRSP rats showed impaired glucose tolerance, 
increased plasma triglycerides and NEFA levels compared to fructose-fed WKY rats 
(Strahorn et al. 2005). In the same study, using congenic and consomic SHRSP rats 
harbouring WKY genes, it was demonstrated that genes on chromosome 2 and the Y 
chromosome act individually and interact to influence glucose metabolism (Strahorn et al 
2005). 
1.2.2 Identifying Quantitative Trait Loci 
Genome-wide scans in segregating rat populations involve an initial cross between a 
hypertensive and a normotensive strain to generate heterozygotic F1 progeny. Typically, 
these crosses involve equal numbers of matings between hypertensive males and 
normotensive females and between hypertensive females and normotensive males. The F1 
generation are brother-sister mated to generate F2 animals of random genetic compliments 
of the original parental strains. All F2 animals are genotyped with polymorphic markers 
spanning the genome and phenotyped for continuous traits (such as blood pressure, pulse 
pressure, left-ventricular mass etc.). Genotype and phenotype data is entered into computer 
software that calculates for each trait the probability that set genomic positions are linked 
to it. This probability is presented as a logarithm of odds (LOD) ratio of the likelihood that 
a position is linked to a trait versus the likelihood that it isn't linked, given the positions 
and genotypes of flanking markers and the phenotype of animals with each genotype. The 
significance LOD threshold for a QTL is traditionally set at >3.0 (corresponding to an odds 
ratio of 1/1000), however, specific thresholds can be derived for each QTL calculation 
based on individual experimental factors such as genome size, genetic model for 
inheritance of the QTL (e.g. dominant/recessive etc.) and breeding regime (Lander et al. 
1995). QTL prediction provides an estimation of the percentage of variance in the 
quantitative trait accounted for by the QTL; blood pressure QTLs typically individually 
account for 5-15% of blood pressure variance, increasing marker density in the genome 
wide scan beyond every 10 cM does not improve QTL localisation (Darvasi et al. 1993), 
the greater the phenotypic effect the more likely it will be identified. Increasing the number 
of animals in the study also increases precision, however there are obvious cost 
implications, studies with 200-300 F2 rats generally locate a QTL within 20 to 35 cM James Polke, 2008    Chapter 1         47 
   
(Rapp 2000), a region likely to contain over a thousand genes. A genome-wide scan may 
provide a complicated picture of genomic linkage to a trait. Multiple QTL peaks may 
cluster in a particular region of a chromosome, overlapping to obscure the number of 
linked sites and their exact locations. It is important to emphasise that a QTL identified in a 
cross between two inbred strains may not be identified in experiments involving other 
strains, or in the same strains under different environmental conditions (such as diet and 
age of rats) since the gene(s) underlying a QTL may not be functionally polymorphic in all 
situations. For example there may not be sequence differences between other pairs of 
strains at the loci underlying the QTL, or the gene(s) may only affect blood pressure 
control at a certain developmental stage our dietary regime. Genome-wide scans have 
identified over 80 QTLs for blood pressure and associated phenotypes on almost every rat 
chromosome (Rapp 2000;Twigger et al. 2007). 
1.2.3 Recombinant Inbred Strains 
Recombinant inbred strains can be generated for QTL identification as an alternative to 
linkage analysis in segregating populations. The principal of the breeding program is 
similar: inbred hypertensive and normotensive strains are bred to produce F1 progeny 
which are brother-sister mated to produce an F2 generation. F2 rats are randomly 
segregated into breeding pairs that become founders of strains bred to homozygosity by 20 
generations of brother/sister mating. Rather than a single generation of rats, a panel of 
recombinant inbred strains is generated each with a random genomic compliment from the 
hypertensive and normotensive parental strains. Each strain can be genotyped and 
phenotyped to identify QTLs as in segregating populations. There are advantages of 
recombinant inbred strains such as the ability to phenotype many animals from the same 
strain, potentially in different environments to assess genotype/phenotype interactions, and 
to examine many different animals at different stages of development to measure genetic 
effects at different developmental stages. The cost of developing and maintaining the 
strains is the main disadvantage. A panel of recombinant inbred strains for the study blood 
of pressure genetics were bred by Pravenec and colleagues using SHR and normotensive 
Brown Norway (BN) rats as progenitor strains. The 31 strains showed blood pressure 
continuously distributed between the BN and SHR (Pravenec et al. 1989). This panel of 
strains has subsequently been used in a number of studies examining multiple 
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and was also applied in a landmark expression genetics study, discussed in section 1.2.3.4 
(Hubner et al. 2005). 
1.2.3.1 Congenic Strains 
QTLs identified by genome wide scans are too large for gene identification by positional 
cloning methods, a powerful method for interrogating and narrowing QTL intervals is the 
generation of congenic and subcongenic strains. Congenic breeding involves selectively 
introgressing the genetic compliment covering the QTL from a 'donor' strain onto the 
background of the 'recipient' strain to produce a rat of entirely recipient genotype except at 
the QTL (figure 1.2). The phenotypes of the congenic rats compared to those of the 
original donor and recipient strains are used to confirm the effects of the genes underlying 
the QTL. In traditional congenic breeding once the QTL has been introgressed, the 
background is 'cleaned' of excess donor genotype by at least 8 backcrosses to the recipient 
parental strain, guaranteeing >99% recipient genotype in the final congenic strain. This 
strategy has been superseded in most congenics laboratories by 'speed' or marker-assisted 
congenic breeding, where polymorphic markers throughout the genome are genotyped at 
each back-cross to select the offspring with the least genetic input from the donor strain 
(except at the QTL) (Lander et al. 1994). With marker-assisted breeding, a congenic strain 
is typically produced within 4 backcrosses (Jeffs et al 2000), figure 1.2.  
1.2.3.2 Subcongenics 
Since a congenic strain necessarily has to encompass an entire QTL to confirm its effect, 
the introgressed region will contain too many genes to provide a workable number of 
functional candidate genes. Thus, progressively smaller genomic regions can be captured 
in congenic substrains (subcongenics) in order to localise the QTL to smaller genetic 
intervals with fewer candidate genes. Subcongenics are generated in the same manner as 
congenics, using the original congenic as the donor strain and relying on recombination 
events within the original congenic region to truncate the congenic interval in the resultant 
strain.  
Successful application of congenic breeding is exemplified by the series of experiments 
that confirmed the gene encoding 11-β-hydroxylase (Cyp11b1, the human homologue of 
which is mutated monogenic GRA – see section 1.1.3.1), as responsible for a blood James Polke, 2008    Chapter 1          49 
 
Figure 1.2 - Traditional and speed congenic breeding 
 
 
 
pressure QTL on chromosome 7 in the Dahl salt sensitive rat. Biochemical studies showed 
that the Dahl salt-sensitive rat (DSS) has higher 11-β-hydroxylase activity than the Dahl-
salt resistant rat (DSR), resulting in a higher adrenal concentration of 18-hydroxy-
11deoxycorticosterone (18-OH-DOC) in the DSS (Rapp et al. 1971). 18-OH-DOC has 
weak mineralocorticoid activity, its increased abundance was proposed to account for a 
degree of the salt sensitivity in the DSS (Rapp et al. 1972). Five nucleotide differences 
causing amino acid changes were identified between the DSR and DSS Cyp11b1 
sequences, of which those affecting amino acid residues 381 and 384 were shown to be the 
main determinants of 11-β-hydroxylase activity in-vitro (Matsukawa et al. 1993;Nonaka et 
al. 1998). F1 rats from crosses between DSS and DSR rats were backcrossed with DSS rats 
to generate an F2 population which were phenotyped and genotyped at informative 
markers throughout chromosome 7 (Cicila et al. 1997). Note that this differs from the 
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protocol for linkage analysis outlined in section 1.2.2, where the F1 generation is brother- 
sister mated. In this instance the DSS allele had a greater effect in animals with a greater 
proportion of DSS background genotype (Cicila et al. 1993), hence the backcross was 
'weighted' to generate rats with measurable phenotypic differences to the parental strains. 
The linkage analysis showed suggestive linkage for blood pressure at the locus on 
chromosome 7 covering Cyp11b1 and a congenic strain (S.R-Cyp11b1) was generated by 
introgressing a 20.2 cM region from DSR on to the DSS background. S.R-Cyp11b1 had a 
significantly lower blood pressure (by >20mmHg) compared to the DSS on a 4% NaCl diet 
(Cicila et al 1997). Subsequent studies generated subcongenic strains from S.R-Cyp11b1 to 
ultimately narrow the congenic interval to a 177 kb segment containing Cyp11b1 that is 
responsible for approximately 15 mmHg lower blood pressure in the congenic strain 
compared to DSS on a 2% NaCl diet (Cicila et al. 2001;Garrett et al. 2003). Although this 
region also contains eight other genes, they have no known physiological role in blood 
pressure regulation and 177 kb remains the smallest individual congenic interval 
containing a QTL in mammalian genetics (Garrett et al 2003). 
The Glasgow laboratory maintains a number of congenic strains harbouring blood pressure 
QTLs. The original  blood pressure genome-wide scan involved 1 male SHRSP mating 
with 2 female WKYs and 1 male WKY mating with 2 female SHRSPs, 3 males and 6 
females from each F1 generation were brother-sister mated to produce the F2 generation. 
At 16 weeks of age, blood pressure telemetry catheter/transmitters were implanted into the 
abdominal aorta of the rats, following 12 days post-operative rest, systolic and diastolic 
blood pressure, heart rate and motor activity were monitored via receivers placed under the 
cages and 'baseline' blood pressure was recorded for 4 days. Subsequently, animals were 
administered 1% NaCl in drinking water for 12 days, the last four days of which 
constituted 'salt loaded' haemodynamic measurement. The animals were then euthanized 
and body weight, heart weight, and left ventricular and septum mass were determined 
(Clark et al 1996). Genotyping was performed with a panel of 181 informative 
microsatellite markers throughout the genome. Using these markers, MAPMAKER 
software (Lander et al. 1987) identified two significant (LOD>3.0) blood pressure QTLs 
for blood pressure on chromosome 2 in males, one for baseline and salt-loaded systolic and 
diastolic blood pressure (for the purposes of this discussion named QTL1), and one for 
salt-loaded diastolic blood pressure (QTL2). Each QTL accounted for 24-31% of variance 
in blood pressure. A third significant QTL for baseline pulse pressure and salt-loaded James Polke, 2008    Chapter 1         51 
   
diastolic and systolic blood pressure was identified on chromosome 3 in males, each 
accounting for over 30% of trait variance, while a suggestive QTL for left-ventricular 
hypertrophy was also located on chromosome 14 in males (Clark et al 1996). The 
chromosome 2 blood pressure QTLs (QTL1 and QTL2) were further analysed by the 
creation of four congenic strains, utilising the 'speed' congenic strategy to introgress 
sections of WKY chromosome 2 onto the background of the SHRSP, and vice-versa (Jeffs 
et al 2000), figure 1.3. SP.WKYGla2a, in which both QTLs were transferred, showed an 
approximate 20 mmHg reduction in basal blood pressure compared to the SHRSP and a 40 
mmHg reduction under salt loading. WKY.SPGla2c is the reciprocal strain, and showed a 
similar increase in blood pressure compared to the WKY at baseline, but no further 
increase under salt loading. The difference between these responses highlights an 
interesting and commonly observed phenomenon in congenic breeding whereby the 
background genotype of the recipient strain dictates the phenotypic effect observed (Rapp 
2000). The SHRSP is more permissive to blood pressure changes by introduction of WKY 
genetic material than the reciprocal transfer; the complex deleterious phenotype is more 
likely to be corrected than induced by the transfer of a small chromosomal segment. 
Comparisons between the blood pressures of SP.WKYGla2b versus SHRSP and 
WKY.SPGla2d versus WKY showed no significant differences, the region transferred in 
the construction of SP.WKYGla2b does not cover either blood pressure QTL, while the 
introgressed region in WKY.SPGla2d covers QTL1 alone (Jeffs et al 2000), figure 1.3.   
Other research groups have also identified blood pressure QTLs on rat chromosome 2, 
indeed 19 are listed with a LOD score of over 3.0 in the Rat Genome Database (Twigger et 
al 2007). Notably, two genome-wide scans were published concurrently involving crosses 
between salt-challenged (8% NaCl) Dahl salt sensitive (DSS) and Milan normotensive 
(MNS) rats and between DSS and WKY rats, (Deng et al. 1994). Both scans identified a 
blood pressure QTL on chromosome 2 that overlaps QTL2 found in the genome-wide scan 
between SHRSP and WKY in the Glasgow laboratory. Numerous congenic and 
subcongenic strains have been generated to investigate these QTLs, substitution mapping 
(where the limits of a QTL are inferred by analysing the blood pressures of subcongenic 
strains with overlapping congenic intervals) in DSS/MNS and DSS/WKY subcongenics 
have dissected the QTLs to at least 3 smaller interacting QTLs in each  case (Dutil et al. 
2001;Garrett et al. 2002;Dutil et al. 2005). James Polke, 2008    Chapter 1          52 
Figure 1.3 - Chromosome 2 congenic strains and blood pressures 
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1.2.3.3 Microarray Expression Analysis and Congenics 
The advent of microarray technology has enabled the simultaneous measurement of many 
thousands of messenger RNAs in tissue or blood samples. They are very well suited to 
investigation of congenic strains for identification of candidate genes. Gene expression in 
parental strains can be compared to that of congenics, genes mapping to the congenic 
interval that are differentially expressed between the congenic and recipient parental strain 
but not between the congenic and donor parental strain are candidates that can be followed 
up in further experiments.  
Research in the Glasgow laboratory employed subcongenic breeding and microarray 
expression analysis to follow up the work performed by Jeffs et al (2000). The 
SP.WKYGla2c* strain (from here referred to as 2c*) was derived from the SP.WKYGla2a 
(referred to as 2a) strain, the congenic interval covers QTL2 only, spanning approximately 
20 cM and 2c* rats exhibit significantly reduced baseline blood pressure compared to the 
SHRSP, at levels comparable to the 2a strain (figure 1.4) (McBride et al. 2003). 
Microarrays measuring expression of 26379 probe sets were performed on cDNA derived 
from the kidneys of WKY, SHRSP and 2c* rats. 45 probe sets were found to be 
significantly differentially expressed between the WKY and SHRSP strains, of these, 12 
were also differentially expressed between the SHRSP and 2c*, four of which had a known 
chromosomal location, with 3 of them mapping to the 2c* congenic interval. These three 
probe sets represented the glutathione s-transferase  -type 1 (Gstm1) gene (NB – in the 
publication the gene is referred to as Gstm2, it was incorrectly annotated in the rat genome 
databases at the time). Quantitative reverse transcription polymerase chain reaction (PCR) 
was employed to measure mRNA expression levels of Gstm1 in SHRSP, 2c* and WKY 
kidneys, confirming the differential expression seen in the microarrays (McBride et al 
2003). Gstm1, an oxidative stress-defence gene, has subsequently become a focus of 
further investigation into hypertension genetics in the Glasgow laboratory, and is the 
subject for much of the research in this thesis, part of which contributed to a publication in 
2005 (McBride et al. 2005). This paper demonstrated that reduced Gstm1 expression 
coincided with hypertension in comparisons between a number of hypertensive and 
normotensive strains, and that promoter polymorphisms in the SHRSP and SHR may affect 
Gstm1 expression. Furthermore, Gstm1 protein was localised to the principal cells of the 
collecting ducts and increased renal oxidative stress was demonstrated in the SHRSP,  James Polke, 2008    Chapter 1         54 
   
 
Figure 1.4 - Chromosome 2 subcongenic strains derived from SP.WKYGla2a 
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suggesting a pathophysiological role for Gstm1 in hypertension and oxidative stress 
(Mcbride et al. 2005, see also chapter 4).  
A recent publication also investigated transcriptional changes in chromosome 2 genes 
thought to influence salt sensitivity in the SHRSP and congenic rats (Graham et al. 2007). 
Despite reduced baseline blood pressure compared to the SHRSP, the 2c* shows similar 
blood pressure to the SHRSP after 3 weeks on a high salt diet. In contrast, the 2a strain is 
salt resistant, showing no further increase in blood pressure on a high salt diet. This 
implicates genes within the 6 Mb region at the distal end of the 2a congenic interval that 
are not covered by the 2c* region. The subcongenic strain, SP.WKYGla2k (referred to as 
2k) was generated from the 2a, capturing the 6 Mb region in a WKY congenic interval 
(figure 1.4) and has a similar baseline and salt loaded blood pressure profile to the 2a, both 
being significantly lower than the SHRSP. Microarray expression profiling was performed 
on kidneys from 21 week-old salt-loaded SHRSP, WKY and 2a rats, implicating two genes 
encoded within the 6 Mb region, endothelial differentiation gene receptor 1 (Edg1) and 
vascular cell adhesion molecule 1 (Vcam1), that were increased the SHRSP compared to 
the WKY and 2a, and subsequently also shown to be reduced in the 2k by quantitative RT-
PCR (Graham et al 2007).  
Another example of microarray expression profiling in congenic rats identified Cd36 as a 
gene responsible for defective fatty acid and glucose metabolism in the SHR, contributing 
to symptoms of the metabolic syndrome. A QTL for defective catecholamine activity and 
reduced insulin activity in the SHR had been located on chromosome 4 in a genome wide 
scan involving crosses between SHR and Brown Norway (BN) rats (Aitman et al. 1997). A 
congenic rat strain was generated (SHR.4) whereby the region covering the QTL was 
replaced by the equivalent region from the normotensive Brown Norway (BN) rat. The 
SHR.4 rat showed a partial correction of the defects in fatty acid and glucose metabolism 
seen in the SHR. Differential gene expression profiling was performed on SHR, SHR.4 and 
BN adipose tissue using cDNA microarrays. Probes for Cd36 consistently showed reduced 
expression in the SHR compared to BN and SHR.4 samples and Cd36 was mapped to 
within 5cM of the peak of the QTL. Comparisons of the BN, WKY and SHR cDNA Cd36 
sequences revealed that whilst the BN and WKY have a functional copy of Cd36 and an 
adjacent non-functional copy (which is thought to have arisen via an ancestral duplication 
event), the SHR carries a chimeric Cd36 sequence comprising the functional sequence at 
the 5' end and the non-functional Cd36 from exon 6 to the 3' UTR (thought to have arisen James Polke, 2008    Chapter 1         56 
   
by a deletion event unique to the ancestry of the SHR strain used in this series of 
experiments). Northern blot analysis showed that mRNA levels of Cd36 expression in the 
WKY, BN and SHR were comparable, the differential expression shown in the microarrays 
was due to the probe sequences for Cd36 being specific for the 3' UTR found in BN and 
WKY mRNA. Western analysis confirmed an absence of Cd36 protein in the adipocytes of 
SHR rats (Aitman et al. 1999). Ultimate experimental proof that Cd36 deficiency 
contributes to insulin resistance in the SHR was provided by transgenic rescue of SHR rats 
expressing up to 10 copies of functional Cd36. The amount of Cd36 protein produced in 
the transgenic strains was lower than that produced by WKY controls, but was sufficient to 
induce improvements in glucose tolerance, insulin-stimulated conversion of glucose to 
glycogen and serum fatty-acid levels (Pravenec et al. 2001b).  
A number of other publications have also applied microarrays in the search for 
hypertension loci. Moujahidine et al (Moujahidine et al. 2004) generated a double congenic 
strain with Dahl salt-sensitive genetic background and regions introgressed from the 
normotensive Lewis strain  corresponding to blood pressure QTLs on chromosomes 10 and 
16. Kidney microarrays were performed on the double congenic and DSS rats though no 
differentially probe sets genes were mapped to the congenic intervals. Yasui et al (Yasui et 
al. 2007) performed kidney expression microarrays to search for differentially expressed 
genes in a blood pressure QTL on chromosome 10. They identified small inducible 
cytokine A2 precursor (Ccl2) as a differentially expressed candidate between DSS and 
Lewis rats, its upregulation in the DSS under salt loading potentially contributing to salt 
sensitive hypertension via overactivation of inflammatory pathways. However, the absence 
of a congenic strain confirming a blood pressure effect of the chromosome 10 QTL 
compromises Ccl2 as a candidate (Deng 2007). Yagil et al (Yagil et al. 2005) utilised 
DOCA salt sensitive (SBH) and salt resistant Sabra (SBN) rats in a microarray study 
measuring renal gene expression in the presence and absence of salt loading in each strain. 
The salt loading protocol involved the implantation of a 25 mg deoxycorticosterone acetate 
(DOCA) pellet into the back of the neck of the rats, and 1% NaCl in drinking water. The 
same group had previously identified 2 salt sensitivity QTLs on chromosome 1 in this 
model (Yagil et al. 1998) and confirmed their effect by the generation of two congenic 
strains (Yagil et al. 2003). In order to find genes involved in salt sensitivity, the microarray 
data was analysed to find genes located in the chromosome 1 QTLs and consistently 
differentially expressed in comparisons between salt loaded SBH rats versus all other James Polke, 2008    Chapter 1         57 
   
groups or between non-salt loaded SBH rats versus all other groups. Eight such genes were 
found, of which 7 were confirmed by quantitative real-time PCR (qRT-PCR) and proposed 
as candidates for further investigation (Yagil et al 2005). 
1.2.3.4 Expression Genetics 
As mentioned above, Pravenec et al (1999) derived a panel of RI strains in crosses between 
the BN and SHR. Thirty of these strains, plus the BN and SHR were used in a recent study 
that integrated microarray genome-wide expression profiling and linkage analysis (Hubner 
et al 2005), effectively treating gene expression as a phenotype that can be linked to loci 
throughout the genome in a technique known as expression genetics, or genetical genomics 
(Jansen et al. 2001). Such loci are known as expression QTL (eQTL) and can either act in 
cis (defined in this paper as a locus within 10 Mbp of the probe set in question), or in trans 
(affecting the expression of a probe set on a different chromosome or over 10 Mbp distant). 
The SHR is also a model of the metabolic syndrome, therefore linkage data on the RI panel 
from previous studies (Pravenec et al. 1996;Pravenec et al. 1999;Jirout et al. 2003) was 
combined with genome-wide microarray expression analysis of 15923 transcripts in kidney 
and fat tissue. Several interesting observations were made in this publication. Firstly, the 
proportion of eQTLs acting in cis or trans in the analysis depended on the genome-wide 
significance thresholds applied: at a significance level of p<0.05, 60-65% of the eQTLs 
were regulated in trans, while at p≤10
-4, 85-100% of eQTL were regulated in cis. This was 
thought to reflect the larger effects of cis acting eQTL on gene expression levels. Secondly, 
of the 15% of eQTL that were detected in both fat and kidney, a high proportion (70% at 
p<0.05) had cis-acting effects, suggesting that the excess of trans-acting eQTLs found only 
in the kidney or fat data sets belong to tissue-specific gene expression networks. In 
addition, many of the cis-acting eQTLs showed similar gene expression levels across 
parental and recombinant strains when segregated by marker genotype, indicating a near-
monogenic regulation of gene expression at these loci. However, a large number of 
transcripts showed linkage to two or more eQTLs, indicating the generally complex nature 
of gene expression control. In order to identify sequence variants that may be responsible 
for the observed effects of eQTLs, genes at the seven of the most significant cis-acting 
eQTLs were sequenced for promoter and coding SNPs in 3 inbred normotensive and 3 
hypertensive strains. Genotypes at two SNPs in one of these genes, phosphatidylinositol 3-
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normotensive strains. Pik3c3 lies on a known blood pressure QTL in the SHR, and kidney 
expression of Pik3c3 (measured by real-time PCR) was significantly increased in the SHR 
compared to the BN, Pik3c3 is consequently a robust candidate for blood pressure from 
this analysis. Another method to analyse this dataset involved comparing the locations of 
cis-eQTLs with known blood pressure and left-ventricular mass QTLs identified in 
previous phenotypic scans (or pQTLs); orthologous genes from the human genome were 
then identified to generate a list of 73 genes proposed as candidates for human essential 
hypertension. Trans-acting eQTLs that affected expression at several distant genomic loci 
were highlighted as strong candidates for genes involved in regulatory pathways. Two such 
clusters were identified on chromosomes 3 and 17 in kidney and fat tissue, respectively, 
though neither of these coincide with well-characterised pQTLs (Hubner et al 2005). 
1.2.3.5 QTL Interactions in Complex Disease 
As far as possible, laboratory conditions limit or control for environmental influences on 
blood pressure control. When inbred hypertensive rat strains were initially derived, 
optimistic predictions were forwarded that high blood pressure in the SHR was potentially 
controlled by 2-3 genes, and possibly only one major gene (Tanase et al. 1970;Yen et al. 
1974). Analysis of blood pressure in the SHR/BN recombinant inbred strains produced by 
Pravenec et al suggested that more than seven loci were involved, with potentially three 
major effect genes and numerous minor effect genes (Pravenec et al 1989). While the exact 
number of loci concerned remains unknown, it is increasingly apparent that numerous 
genetic factors are involved, and that they interact in a complex manner to affect 
phenotype in hypertensive and normotensive animals; the blood pressure of a 
normotensive animal is such because the blood pressure raising loci it harbours are 
balanced by blood-pressure lowering loci, while hypertensive animals have an excess of 
blood-pressure raising loci. This is backed up by published reports of congenic breeding 
that produce counter-intuitive blood pressure effects. For instance, in order to investigate a 
blood pressure QTL on chromosome 2, Elipopoulos et al generated congenics by 
introgressing regions from the normotensive Lewis strain onto the DSS genome. Two of 
the congenic strains had blood pressures approximately 30 mmHg higher than the DSS 
under salt challenge, the boundaries of the responsible QTL were defined by overlapping 
congenic intervals in two other strains (that had similar blood pressures to DSS) to a 3 cM, 
a region encoding 19 genes (Eliopoulos et al. 2005). A similar study found an increase in James Polke, 2008    Chapter 1         59 
   
blood pressure compared to the DSS in a congenic strain carrying a region from the 
normotensive Lewis strain introgressed onto chromosome 3; a neighbouring QTL reduced 
blood pressure in congenics, while a congenic strain harbouring both QTLs had reduced 
blood pressure, indicating that these QTLs interacted epistatically, the blood-pressure 
lowering locus prevailing when both are present (Palijan et al. 2003). Other QTL 
interactions have also been published. For example, congenic breeding experiments were 
performed to investigate an interaction observed between loci on chromosomes 2 and 10 in 
candidate gene studies involving DSS and MNS rats (Deng et al. 1992). Congenic strains 
were generated to introgress the chromosome 2 and 10 regions from the WKY and MNS, 
respectively onto the background of the DSS, both showed blood pressure lowering effects, 
they were subsequently cross-bred to generate a double congenic strain carrying both 
transferred regions. The systolic blood pressure of the double congenic strain was 47 
mmHg lower than that of the DSS; DSS genotypes at the chromosome 2 and 10 QTLs 
were respectively responsible for 8 mmHg and 15 mmHg alone, thus the epistatic 
interaction between the loci causes a 24 mmHg rise in blood pressure in the DSS (Rapp et 
al. 1998). Complex interactions have also been observed between blood pressure QTLs on 
the same chromosomes. Dutil et al (Dutil et al 2005) and Charron et al  (Charron et al. 
2005) showed additive and epistatic interactions between QTLs on chromosomes 2 and 10, 
respectively. The complexity of blood pressure regulation genetics has led to the 
development of increasingly sophisticated experimental models and analytical techniques. 
There is recognition in the scientific community that we should consider interactions 
between genetic elements in the search for candidate genes and focus on the study of 
metabolic pathways where more than one element may contribute to phenotype 
(Dominiczak et al. 2005). Such a technique was applied in the analysis of gene expression 
microarray data in chapter 3 of this project, using Ingenuity Pathway Analysis (IPA) 
software to identify multiple differentially expressed genes from metabolic pathways 
between parental and chromosome 2 congenic strains.  
1.3  Oxidative Stress and Endothelial Dysfunction 
One of the most widely studied molecular pathological processes linked to cardiovascular 
diseases is the regulation of vascular oxidative stress. Oxidative stress refers to molecular 
damage caused by reactive oxygen species (ROS), including free radicals such as the 
superoxide anion (O2
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species such as hydrogen peroxide (H2O2) and peroxynitrite (ONOO
-). Damage caused by 
ROS has myriad downstream effects on cellular processes as a result of oxidative chain 
reactions triggered by the initial damage. Oxidised macromolecules consequently 
accumulate and can affect cellular function by damaging lipid membranes, enzymes and 
nucleic acids, with potentially cytotoxic and mutagenic effects.  
The principal relationship between ROS and cardiovascular disease concerns the balance 
between ROS and nitric oxide (NO). The discovery of cellular NO production is regarded 
as one of the most important advances in vascular biology in the late 20
th century. In 1980 
an unknown endothelium-derived relaxing factor (EDRF) was proposed to account for 
vascular smooth muscle cell (VSMC) relaxation in response to acetylcholine, the release of 
which was dependent on the presence of endothelial cells (Furchgott et al. 1980). The 
endothelium is the layer of epithelial cells that lines the inner surface of the circulatory 
system, including blood vessels and the heart. NO was conclusively identified as EDRF by 
two independent groups in 1987 (Ignarro et al. 1987;Palmer et al. 1987). NO is derived 
from O2 and the amino acid L-arginine (Palmer et al. 1988), its production in the 
endothelium is regulated by endothelial nitric oxide synthase (eNOS), it is also produced 
by neuronal NOS (nNOS), which is not restricted to neural cells, but was discovered in the 
brain, and inducible NOS (iNOS), which was identified in macrophages but is also 
expressed in several cell types. NO (itself an oxygen free radical) has a very short half life 
in-vivo (6-10 seconds), and acts as a local endothelial signalling molecule. NO mediates 
several functions of endothelial cells besides VSMC relaxation, including platelet 
aggregation, platelet and monocyte endothelial adhesion, low-density lipoprotein (LDL) 
oxidation, adhesion molecule expression, endothelin production and inhibition of smooth 
muscle cell proliferation. NO is very susceptible to reactions with other oxygen species, 
these reactions not only result in the production of a cascade of reactive oxygen species 
(such as ONOO
- when NO combines with O2
-·), but also reduce the levels of NO itself. 
Reduced bioavailability of NO and vascular oxidative stress is known as endothelial 
dysfunction and is associated with all cardiovascular diseases, figure 1.5 illustrates 
endothelial dysfunction caused by oxidative stress and also includes mechanisms of 
oxidative stress defence, which are discussed in more detail below.  
There are many lines of evidence that show increased oxidative stress can cause 
hypertension. For example, rats given lead in drinking water develop vascular and organ 
oxidative stress and hypertension that can be relieved by co-administration of the free  James Polke, 2008    Chapter 1         61 
   
 
Figure 1.5 - Oxidative stress in cardiovascular disease 
 
 
 
 
 
radical scavenger, vitamin E (Vaziri et al. 1999). Administration of the superoxide 
scavenger tempol to the SHR decreases blood pressure and urinary markers of oxidative 
stress (Schnackenberg et al. 1999). Targeted endothelial adenoviral overexpression of 
eNOS in the SHRSP reduced blood pressure (Miller et al. 2005), while overexpression of 
superoxide dismutase, one of the enzymes involved in oxidative stress defence (see below), 
also reduced blood pressure in the SHR (Chu et al. 2003). 
ROS are generated by a number of cellular processes including respiration, arachidonic 
acid pathways, cytochrome p450s, xanthine oxidase and others. In the vasculature the main 
source of ROS is nicotinamide adenine (phosphate) dinucleotide oxidase (NAD(P)H 
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oxidase), a multisubunit enzyme that catalyses the formation of O2
-· from O2. NAD(P)H 
oxidase is upregulated in VSMCs by Ang II and a number of growth factors such as 
tumour necrosis factor alpha and platelet derived growth factor (Marumo et al. 1997;De 
Keulenaer et al. 1998a), its activity is also upregulated in the endothelium by shear stress 
caused by increased blood flow (De Keulenaer et al. 1998b). Vascular ROS are thought to 
act as signalling molecules, they stimulate VSMC and fibroblast growth responses (Irani et 
al. 1997;Zafari et al. 1998) and are intracellular second messengers is signalling cascades 
following ligand binding to growth, apoptotic, and stress signals (Sundaresan et al. 
1995;Abe et al. 1996). Thus the equilibrium between ROS and NO in the vasculature is 
extremely complex, ROS have a physiological role in normal homeostasis, but their over-
production or reduced NOS activity leads to an imbalance that causes endothelial 
dysfunction. In addition to existing cardiovascular disease, a number of behavioural and 
environmental factors contribute to an overabundance of ROS in endothelial dysfunction, 
such as smoking, excessive alcohol consumption, obesity and lack of exercise (figure 1.5). 
There is also a mechanism whereby eNOS itself can generate superoxide. The generation 
of NO by eNOS is dependent on its homodimerisation in the presence of 
tetrahydrobiopterin (BH4), however BH4 is sensitive to oxidation by ONOO
-, and in the 
absence of BH4 during oxidative conditions, eNOS does not dimerise fully (it is 
'uncoupled') and generates O2
-· and H2O2 (Vasquez-Vivar et al. 1998), further contributing 
to oxidative stress.  
Renal oxidative stress has been linked to hypertension in a number of models. Markers of 
oxidative stress such as urinary 8-isoprotane prostaglandin F2α and malondialdehyde are 
increased in Ang II-infused Sprague Dawley rats (Chabrashvili et al. 2003), and in the 
SHR (Welch et al. 2001). Increased renal nitrotyrosine levels have also been measured in 
the SHR (Welch et al. 2000) and in the SHRSP, see the results of anti-nitrotyrosine 
western blotting in section 4.4.3 and Mcbride et al. (2005). A number of specific 
mechanisms have been proposed that link renal oxidative stress and hypertension, for 
example O2
-· has been shown to directly stimulate chloride reabsorption in the ascending 
limb of the loop of Henle, a response that was blunted by tempol, which also reduced 
chloride reabsorption alone (Ortiz et al. 2002). Renal oxidative stress is also proposed to 
contribute to the onset of high blood pressure via increased afferent arteriolar tone, both as 
a direct result of endothelial dysfunction and via indirect effects of ROS on macula densa 
function in tubuloglomerular feedback (TGF) responses (Wilcox 2003). Expression of 
nNOS is upregulated in the macula densa during tubular fluid reabsorption, reducing 
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mechanism is thought to be compromised as a result of increased expression of NAD(P)H 
oxidase subunits in the macula densa (Chabrashvili et al. 2002).  
1.3.1 Oxidative Stress Defence 
1.3.2 Direct ROS metabolism 
A number of mechanisms exist to defend against the cytotoxic effects of oxidative stress 
(figure 1.5). The first line of defence act directly on ROS themselves, converting them to 
less reactive molecules, while the second line of defence catalyses the metabolism of 
oxidised molecules that have been attacked by ROS. The principal enzymes involved in 
metabolism of superoxide are the superoxide dismutase (SOD) enzymes, they catalyse the 
conversion of O2
-· to H2O2 and molecular O2. There are 3 SOD genes, SOD1, SOD2 and 
SOD3. SOD1 encodes cytosolic copper zinc (Cu/Zn)-SOD, which is thought to lower O2
-· 
levels from nanomolar to picomolar concentrations. SOD2 encodes mitochondrial 
manganese (Mn)-SOD and SOD3 expresses the principal extracellular SOD isoform in the 
vascular wall, commonly known as extracellular SOD (ecSOD) (Zelko et al. 2002). The 
importance of SODs in anti-oxidant defence was demonstrated in gene transfer 
experiments, SOD overexpression improved endothelial function  (Zanetti et al. 
2001;Fennell et al. 2002) and provided protection against myocardial infarction (Li et al. 
1998). Expression of SOD genes is regulated by mechanical, chemical or biological stimuli 
and is downregulated in certain pathological conditions (Fridovich 1998;Mates 2000).  
The enzyme principally responsible for H2O2 metabolism following dismutation of O2
-· is 
catalase, an intracellular anti-oxidase mainly located in peroxisomes, but also in the cytosol 
(Fridovich 1998). Genetic autosomal recessive catalase deficiency has been linked to a 
higher risk of cardiovascular disease and increased incidence of diabetes mellitus in 
affected families (Leopold et al. 2005) and a catalase promoter polymorphism has been 
associated with cardiovascular risk in a Chinese population (Jiang et al. 2001), however 
experimental studies have provided evidence of only moderate protection against oxidative 
stress by catalase (Muzykantov 2001). Protection against oxidative damage was provided 
by co-expression of SOD and catalase but the relative contribution of each gene was not 
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1.3.3 Glutathione and Glutathione s-Transferases 
Interactions between ROS and macromolecules results in the generation of reactive 
products that can damage lipids, proteins and nucleic acids. A number of mechanisms exist 
to protect the cell from these species, the primary cofactor in many of these reactions is 
glutathione, a tripeptide of glutamate, cysteine and glycine. Glutathione is the main non-
protein thiol in the cell and has numerous functions in metabolism, synthesis, signal 
transduction and gene expression (Wu et al. 2004). It is mainly found in its reduced state 
(GSH) since the glutathione reductase enzyme that converts glutathione disulfide (GSSG) 
to GSH is constitutively active in cells. The liver is the main detoxification organ of the 
body and it is also the major source of plasma GSH, which circulates to other organs. GSH 
can be transported directly across cell membranes (Hagen et al. 1988;Parks et al. 1998), 
however the major source of intracellular GSH involves catabolism of GSH by 
extracellular gammglutamyltranspeptidase I (GGT1) and aminopeptidase enzymes 
followed by uptake of the constituent amino acids and de-novo synthesis (Lash et al. 
1988). The synthesis of GSH is a two-step reaction, cysteine (the rate limiting substrate) is 
first conjugated to glutamate by glutamate cysteine ligase (Gcl), generating γ-
glutamylcysteine, glycine is then conjugated by glutathione synthase (GSS). GCL is a 
dimeric enzyme consisting of a catalytic subunit (GCLC) and modulatory subunit (GCLM) 
that regulates GCL activity via negative feedback by GSH (Deneke et al. 1989). 
GSH acts as an electron donor and can directly scavenge reactive oxygen species, it is also 
a cofactor in the conversion of H2O2 to H2O by glutathione peroxidase (GPx). In its 
interaction with glutathione s-transferase (GST) enzymes, GSH is conjugated to 
xenobiotics such as drugs, insecticides, herbicides, carcinogens, and endogenous 
compounds such as oxidative by-products of cellular processes and damage. This generates 
more water-soluble compounds that are less reactive and amenable to further metabolism 
by the mercapturic acid pathway. Such a reaction is exemplified in figure 1.6, showing the 
conjugation of GSH to 1-chloro-2,4-dintrobenzene (CDNB).  James Polke, 2008    Chapter 1         65 
   
 
Figure 1.6 - Catalysis of glutathione conjugation to CDNB by GST enzymes 
 
There are seven classes of mammalian cytosolic, or soluble GST proteins, including Alpha, 
Mu, Pi, Theta, Zeta, Omega and Sigma. Cytosolic GST class nomenclature in rodents and 
humans is based on sequence similarity, members of the same class within a species share 
40-90% identity, different classes typically share less than 25% identity (Hayes et al. 
2005). There are a total of 17 human GSTs including GSTA1-5, GSTM1-5, GSTP1, 
GSTT1-2, GSTZ1, GSTO1-2 and GSTS1 (Mannervik et al. 2005). Each class is encoded on 
a different chromosome, classes with multiple members reside in closely linked gene 
clusters and have arisen by gene duplication events from ancestral genes. The rat Gsts 
include Gstm1-5, Gstm6a and 6b and Gstm7, Gsta1-5, Gstp1, Gstt1-2, Gstz1 and Gsts1. 
GST enzymes were named in the order of their identification in each species, the ortholog 
of a particular GST in another species cannot necessarily be identified by its name, in fact 
the evolution of GST gene families largely post-dates rodent and human common ancestry 
such that, for example, with the exception of human GSTM3 and rat Gstm5, the rat Gstms 
are more closely related to each other than any of the human GSTMs. In contrast, some of 
the rat and mouse Gstms are highly orthologous, rat Gstm1 is the ortholog of mouse 
Gstm1, they share 94% coding sequence identity and 81% genomic identity (Reinhart et al. 
1993). 
GSTs are primarily dimeric enzymes, they form homodimers or heterodimers of two 
subunits of the same class, though catalytically active heterodimers of pig GSTP1 and rat 
Gstm2 subunits have also been generated in-vitro (Pettigrew et al. 2001). 
Heterodimerisation is thought to broaden the catalytic range of GSTs by generating 
enzymes with different substrate affinities (Wang et al. 2000). Human GSTP1 has also  
been shown to act monomerically in cellular stress-defence signalling cascades (Yin et al. 
2000). The GSTs catalyse a number of different reactions including conjugation, reduction, 
thiolysis and isomerisation, though the most widely shared catalytic activity, and the most 
studied, is the conjugation of reduced glutathione to electrophilic compounds. The 
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A majority of GST enzymes catalyse this reaction, it is used in biochemical assays to 
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metabolism of oxidised membrane fatty acids by GSTs has been well studied; lipid 
peroxidation is toxic to cells since it can result in chain reactions generating 
hydroperoxides that can form secondary electrophiles such as epoxaldehydes, 2-alkenals, 
and ketoaldehydes, which can be genotoxic (Marnett et al. 2003). GSTs have been shown 
to reduce phosphatidylcholine hydroperoxide, cholesterol hydroperoxides and fatty acid 
hydroperoxides (Hiratsuka et al. 1997;Yang et al. 2002;Prabhu et al. 2004). Metabolising 
such compounds prevents the formation of downstream secondary electrophiles, though 
GSTs also reduce several end products of lipid peroxidation including the 2-alkenals 
acrolein and crotonaldehyde (Hayes et al. 1995;Hayes et al. 1999). GSTs have also 
experimentally been shown to catalyse the conjugation of GSH to oxidised proteins: co-
incubation of peroxynitrite-pre-treated histones with GSH and GST reduced nitrotyrosine 
immunoreactivity compared to histones incubated without GSH (Kuo et al. 2002). In 
addition, catalase pre-treated with peroxynitrite showed reduced catalytic activity and 
increased nitrotyrosylation, which were reversible by incubation with GSH and GST 
(Kocis et al. 2002). GSTs also catalyse the conjugation of GSH to oxidised nucleotides 
such as adenine and thymine propenols and thymine hydroperoxides (Okuno et al. 
1993;Berhane et al. 1994) that may otherwise cause further damage to DNA-binding 
proteins or chromosomal DNA. 
The GSTs are widely expressed in all tissues, they are particularly abundant in the liver, 
the major site of detoxification in the body. Some isoforms are tissue-specific, for example, 
GSTM2 is highly expressed in human striated muscle (Hussey et al. 1991) and the human 
GSTM3 is selectively expressed in testes and brain (Listowsky 2005). Comprehensive 
tissue distribution expression profiles of the Gst genes have not been published for the rat, 
though unpublished data from our laboratory shows that Gstm1 is the major Gstm isoform 
expressed in the WKY kidney. Expression profiling in the mouse has shown that the 
Gstm1 is constitutively expressed in the mouse, but at low levels in the intestine, placenta 
and gonads (Knight et al. 2007).  
Given the known function of GST enzymes and the proven involvement of increased 
oxidative stress in cardiovascular disease, the finding that Gstm1 expression is reduced in 
the kidneys of the SHRSP compared to the WKY and 2c* rats (McBride et al 2003) 
presented Gstm1 as a functional and positional candidate gene in hypertension. This 
finding formed the basis for the work performed in this project, part of which contributed 
to a publication showing that reduced renal Gstm1 expression coincides with increased 
renal oxidative stress (McBride et al 2005). Several aspects of Gstm1 expression and 
function were investigated using a variety of functional genomic techniques.James Polke, 2008    Chapter 2         67 
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2.1  General Laboratory Practice 
This chapter outlines general laboratory practises and laboratory methods that are common 
to more than one chapter. Each of the other chapters also has a specific methods section.  
Laboratory equipment and reagents were of the highest commercially available grades. A 
laboratory coat and latex or non-latex powder-free gloves were worn during all procedures. 
Hazardous reagents were handled appropriately as described in the Control of Substances 
Hazardous to Health regulations, using laboratory spectacles or facemask and/or a fume 
hood where appropriate. 
Laboratory glassware was cleaned in Decon 75 detergent, rinsed with distilled water and 
dried in a 37°C cabinet. Otherwise, sterile disposable plastic ware was used, including 0.5 
ml, 1.5 ml and 2 ml microcentrifuge tubes (Greiner Bio-one) 15 ml and 50 ml Corning 
centrifuge tubes and 5 ml and 20 ml 'Universal' containers (Sterilin). Reagents were 
weighed using an Ohaus Portable Advanced balance (sensitive to 0.01 g), or a Mettler 
HK160 balance (sensitive to 0.0001 g). Solutions were pH'd using a Mettler Toledo digital 
pH meter calibrated with pH 4.0, 7.0 and 10.0 standards (Sigma). Volumes from 0.1  l to 
1,000  l were dispensed with Gilson Medical Instruments pipettes. Volumes from 1 ml to 
25 ml were measured with sterile disposable pipettes (Corning) and a Gilson battery-
powered pipetting aid. Autoclaved distilled water was used to prepare aqueous solutions 
unless stated otherwise, a Jenway 1000 hotplate/stirrer was used to aid dissolving and 
mixing. Vortexing was carried out using an FSA Laboratory Supplies WhirliMixer. 
Centrifugation for samples up to 2 ml was performed at 4-20°C in an Eppendorf 4515 
microcentrifuge, larger samples were centrifuged in a Sigma 4K15, compatible with 15 ml 
and 50 ml centrifuge tubes, 20 ml 'Universal' tubes and with carriers for standard reaction 
plates. Laboratory-ware or liquids requiring sterilisation were autoclaved in a Priorclave 
Tactrol 2. A Julabo TW8 water bath was used for experiments requiring incubations from 
37°C to 90°C, a Grant SBB14 boiling water bath was used for temperatures up to 100°C. 
Certified Nuclease-free reagents and plastic ware was used for experiments involving 
RNA, including Ambion RNase-free microcentrifuge tubes, RAININ nuclease-free filtered 
pipette tips and Ambion nuclease-free H2O. Pipettes and benches were wiped with Ambion 
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2.2  General Techniques 
2.2.1 Nucleic Acid Extraction 
Specific protocols used for genomic DNA extraction from different tissues are outlined in 
relevant chapters. Plasmid DNA purification is described in section 2.5.3. Qiagen column 
and filter-based RNeasy Mini or Maxi kits were used for RNA extraction. Whole tissues or 
cells were homogenised in buffer RLT lysis solution, 10  l/ml β-mercaptoethanol (350-600 
 l for Mini columns, 7.5-10 ml for Maxi columns). Cultured cells were rinsed with PBS 
and homogenised by scraping with a pipette tip. Unless otherwise stated tissues were 
homogenised with a Polytron 2100 rotor homogeniser at full speed, then centrifuged at 
5000 g to collect debris and lysates were transferred to fresh tubes. An equal volume of 
70% ethanol was added to cell lysates before applying them to the RNeasy columns, 
followed by centrifugation (15 seconds at 8000 g for mini columns, 5 minutes at 5000 g for 
Maxi columns) to wash cellular debris through the column, binding RNA. Buffer RW1 
was added to columns (700  l for Mini columns, 15 ml for maxi columns) and washed 
through by centrifugation (15 seconds at 8000 g for Mini columns, 5 minutes at 5000 g for 
Maxi columns). Columns were transferred to new collection tubes, and 2 washes were 
performed with RPE buffer (70% ethanol): 500  l for Mini columns, 10 ml for Maxi 
columns, centrifugation at 8000 g for 15 seconds (first wash) then 2 minutes (second wash) 
for Mini columns and at 5000 g for 5 minutes (first wash) then 15 minutes for Maxi 
columns (second wash). Columns were transferred to new collection tubes and centrifuged 
at full speed for 1 minute (Mini columns) or 5 minutes (Maxi columns) to completely dry 
membranes. RNA was eluted in 30-50  l RNase-free H2O (Mini columns) or 800  l 
RNase-free H2O (Maxi columns). 
2.2.2 Measuring Nucleic Acid Concentration 
DNA and RNA concentrations were measured using a Nanodrop ND-1000, a 
spectrophotometer that is sensitive from 2-37000 ng/ l double-stranded DNA. Absorbance 
at 260nm were used for quantification of nucleic acids, optical density of 1 corresponding 
to 50ng/ l DNA and 40ng/ l RNA. Absorbance ratios (260 nm/280 nm) of approximately 
1.8 for DNA and 2.0 for RNA indicated that the nucleic acid preparations were sufficiently 
free from protein contamination for downstream experiments. Averages of duplicate or 
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2.2.3 Polymerase Chain Reaction 
All thermal cycling for standard PCRs was performed on an MJ Research PTC Gradient 
Cycler in 96-well plates (ABgene). PCR primers were designed using the online design 
tool Primer3 (Rozen et al. 2000) and purchased from MWG Biotech. Oligonucleotide 
sequences for all PCR primers used are in table A1 in the appendix. 
Two commercial 'Hotstart' Taq polymerase PCR systems were used for standard PCRs in 
this project, Qiagen HotStar and Roche FastStart. For amplifying from genomic DNA 
templates, 100 ng of genomic DNA was used, while 5-10 ng of template was used for 
amplifying from plasmid templates. 7.5 pmol of each primer were used in all reactions. 
The standard reaction mixes and temperature cycling parameters for each system were as 
follows: 
Qiagen HotStar: 
 
Reaction mix      Heat Cycling 
  Vol. ( l)        
10x PCR buffer    2.0    95°C  15 min 
dNTPs (1mM ea.)    4.0    94°C  15 sec 
Fwd primer (5pmol/ l)    1.5    58-62°C  30 sec 
Rvs primer (5pmol/ l)    1.5    72°C  30 sec 
DNA*    1.0-5.0   72°C  10 min 
Taq (5U/ l)    0.2 
H2O     Up to 20ul 
 
Roche FastStart: 
 
Reaction mix      Heat Cycling 
  Vol. ( l)        
10x PCR buffer    2.0    95°C  4 min 
dNTPs (1mM ea.)    4.0    94°C  30 sec 
Fwd primer (5pmol/ l)    1.5    58-62°C  30 sec 
Rvs primer (5pmol/ l)    1.5    72°C  1 min 
DNA    1.0-5.0   72°C  7 min 
Taq (5U/ l)    0.2 
H2O     Up to 20 l 
 
 
The Taq DNA polymerases used in the above PCR systems have fast processivity, but lack 
a proofreading capability, they are suitable for a majority of PCR applications but 
incorporate incorrect nucleotides approximately every 10,000 nucleotides. For applications 
where absolute fidelity of DNA replication was required, for example for cloning promoter 
or cDNA sequences, 'Kod Hot Start' DNA polymerase (Novagen) was used. Kod DNA 
polymerase is derived from Thermococcus kodakaraensis thermophilic bacteria and 
x35 cycles 
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possesses 3'-5' exonuclease activity that excises mis-incorporated bases during PCR. Kod 
PCRs were performed according to the manufacturers instructions, reaction mixtures and 
temperature cycling parameters were as follows: 
Reaction mix      Heat Cycling 
  Vol. ( l)        
10x PCR buffer    2.5    94°C  2 min 
dNTPs (1mM ea.)    2.5    94°C  15 sec 
MgSO4 (25mM)    1.0    58-62°C  30 sec 
Fwd primer (5pmol/ l)    1.5    68°C  2.5 min 
Rvs primer (5pmol/ l)    1.5    68°C  10 min 
DNA    1.0-5.0    
Kod (1U/ l)    0.5 
H2O     Up to 25ul 
 
 
2.2.4 Agarose Gel Electrophoresis 
Unless otherwise stated 1% agarose (Eurogentec) gels were used throughout, dissolved and 
electrophoresed in 1 X Tris-Borate EDTA (TBE) buffer (Fisher Bioreagents). Gels were 
electrophoresed at 6 V per cm of gel. BIO-RAD Power Pac 300 and BIO-RAD 
electrophoresis tanks were used, 1 ng / 100 ml ethidium bromide (Sigma) was added to 
molten agarose before pouring gels, unless stated otherwise. Gels were visualised by UV 
transillumination on a BIO-RAD Fluor-S MultiImager. Promega 1kb DNA ladder was 
used for sizing products. Samples were loaded with 6 X loading dye (50% glycerol, 0.05% 
bromophenol blue). 
2.2.5 Determining Protein Concentration 
Protein samples were prepared from cultured cells by rinsing with PBS and scraping with a 
pipette tip in PBS/0.2% Triton. Samples were freeze-thawed to -80°C and passed through a 
hypodermic needle 10 times before briefly centrifuging to collect debris. Tissues were 
homogenised in PBS buffer containing protease inhibitors, centrifuged at 5000 g for 5 
minutes and supernatants were transferred to fresh tubes.  
Protein concentrations were determined using a Pierce BCA (bicinchoninic acid assay) kit. 
The assay was performed in 96-well plates. Dilutions of an albumin protein standard 
(Pierce) in phosphate-buffered saline (PBS) (Gibco) from 25 ng/ l – 2  g/ l were used to 
generate a standard curve for each assay. The kit consists of reagents A and B, which are 
mixed at a ratio of 50:1 before being added to protein samples and standards at a ratio of 
8:1 (25  l sample or standard, 200  l BCA reagents). 96-well plates were then protected 
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from light by wrapping in aluminium foil and placed at 37°C for 30 minutes. Absorbance 
at 560 nm was ascertained in all wells using a Wallac Victor 2 plate reader. Samples and 
standards were measured in duplicate and averaged, the concentration of protein in the 
samples was interpolated from the standard curve by 'Work-Out' software (Wallac). If the 
concentration of protein samples fell beyond the range of the standard curve, appropriate 
dilutions were made in PBS and they were re-assayed, the concentration of the dilutions 
were multiplied by the dilution factor to ascertain the concentration of the samples. 
2.3  Tissue Culture 
Eukaryotic cell lines were handled under sterile conditions using class II biological safety 
cabinets (Holten Safe 2010). Cabinets were cleaned before and after use with distilled 
water and 70% ethanol. Waste plastics and fluid were decontaminated by steeping for 24hr 
in (10%) bleach, plastics were then incinerated, fluids were poured into domestic waste 
drains. Cells were maintained in 150 cm
2 tissue culture flasks with vented caps (Corning) 
in inCusafe 37°C, 5% carbon dioxide (CO2) incubators. Tissue culture experiments 
involving genetic modification, such as recombinant adenoviruses or plasmid transfections, 
were performed in a dedicated tissue culture laboratory and maintained in separate 
incubators.  
2.3.1 Cell Passage and Cryostorage 
Details of specific cell lines used and media requirements are given in relevant chapters. 
Cell were passaged regularly to prevent overcrowding in culture flasks, experiments were 
performed with cells of lowest possible passage number and experiments were completed 
in as few passages as possible. Fresh cell culture stocks were recovered from storage in 
liquid nitrogen after approximately 25 passages. 
Unless stated otherwise, passaging was performed by removing culture media and rinsing 
cells gently twice with 10ml sterile PBS (Lonza) before detaching them from the flask with 
2-10 minutes incubation at 37°C with 2ml 1X TE (0.05% trypsin; 0.2% ethylenediamine 
tetraacetic acid (EDTA)). Cells were collected in 10 ml foetal bovine-serum (FBS)-
containing medium, which inactivates the trypsin, and centrifuged at 1500 rpm for 5 
minutes. Media/TE was poured off and the cell pellets were resuspended in cell media, 
fresh 150 cm
2 flasks with 25ml media were seeded with 1/20-1/5 of the cells from the 
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For cryostorage, cells from 3 x 150 cm
2 flasks were resuspended in 10ml media/10% 
dimethylsulfoxide (DMSO) and aliquotted into 6 x 2 ml cryoviles. The cryoviles were 
placed in an isopropanol freezing container (Nalgene) in a -80°C freezer overnight, 
ensuring freezing no faster than 1°C per minute. The next day cells were transferred for 
long-term storage in liquid nitrogen. When recovering cells from liquid nitrogen they were 
thawed to room temperature and pipetted into 25 ml media in a fresh 150 cm
2 flask, the 
media was changed the next day, cells were not used for experiments until at least two 
passages and a week out of liquid nitrogen. 
2.3.2 Cell Counting 
In order to accurately seed cell culture flasks and plates with a known number of cells, 
cells were counted with a haemocytometer (Hausser Scientific). Approximately 10  l of a 
cell suspension was pipetted under a cover slip onto the grid, the number of cells in each 1 
mm square was recorded by counting the cells in each 0.25 mm  squares, cell crossing the 
bottom or right-hand edge of any square were not counted. The average number of cells in 
each 1 mm square was derived, was multiplied by 10
4 to give the number of cells per ml in 
the suspension. Dilutions of the cell suspension were made in media to seed the correct 
number of cells per flask or well. 
2.3.3 Plasmid Transfection of Cultured Cells 
Roche FuGENE 6.0 lipofection reagent was used for all experiments involving transfection 
of cultured cells. FuGENE is a proprietary mix of lipids in 80% ethanol, it binds to and 
packages plasmid DNA into a lipid complex that allows the plasmids to cross cell 
membranes. Transfection protocols were optimised individually for each cell type used in 
experiments following suggested methods in the FuGENE product literature. This involved 
ascertaining the optimal ratio of FuGENE:DNA for maximal gene expression and minimal 
cytotoxicity. Specific optimisation procedures are described in each chapter.  
Regardless of the final conditions used, the same transfection protocol was followed: Cells 
were seeded the day before to be at 50-70% confluence at transfection. FuGENE/DNA 
mixtures were made in additive-free media in 1.5 ml centrifuge tubes, FuGENE was added 
to the media and mixed by gently flicking the tube, plasmid DNA was added after five 
minutes and tubes were flicked to mix once more then left for 15 minutes to allow 
FuGENE/DNA complex formation. Transfection mixtures were then applied to cells, gene 
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2.3.4 Β-Galactosidase Expression Staining 
Plasmids and viruses expressing the LacZ gene, which encodes β-galactosidase, were 
employed as controls to assess gene delivery and expression in many experiments. 
Regardless of the method of gene delivery, the same protocol was used to assay for β-
galactosidase expression in cultures cells: Cells were fixed by removing culture media and 
washing cells twice with PBS, then adding sufficient 2% paraformaldehyde in 0.1M 
sodium phosphate (NaPO4) (72mM Na2HPO4; 23mM NaH2PO4) to cover the cells and 
placing the cells on ice for 10 minutes. The paraformaldehyde was removed and cells were 
washed twice very gently with PBS to prevent dislodging the fixed cells. X-gal (5-Bromo-
4-chloro-3-indolyl β-D-galactopyranoside) stain solution constituted 0.077 M Na2HPO4; 
0.023 mM NaH2PO4; 0.03 M MgCl2; 3 mM K3Fe(CN)6; 3 mM K4Fe(CN)6; 1 mg/ml X-gal, 
the X-gal stock solution was 20 mg/ml in dimethylformamide. X-gal stain was added to 
cover cells and plates or flasks were returned to a 37°C incubator overnight. β-gal-
galactosidase cleaves X-gal to produce a dark blue precipitate, indicating cell transfection 
or infection.  
2.4  DNA Sequencing 
Unless otherwise stated, DNA sequencing was performed by purifying PCR products to 
remove un-incorporated dNTPs, primers and salts, followed by dideoxy sequencing 
reactions, and a second purification step before capillary electrophoresis to separate 
sequencing products by size. Each step is outlined below. 
2.4.1 PCR Clean-up 
PCR products were retained in PCR reaction plates and purified for sequencing using the 
Agencourt AMPure kit. This relies on binding of DNA products over 100bp in length to 
paramagnetic beads in the kit solution (i.e. they are attracted to magnets but do not exhibit 
magnetism themselves). 36 l of AMPure was added to each 20 l PCR reaction, the plates 
were briefly vortexed and centrifuged to 1000 rpm for 1 second to collect the liquid to the 
bottom of the wells. They were left to stand for 5 minutes and then placed onto an 
SPRIPlate (solid phase reversible immobilisation plate) magnetic plate holder (Agencourt) 
for 10 minutes. The SPRIPlate has an individual ring magnet for each well in a 96-well 
plate, AMPure beads are held onto the sides of the wells of the 96-well plate. Keeping the 
PCR plate on the SPRIPlate, the PCR reaction constituents were removed by inverting the 
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freshly prepared 70% ethanol for 30 seconds before shaking forcefully upside-down and 
centrifuging upside-down to 600rpm for 1 second to remove as much ethanol as possible. 
PCR Plates were removed from the SPRIPlate and left to air-dry for 20 minutes before the 
addition of 40 l H2O per well. The PCR plates were vortexed to resuspend the AMPure 
beads, then returned to SPRIPlates plates, 10 l was carefully pipetted out per sequencing 
reaction. If a PCR product was to be sequenced more than 3 times, multiple 20 l PCRs 
were performed. 
2.4.2 Dideoxy Sequencing 
Applied Biosystems BigDye Terminator n3.1 Cycle Sequencing kits were used all for 
sequencing reactions in this project, reactions were performed in 96-well plates. Unless 
stated otherwise all sequencing reactions included 3.5 l 5X sequencing buffer; 0.5 l 
Ready Reaction; 10 l template (purified PCR product); 3.2 l primer (1pmol/ l); 2.8 l 
H2O. The temperature cycling program was: 
96°C  45 sec 
50°C  25 sec 
60°C  4 min  
 
 
2.4.3 Sequencing Reaction Purification 
Sequencing reactions were purified to remove reaction constituents and unincorporated 
nucleotides and primers prior to electrophoresis using Agencourt CleanSEQ reagent. 10 l 
of CleanSEQ reagent was added to each sequencing reaction, followed by 62 l of freshly 
prepared 85% ethanol. Plates were briefly vortexed and centrifuged to 1000 rpm for 1 
second to collect the liquid to the bottom of the wells, then placed on an SPRIPlate for 3 
minutes. Wells were emptied by forcefully shaking the plates upside-down, the CleanSEQ 
beads were washed twice with 100  l 85% ethanol for 30 seconds each, emptying the wells 
between washes. Wells were then emptied as much as possible by centrifugation of 
inverted plates to 600 rpm for one second. Plates were removed from the SPRIPlates and 
air dried for 20 minutes, 40  l of H2O was added to each well and CleanSEQ beads were 
resuspended by vortexing. Plates were briefly centrifuged to 1000 rpm for 1 second and 
returned to SPRIPlates. 20  l of sequencing products were loaded into optically clear 
barcoded 96 well plates. H2O was added to unused wells to prevent drying of capillaries 
and plates were covered with Applied Biosystems Septa Seals, they prevent evaporation of 
products but allow capillaries to enter wells. 
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2.4.4 Capillary Electrophoresis 
Sequencing capillary electrophoresis was performed on a 48-capillary Applied Biosystems 
3730 Genetic Analyser with 36 cm capillaries. Electrophoresis was preceded by filling the 
capillaries with fresh POP-7 polymer (Applied Biosystems) and warming the capillaries to 
60°C. Sequencing products were separated by size by electrophoresis at 8500 volts for 50 
minutes. 
2.4.5 Sequencing Analysis 
Sequencing was analysed using Applied Biosystems SeqScape software version 2. 
Experimental sequences were aligned with known sequences derived from bioinformatic 
databases such as UCSC or ENSEMBL genome browsers or product information such 
plasmid sequences. 
 
2.5  DNA Cloning 
Eukaryotic expression plasmids were employed in this project in promoter studies, for the 
generation of recombinant adenoviruses and to make expression cassettes for rat 
transgenesis. Specific manipulations and protocols are outlined in each chapter, a number 
of common techniques are outlined below. 
2.5.1 Transformation of Competent Bacteria 
JM109 competent Escherichia coli (E.coli) bacteria (Promega) were used as hosts for 
eukaryotic expression vectors throughout this project unless stated otherwise. For 
transformation, competent cells were thawed on ice and separated into 50 l aliquots in 
chilled 1.5ml centrifuge tubes. For transformation of an intact plasmid, 2ng plasmid DNA 
was added to the bacteria, for transformation of ligated plasmid/insert mixes 2-5 l of the 
ligation reaction was added to JM109s. Tubes were flicked gently to mix and returned to 
ice for 10 minutes, then 'heat shocked' at 42°C for 45 seconds before returning to ice for a 
further 2 minutes. 900  l of chilled SOC medium (Sigma) was added to the cells and they 
were placed in a shaking incubator (New Brunswick Scientific Inova 44) at 37°C, 180 
oscillations per minute, for one hour. Unless otherwise stated all plasmids used in this 
project encoded ampicillin resistance for selection of transformed cells. Transformation 
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100  g/ml ampicillin (Sigma). For transformations of intact plasmids 100  l of neat, 1 in 
10 and 1 in 100 dilutions in SOC media were spread, for transformations of ligation 
reactions, the entire transformation culture was spread onto 5 plates. Culture plates were 
inverted and placed in a 37°C incubator (Heraeus) overnight. Plates were checked for 
bacterial colonies the next morning and if necessary screened for positive clones as 
detailed in section 2.5.7. 
2.5.2 Glycerol Stocks 
Successfully transformed bacteria were preserved for long-term storage by preparing 
glycerol stocks. 1 ml of overnight broth cultures was mixed with 1 ml sterile 40% glycerol 
solution and frozen at -20°C or -80°C. Bacteria were recovered from glycerol stocks by 
streaking for single colonies on selective agar.  
2.5.3 Plasmid DNA Purification 
Plasmid DNA was extracted from bacteria using the filter column based Qiagen Plasmid 
Maxi kit. Bacterial cultures were streaked and grown overnight at 37°C on ampicillin Luria 
agar plates. Single colonies were picked and used to inoculate a 'starter' culture grown 
throughout the next day in 5 ml Luria broth (Sigma) containing 100  g/ml ampicillin in a 
shaking incubator at 37°C. 1 ml of this culture was used to inoculate 100-500 ml 100 
 g/ml ampicillin Luria broth to produce an overnight culture from which the plasmid was 
extracted (100 ml was sufficient for most plasmids, however when low yields were 
obtained, the extraction was repeated with 500 ml culture). Bacteria were harvested by 
centrifugation at 6,000 g for 15 minutes at 4°C in a Beckman Coulter Avanti J-26XP. 
Culture media was poured off and the bacteria were resuspended in 10 ml buffer P1 
(50mM 2-amino-2-hydroxymethyl-1,3-propanediol, pH8; 10 mM EDTA, 100  g/ml 
RNase A). 10 ml buffer P2 (200 mM NaOH; 1% sodium dodecyl sulphate (SDS)) was 
added and the solutions were kept on ice for exactly five minutes. 10 ml chilled buffer P3 
(3 M potassium acetate at pH5.5) was added to neutralise the lysate. The precipitated 
lysates were centrifuged at 20000 x g at 4°C for 30 minutes, the supernatant was retained 
and centrifuged again at the same speed for a further 15 minutes. Columns were pre-wetted 
with 10ml buffer QBT (750 mM NaCl; 50 mM 3-morpholinopropanesulfonic acid pH7 
(MOPS); 15% isopropanol; 0.15% Triton-X 100). The supernatant was applied and the 
columns were allowed to empty by gravity flow, the columns were washed twice with 30 
ml buffer QC (1 M NaCl; 50 mM MOPS pH7; 15% isopropanol), and the plasmid DNA 
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polypropylene centrifuge tubes. Plasmid DNA was precipitated with 10.5 ml isopropanol 
and centrifuged at 15000 x g for 30 minutes at 4°C. The supernatant was carefully poured 
off, pellets were resuspended in 5 ml 70% ethanol and aliquoted into five 1.5 ml microfuge 
tubes. They were centrifuged at maximum speed for 10 minutes at 4°C. The ethanol was 
carefully pipetted off and the pellets were thoroughly air-dried (10-20 minutes) before 
resuspending the DNA in 70  l H2O per tube and pooling the contents of the five tubes. 
Total plasmid yields were typically 50-90% of the maximum yield quoted for the maxi 
columns (500  g). 
2.5.4 Restriction Digestion 
Restriction enzymes were used in this project to enable the targeted ligation of specific 
DNA 'insert' sequences into plasmid backbones. Inserts and plasmids were digested with 
appropriate restriction endonuclease enzymes to generate compatible ends for ligation. 
Restriction endonucleases were purchased from Promega or New England Biolabs. 
Manufacturer's protocols were followed for digestions, a typical digest included 1-2  g 
template DNA in a final volume of 25  l, including 2.5  l 10x restriction buffer, 0.25  l 
bovine serum albumin (BSA) and 10-20 units of enzyme, making the reaction a '10-fold 
overdigest': one unit of restriction enzyme is defined as the amount required to digest 1  g 
of template in one hour. Reaction mixtures were mixed gently by pipetting and briefly 
pulsed in a bench microcentrifuge, then incubated at 37°C for between 1 and 16 hours. 
Wherever possible, cloning was performed using 'double digests', wherein the insert and 
backbone were digested with two restriction enzymes, resulting in different overhanging 
ends on each end, allowing directional cloning and minimising the likelihood of self-
ligation of the plasmid backbone.  
2.5.5 Agarose Gel DNA Extraction 
Unless stated otherwise agarose gel extraction of PCR products or restriction-digested 
DNA was performed with the Qiagen QIAquick Gel Extraction kit following the 
manufacturer's instructions, using a bench microcentrifuge at full speed. Bands in agarose 
gels were visualised on a UV transiluminator (UVP) and carefully excised with a scalpel 
blade. The bands were weighed and 300  l of buffer QG was added per 100  g of agarose 
before heating the agarose/buffer QG mixture to 50°C for 10 minutes. After centrifugation 
to adsorb the DNA to the membrane, the membrane was washed with centrifugations with 
500  l of buffer QG followed by 750  l buffer PE (which contains 70% ethanol). All traces James Polke, 2008    Chapter 2         79 
   
of ethanol were removed by a final centrifugation for 1 minute, DNA was eluted in 
nuclease-free water. 
2.5.6 Ligation 
Unless stated otherwise, digested plasmid fragments, digested PCR products or annealed 
oligonucleotides were ligated into digested plasmid backbones using the New England 
Biolabs Quick Ligation Kit. The kit includes a 2X reaction buffer (1332mM Tris pH7.6; 
20mM MgCl2; 2mM dithiothreitol; 2mM ATP; 15% polyethylene glycol) and 'Quick' T4 
DNA ligase (supplied in 50 mM KCl, 10 mM Tris (pH7.4), 0.1 mM EDTA, 1 mM 
dithiothreitol, 200  g/ml BSA and 50% glycerol). Ligation reactions constituted 10  l 2X 
quick ligation buffer, 1  l quick T4 DNA ligase, 50-100 ng backbone, insert to provide an 
insert:backbone molar ratio of 100:1 to 3:1 and H2O up to 20  l. Reactions were mixed by 
gentle pipetting, pulsed in a microcentrifuge and incubated at room temperature for five 
minutes, and then put on ice. Ligations were transformed immediately or stored at -20°C 
before transformation. The 100:1 insert:backbone ratio was only used for ligation of 
oligonucleotides, otherwise ratios of 3:1, 5:1 or 7:1 were used. The amount of insert DNA 
to add to the ligation reaction for a given Insert:backbone ratio and given amount of 
backbone DNA was calculated according to the following formula: 
 
 
2.5.7 Selecting Positive Clones 
Following transformation of ligation reactions, colonies were screened by PCR across the 
cloning site. PCR primers depended on the backbone of the recipient plasmid, but the 
protocol was otherwise identical: Individual colonies were picked with a sterile wooden 
toothpick, streaked onto a numbered 0.8 cm grid on a selective agar plate and then washed 
in a numbered well of a 96-well plate containing 10  l H2O. 10  l of Roche FastStart or 
Qiagen HotStar PCR reaction master mixes were added to each well to make a 20  l PCR 
reaction, where possible a positive control well was also included. Following PCR, PCR 
products were electrophoresed against a size marker to screen for products of the expected 
size. Positive PCR results were later confirmed by DNA sequencing, bacterial colonies on 
the grid plate were used as stocks for sequencing and future amplification of positive 
clones. 
  (Molar ratio insert:backbone) x (ng backbone) x (insert length,bp) 
ng insert DNA =  
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2.6  Western Blotting 
Each step in the western blotting protocol used in this project are described below. 
2.6.1 SDS-Polyacrylamide Electrophoresis 
Hoefer SE600 gel tanks were used unless otherwise stated; gels were poured between 18 
cm x 16 cm glass plates, 1.5 ml apart. Up to 15 samples were loaded in 6 mm wide wells. 
A 30% stock solution of acrylamide was used with a 19:1 acrylamide: bis-acrylamide ratio 
(BIO-RAD). 11 cm 12% 'resolving' gels were overlayed with 5cm 4% 'stacking' gels. The 
mix for each resolving gel constituted 12 ml 30% acrylamide; 7.5 ml 1.5 M Tris pH8.8; 
300  l 10% SDS; 10.2 ml H2O; 30  l TEMED (N,N,N',N'-tetramethylethylenediamine); 
300 l 10% APS (w/v, g/ml) (ammonium persulphate). Stacking gel consisted of 2 ml 30% 
acrylamide; 3.75 ml 0.5M Tris pH6.8; 159  l 10% SDS; 9.1 ml H2O; 15  l TEMED; 150 
 l 10% APS (w/v, g/ml). 
10-60 g of protein samples were prepared in a total volume of 20-60  l, incorporating the 
appropriate volume of 6 X Laemmli loading dye (constituting 50% glycerol; 9% SDS; 
0.375 M Tris pH6.8; 10% β-mercaptoethanol; 0.05% bromophenol blue dye). Positive 
protein controls were included in each blot, as were 15  l of Amersham 'Rainbow markers' 
– protein molecular weight markers (low range 2.5 k Daltons (kDa) - 45 kDa or full range 
10 kDa -250 kDa) linked to coloured dyes for easy identification on the blotting 
membrane. Samples and positive controls were heated to 95°C for 5 minutes to ensure 
denaturation of proteins. Empty wells were loaded with 10 l 6X Laemmli loading dye to 
help provide a constant resistance across the gel and avoid 'smiling' of the bands. 
Electrophoresis buffer consisted of 0.025 M Tris pH10.5; 0.2 M Glycine; 0.1% SDS. 
Electrophoresis began at 100 v for 1-1.5 hours until the dye entered the resolving gel, 
whereupon the voltage was increased to 200 v for 3-4 hours, separation of the rainbow 
markers was used a guide to ensure the target proteins were sufficiently resolved. 
2.6.2 Protein Blotting 
After electrophoresis the electrophoresis apparatus was dismantled, the stacking gel was 
removed and any lanes not including protein were cut from the resolving gel. 6 pieces of 
Whatman 3 mm chromatography blotting paper and a piece of Amersham Hybond-P 
membrane were cut to the same size of the gel. Gels and Whatman paper were equilibrated 
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then H2O for 5 minutes and transfer buffer for 10 minutes. Transfer buffer consisted of 
0.025 M Tris pH10.5; 0.2 M Glycine; 0.1% SDS; 20% methanol. Transfer apparatus was 
prepared as follows (cathode to anode): 3 x Whatman sheets, gel, membrane, 3 x Whatman 
sheets. Blots were transferred overnight at 88 mAmps, 7 volts overnight in a Hoefer TE 
50X transfer tank. 
2.6.3 Antibody Probing and Washing 
Following transfer membranes were inspected for transfer of the coloured rainbow marker 
bands. The positions of bands were marked by snipping the edge of the membrane in the 
event that the coloured bands faded in subsequent washing steps. The membrane was 
blocked through the day in Tris-buffered saline Tween buffer (TBST) (0.025 M Tris 
pH7.4; 0.14 M NaCl; 0.0027 M KCl; 0.1% Tween (Sigma)), 5% (w/v, g/ml) dried 
skimmed milk (Marvel), on lab shaker (Luckham R100) at 50 oscillations per minute. 
Primary antibody exposure was performed in a total volume of 10-20 ml TBST, 5% milk. 
Membranes were heat-sealed into plastic bags using a Russell Hobbs heat sealer with 
minimal airspace to enhance contact of the antibody preparations with the membrane. The 
bags were taped to a lab shaker and left overnight at 4°C at 180 oscillations per minute. 
Primary antibody dilutions are detailed in specific methods sections.  
The following morning the membranes were washed with 100ml TBST in 10 x 5 minute 
washes. Primary antibody preparations were recovered and stored at -20°C, each 
preparation was used up to four times. Horse-radish peroxidase (HRP) conjugated 
secondary antibodies targeting the species in which the primary antibody was raised 
(purchased from DAKO). Membranes were incubated with 50 ml antibody dilutions for an 
hour at room temperature, details of specific antibodies used and dilutions are given in 
relevant chapters. Membranes were then washed for 10 further 5 minute washes with 100 
ml TBST. 
2.6.4 Enhanced Chemiluminescence and Detection 
Amersham enhanced chemiluminescence (ECL) Western blotting detection reagents were 
used to detect binding of the HRP-conjugated secondary antibodies. The kit includes two 
reagents that are mixed in equal quantities and applied to the membrane. Typically 10 ml 
of each reagent was used per membrane, the reagents were left in contact with the 
membranes for 1 minute and excess liquid was blotted off before carefully wrapping the 
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Membranes were then taped into an 18 x 24 cm autoradiography cassette and taken to a 
dark room. Kodak general purpose blue medical X-ray film was used in the first instance 
for all blots. Films were first exposed for 1 minute, folding the top corner of the film to 
record its orientation. Films were developed in a Kodak X-Omat 1000. The first exposures 
were inspected to judge if further exposures were required, repeated exposures of 1 second 
to overnight were performed as necessary. Sensitive Amersham Hyperfilm was used for 
blots giving very faint results. Once the required image of protein bands was acquired the 
developed film was returned to the cassette to mark onto it the position of the edges of the 
membrane and of the rainbow size markers, allowing accurate sizing of protein bands. 
2.6.5 Membrane Stripping and Re-Probing 
Every effort was made to load exactly the same amount of protein in each well of a 
Western blot. However, in order to accurately measure the level of a particular protein in a 
sample, it was always measured relative to the level of a 'housekeeping' protein that is 
present at the same level in all cells, such as glyceraldehyde-3-phosphate dehydrogenase 
(Gapdh) or beta-actin (β-actin). Membranes were stripped to remove conjugated antibodies 
and re-probed with antibodies specific for the housekeeping protein. Stripping involved 
placing the membrane in 100ml 0.2M Glycine; 1%SDS for 30 minutes at room 
temperature on a shaker at 50 oscillations per minute, then rinsing the membrane twice in 
TBST. Membranes were then re-blocked for 4 hours in TBST, 5% milk and probed, 
washed and analysed for the housekeeping protein exactly as described above. 
2.6.6 Densitometry 
The intensities of protein bands on the photographic films were measured to compare 
protein levels between samples on a western blot using the BIORAD Fluor-S MultiImager 
and 'Quantity One' software (BIORAD). X-ray films were scanned to generate a digital 
image, individual bands were labelled and demarked by boxes using a drawing tool in the 
Quantity One software. The intensity of the bands was then measured by the software and 
expressed in units of optical density per mm
2 (ODU/mm
2). The intensity of the protein 
band of interest was divided by the intensity of the band for the housekeeping gene to find 
the relative level of the protein of interest in each sample. 
Two methods of background subtraction were used for densitometry. A 'global' 
background subtraction method was used for blots with clean and constant background 
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background, the software then calculated the average intensity of all pixels in this box and 
subtracted it from all pixels in boxes containing bands. A 'local' background subtraction 
method was used for blots where the background intensity level was variable across the 
blot, the software calculated an average background intensity for each box by measuring 
the average intensity of all pixels in a one-pixel border around each box and subtracted this 
from each pixel in the box to find the band intensity.  
2.7  Quantitative Real-Time PCR 
An Applied Biosystems 7900HT Sequence Detection System (Taqman) was used for all 
quantitative real-time PCRs in this project. The system encompasses a heating block for 
thermal cycling and detectors to measure fluorescence in each well of a 96-well or 384-
well optical plate. Fluorescence is measured after every amplification cycle to quantify the 
accumulation of PCR product; during the exponential phase of PCR cycling the rate of 
product accumulation is proportional to template concentration, relative template 
abundance can therefore be quantified by monitoring increasing fluorescence in each well 
during temperature cycling. This is explained in more detail below along with the specific 
protocols for cDNA template preparation of and reaction set up. 
2.7.1 Preparation of DNA-free cDNA 
cDNA preparations for quantitative real-time PCR (qRT-PCR) were made by reverse 
transcription from RNA templates. Unless stated otherwise stated, RNA was first treated 
with DNA-Free (Ambion) in order to prevent carry-over of genomic DNA that may 
amplify in real-time PCR reactions. If necessary the concentration of RNA preparations 
were adjusted down to 200 ng/ l to ensure rigorous DNase treatment as per the kit 
instructions. 30  l reactions were performed including RNA template, 3  l 10X DNAse I 
buffer and 0.6  l rDNAse I (recombinant DNase I). Reactions were heated to 37°C for 30 
minutes. 3  l DNAse Inactivation Reagent was added per well and reactions were mixed 
by pipetting and flicking tubes. The DNase Inactivation Reagent is a dense slurry that 
binds and inactivates rDNase I, after incubation for 2 minutes at room temperature 
reactions were centrifuged for 1.5 minutes at 10000 x g, to collect the DNase Inactivation 
Reagent at the bottom of the tubes and the DNA-free RNA was pipetted into fresh 0.5 ml 
centrifuge tubes. RNA concentration was re-measured. 
Clontech 'Advantage RT for PCR' and Applied Biosystems 'TaqMan Reverse Transcription 
Reagents' were used for cDNA synthesis using random hexamer or oligo dT primers. 1  g James Polke, 2008    Chapter 2         84 
   
of RNA template was used unless RNA concentrations were too low; the same amount of 
RNA template was always used in all reactions in the same experiment, dictated by the 
lowest RNA concentration. Reverse transcription reactions were performed in 96-well 
plates to allow multichannel pipettes to be used for PCR reaction set up, the reaction 
constituents and temperature programs used for each kit were: 
Clontech Advantage RT for PCR: 
 
      Vol. 
RNA      Up to 1 g        
H2O      Adjust to 12.5 l     
Primers (20 M)      1.0 l 
 
Heat to 70°C for 2 minutes, then straight on to ice. Add the following to each reaction from 
a master-mix: 
 
      Vol.( l) 
5X Reaction Buffer      4.0 
dNTPs (10mM ea.)      1.0 
RNase Inhibitor (40U/ l)     0.5 
MMLV RT    1.0 
 
Heat to 40°C for 1 hour, then 94°C for 5 minutes. 
 
 
Applied Biosystems TaqMan Reverse Transcription Reagents: 
 
      Vol. 
RNA      Up to 1 g 
H2O      Adjust to 7.7 l 
 
Then add the following to each tube from a master mix: 
 
      Vol.( l) 
10X Reaction Buffer      2.0 
MgCl2 (25mM)      4.4 
dNTPs (2.5mM ea.)      4.0 
Primers (50 M)      1.0 
RNase Inhibitor (20U/ l)     0.4 
MultiScribe RT (50U/ l)  0.5 
 
Heat to 25°C for 10 minutes, 48°C for 30 minutes then 95°C for 5 minutes. 
2.7.2 Real-Time PCR 
Applied Biosystems Gene Expression Assays and Custom Gene Expression Assays were 
used for all qRT-PCRs in this project. If a pre-designed assay was not available, a custom 
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reaction mix containing template-specific forward and reverse primers (18 mM each) and a 
probe that anneals between the two primers (5 mM). The probe DNA is fluorescently 
tagged at its 3' end, but fluorescence from intact probes is prevented by a quencher 
molecule that is bound to its 5' end. During PCR amplification, the 5'-3' nucleolytic activity 
of the DNA polymerase cleaves the quencher from the probe, resulting in fluorescence 
levels proportional to the amount of PCR product present. All Gene Expression Assays and 
Custom Gene Expression Assays used in this project were designed to anneal across two 
exons in cDNA, guaranteeing that non-specific amplification did not occur from residual 
genomic DNA.  
Every effort was made to ensure that the amount of template cDNA was the same in each 
reaction of an experiment, however, given the sensitivity of qRT-PCR, expression of the 
gene of interest was always measured relative to the β-actin housekeeping control gene. 
The gene of interest and β-actin were amplified in duplex PCR reactions, probes for the 
gene of interest were tagged to 'FAM' labelled fluorescent dyes, while β-actin probes were 
labelled with 'VIC' dye, they fluoresce at different wavelengths, allowing them to be 
measured in the same reaction without interference. Reactions were performed in 20  l or 
5  l volumes in 96-well or 384-well plates, respectively. The reaction constituents and 
temperature cycling parameters were: 
Reaction Mixtures: 
      20µl:    5µl: 
      Vol.( l)    Vol.( l) 
2X PCR Master Mix      10.0    2.5 
20X Gene Expression Assay  2.0    0.25 
20X β-actin Expression Assay  2.0    0.25 
cDNA      2.0-4.0    2.0 
Nuclease-free H2O      Up to 20 l      – 
 
Temperature cycling: 
 
50°C  2 min 
95°C  10 min 
95°C  15 sec 
60°C  1 min 
 
 
All samples were amplified in duplicate or triplicate, at least three treatment replicates 
were included per experiment. Fluorescence of FAM and VIC dyes was measured for all 
reactions during temperature cycling, data was analysed using a combination of Applied 
Biosystems SDS (Sequence Detection Software) and Microsoft Excel software. SDS 
plotted amplification curves as cycle number vs. fluorescence for both dyes in every well. 
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FAM and VIC fluorescence were analysed as separate data sets, a fluorescence threshold 
was identified for each data set where amplification curves were in their exponential phase. 
The 'cycle threshold value' (Ct value) for each amplification curve was interpolated by 
finding the precise fractional cycle number (to 5 decimal places) at which the curve 
crossed the fluorescence threshold. Ct values for FAM and VIC data were exported from 
SDS as text files and converted to Excel documents for data analysis. Relative levels of 
gene expression were calculated by the '  Ct method' (Livak et al. 2001). This method 
calculates gene expression normalised to the endogenous control relative to a calibrator 
from within the experiment (i.e. a sample or sample group designated to have relative gene 
expression level of 1.0), it is advantageous because it does not require the inclusion of a 
standard curve from a serial dilution of template in each experiment. The   Ct method is 
logically derived from the equation that dictates the rate of product accumulation during 
PCR: 
For a given PCR reaction, the amount of product (XT) accumulated when amplification 
reaches the Ct threshold is: 
XT = X0 x (1 + EX)
Ct,X = KX 
Where: 
X0 = Initial number of target molecules 
EX = Efficiency of amplification 
KX = Constant 
Ct,X = Ct for target  
 
Similarly, the equation for the endogenous reference reaction (R) is: 
RT = R0 x (1 + ER)
Ct,R = KR 
In correcting for the level of expression of the endogenous control, the level of target 
amplification is divided by the level of endogenous control:  
K
K
K
R
X
R
X
T
T = =
+
+
=
  ) E     (1  x  R
) E     (1  x  X
R Ct,
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X Ct,
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Assuming the efficiencies of the target and control amplification reactions are the same, 
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Or: 
 
( ) K E X
Ct
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D 1  
 
Where: 
XN = X0/R0, the normalised amount of target 
 Ct = Ct,X – Ct,R, the difference in Ct values for target and control 
 
This equation can be rearranged: 
 
( )
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To quantify expression relative to the calibrator, divide by the XN for the calibrator sample 
(Xcb): 
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Where:  
  Ct =  Ct- Ct,cb 
For Gene Expression Assays designed by Applied Biosystems the efficiency is close to 1, 
therefore the amount of target can be calculated as: 
Relative quantification (RQ) = 2
-  Ct 
 
 
In order to use the   Ct it was imperative to experimentally confirm that the amplification 
efficiencies of the target and control gene PCRs were the same (i.e. that EX = ER). 
Therefore the amplification efficiencies of each Gene Expression Assay were measured in 
duplex PCRs with the β-actin assay using a serial dilution of template. This process was 
performed for all Gene Expression Assays and Custom Gene Expression Assays for each 
different cDNA template (e.g. for cDNA from kidneys, carotid arteries and for each 
cultured cell line). A dilution series of cDNA template was prepared from neat to 1/1,000, 
typically including 1/5, 1/10, 1/50, 1/100, 1/500 and 1/1000 dilutions. Graphs were plotted 
of log(dilution) versus Ct for the target template and β-actin, the gradient of each line was 
compared, according to the Applied Biosystems guidelines they had to be within ±0.1 to be 
used to measure gene expression in this tissue. Each Gene Expression Assay for RNA from 
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2.8  Statistical Analysis 
Where specialised statistical analysis techniques have been applied (for example the use of 
Rank Products and False Discovery Rates in microarray data analysis in Chapter 3), details 
and references are provided in the relevant methods or results sections. A number of 
experiments throughout the project applied straightforward parametric statistical tests. All 
statistical comparisons were performed on data collected in individual assays, eliminating 
error from inter-assay variability. For comparisons of a continuous variable between two 
experimental groups, 2 sample t-tests were applied (Bland 2000). For statistical 
comparisons of a continuous variable in data sets with more than two groups, analysis of 
variance (ANOVA) was applied, followed by the Tukey post-test for comparisons between 
all data sets or the Dunnett's post-test for comparison of all sample groups against a 
designated control (Bailer et al. 1997). The significance threshold for p-values in these 
analyses was set at 0.05; the specific tests applied in each experiment are detailed in figure 
legends. 
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3.1  Introduction 
As discussed in section 1.2.3.3, a number of studies have been performed to dissect the 
genetic causes of hypertension and other cardiovascular diseases by comparing microarray 
gene expression levels between inbred parental and congenic strains. A notable example of 
this approach identified Cd36 as a causative gene underlying a QTL for fatty acid and 
glucose metabolism on the SHR chromosome 4 (Aitman et al 1999), and Gstm1 was 
identified as a hypertension candidate gene in the SHRSP in this manner (McBride et al 
2003). However, such experiments may be limited by the fact that in many of these studies 
gene expression is measured in adult rats where hypertension is fully established, leading 
to the likelihood that data could be misinterpreted: candidate genes could be differentially 
expressed as a secondary response to high blood pressure rather than as a primary cause of 
hypertension.  
Blood pressure measurements in the Glasgow SHRSP and WKY colonies have 
demonstrated that blood pressures of SHRSP rats are higher than the WKY by 8 weeks of 
age, and that they rise sharply in the SHRSP between 8 and 12 weeks of age (Davidson et 
al 1995). It is technically very challenging to measure blood pressures accurately in young 
rats, though published research has demonstrated equivalent blood pressures between 6 
week-old SHRSP and WKY strains (Kopf et al. 1993), and the period between 3-10 weeks 
after birth is thought to be important to the development of genetic hypertension in rat 
model strains (Zicha et al. 1999). A number of microarray studies have measured 
differential gene expression between normotensive, hypertensive and congenic or 
recombinant strains during this period (Hubner et al 2005;Garrett et al. 2005;Lee et al. 
2007), and others have measured expression at more than one timepoint to assess temporal 
changes in gene expression during the development of hypertension. For example, gene 
expression was analysed during the development of hypertension in the SHR with the 
premise that genes consistently differentially expressed between three different substrains 
of the SHR and the WKY represent strong essential hypertension candidates (Hinojos et al. 
2005). Renal gene expression was measured at 4, 8, 12 and 18 weeks in strains SHR-A3, 
SHR-B2, SHR-C and WKY, the SHR strains were all fixed at various generations of 
derivation during the original breeding of the SHR and SHRSP from the WKY (Okamoto 
et al 1974). Gene expression data reflected the relatedness of the strains: SHR-B2 and 
SHR-C are most closely related, sharing common ancestors at generations F11 an F14 and 
showed greatest concordance of gene expression, while SHR-A3 shares closest ancestors 
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expression. The list of consistently differentially expressed genes between the WKY and 
all 3 SHR strains at all timepoints was refined to find candidate hypertension genes by 
finding those within established blood pressure QTLs in the SHR. In this manner, 14 genes 
and expressed sequence tags (ESTs) were identified on 11 chromosomes and proposed as 
potential hypertension genes, though microarray expression data was not corroborated by a 
second method and no specific analysis was performed on metabolic pathways known to 
influence blood pressure control (Hinojos et al 2005). The Spon1 gene was identified as a 
hypertension candidate gene in renal microarray studies on 6 and 24 week SHR, WKY and 
2 congenic strains of SHR background introgressed with overlapping regions of WKY 
chromosome 1 (Clemitson et al. 2007); in this study Spon1 was the only gene from within 
the minimal congenic interval that was consistently differentially expressed between the 
congenic strains and the SHR and between the SHR and WKY at both timepoints.  
Seubert et al measured renal gene expression in 3 week-old and 9 week-old SHR and 
WKY rats, (Seubert et al. 2005), allowing comparison of gene expression between the 
SHR and WKY at 3 weeks of age and at 9 weeks of age, and also between 3 week-old and 
9 week-old rats of the same strain. The major findings of the paper included the 
observation that 20 genes were differentially expressed between the SHR and WKY at 3 
weeks of age, while 104 were differentially expressed at 9 weeks of age, 7 genes were 
common to both timepoints. The soluble epoxide hydrolase (sEH) gene was upregulated in 
the SHR compared to the WKY at both timepoints, the authors proposed sEH as a 
candidate hypertension gene in the SHR given its role in arachidonic acid metabolism, it 
converts vasodilatory epoxyeicosatrienoic acids to less active diol forms. The within-strain 
comparisons showed that 211 genes were differentially expressed between 3 week-old and 
9 week-old SHRs, while 508 genes were differentially expressed in the same comparison 
in the WKYs; 174 of these genes were common to both groups. The authors concluded 
from these analyses that there are likely to be developmental differences in renal gene 
expression accounting for hypertension in the SHR (Seubert et al 2005). Custom cDNA 
microarray chips measured the expression of just 6700 transcripts in these experiments, 
this, in conjunction with the lack of a congenic strain to narrow-down analysis to an 
established QTL, limited the power of the study. In addition, while specific analysis of 
arachidonic acid metabolism and blood pressure related genes was undertaken (finding no 
other differentially expressed genes), analysis was restricted to just these pathways. More 
sophisticated analysis techniques are now available, such as Ingenuity Pathway Analysis 
(IPA), to interrogate data from the perspective of interlinked metabolic pathways. IPA is a 
web-based microarray and proteomic data analysis tool that utilises published Kyoto 
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linked to pathway maps to identify instances where multiple genes involved in a particular 
pathway are differentially expressed in comparisons between experimental groups. When 
applied to gene expression comparisons between congenic and parental strains this is a 
very powerful analysis technique, allowing the influence of the congenic interval on 
genome-wide expression to be functionally linked to multiple genes in a physiological 
pathway, identifying genes whose expression is regulated in trans from within the 
congenic interval. 
The experimental work performed in this chapter assessed the changes in renal gene 
expression in the SHRSP and WKY and congenic 2c* strains at 5 weeks of age to assess 
the differential expression of Gstm1 during the development of hypertension and to 
identify other hypertension candidate genes. The 5-week expression dataset was also 
analysed in conjunction with previously published data analysing renal gene expression in 
the same strains at 16 weeks of age (McBride et al 2003). This allowed the changes in gene 
expression over time to be measured in each strain, and between strains at each timepoint. 
Gene expression data was analysed with Ingenuity Pathway Analysis (IPA) software to 
find pathways with multiple differentially expressed genes. Secondary phenotypes related 
to an implicated pathway, glutathione metabolism, were measured in parental and congenic 
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3.2  Aims 
·  To measure renal gene expression in the SHRSP, WKY and congenic 2c* inbred strains 
at 5 weeks of age. 
·  To  assess  differential  expression  of  Gstm1  and  to  identify  other  consistently 
differentially expressed genes from the congenic interval in comparisons between the 
SHRSP and WKY and between the SHRSP and 2c*. 
·  To apply Ingenuity Pathway Analysis to 5-week microarray data and 16-week renal 
expression data generated in the same strains in 16-week old animals (McBride et al 
2003) to identify canonical metabolic pathways affected by differential expression of 
genes within and outwith the congenic interval. 
·  To  compare  renal  glutathione  and  superoxide  levels  in  all  strains,  and  to  confirm 
differential expression of glutathione metabolism genes in parental and congenic strains 
with quantitative real-time PCR.  
·  To sequence the coding and regulatory regions of candidate genes. James Polke, 2008    Chapter 3         94 
   
3.3  Methods 
3.3.1 Renal Microarray mRNA Expression Analysis 
Affymetrix GeneChip RGU34A, B and C microarray chips, with a total of 26379 gene and 
EST probe sets, were used to measure renal gene expression in male 5 week old WKY, 
SHRSP and 2c* rats. RGU34A analyses approximately 7000 full-length sequences and 
1000 expressed sequence tags (ESTs), RGU34B and C analyse approximately 8000 ESTs 
each. Three animals from each strain were used. Microarray hybridisations were performed 
by Martin McBride at the microarray facility at the Sir Henry Wellcome Functional 
Genomics Facility, University of Glasgow. 
3.3.1.1 RNA Extraction and Validation 
Whole kidneys were excised from freshly killed 5 week-old rats, snap-frozen in liquid 
nitrogen and stored at -80°C until RNA extraction. RNA was extracted using Qiagen 
RNeasy Maxi columns as per section 2.5.3. RNA concentrations were quantified by 
Nanodrop as per section 2.2.2, and where necessary ethanol-precipitated (0.1 volume 3M 
NaOH pH5.5; 2.5 volumes ethanol, precipitated at -20°C for 1 hour, collected by 
centrifugation, removed supernatant and air dried before resuspending in a reduced volume 
of H2O) to at least 2  g/ l concentration. mRNA sample integrity was verified by 
electrophoresis 250 ng of RNA on an Agilent Bioanalyser 2100. 
3.3.1.2 First and Second Strand cDNA Synthesis 
The Invitrogen ds-cDNA synthesis kit was used for first and second strand cDNA 
synthesis. Ten  g of RNA was diluted with 100 pmol T7 oligo dT primer (sequence 
GGCCAGTGAATTGTAATACGACTCACTATAGGGAGGCGG(T)24) in a total volume 
of 11  l with RNase-free H2O. Samples were denatured at 70°C for 10 minutes, placed on 
to ice and 4  l 5 X first strand buffer, 2  l 0.1 M DTT, 1  l 10 mM dNTP was added to 
each. Reactions were heated to 42°C for 2 minutes before adding 2  l 200 U/ l 
SuperScript II reverse transcriptase and heating to 42°C for 1 hour, then placing on ice to 
stop the reaction. 
For second strand cDNA synthesis, 91  l RNase-free H2O, 30  l 5 X second strand buffer, 
3  l 10 mM dNTP mix, 1  l 10 U/ l E.coli DNA ligase, 4  l 10 U/ l E.coli DNA 
polymerase I, 1  l 2 U/ l E.coli RNase H was added to each tube and reactions were James Polke, 2008    Chapter 3         95 
   
incubated at 16°C for 2 hours. 2  l of T4 DNA polymerase was added to each reaction and 
incubated at 16°C for a further 2 minutes; 10  l 0.5 M EDTA was added. 
3.3.1.3 Double Stranded cDNA Clean-up 
ds-cDNA was purified for cRNA synthesis using the filter-based Affymetrix GeneChip 
Sample Cleanup Module. ds-cDNA was transferred to a 1.5 ml microfuge tube and 600  l 
cDNA binding buffer was added. Samples were applied to cDNA Cleanup Spin Columns 
and centrifuged for 1 minute at 10000 rpm. Spin columns were transferred to new 
collection tubes and filters were washed by centrifugation of 750  l cDNA wash buffer at 
full speed for 1 minute, discarding the flow-through. Membranes were dried by 
centrifugation at full speed for 5 minutes, 14  l H2O was added to membranes and they 
were incubated at room temperature for 1 minute before eluting by centrifugation at full 
speed for 1 minute. 
3.3.1.4 Biotin-labelled cRNA Synthesis, Clean-up and Validation 
Biotinylated cRNA was synthesised for each ds-cDNA using the Enzo Bioarray High 
Yield Transcript Labelling kit from Enzo Biochem. 5  l cDNA, 17  l RNase-free H2O, 4 
 l 10 x HY reaction buffer, 4  l 10 x biotin-labelled ribonucleotides, 4  l 10 x DTT, 4  l 
RNase inhibitor mix and 2  l T7 RNA polymerase was added per reaction, tubes were 
heated to 37°C for 4.5 hours. 
Biotinylated cRNA was purified using the Affymetrix GeneChip Sample Cleanup Module. 
In-vitro reverse transcription reactions were transferred to 1.5 ml microfuge tubes, 60  l 
RNase-free H2O was added, followed by 350  l cRNA binding buffer and 250  l ethanol. 
Samples were mixed by pipetting and applied to IVT cRNA Cleanup Spin columns, 
centrifuged at full speed for 15 seconds, then the flow-through was reapplied to the 
columns and centrifuged at full speed for 15 seconds once more. Columns were transferred 
to new collection tubes and membranes were washed with 500  l IVT cRNA wash buffer, 
centrifuging for 15 seconds at full speed. Flow-through was discarded and 500  l 80 % 
ethanol was applied to each column, centrifuging for 15 seconds at full speed. Flow-
through was discarded and membranes were thoroughly dried by centrifugation at full 
speed for 5 minutes. 15  l RNase-free H2O was added to columns, incubated for 1 minute 
at room temperature and eluted by centrifugation for 1 minute at full speed, an additional 
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One  l of each biotinylated cRNA was added to 4  l H2O and electrophoresed on an 
Agilent Bioanalyser 2100 to confirm successful cRNA amplification. Final cRNA 
concentration was calculated by subtracting the carried-over template genomic RNA from 
the total yield measured by Nanodrop. 
3.3.1.5 cRNA Fragmentation  
cRNA fragmentation was performed using 5 X fragmentation buffer from the Affymetrix 
GeneChip Sample Cleanup Module. Twenty-five  g of each cRNA sample was diluted to a 
total volume of 40  l in H2O, 8  l 5 X fragmentation buffer was added and samples were 
incubated at 94°C for 35 minutes. 
3.3.1.6 Microarray Hybridisation and Data Collection 
Hybridisation mixes were prepared using Affymetrix microarray hybridisation reagents in 
a total volume of 500  l per sample, including: 40  l of fragmented cRNA, 8.5  l B2 
Control oligo (3 nM), 25  l 20 X eukaryotic hybridisation controls, 5  l herring sperm 
DNA (10 mg/ml), 5  l acetylated BSA (50 mg/ml), 250  l 2 X hybridisation buffer and 
166.5  l H2O. Hybridisation mixes were denatured at 99°C for 5 minutes, then to 45°C for 
5 minutes, and centrifuged at 14500 rpm for 5 minutes before applying to chips. 
Prior to performing experimental microarrays, Affymetrix 'Test3' quality control chips 
were hybridised and scanned with each hybridisation mix. Test3 chips were pre-wet with 
100  l 1 X hybridisation buffer and incubating at 45°C for 10 minutes in a rotating oven at 
60 rpm, after which hybridisation buffer was removed and 80  l hybridisation mix was 
added, chips were returned to the 45°C oven rotating at 60 rpm for 16 hours. Hybridisation 
mixes were stored at -20°C until Test3 quality control checks were complete, they were 
then thawed, reheated to 45°C and re-centrifuged before applying to the RGU34A,B and C 
chips. RGU34A,B and C microarrays were hybridised using exactly the same incubation 
protocol as Test3 chips, but 250  l 1 X hybridisation solution was used for pre-wetting and 
200  l hybridisation mix was used per chip. Where necessary hybridisation mixes were 
recovered and reused in repeat hybridisations. 
Test3 and RGU34 chips were washed and stained following standard protocols in an 
Affymetrix Fluidics Station 400 operated by GeneChip software. Hybridisation mixtures 
were removed from the arrays and replaced with 250  l non-stringent wash buffer at room 
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MES stain buffer, 48  l 50 mg/ml acetylated BSA, 12  l 1 mg/ml SAPE, 540  l H2O per 
chip), separated into 2 x 600  l aliquots and loaded onto the fluidics station (wrapped in 
foil to protect from light). A 600  l aliquot of antibody solution (300  l 2 X MES stain 
buffer, 24  l 50 mg/ml acetylated BSA, 6  l 10 mg/ml normal goat IgG, 3.6  l 0.5 mg/ml 
biotinylated antibody, 266.4  l H2O per chip) was prepared and loaded onto the fluidics 
station. Microarray washing included washes with low stringency buffer followed by high 
stringency buffer. Test3 and RGU34 chips were scanned using specific scanning protocols 
on an Affymetrix GeneChip scanner. 
3.3.1.7 Microarray Data Analysis 
Microarray data quality control was performed on Test3 and RGU34 chips using 
Affymetrix microarray suite 4 (Mas4) software. Fluorescence scaling values were 
compared across chips and hybridisations of control RNAs were verified. 5-week raw 
scanning data was combined with the raw data from 16-week renal microarrays in the same 
strains (McBride et al 2003), data was normalised using the robust multi-array average 
method (Irizarry et al. 2003) with BioConductor software. RMA applies background 
correction to compensate for non-specific binding and normalises probeset intensity signals 
across all of the chips in the experiment, allowing comparisons between arrays. 
Differentially expressed probesets between strains and timepoints were identified using the 
rank product (RP) method (Breitling et al. 2004). RP data from all microarrays was 
uploaded onto the IPA website (www.ingenuity.com) and analysed to identify the 
metabolic pathways with most genes significantly differentially expressed in pairwise 
comparisons between each strain at each timepoint, and in within-strain comparisons 
between 5 and 16 week animals. 
3.3.2 Gstm1 western blotting  
Gstm1 protein levels in 5 week-old SHRSP, 2c* and WKY kidneys were assessed by 
western blotting. Experimental protocols were follwed as per section 2.6 and 5.3.6. Forty 
 g of kidney protein was loaded per lane.  
3.3.3 Kidney Glutathione Measurements 
Tissue glutathione assays were performed by Dr Carlene Hamilton. Total GSH levels were 
measured in kidneys of 5 and 16 week old WKY, SHRSP and 2c* rats using the Cayman 
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homogenised in 2 ml/g 4°C 0.2 M 2-(N-morpholino) ethanesulphonic acid; 0.05 M 
phosphate, 1 mM EDTA pH6 (MES buffer) using a Polytron PT 2100 homogeniser. 
Homogenates were centrifuged at 10000 g for 15 minutes at 4°C, supernatants were 
pipetted off and stored on ice. Supernatants were de-proteinated by adding an equal 
volume of 0.1 g/ml metaphosphoric acid, vortexing, centrifuging at 20000 g for 2 minutes 
and collecting the supernatant. Directly before performing GSH assays, 4 M 
triethanolamine was added at 50  l/ml. Standards were prepared from 0  M – 16  M GSH, 
50  l of each standard and sample were measured in duplicate in a clear 96-well plate. 
Assay  reagent was prepared with 11.25 ml MES buffer, 0.45 ml cofactor mixture (NADP
+ 
and glucose 6-phosphate), 2.1 ml enzyme mixture (glutathione reductase and glucose 6-
phosphate in MES buffer), 2.3 ml H2O, and 0.45 ml 5,5'-dithiobis-2-nitrobenzoic acid 
(DTNB) solution. 150  l of assay reagent was added to each standard and control well and 
the assay plate was left for 30 minutes to allow colour development before measuring 
absorbance at 405 nm on a Victor Wallac2 plate reader. Standard curves were plotted 
(GSH concentration vs. absorbance), sample GSH concentrations levels were interpolated 
and converted to nM GSH per g kidney tissue. 
3.3.4 Kidney Superoxide Measurements 
Kidney superoxide measurements were performed by Dr Carlene Hamilton. Whole 
kidneys from 5 week-old SHRSP, 2c* and WKY rats (n=5 per group) were homogenised 
in phostphate buffered sailne, pH7.8, centrifuged at 1000 rpm for 2 minutes at 4°C and 
supernatants were frozen at -80°C until the assay. Protein concentrations were determined 
using a BCA assay as detailed in section 2.2.5. NADH-stimulated superoxide levels were 
measured in duplicate for each kidney using a Packard Tri-Carb 2100TR liquid 
scintillation counter. 2 ml assays were prepared in scintillation vials including 0.5 ml 
kidney homogenate, 1  M lucigenin, and 100  M NADH in PBS buffer. Total 
luminescence was measured for 3 minutes in each sample. Superoxide levels were 
calibrated against a standard curve generated with 70-840mM xanthine and xanthine 
oxidase (0.001 U/ml), superoxide measurements were expressed as n moles O2
-· /  g total 
protein. 
3.3.5 Quantitative RT-PCR 
Taqman qRT-PCR was applied to confirm differential expression measured in microarray 
experiments. The same kidney mRNA from microarray experiments were used as 
templates for the synthesis of DNA-free cDNA as described in section 2.7.1 plus 2 James Polke, 2008    Chapter 3         99 
   
additional kidney mRNAs from other animals of each strain. Duplex 5  l RT-PCR 
reactions were performed using Applied Biosystems Taqman Gene Expression Assays for 
Gstm1 (assay no. Rn00755117_m1), Gamma-glutamyltransferase 1 (Ggt1) 
(Rn00587709_m1), aminopeptidase N (Anpep) (Rn01478171_m1), solute carrier family 7, 
member 12-like (Slc7a12-like) (Rn02607204_mH) glutamate-cysteine ligase, modifier 
subunit (Gclm) (Rn00568900_m1), and thioesterase 4 (Them4) (Rn_01533922_m1) 
measuring expression relative to β-actin as outlined in section 2.7.  
3.3.6 DNA Sequencing 
2500 bp of promoter sequence and all coding exons of, Anpep, Slc7a12-like, Gclm, Them4, 
and HistH2aa were sequenced in WKY, and SHRSP and SHR rats according to protocols 
in sections 2.4.2 – 2.4.5. See section 4.4.2 for equivalent analysis for Gstm1. Only the 
coding sequence of Ggt1 was sequenced since this gene is currently not mapped in the rat 
genome. Renal cDNA was used as template for coding sequences, and genomic DNA was 
used for promoter sequencing, two rats per strain were sequenced. Sequences were aligned 
to Brown Norway reference sequences from Ensembl.  James Polke, 2008    Chapter 3         100 
   
3.4  Results 
3.4.1 mRNA and cRNA Validation  
Electrophoresis of 5 week kidney mRNA samples on the Agilent Bioanalyser 2100 
confirmed RNA quality prior to cDNA synthesis, indicated by defined bands for 28S and 
18S ribosomal RNA (rRNA) species and very little evidence of small RNA species smaller 
than the 18S band (figure 3.1).  
 
Figure 3.1 - Agilent Bioanalyser 2100 assessment of mRNA quality 
 
 
Following in-vitro transcription to synthesise biotinylated cRNA, cRNA quality was 
assessed by electrophoresis on the Agilent Bioanalyser 2100, showing approximately 
normally-distributed cRNA species, all samples showed similar-shaped distributions of 
cRNA species and similar concentrations (figure 3.2). 
 
 
 
18S  28S  B 
18S 
28S  
Samples 
A 
0.2 kb 
0.5 kb 
1 kb 
6 kb 
2 kb 
4 kb 
(A) Electrophoresis of mRNA samples showing bands for 28S and 18S rRNA. The 
lower band in each lane is a 200 bp size marker to align samples and controls. (B) 
Representative individual electropherogram, with sharp peaks for 28S and 18S rRNA 
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Figure 3.2 - Agilent Bioanalyser 2100 assessment of cRNA quality 
 
 
3.4.2 Renal Microarray mRNA Expression Profiling 
3.4.2.1 Microarray Data Quality Control  
Mas4 software was applied in Test3 and RGU34A quality control analysis, using quality 
control benchmarks stipulated by Affymetrix. Data for Test3 chips is shown in table 3.1. 
The scaling factors used to scale total chip fluorescence values to 100 relative units were 
compared between chips, a ratio of less than 3 between any scaling factors was required for 
the chips to pass batch analysis. All microarray chips include control probesets for β-actin 
and Gapdh that correspond to the 3' and 5' end of the genes. In-vitro transcription of cRNA 
has a 3'-bias since it is transcribed from DNA transcripts created by a polyT primer, 
therefore binding intensities are expected to be higher at 3' probsets than 5' probesets, 
however, a 3':5' intensity ratio of greater than 3 for β-actin  and Gapdh would indicate 
inefficient in-vitro transcription and rejection of the chip in question. Hybridisation master 
mixtures were spiked with cRNAs for the E.coli genes bioB, bioC, bioD (from the biotin 
synthesis pathway), and cre (Cre recombinase), probeset intensities for these were required 
to exceed specific thresholds for a chip to pass the quality control process. An additional 
control RNA, the synthetic B2 oligo was also present in the hybridisation mix, correct 
hybridisation patterns of B2 were required to align chips for scanning. All hybridisation 
mixes passed the Test3 quality control tests, and RGU34 hybridisations were subject to the 
Samples 
A  B 
0.2 kb 
0.5 kb 
1 kb 
6 kb 
2 kb 
4 kb 
(A) Electrophoresis of samples showing the distribution of cRNA species separated by size. 
(B) Representative electropherogram, showing approximately normal-distrubution of cRNAs. 
The sharp peak at the extreme left of the trace corresponds to the 200 bp size marker in all 
samples used to align samples and controls. James Polke, 2008    Chapter 3         102 
   
same tests plus additional analysis of the number of present, marginal and absent 
fluorescence calls across the chips.  
3' : 5' Ratio  Pass / Fail  Hyb 
Mixture 
 
Scaling 
Factor  β-actin  Gapdh  bioB  bioC  bioD  cre 
SHRSP A 
 
0.801  1.26  1.82  Pass  Pass  Pass  Pass 
SHRSP B 
 
0.534  1.29  1.43  Pass  Pass  Pass  Pass 
SHRSP C 
 
0.729  2.46  2.52  Pass  Pass  Pass  Pass 
2c* A 
 
0.557  1.40  1.33  Pass  Pass  Pass  Pass 
2c* B 
 
0.716  1.52  1.64  Pass  Pass  Pass  Pass 
2c* C 
 
0.650  1.32  1.47  Pass  Pass  Pass  Pass 
WKY A 
 
0.528  1.36  1.40  Pass  Pass  Pass  Pass 
WKY B 
 
0.474  1.40  1.35  Pass  Pass  Pass  Pass 
WKY C 
 
0.589  1.34  1.49  Pass  Pass  Pass  Pass 
Table 3.1 - Quality control data from Test3 chips. 
 
3.4.2.2 Rank Products Analysis 
Following normalisation of gene expression data by RMA, pairwise comparisons of renal 
gene expression were carried out between each strain in 5 week-old rats using the rank-
products (RP) method. RP performs pairwise comparisons of probeset intensities across all 
replicates and ranks the comparisons according to the magnitude of the intensity 
differences. Differentially expressed probesets are identified by computing the average 
rank for all of the pairwise comparisons, false-discovery rates are calculated by performing 
1100 permutations of the data to generate a null distribution. RP has been demonstrated to 
be superior to microarray analysis software based on comparing absolute fold-changes for 
data sets with small sample sizes (Jeffery et al. 2006).  
At a false-discovery rate (FDR) threshold of 0.05 a total of 294 probesets were 
differentially expressed between the SHRSP and WKY, 267 were differentially expressed 
between the 2c* and WKY, while 95 were differentially expressed between the SHRSP 
and 2c*, reflecting the genomic similarity between the SHRSP and 2c*. These data were 
compiled into a Venn diagram depicting the number of probesets common to multiple 
pairwise comparisons, highlighting the probesets common to comparisons between the 
WKY and SHRSP and between the 2c* and SHRSP that implicate the involvement of the 
See text for details of quality control parameters. James Polke, 2008    Chapter 3         103 
   
2c* congenic interval (figure 3.3A). The same comparisons were performed for the 16 
week microarray data (figure 3.3B) and in comparing within-strain gene expression 
between 5 and 16 weeks (figure 3.3C).  
 
Figure 3.3 - Differential renal mRNA expression in pairwise comparisons of different 
strains and timepoints 
 
 
 
2c*vSHRSP 
WKYvSHRSP  WKYv2c* 
30 
44 
17 
97 
4 
149  111 
A:  5 week 
SHRSP 
2c*  WKY 
116 
241 
71 
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101 
60 
 
126 
C:  16wk vs. 5wk 
2c*vSHRSP 
WKYvSHRSP  WKYv2c* 
4 
0 
0 
58 
1 
227  188 
B:  16 week 
Venn diagrams illustrating microarray results of renal gene expression in 5 and 16 
week SHRSP, WKY and 2c* rats. The number of probesets significantly differently 
expressed in each pairwise comparison are shown, numbers in red represent 
probesets that implicate the 2c* congenic interval. (A) 5 week inter-strain 
comparisons. (B) 16 week inter-strain comparisons (C) 5 week versus 16 week 
comparisons. 
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Complete lists of the differentially expressed probesets implicating involvement of the 2c* 
congenic interval in the three comparisons are in tables A2-A4 in the appendix. Probeset 
mapping was performed by interrogating Affymetrix databases to locate all consistently 
differentially expressed transcripts transcribed from within the 2c* congenic interval in 
each of the comparisons (table 3.2). This confirmed differential expression of Gstm1 at 
both timepoints, and identified further genes from the congenic interval differentially 
expressed between the SHRSP and both the WKY and 2c*: Solute carrier family 7, 
member 12-like (Slc7a12-like), histone 2, H2aa (Hist2H2aa), and thioesterase 4 (Them4). 
The differential expression of Slc7a12-like was significant in the light of differential Gstm1 
expression and glutathione metabolism, it encodes a protein with 98.8% amino-acid 
homology to the mouse Slc7a12 amino acid transporter that is highly expressed in the 
kidney has high specificity for cysteine transport (Chairoungdua et al. 2001), cysteine is 
the rate-limiting substrate in the synthesis of GSH . In addition, 2 genes from the congenic 
interval were identified whose expression was significantly different between 5 and 16 
weeks in the WKY and 2c* but not the SHRSP: Claudin 11 and papillary renal cell 
carcinoma (Prcc). 
3.4.2.3 Gstm1 qRT-PCR and Western Blotting 
Taqman qRT-PCR measured Gstm1 expression relative to β-actin in each strain and 
timepoint. Reduced expression of Gstm1 was demonstrated in the SHRSP compared to the 
WKY and 2c* at 5 and 16 weeks by 4-7 fold (figure 3.4). This indicates that reduced renal 
Gstm1 expression precedes the onset of severe hypertension in the SHRSP, supporting the 
hypothesis that it contributes to the hypertensive phenotype, rather than being down-
regulated in response to elevated blood pressure. 
Differential renal Gstm1 expression was also confirmed at the protein level. Western 
blotting showed reduced Gstm1 protein in the SHRSP kidney compared to the WKY and 
2c* (figure 3.5). 
3.4.2.4 Ingenuity Pathway Analysis 
RP data from 5 and 16 week microarrays was uploaded into Ingenuity Pathway Analysis 
(IPA) software for analysis with respect to differential expression of groups of genes 
involved in specific metabolic pathways (figure 3.6). Glutathione metabolism consistently 
featured within the top 6 most significantly affected metabolic pathways, ranked by the 
significance of SHRSP vs. 2c* for 5 and 16 week inter-strain comparisons and ranked by James Polke, 2008    Chapter 3         105 
   
significance of 16 week SHRSP vs. 5 week SHRSP for within-strain comparisons. 
Glutathione metabolism was also differentially affected at 5 weeks of age in comparisons 
between both the SHRSP and 2c* and between the SHRSP and WKY, implicating an 
effect of genes encoded from the 2c* congenic interval. 
 
  Probeset  Gene  Location  2c* vs. 
SP 
WKY vs. 
SP 
J02810mRNA_s_at  Gstm1  2q34  2c*(9.4)  WKY(7.5) 
X04229cds_s_at      2c*(11.2)  WKY(7.2) 
H32189_s_at      2c*(4.2)  WKY(4.1) 
rc_AI060176_at  Slc7a12-
like  2q23  SP(3.0)  SP(2.3) 
AA801165_at  Hist2H2aa  2q34  SP(1.9)  SP(1.9) 
5
 
w
k
 
rc_AA997142_at  Them4  2q34  SP(2.4)  SP(2.4) 
  Probeset  Gene  Location  2c* vs. 
SP 
WKY vs. 
SP 
H32189_s_at  Gstm1  2q34  2c*(7.6)  WKY(9.5) 
J02810mRNA_s_at      2c*(4.6)  WKY(6.2) 
1
6
 
w
k
 
X04229cds_s_at      2c*(9.7)  WKY(13.8) 
Probeset  Gene  Location  2c*  WKY 
rc_AA901342_at  Claudin 11  2q24  5 wk(2.4)  5 wk(2.2) 
5
 
w
k
 
v
s
.
 
 
1
6
 
w
k
 
rc_AA996628_at  Prcc  2q34  5 wk(2.9)  5 wk(3.2) 
Table 3.2 - Differentially expressed probesets encoded from the 2c* congenic 
interval 
 
 
 
 
 
 
 
 
 
 
Differentially expressed probesets located within the 2c* congenic interval common to 
comparisons between SHRSP and WKY and between SHRSP and 2c* at five weeks of 
age and 16 weeks of age. And 2c* congenic interval genes differentially expressed in 
within-strain comparisons between 5 and 16 week-old WKY rats and between 5 and 16 
week-old 2c* rats, but not between 5 and 16 week-old SHRSP rats. Strain or age with 
highest expression is indicated, fold change in brackets. FDR<0.05.  
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Figure 3.4 - Differential expression of Gstm1 at 5 and 16 weeks of age confirmed by 
qRT-PCR 
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Taqman qRT-PCR confirming 4-7 fold reduced renal expression of Gstm1 in the SHRSP 
at 5 and 16 weeks compared to the 2c* and WKY. n=5 per group. Mean ±SE. * p<0.01 
(ANOVA and Dunnett's post-test). 
SP  2c*  WKY  SP  2c*  WKY 
B-Actin 
Gstm1 
Figure 3.5 - Reduced renal Gstm1 protein in the 5 week-old SHRSP 
  Western blotting confirmed reduced renal Gstm1 protein (26kDa) in the SHRSP 
compared to the WKY and 2c*. 40  g of protein per lane, Β-actin 
immunoreactivity observed at the expected molecular weight (42 kDa). 
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Figure 3.5 - IPA canonical pathway analysis of renal 5 and 16 week microarray data 
 
 
 
 
 
A: 5wk 
B: 16wk 
C: 5 vs. 16 wk 
Data output grouped by canonical metabolic pathway. Significance is based on the 
number of genes in the pathway that were differentially expressed, threshold line: 
p<0.05. (A) and (B): 5 and 16 week inter-strain pairwise comparisons, respectively; 
pathways ranked by significance of SHRSP vs. 2c* comparison. (C) Within-strain 
comparisons between 5 and 16 week gene expression, ranked by significance of 16 
week vs. 5 week SHRSP. James Polke, 2008    Chapter 3         108 
   
Examining the KEGG glutathione metabolism pathway in detail with IPA identified a 
number of differentially expressed genes, an example is shown in figure 3.7 for the SHRSP 
vs. 2c* comparison at 5 weeks of age: Gstm1 and gamma glutamyltransferase 1 (Ggt1) 
were downregulated in the SHRSP (FDR<0.05), while aminopeptidase N (Anpep) also had 
reduced expression in the SHRSP, but with a FDR of 0.051. This analysis was repeated for 
the glutathione pathway in all pairwise comparisons and combined with the expression 
data for Slc7a12-like (which is not linked to glutathione metabolism by IPA), where more 
than one probeset for a gene was differentially expressed, only the probeset with the largest 
fold-change was included (table 3.3).  
Anpep (encoded on chromosome 1) and Ggt1 (not mapped) expression were both increased 
in the 2c* and WKY compared to the SHRSP, implying a trans expression effect from the 
2c* congenic interval. Anpep expression was increased in all strains at 16 weeks compared 
to 5 weeks. Glutamate-cysteine ligase, modifier subunit (Gclm) differential expression was 
unique to within-strain comparisons between 5 and 16 week rats, it was upregulated in the 
5 week-old SHRSP and 2c* but not the WKY, indicating differential expression dependent 
on SHRSP alleles. Gclm is situated on chromosome 2, distal of the 2c* congenic region. 
3.4.3 Kidney GSH Concentrations 
Following the evidence from microarray studies that GSH metabolism may be impaired in 
the 5 week SHRSP kidney, renal GSH levels were measured in 5 and 16 week old SHRSP, 
2c* and WKY rats. Kidney GSH levels at 5 weeks in WKY rats was significantly higher 
than the SHRSP and 2c* by approximately 2-fold. At 16 weeks of age, despite 
significantly reduced GSH levels in the WKY, SHRSP GSH levels were significantly 
reduced compared to the WKY, but GSH levels were increased in the 2c* compared to 
levels at 5 weeks in the 2c* (figure 3.8). This led to the hypothesis that 2c* GSH levels 
were reduced at 5 weeks of age despite a WKY-like expression pattern of GSH-
metabolism genes, presumably mediated by SHRSP alleles from outwith the congenic 
interval, but by 16 weeks of age WKY GSH levels were increased in the 2c* by 
chromosome 2 WKY genes. 
   
  Figure 3.7 - KEGG glutathione metabolism pathway 
Glutathione metabolism pathway showing differentially expressed genes between the SHRSP and 2c* at 5 weeks of age (IPA analysis). Nodes 
shaded red indicate genes with significantly reduced expression in the SHRSP (FDR<0.05), nodes in grey were not significantly differentially 
expressed in this pairwise comparison, but were in other comparisons, nodes in white were not differentially expressed in any comparisons. 
2.3.2.2: Ggt1, 2.5.1.10: Gstm1,  6.3.2.2: Gclm.  Anpep (3.4.11.2) expression was reduced in the SHRSP with an FDR of 0.051 in this analysis. 
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  Probeset   Gene  Loc.  2c*    
vs. SP 
WKY vs. 
SP 
WKY 
vs. 2c* 
AF039890mRNA_s_at  Anpep  1q31  2c*(2.0)#  WKY(2.9)  - 
rc_AI232192_s_at  Ggt1  Unk.  2c*(2.1)  WKY(2.2)  - 
H32189_s_at  Gstm1  2q34  2c*(9.4)  WKY(7.5)  - 
5
 
w
k
 
rc_AI060176_at  Slc7a12
-like  2q23  SP(3.0)  SP(2.3)  - 
Probeset  Gene  Loc.  2c*    
vs. SP 
WKY    
vs. SP 
WKY 
vs. 2c* 
X04229cds_s_at  Gstm1  2q34  2c*(9.7)  WKY(13.8)  - 
1
6
 
w
k
 
Probeset  Gene  Loc.  SP  2c*  WKY 
AF039890mRNA_s_at  Anpep  1q31  16wk 
(7.9) 
16 wk 
(3.8) 
16 wk 
(3.8) 
5
 
w
k
 
v
s
.
 
 
1
6
 
w
k
 
Rc_AC233261_i_at  Gclm  2q42  5 wk 
(5.6) 
5 wk 
(4.6)  - 
Table 3.3 - Differentially expressed glutathione metabolism genes 
 
   
 
 
Figure 3.6 - Kidney GSH concentrations in 5 and 16 week-old SHRSP, 2c* and WKYs 
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Differentially expressed glutathione metabolism genes in pairwise comparisons 
between the SHRSP, 2c* and WKY in 5 and 16 week renal microarrays. Strain or age 
with highest expression is indicated, fold change in brackets. FDR<0.05, except #: 
FDR = 0.051. 
 
Kidney GSH concentrations in 5 and 16 week-old SHRSP, 2c* and WKY rats. 5 week 
data, n=6 per group; 16 week data SHRSP n=11, 2c* n=7, WKY n=10.  *p<0.05, 
F=20.95; † p<0.05, F=9.04 (ANOVA and Tukey post-test); # p<0.05 (2 sample t test). 
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3.4.4 Kidney Superoxide Measurements 
Kidney superoxide levels in 5 week old SHRSP rats were significantly higher than in the 
WKY and 2c* (figure 3.9), indicating that oxidative stress defence mechanisms are 
compromised in the SHRSP prior to the onset of hypertension. Equivalent superoxide 
levels in the WKY and 2c* at this timepoint suggest that differential expression of one or 
more genes in the 2c* congenic interval may have a protective effect, enhancing oxidative 
stress defence. 
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Figure 3.7 – Kidney superoxide levels in 5 week old SHRSP, 2c* and WKY rats 
 
 
3.4.5 qRT-PCR of Other Candidate Genes 
Differential expression of genes identified in microarray studies was assessed by Taqman 
qRT-PCR. Relative expression of genes was measured between strains at the 5 and 16 
week timepoints, comparing expression to the SHRSP in each case (figure 3.10). 
Differential expression of Them4 was shown at both 5 and 16 weeks, SHRSP expression 
was 3-5 fold higher than in the WKY and 2c*. The only other gene for which differential 
expression was observed by qRT-PCR was Slc7a12-like, confirming the 5-week 
microarray results, SHRSP expression was approximately 2.5-fold higher than the WKY 
and 2c*.  
NADH-stimulated superoxide levels were measured in triplicate kidney homogenates. 
SHRSP superoxide levels were higher compared to both other strains. Mean ± SE  
*p<0.05 (ANOVA and Tukey post-test). 
* 
*  
   
 
Figure 3.8 - Taqman qRT-PCR of genes differentially expressed in microarrays
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Expression of each gene was quantified relative to β-actin and calibrated to the lowest WKY or SHRSP expression levels at 
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3.4.6 Promoter and Coding DNA Sequencing 
DNA sequencing was carried out to identify coding and promoter polymorphisms in 
differentially expressed genes from microarray data. Equivalent data for Gstm1 is 
presented in section 4.4.2. Representative images from PCR and sequencing are presented 
(figure 3.11). Polymorphisms were identified in Ggt1, Them4 and Hist2H2aa (table 3.4). 
Sequencing of Slc7a12-like coding sequences was unsuccessful, generating mixed 
sequence, this is likely to be due to the existence of several closely-related members of the 
slc7a gene family in the rat genome. The single polymorphism identified in Ggt1 was a 
conserved G at base 137 in the SHRSP, SHR and WKY, differing from the BN reference 
sequence, which encodes T at this position, this results in an amino acid change at residue 
46, encoding a serine in the BN and an alanine in the other strains. Two polymorphisms 
were identified in the Them4 3'UTR, the polymorphism at position +465 was unique to the 
BN, the polymorphism at base +833 was unique to the WKY; a promoter variant unique to 
the WKY was also identified at base -105 in Them4. A single promoter polymorphism was 
identified in HistH2aa with a C in the SHRSP and SHR, an A in the WKY and BN. No 
polymorphisms were observed in Anpep or Gclm coding or promoter sequences.  
 
Figure 3.9 – PCR and sequencing candidate gene coding and regulatory regions 
 
SHR 
SHRSP 
WKY 
500 bp 
600 bp 
A 
Them4 3'UTR sequences. (A) PCR amplification from duplicate SHRSP, WKY and 
SHR genomic DNAs with THEM4upAF+R primer pair, expected product size: 532 bp. 
(B) DNA sequencing electropherogram showing 3'UTR SNP in the WKY Them4 3'UTR 
at base +465. 
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Gene  Position  SHRSP  SHR  WKY  BN 
Ggt1  137  G  G  G  T 
Them4  +465  G  G  C  G 
  +833  C  C  C  T 
  -105 
 
G  G  A  G 
Hist2H2aa  -2293 
 
C  C  A  A 
Table 3.4 - Candidate gene coding and regulatory sequence variants 
Polymorphisms identified by DNA sequencing of coding and regulatory regions of Ggt1, 
Them4 and Hist2H2aa, Slc7a12-like, Anpep and Gclm. Sequence variants were only 
identified in Ggt1, Them4 and Hist2H2aa, patterns of conservation of SNPs varied 
between the SNPs.  
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3.5  Discussion 
The experiments presented in this chapter examined differential gene expression in the 
SHRSP, WKY and the 2c* congenic strain, which is of SHRSP genotype except for a 20 
cM region covering a blood pressure QTL on chromosome 2, which is derived from the 
WKY (McBride et al 2003). Expression levels of over 26000 mRNA transcripts were 
measured using Affymetrix GeneChip RGU34A, B and C microarrays in kidneys from five 
week old animals, a timepoint prior to the onset of severe hypertension in the SHRSP. 
Reduced expression of Gstm1 mRNA was measured in the SHRSP and validated by qRT-
PCR, this is a significant finding that strengthens the case for Gstm1 as a hypertension 
candidate gene. Impaired renal oxidative stress defence is likely to contribute to the onset 
of hypertension through cytotoxic effects leading to disrupted regulation of salt and water 
homeostasis (McBride et al 2003;McBride et al 2005). The 5-week gene expression data 
was also combined with an equivalent microarray dataset from 16 week-old rats (McBride 
et al 2003); pairwise comparisons between each strain at 5 and 16 weeks of age and IPA 
data analysis identified several genes involved in glutathione metabolism in addition to 
Gstm1 that were differentially expressed in microarray analysis, of which Slc7a12-like is 
also encoded from within the 2c* congenic interval. Analysis of secondary phenotypes 
related to hypertension included renal superoxide and GSH levels, showing that the 
SHRSP has increased renal oxidative stress during the onset of hypertension, and that the 
SHRSP and 2c* have reduced glutathione levels at 5 weeks of age compared to the WKY. 
At 16 weeks of age renal superoxide levels are significantly higher in the SHRSP than the 
WKY and the 2c* is intermediate (McBride et al. 2005), data presented here showed that at 
16 weeks renal GSH levels are reduced in the SHRSP compared to the WKY, while levels 
in the 2c* were significantly increased compared to 5 week levels, indicating that changes 
in expression of chromosome 2 WKY alleles may affect GSH cycling and renal oxidative 
stress in the 2c* by 16 weeks of age. The hypothesis that impaired renal GSH metabolism 
and reduced renal GSH contributes to hypertension in the SHRSP is consistent with 
published observations that glutathione depletion by two week administration of 
buthionine sulphoxide (BSO), an inhibitor of GSH synthase, to Sprague Dawley rats 
causes renal oxidative stress and severe hypertension (Vaziri et al. 2000). 
IPA allows the expression of several genes involved in numerous metabolic pathways to be 
inspected automatically in multiple comparisons of large datasets. Analysis of the 
canonical glutathione metabolism pathway with IPA identified probesets for 
gammaglutamyltransferase 1 (Ggt1) and aminopeptidase N (Anpep) that were James Polke, 2008    Chapter 3         116 
 
   
downregulated in microarray data in the SHRSP compared to the WKY and 2c* at 5 weeks 
of age. These results, in conjunction with the differential expression of Gstm1 and 
Slc7a12-like from RP data analysis suggested that renal glutathione metabolism in the 5-
week SHRSP is impaired (figure 3.12).  
 
Figure 3.10 - Renal glutathione metabolism 
 
 
 
 
 
 
 
 
One of the major functions of plasma GSH circulation is to supply cysteine for de-novo 
intracellular GSH synthesis (Lash et al 1988); in aqueous conditions at physiological pH 
cysteine oxidises to insoluble cystine (cysteine dipeptide). The liver is the major source of 
plasma GSH, and while there is evidence that GSH can be absorbed directly by kidney 
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Genes differentially expressed in renal 5 week microarrays between the SHRSP and 
WKY and between the SHRSP and 2c* are highlighted in orange (downregulated in 
the SHRSP) or green (upregulated in the SHRSP). Genes not found to be 
differentially regulated in the microarrays are coloured grey, Gclm (yellow) was 
upregulated in the SHRSP and 2c* at 5 weeks compared to 16 weeks. Following 
conjugation of GSH with oxidative or xenobiotic molecules (X) by Gstm1 (or other 
GST enzymes), the GSX conjugate is exported from the cell by the GSX transporter 
(GSX Trans). GSH is also exported to the extracellular space by the GSH transporter 
(GSH Trans) and the kidney is also a major site of plasma GSH uptake. Both GSX 
and GSH are metabolised by Ggt1 to generate cysteinylglycine (cys-gly) dipeptide, 
which is further metabolised by Anpep dipeptidase. Cysteine (cys), the limiting 
substrate for GSH synthesis, is recycled into the cell by amino-acid transporters such 
as Slc7a12-like. The first step in de-novo GSH synthesis is catalysed by glutamate 
cysteine ligase, a heterodimeric enzyme consisting of the catalytic subunit (Gclc) and 
the rate-limiting modulatory subunit (Gclm), generating γ-glu-cys. GSH synthase 
catalyses the final enzymatic addition of glycine (gly). Figure adapted from (Zhang et 
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proximal tubular membranes (Hagen et al 1988;Parks et al 1998), the GSH cycling 
pathway is the principal source of renal GSH. Ggt1 is central to GSH metabolism, it is the 
only known peptidase able to hydrolyse γ-glutamyl peptide bonds, catalysing the cleavage 
of GSH to liberate cysteinylglycine, and, following the export of GSH-conjugated 
oxidative or xenobiotic molecules, also catalyses the first step in their detoxification, also 
generating cysteinylglycine. Ggt1 is expressed in several cell types in the body including in 
the small intestine, choroid plexus, retinal pigment epithelium and lung, though its 
expression and activity in are highest in the proximal tubular epithelium (Hinchman et al. 
1990). Further evidence that renal GSH levels are maintained by glutathione cycling comes 
from the observation that the Ggt1-null mouse (Lieberman et al. 1996) has reduced GSH 
and cysteine levels and increased levels of DNA oxidative damage in the kidney, liver and 
lung (Rojas et al. 2000). The Ggt1-null phenotype is significantly ameliorated by n-
acetylcysteine supplementation, which increases cysteine and GSH levels (Lieberman et al 
1996;Barrios et al. 2001). Increased serum GGT1 in humans has long been recognized as a 
marker of alcohol abuse and/or liver damage (Teschke et al. 1977) however there is also 
recent epidemiological evidence that serum GGT1 levels are also an independent risk 
factor for hypertension, diabetes and cardiovascular disease (Lee et al. 2003;Lee et al. 
2006), these associations are thought to relate to persistent increased oxidative stress in at-
risk individuals, resulting in increased GGT1 expression. Conversely, accumulation of 
GGT1 has also been associated with increased oxidative stress in atherosclerotic plaques, 
contributing to the likelihood of plaque rupture, though this mechanism is unique to the 
atherosclerotic milieu and relates to reduction of Fe
3+ ions by γ-glutamylcysteine generated 
by GGT1 catalysis (Paolicchi et al. 1999). 
Anpep is a membrane bound dipeptidase that has been demonstrated to cleave 
cysteinylglycine to cysteine and glycine, providing amino acids for recirculation into the 
cell in GSH cycling (Tate 1985). Renal Anpep expression has also been implicated in other 
experimental rat models of hypertension; it is located on a chromosome 1 QTL between 
the DSS and DSR rats and while DSR and Lewis respond to high salt diet by increased 
renal Anpep expression, the same response was not observed in the DSS (Farjah et al. 
2004). In this model, Anpep is hypothesized to regulate renal salt reabsorption by 
catalysing conversion of AngIII – AngIV, which suppresses Na/K ATPase, leading to 
increased sodium excretion. In the DSS, decreased Anpep expression under salt loading 
was therefore proposed to contribute to salt retention and increased blood pressure (Kotlo 
et al. 2007b). Alternative dipeptidase enzymes may also be responsible for catabolism of 
cysteinylglycine in the kidney, indeed, dehydropeptidase I has been suggested to play a James Polke, 2008    Chapter 3         118 
 
   
greater role than Anpep in cysteinylglycine metabolism (Kozak et al. 1982;Hirota et al. 
1987). 
It is hypothesised that upregulation of the cysteine transporter Slc7a12-like in the SHRSP 
at 5 weeks of age in the SHRSP is a response to reduced intracellular GSH, cysteine supply 
is the rate-limiting substrate for GSH synthesis. However it is likely that Slc7a12-like is 
not the only membrane amino acid transporter involved in cysteine transport and 
glutathione cycling in the kidney, the human isoforms of other solute carrier family 
proteins show specificity for cysteine transport, such as SLC1A4 (Arriza et al. 1993) and 
SLC1A5 (Kekuda et al. 1996), and Slc1a5 expression has been specifically detected in 
rabbit kidney proximal tubules (Avissar et al. 2001). In addition, though principally a 
neuronal amino acid transporter, pharmacological inhibition of SLC1A1 in human 
embryonic kidney cells has been shown to reduce cellular GSH levels in-vitro (Watabe et 
al. 2007). Therefore differential expression or activity of alternative amino acid 
transporters may account for the fact that Slc7a12-like was not differentially expressed at 
16 weeks of age in SHRSP, despite reduced glutathione. Furthermore, a mechanism exists 
in the kidney to directly import γ-glutamylcysteine into cells for glutathione synthesis 
(Anderson et al. 1983), bypassing the conjugation of cysteine and glycine catalysed by 
glutamate cysteine ligase, though this mechanism is thought to be an adjunct to de-novo 
GSH synthesis (Lash 2005). The difficulties in sequencing the Slc7a12-like transcripts in 
kidney cDNA are likely to be due to multiple closely-related solute-carrier genes in the 
transcriptome; Ensembl lists 11 paralogues with 24-92% identity to Slc7a12-like. However 
this observation does not compromise the qRT-PCR results for Slc7a12-like, Gene 
Expression Assays from Applied Biosystems for genes that are part of closely related 
families are validated to amplify the intended sequence with 1000-3000 fold higher 
sensitivity than the closest-related family member. Slc7a12-like exonic sequencing could 
be accomplished in future studies by designing PCR primers that anneal in the introns of 
the gene.  
qRT-PCR did not verify differential expression of Ggt1 and Anpep from the 5 week 
microarray data and the hypothesis to explain reduced GSH levels in the SHRSP by 
reduced expression of Ggt1 and Anpep was not supported. There are several possible 
explanations for the disparity between the microarray and Taqman results. First, one would 
expect a certain rate of false-positive calls in any data set, and the false discovery rate 
threshold was set at 5% for the RP analysis. Other published studies have reported non-
validation of microarray data by qRT-PCR, for example, Yagil et al. 2005 reported 9 out of 
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with one probe showing discordant results, i.e. increased expression in a strain in Taqman 
results where the microarray had shown decreased expression (Yagil et al 2005). Alternate 
splicing of Ggt1 and Anpep mRNA could also explain the discordant results, microarray 
probesets and Taqman probes may target different isoforms that differ in transcript 
abundance. Only one transcript is listed for Anpep in the Ensembl database, and while 7 
different transcripts for Ggt1 are known to exist in the rat, they differ in the 5'UTR only 
(Chikhi et al. 1999).  
Despite the Taqman results for Ggt1 and Anpep, these data nevertheless provide evidence 
of a genetic effect of the 2c* congenic interval on GSH metabolism and oxidative stress: 
Renal GSH levels at 5 weeks in the 2c* were similar to the SHRSP, but at 16 weeks of age 
were similar to the WKY, meanwhile kidney superoxide levels at 5 weeks of age in the 2c* 
were similar to the WKY, but at sixteen weeks are intermediate between the SHRSP and 
WKY (McBride et al 2005). Thus WKY alleles in the 2c* congenic interval are proposed 
to have a protective effect on kidney oxidative stress at 5 weeks despite decreased GSH, 
but by 16 weeks of age the preponderance of SHRSP genotype in the 2c* increases kidney 
oxidative stress despite increased GSH. The identity of the genes responsible for the 
phenotypic differences between the SHRSP, 2c* and WKY could be identified in future 
experiments using microarrays with improved coverage, for example, Affymetrix now 
produce a microarray chip that surveys expression of all known exons, enabling analysis of 
gene expression and alternative splicing of genes.  
An intriguing hypothesis regarding Gclm expression was also raised by the microarray data 
that showed increased expression in the SHRSP and 2c* strains, but not the WKY, at 5 
weeks of age compared to 16 weeks of age. This implied an SHRSP allele-specific 
expression pattern for Glcm that may contribute to the development of hypertension over 
time in the SHRSP and 2c*, however, Taqman mRNA measurements did not confirm the 
microarray results and no promoter polymorphisms were identified in the SHRSP Gclm 
promoter. 
The renal differential expression of Hist2H2aa and Them4 at 5 weeks of age, both 
expressed from within the 2c* congenic interval provide novel candidates for genes 
involved in the development of hypertension in the SHRSP. Them4 differential expression 
was confirmed by qRT-PCR, and also a showed similar differential expression pattern at 
16 weeks of age, being upregualted in the SHRSP compared to both other strains at both 
timepoints. No functional data is published for rat Them4, though the human ortholog, 
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regulate phosphorylation and thus activity of protein kinase B alpha (PKBα) (Maira et al. 
2001;Ono et al. 2007). PKBα, also known as AKT1, is a well described target of 
downstream receptor tyrosine kinases that signal via phosphatidylinositol 3-kinase (PI 3-
kinase), mediating mitogenic responses to a range of growth factors such as platelet-
derived growth factor, insulin and insulin-like growth factor-1 (IGF-1) (Galetic et al. 
1999). Among many cellular effects, activation of PKBα has been associated with the 
inactivation of glycogen synthesis (Cross et al. 1995), suppression of apoptotic signals 
(Ahmed et al. 1997) and increasing cellular glucose uptake (Kohn et al. 1996). There are 
conflicting reports of the regulatory effects of CTMP on PKBα activity, a study has shown 
that CTMP negatively regulates PKBα phosphorylation and reverses oncogenic phenotype 
of cells expressing the PKBα-related oncogene v-Akt (Maira et al 2001), while a recent 
study showed that upregulation of CTMP leads to increased PKBα phosphorylation and 
enhanced antiapoptotic and glucose metabolic processes (Ono et al 2007). Hist2H2aa 
encodes one of the core histone proteins that are the structural subunits of nucleosomes, a 
Taqman probe is not available for Hist2aa, hence confirmation of its differential 
expression would depend on designing a custom probe. 
Claudin11 and Prcc genes were differentially expressed between 5 and 16 week 2c* and 
WKY rats, both are encoded within the chromosome 2 congenic interval and their reduced 
expression at 16 weeks may therefore be related to a blood-pressure lowering effect. 
Claudin 11 is one of a large family of tight junction transmembrane proteins that mediate 
cell-cell associations and can ion channels. The Claudin 11-null mouse shows neurological 
defects and male sterility due to reduced parallel tight-junction strands in central nervous 
system myelin and between sertoli cells (Gow et al. 1999). Interestingly, WNK4 protein 
has been shown to mediate phosphorlyation of claudin protiens (though only claudins 1-4 
were examined) in in-vitro canine kidney cells, leading to increased chloride permeability 
(Yamauchi et al 2004). Psuedohypoaldosteronism type II-mutant WNK4 upregulated 
chloride permeability to a greater extent than wild-type WNK4, leading to the postulation 
that the phenotypic effects of WNK4 mutations may be related in part to regulation of 
claudins (Yamauchi et al 2004). Claudin 11 expression has been co-localisesd to the thick 
ascending limb of the loop of Henle in the mouse (Kiuchi-Saishin et al. 2002), the region 
of the nephron largely responsible for active sodium and chloride reabsorption. The human 
ortholog of Prcc was first identified in a subset of renal carcinoma patients with a 
translocation between Xp11 and 1q21 that generated a novel fusion protein between the 
TF3 transcription factor gene and the gene that subsequently became known as PRCC 
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interaction between the TF3/PRCC fusion protein and the mitotic checkpoint control 
protein MAD2B which is thought to account for tumourigenesis (Weterman et al. 2001), 
though the role of PRCC remains unknown.  
DNA sequencing identified single nucleotide polymorphisms in the promoter region of 
Them4 and Hist2H2aa, a missense mutation in Ggt1 and 2 3'UTR variants in Them4. The 
patterns of conservation of these mutations differed, with most being unique to the BN or 
WKY strains, hence they were not implicated in hypertension in the SHRSP. Only the 
Hist2H2aa -2293 C>A polymorphism was found uniquely in hypertensive strains (both the 
SHRSP and SHR) and hence may be a functional candidate for increased expression in the 
SHRSP once differential expression of Hist2H2aa is confirmed. See chapter 4 for 
experiments performed to investigate the polymorphisms identified in the Gstm1 promoter. 
The major finding in this chapter was reduced renal Gstm1 expression in the 5 week old 
SHRSP compared to the WKY and 2c*; the following chapters outline the work that was 
subsequently performed to investigate the control of Gstm1 expression and the functional 
effects of modulating Gstm1 expression in-vitro and in-vivo. The transcriptomic and 
pathway analysis techniques applied in this chapter represent a significant advance on 
traditional microarray data analysis. The ability to automatically consider differential 
expression of multiple genes affecting specific physiological pathways in pairwise 
comparisons with parental and congenic strains is an extremely efficient technique for very 
large data sets. Even given that differential expression of candidate genes was not 
confirmed in follow-up analysis, the hypothesis that GSH metabolism may be controlled 
by the influence of genes within the congenic interval is supported by analysis of renal 
GSH levels and warrants additional study.  
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4.1   Introduction 
Following the discovery of reduced Gstm1 mRNA expression in the 16-week old SHRSP 
kidney compared to the WKY (McBride et al 2003), and the results presented in chapter 3 
that showed similarly reduced renal Gstm1 expression in the prehypertesnive SHRSP, one 
of the focuses of this project was to investigate the molecular mechanisms of differential 
Gstm1 expression and its relation to renal oxidative stress. As discussed in section 1.3, 
reactive oxygen species inflict damage on macromolecules including lipids, nucleic acids 
and proteins, such damage impairs cellular function and may lead to apoptotic or 
carcinogenic effects. It is hypothesised that reduced Gstm1 expression contributes to 
hypertension in the SHRSP by compromising renal oxidative stress defence, leading to 
cytotoxicity and impaired salt and water homeostasis (McBride et al 2005).  
The large number of closely related GST isoforms and their widely overlapping substrate 
specificities present a particular challenge to researchers investigating individual GST 
enzymes. A vast majority of this research has focussed on investigations of the roles of 
specific GSTs in drug metabolism, and particularly in resistance to chemotherapeutic 
agents (Hayes JD et al. 1995). Considerable research has also been performed in humans to 
assess whether polymorphisms in GST genes confer increased risks to disease. For 
example, there are common deletion polymorphisms of human GSTM1 and GSTT1 that 
have been the focus of much study. The deletions arise through unequal crossover between 
repeat sequences either side of the genes and result in individuals with 0, 1 or 2 copies of 
the genes. GSTM1 and GSTT1 deletions occur on 50% and 13% of chromosomes in 
Caucasians, respectively (Garte et al. 2001). Many studies have linked GSTM1 and GSTT1 
deletions to susceptibility to a number of cancers, including colorectal, lung, skin, bladder 
and breast cancers, however there have been many conflicting publications (Hayes et al 
2005). Other studies correlating an increased incidence of lung and bladder cancer with 
smoking and GSTM1 deletions have shown to be much more reproducible (Norppa 2003).  
There is also evidence that human GST polymorphisms may influence cardiovascular 
diseases. For example, a case-control study in a Chinese population found a significant 
increase in type 2 diabetes risk among GSTT1-null individuals compared to those with at 
least one copy (Wang et al. 2006a). In addition, GSTM1-null and GSTT1-null genotypes 
have been associated with an increased risk of coronary heart disease in smokers in 
American populations (Li et al. 2000). Faster progression of atherosclerotic lesions has 
also been demonstrated among GSTM1-null smokers (de Waart et al. 2001). Paradoxically 
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lower extremity arterial disease compared to GSTT1-null smokers (Li et al. 2001), while 
the GSTM1-null genotype has also been shown to be associated with a decreased risk of 
acute myocardial infarction in smokers (Wilson et al. 2000).  
A majority of the experimental work relating to the control of GST gene expression relates 
to the antioxidant response element (ARE), a transcription factor (TF) binding motif first 
characterised in the rat Gsta2 gene where it was demonstrated to mediate basal and 
stimulated expression of Gsta2 in response to xenobiotic phenolic antioxidants, hydrogen 
peroxide and di- and trihydroxybenzene ROS generators (Rushmore et al. 1991). A number 
of publications have characterised the minimum functional ARE consensus sequence, there 
is widespread agreement that the core sequence is: TGACnnnGCA (Wasserman et al. 
1997;Yang et al 2002). The transcription factor Nuclear-factor-erythroid 2-related factor 2 
(Nrf2) was first identified as the activating ligand for the ARE in the rat Nqo1 gene 
(Venugopal et al. 1996), and was firmly identified as a crucial factor in mediating antitoxic 
and oxidative stress defence mechanisms in Nrf2-knockout (Nrf2
-/-) mice that showed 
reduced expression of a number of detoxifying enzymes (Itoh et al. 1997). Further studies 
in the Nrf2
-/- mice showed reduced liver constitutive and inducible expression of Gsta1, 
Gsta2, Gstm1, Gstm2, Gstm3 and Gstm4 (Chanas et al. 2002), though functional ARE 
sequences have not been published for all of these genes. The ARE has subsequently been 
found in the regulatory regions of many genes encoding proteins involved in detoxification 
and oxidative stress defence, including other GSTs, NADP(H):quinone reductase (NQO1), 
Glutamate cysteine ligase, UDP-glucuronyl transferase and Metallothionein-1 (Lee et al. 
2004). Other transcription factors that have been experimentally linked to control of rat, 
mouse and human GST expression are listed in table 4.1. Very little is known about the 
control of rat Gstm1 expression though it has been shown to be up-regulated by induction 
of MAPK signalling pathways in response to geniposide, an extract of gardenia fruit (Kuo 
et al. 2005). 
The work performed in this chapter investigated the differential expression of renal Gstm1 
in a panel of hypertensive and normotensive rat strains and correlated reduced Gstm1 
expression with hypertension and renal oxidative stress, measured by nitrotyrosine western 
blotting. Luciferase promoter constructs and in-silico sequence analysis examined the 
Gstm1 promoter in the SHRSP and WKY, identifying polymorphisms at several potential 
transcription factor binding sites that may affect Gstm1 expression in the SHRSP.  
   
Gene  Species  TF binding site  Evidence  Primary Reference 
Gsta1  Rat  Nrf2  Mutation and deletion analysis 
 
(Rushmore et al 1991) 
Gsta1  Rat  C/EBPα  Competition assay, antibody immunodepletion 
 
(Pimental et al. 1993) 
Gsta1  Rat  AR  Site-directed mutagenesis and glucocorticoid receptor 
overexpression 
 
(Falkner et al. 1998) 
Gsta1  Mouse  HNF1, HNF4 
 
5' deletion, EMSA, competition assay  (Paulson et al. 1990) 
Gsta2  Rat  Nrf2, C/EBPβ, 
PPARγ 
 
EMSA, competition assays, deletion analysis  (Park et al. 2004) 
Gsta3  Mouse  Nrf2  Site-directed mutagenesis, Nrf2 overexpression, 
EMSA 
 
(Jowsey et al. 2003) 
Gstm1  Mouse  c-Myb  c-Myb and mutant c-Myb overexpression, EMSA 
 
(Bartley et al. 2003) 
Gstm2  Mouse  SP1, MYB  Deletion analysis, Overexpression of MYB 
 
(Kumar et al. 2001) 
Gstp1  Rat  c-Jun 
 
EMSA, competition assay  (Kawamoto et al. 2000) 
Gstp1  Rat  Nrf2, AR 
 
EMSA  (Ikeda et al. 2002) 
GSTP1  Human  Nrf2 
 
Deletion analysis, EMSA  (Montano et al. 2004) 
GSTP1  Human  NFκB  Site-directed mutagenesis and NFκB overexpression 
 
(Morceau et al. 2004) 
GSTP1  Human  SP1  Site-directed mutagenesis, EMSA 
 
(Moffat et al. 1996) 
GSTP1  Human  AP1, NFκB  Site-directed mutagenesis, NFκB overexpression 
 
(Xia et al. 1996) 
Table 4.1 - Transcription factors implicated in regulation of expression of human, mouse and rat GST genes
Instances where experimental evidence has shown binding of transcription factors to a promoter sequence are included, indicating the 
techniques used. EMSA: Electrophoretic mobility shift assay, AP1: Activator protein 1/2 , NFκB: Nuclear factor kappa B, AR: Androgen 
Receptor, HNF1/4: Hepatic nuclear factor 1/4, C/EBPα/ β: CCAAT enhancer-binding protein alpha/beta, PPARγ: Peroxisome proliferator-
activated receptor gamma, SP1: Specificity protein 1, c-Myb: Myoblastosis oncogene. Modified from: (Pool-Zobel et al. 2005) James Polke, 2008    Chapter 4         126 
 
   
4.2  Aims 
·  To compare the renal mRNA expression levels of Gstm1 in 16 week old SHRSP, WKY, 
BN and SHR rats using Taqman qRT-PCR. 
·  To  assess  renal  oxidative  stress  in  SHRSP,  2c*  and  WKY  strains  with  anti- 
nitrotyrosine western blotting. 
·  To sequence the coding and regulatory regions of Gstm1 in the SHRSP and WKY and 
to  investigate  the  transcriptional  effects  of  promoter  polymorphisms  with  luciferase 
expression constructs. 
·  To use the 'Transfac' transcription factor database to identify candidate transcription 
factor binding sites that affect Gstm1 transcription. James Polke, 2008    Chapter 4         127 
 
   
4.3  Methods 
4.3.1 Renal Gstm1 Quantitative Real-time PCR  
Gstm1 expression levels were measured in mRNA extracts from 16 week old SHRSP, 
WKY, BN and SHR rats (BN and SHR rats were purchased from Harlan UK), three rats 
from each strain. Liquid nitrogen snap-frozen kidneys were homogenised in Qiagen QLT 
buffer and homogenised using a Polytron PT2100 rotor homogeniser and RNA extraction 
was performed as per section 2.5.3 using Qiagen RNeasy Maxi columns. RNA was treated 
with DNA-free and cDNA was synthesised using the Clontech Advantage RT for PCR kit 
as described in section 2.7.1. Applied Biosystems Gene Expression Assay probe for rat 
Gstm1 (assay number Rn00755117_m1) and rat β-actin endogenous control probe (part 
number 4352340E) were multiplexed 20 l reactions in 96-well plates. Probe amplification 
efficiencies were confirmed and relative gene expression was calculated as described in 
section 2.7.2. 
4.3.2 Gstm1 Promoter and Exon Sequencing 
Gstm1 promoters encompassing 2.5kb upstream of the Gstm1 translation initiation site 
were sequenced in WKY, SHRSP, BN and SHR rats using 8 overlapping primer pairs 
(Gstm10R +11F, 12R+13F, 14R+15F, 16R+17F, 18R+19F, 20F+21R, 22F+23R, 
24F+25R). Coding exons were sequenced from kidney cDNA templates with primers 
Gstm1F+2R and Gstm3F+4R. Sequencing protocols were followed as per section 2.4. 
4.3.3 Renal Anti-Nitrotyrosine Western Blotting 
Kidney proteins from 16 week old SHRSP, 2c* and WKY rats were prepared and 
concentrations were ascertained as described in section 2.2.5 Protein from three animals 
per strain was analysed using the standard western blotting protocol, section 2.6. Eighty  g 
of protein in reducing buffer was loaded per lane and full-range Rainbow marker was used 
as a size standard. Mouse anti-nitrotyrosine primary antibody (Abcam ab53232) was used 
at a dilution of 1/750, followed by HRP-conjugated goat anti-mouse secondary antibody 
(Upstate 12-349) at 1/5000 dilution. After ECL detection and membrane stripping, 
immunoreactive Gapdh levels were assayed using mouse anti-Gapdh primary antibody 
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antibody (DAKO P0260) diluted 1/2000. Densitometry was performed as per section 2.6.6 
using 'local' background correction. 
4.3.4 Promoter Sequence Alignment  
2.5kb rat and mouse Gstm1 promoter sequences were aligned using 'zPicture' (Ovcharenko 
et al. 2004), an online sequence alignment and visualisation tool that uses a local alignment 
algorithm to compare input sequences and generate graphical and textual alignments. 
Display settings for graphical output of alignments were set to shade areas of over 70% 
homology in a 100bp sliding window. Textual alignments at the sites of individual rat 
Gstm1 promoter polymorphisms and a putative ARE site were copied and pasted from the 
zPicture browser. 
4.3.5 Promoter Sequence PCR 
SHRSP and WKY promoter sequences were cloned into the Promega pGL3 Basic 
luciferase plasmid for promoter activity analysis. pGL3 Basic is a promoterless eukaryotic 
expression plasmid encoding modified firefly luciferase. A multiple cloning site (MCS) 
immediately 5' of the luciferase coding sequence allows promoter sequences to be cloned 
in, transcriptional efficiencies of different promoter sequences can be compared by 
measuring luciferase activities in transfected cells. 
Four promoter regions were amplified for cloning, ranging in size from 0.9 kb-2.5 kb. Each 
promoter sequence was amplified with the same reverse primer, Gstm1-1R, which anneals 
immediately 5' of the rat Gstm1 translational start site. Forward primers incorporated a 
MluI restriction site preceded by 3xC residues, Gstm1-1R incorporated an XhoI restriction 
site preceded by 3xC residues. Forward primers were named Gstm1-0.9F, Gstm1-1.6F, 
Gstm1-2.2F and Gstm1-2.5F. Promoter sequences were amplified for cloning using 
genomic template DNA from SHRSP and WKY rats. Novagen HotStart polymerase was 
used as detailed in section 2.2.3 with annealing temperatures of 62°C.  
4.3.6 Promoter Sequence Cloning 
PCR products were 'blunt cloned' into Stratagene PCR-Script Amp SK(+) (PCR-Script) 
plasmid following the manufacturer's instructions in the PCR-Script Amp Cloning kit. The 
PCR-Script plasmid is supplied linearised by digestion with SrfI restriction enzyme. This 
cloning platform also allowed blue/white selection based on lacZ gene disruption; IPTG James Polke, 2008    Chapter 4         129 
 
   
(isopropyl-beta-D-thiogalactopyranoside) (20 mM) and X-gal (8  g/ml) were added to 
ampicilin (100  g/ml) selective LB agar, white colonies were screened for the insert. All 
cloning in this chapter utilised plasmids expressing the ampicillin resistance gene, selective 
Luria agar and broth were used with 100  g/ml ampicilin (Sigma). 
Promoter sequence PCR reactions were electrophoresed as described in section 2.2.4, 
bands were excised from the agarose and pooled prior to gel purification as per section 
2.5.5. DNA was eluted in 40  l H2O; 10  l of this was 'polished' using Stratagene Pfu 
(Pyrococcus furiosus) polymerase enzyme that catalyses 5'-3' proofreading polymerisation. 
Reaction conditions were: 10  l PCR product; 1  l 10mM dNTP; 1.3  l 10x Polishing 
buffer; 1  l Pfu DNA polymerase (0.5 U/ l); heat to 72°C for 30 minutes. 5  l of the 
polished PCR products were used in ligation reactions with 10 ng PCR-Script plasmid, the 
precise molar ratio of plasmid:insert was not calculated but the insert was vastly in excess, 
as is necessary in PCR-cloning. The ligation reactions constituted: 1  l PCR-Script vector 
(10 ng/ l), 1  l 10X PCR-Script reaction buffer; 0.5  l 10 mM rATP; 5  l polished PCR 
product; 1  l 5 U/ l SrfI; 1  l T4 DNA ligase; 0.5  l H2O. Ligation reactions were 
incubated at room temperature for an hour, then de-activated by heating to 65°C for 5 
minutes.  
Forty  l of XL-10 Gold cells were thawed on ice and 1.6  l β-mercaptoethanol was added. 
Cells were incubated on ice for 10 minutes, 4  l of ligation reaction was added and cells 
were incubated on ice for 30 minutes, then heat-shocked at 42°C for 30 seconds before 
returning to ice for 2 minutes. Four hundred and fifty  l of 42°C SOC media was added 
and transformation cultures were incubated in a shaking incubator at 37°C for an hour. 
Transformation cultures were spread over IPTG/X-Gal/ampicillin agar plates. The 
following morning, white colonies were selected for PCR screening as detailed in section 
2.5.7. PCR-Script-specific T7F and T3R PCR primers that span the cloning site were used. 
Successful clones were further confirmed by sequencing: T7F/T3R PCR products were 
sequenced with T7F and T3R and Gstm1 promoter primers. 
PCR-Script clones containing SHRSP and WKY promoter sequences were amplified and 
purified using Qiagen plasmid purification Maxi columns as described in section 2.5.3. 
Promoter sequences were digested with MluI and XhoI restriction enzymes prior to 
subcloning into similarly double-digested pGL3 Basic plasmid; digestion was performed as 
per section 2.5.4. Digested PCR-Script plasmids and pGL3 Basic vectors were 
electrophoresed and gel purified. Ligation was performed using 50 ng linearised pGL3 
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2.5.1, colonies were PCR-screened screened as per section 2.5.7 using RV3F and GL2R 
primers that anneal either side of the pGL3 Basic MCS. Positive clones were definitively 
confirmed by DNA sequencing and Maxi-preps were prepared for each pGL3 Basic 
plasmid. The eight pGL3 Basic plasmids were named according to the promoter sequences 
they encoded: pWKY0.9, pSP0.9, pWKY1.6, pSP1.6, pWKY2.2, pSP2.2, pWKY2.5 and 
pSP2.5. 
4.3.7 Promoter Activity Analysis  
Transfection is a variable procedure as transfection efficiency can differ from well to well 
due to differences in cell number and distribution and variable DNA/FuGENE complex 
density in transfection mixtures. Consequently, the pGL3 Basic plasmids were co-
transfected with pMV10 at a ratio of 3:1. pMV10 expresses lacZ driven by a CMV 
promoter. β-galactosidase activity was measured in lysates to correct for variations in 
transfection efficiencies between wells. Total protein concentration per well, measured by 
BCA assay as described in section 2.2.5, was also used to correct for variations in cell 
number between wells. Promoter activities were calculated as: luciferase activity (relative 
light units) / β-galactosidase activity (relative light units) / protein concentration (ng/ l). 
Each pGL3 Basic plasmid was transfected into triplicate wells of NRK52E cells at 
approximately 50-60% confluence. The experiment was repeated 3 times. Triplicate 
untransfected control wells were included in each experiment and triplicate control wells 
were also transfected with 200 ng pGL3 Control (identical to pGL3 Basic except that 
luciferase expression is driven by an SV40 promoter), 200 ng pMV10 or co-transfected 
with 150 ng pGL3 Control and 50 ng pMV10. Luciferase and β-galactosidase activities 
and BCA protein levels were measured in all cell lysates except those transfected with 
200ng pMV10, which were fixed and stained for β-galactosidase activity as per section 
2.3.4. Specific experimental protocols are outlined below. 
4.3.7.1 Optimising Transfection of NRK52E Cells 
NRK52E cells were obtained from the European Collection of Cell Culture (ECACC) and 
maintained in Dulbecco's Modified Eagle Medium containing 4.5g/L D-glucose; 10% 
foetal calf serum (FCS); 2mM GlutaMAX; 1mM sodium pyruvate; 100 U/ml penicillin; 
0.1mg/ml streptomycin. Transfections were optimised and performed in 24-well culture 
plates. All transfections followed the protocol outlined in section 2.3.3, cell culture media 
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Promega pGL3 Control plasmid was used for the initial experiments to optimise NRK52E 
transfection, performed according to the manufacturer's instructions. Ratios of 3:1, 3:2 and 
6:1 FuGENE:DNA ( l: g) were used, with a total amount of DNA per well of 200 ng, 500 
ng and 1  g. Pilot dual transfections were also performed with a 150 ng pGL3 Control and 
50ng pMV10 plasmids to ensure that measurable β-galactosidase activities could be 
achieved. 
4.3.7.2 Luciferase Activity Assay 
Transfected NRK52E cells were lysed using Promega Reporter Lysis Buffer (RLB), 200  l 
1 X RLB was added per well, complete cell lysis was ensured by a cycle of freeze/thawing 
to -20°C. Lysates were collected and centrifuged to collect cellular debris, then stored on 
ice. The luciferase assay reaction was performed in white 96-well flat-bottomed plates. The 
total reaction volume was 200  l, comprising 60  l 1 X RLB, 40  l lysate and 100  l 
Promega luciferase assay reagent (LAR). Each well was read by measuring total 
luminescence in a 10-second period on a Wallac Victor 2 plate reader. Standards were 
measured in duplicate, samples were measured in triplicate. A standard curve using 
recombinant luciferase (0.3 ng/ l to 5  g/ l) was used to confirm that all experimental 
readings were within the linear range of the assay. Background luminescence from control 
wells with no cell lysate or recombinant luciferase were subtracted from all readings. 
4.3.7.3 β-Galactosidase Activity Assay  
The Tropix Galacto-Light Plus β-galactosidase activity assay kit (Applied Biosystems) was 
used for β-galactosidase activity assays. Prior to β-galactosidase activity measurements all 
cell lysates were pretreated by adding dithiothreitol (DTT) to a final concentration of 0.5 
mM and heating to 48°C for 50 minutes. A dilution series of β-galactosidase standards 
from 0.25 ng/ l to 1  g/ l was assayed in each experiment to confirm that all experimental 
readings were within the linear range of the assay. A total volume of 20  l of NRK52E 
cells lysates or diluted standards were aliquoted into white 96-well assay plates. Standards 
were assayed in duplicate, samples were assayed singly. Galacton Plus substrate mix was 
diluted 1:100 in β-galactosidase assay diluent (100 mM NaPO4; 1 mM MgCl2, pH 8) and 
70  l was added to each well. Samples were left at room temperature for an hour. 100  l 
Light-Emission Accelerator II was added to each well. Full-spectrum luminescence was 
measured on a Wallac Victor 2 plate reader. Background luminescence from control wells 
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4.3.7.4 pGL3 Basic Subcloning 
The plasmid sequences of pSP1.6 and pWKY1.6 were analysed for restriction sites that 
occurred in the interval between SNPs 1-7 and SNPs 8-12. A BsrGI restriction site was 
identified within this region and a second BsrGI site was also identified in the pGL3 Basic 
backbone (within the luciferase coding region), figure 4.1.  
 
Figure 4.1 - Subcloning to generate novel 1.6 kb promoter constructs 
 
 
pSP1.6 and pWKY1.6 plasmids were digested with BsrGI, generating 1433 bp and 4987 
bp fragments. All restriction digests products were gel purified. 2.5  g of the 4987 bp 
fragments were dephosphorylated with Roche shrimp alkaline phosphatase (SAP) using the 
following protocol: 5  l 10X buffer, 5  l SAP (1 U/ l), and H2O in a total volume of 50 ul; 
heated to 37°C for 15 minutes followed by 65°C for 15 minutes.  
50 ng of 4987bp digest product from pSP1.6 was ligated with the 1433 bp digest product 
from pWKY1.6, and vice-versa. Ligations were performed with 1433 bp:4937 bp fragment 
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Promoter sequences and the positions of the SNPs in pSP1.6 are indicated. pSP1.6 and 
pWKY1.6 were digested with BsrGI, generating 1.4 kb and 5 kb fragments from each. 
The 1.4 kb fragment of pSP1.6 was ligated to the 5 kb fragment of pWKY1.6 to generate 
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ratios of 3:1 as per section 2.5.6 and transformed into JM109 cells. Colonies were PCR 
screened with RV3F and GL2R primers and sequenced for definitive confirmation of 
successful subcloning. The resultant plasmids all encoded 1.6 kb Gstm1 promoters, 
pSP1.6(1-7) carried only SHRSP SNPs 1-7 with WKY sequence at SNPs 8-12, while 
pSP1.6(8-12) carried only SHRSP SNPs 8-12 with WKY sequence at SNPs 1-7 (figure 
4.1). The promoter activities of the novel promoter sequences were assessed alongside 
pSP1.6 and pWKY1.6. Transfections, luciferase activity, β-galactosidase activity and BCA 
assays were performed as described above. 
4.3.7.5 Site-Directed Mutagenesis 
Site directed mutagenesis was performed by 'PCR sewing', illustrated in figure 4.2. This 
strategy utilises PCR primers to introduce mutations, the mutagenic primers do not anneal 
100% to the template, they have mismatches near the middle of their sequence; in order to 
ensure annealing they are longer than standard PCR primers, 30-33bp in this project. 
Novagen KOD Hotstart was used throughout with a 60°C annealing temperature. Site-
directed mutagenesis primers were named SNP8F, SNP8R, SNP9F, SNP9R, SNP10+11F, 
SNP10+11R, SNP12F, and SNP12R, they were used with Gstm1-1R and Gstm1-1.6F 
primers (represented by primers 1 and 3 in figure 4.2). 
One  g of PCR product from the final PCR reaction was double-digested with MluI and 
XhoI. Digests were gel purified and ligated into MluI and XhoI- digested pGL3 Basic with 
an insert:vector molar ratio of 3:1. Colonies were PCR-screened with RV3F and GL2R 
primers and presence of the correct combination of promoter mutations was verified by 
DNA sequencing. Maxi-preps of the novel plasmids were prepared using Qiagen Plasmid 
Maxi columns. The novel plasmids were named pSP1.6 (1-7+8), pSP1.6 (1-7+9), pSP1.6 
(1-7+10+11) and pSP1.6 (1-7+12). The promoter activities of the mutated plasmids was 
assayed in NRK52E cells alongside pSP1.6, and pWKY1.6 using exactly the same 
protocols as above. James Polke, 2008    Chapter 4         134 
 
   
 
Figure 4.2 – PCR sewing for site-directed mutagenesis 
 
 
 
4.3.8 Transfac Professional Promoter Sequence Analysis 
Transfac Professional is a commercial transcription factor database curated by the 
bioinformatics company Biobase, it includes information on over 8,000 TFs and over 
18,000 TF binding sequences found in vertebrate, bacteria, fungi, insect, nematode and 
plant genomic sequences. Transfac Professional requires a subscription for access, it is 
distinct from the publicly available Transfac databases in that it includes the most up-to 
date releases of the database and allows specialised searches to be performed. The work 
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presented here was performed using release 10.1 of Transfac professional, from 
31/03/2006. From herein, 'Transfac' is used to denote 'Transfac Professional' in this text. 
Biobase use experimental and bioinformatic evidence of TF binding to construct 
nucleotide positional weight matrices that can provide the user with a measure of the 
relative likelihood that a TF binds to particular input sequences. Matrices are constructed 
by aligning multiple known TF binding sequences and recording the frequency that each 
nucleotide occurs at each position. This is collated into a consensus sequence for the 
matrix, typically 7-25 bases long. The five most highly conserved consecutive bases are 
designated the 'core' binding sequence. Many matrices are constructed using the evidence 
of a single experimental study in a particular species, for example where libraries of 
random or mutated sequences were tested for TF binding. Thus a particular TF will have 
multiple matrices, relating to evidence from different studies and species. Other matrices 
are constructed by collating the evidence of several publications, often across several 
species.  
4.3.8.1 Generating Transcription Factor Matrix Tables 
Transfac includes a module called Match (Kel et al. 2003) that accepts input nucleotide 
sequences to be searched for alignment with transcription factor matrices. Fifty base pair 
sequences either side of SNPs 1-13 (SNPs 1+2, and SNPs 10+11 were analysed together 
due to their close proximity) from the SHRSP and WKY were input to Match to generate a 
table of TF binding sites for each. The tables (SHRSP and WKY) generated for each SNP 
site were then compared to find TF binding sites lost or created by the SNPs in the SHRSP. 
Thus this analysis searched for binding sites for activating TFs for which binding is 
disrupted by the SNPs in the SHRSP, or sites for inhibitory TFs for which novel binding 
sites are created. The following parameters were applied for Match searches: 
Groups of Matrices: Only matrices relating to vertebrate TFs were considered 
Matrix Quality: Only 'high quality' matrices were considered, defined as matrices that 
generate less than 10 hits per 1000 nucleotides in test alignments with promoter sequences 
by Biobase. This discounts about 5% of the matrices in the Transfac database that would 
generate a high number of false-positive hits 
Similarity Scores: Transfac searches for motifs within query sequences that pass a 
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to each base in a motif based on the frequency of that particular nucleotide (A, T, C, or G) 
occurring in the core or matrix consensus sequence. The maximum core or matrix score is 
1.0. Similarity thresholds were set at the default values of 0.75 for core sequences and 0.7 
for matrix sequences. Transfac scores the core sequence first, if it passes the threshold it 
then inspects the matrix sequence, if this also passes this threshold, the matrix is included 
in the output. 
Match outputs were converted to Microsoft Excel files, outputs from WKY and SHRSP 
searches were combined for each SNP or pair of SNPs analysed. All TF binding sites that 
were shared by SHRSP and WKY sequences and sites where the core or matrix scores 
differed by less than 0.1 between SHRSP and WKY sequences were deleted. This analysis 
technique has been applied in published research investigating functional effects of 
promoter polymorphisms (Moreno et al. 2007). This generated spreadsheets for each SNP 
(or combined SNPs for SNPs 1+2 and 10+11) of putative TF binding sites that were unique 
in the SHRSP or WKY sequence, or where the presence of the SNP alters affinity of the 
TF to the sequence. Each of these spreadsheets was combined into a single Microsoft 
Excel spreadsheet that was used for detailed searches. 
4.3.8.2 Transcription Factor Binding Site Analysis 
The matrix table generated by Match analysis was interrogated in a number of ways to find 
candidate TF binding sites affected by the polymorphic bases between the WKY and 
SHRSP Gstm1 promoter. Searches were first performed for potential binding sites for 
transcription factors Bach1, Maf and Nrf2, looking for a site affected by a SNP in cluster 
1-7 and a second affected by a SNP in cluster 8-12. Secondly, the table was sorted by 
matrix identifier and carefully inspected to find instances where two binding sites for the 
same TF were lost or created in the SHRSP, one in SNP cluster 1-7, one in SNP cluster 1-
8. The matrix table also was inspected for binding sites of TFs with core match scores of 
over 0.9 and for TFs previously shown to influence GST expression (from table 4.1). 
Candidate TFs were investigated by literature analysis to assess the likelihood that they are 
involved in transcriptional regulation of Gstm1 based on published information such as 
their actual consensus binding sequences (as opposed to Transfac consensus sequences), 
tissue and developmental expression profile, or functional role in cellular and physiological 
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4.4  Results 
4.4.1 Renal Gstm1 Quantitative Real-Time PCR 
Gstm1 mRNA expression, measured by Taqman qRT-PCR relative to β-actin in 16-week-
old rat kidneys, showed approximate 4.5-fold higher expression in the WKY and BN 
relative to the SHRSP and SHR (figure 4.3). These results further confirmed differential 
expression seen in renal microarray and RT-PCR experiments between the WKY and 
SHRSP (McBride et al 2003;McBride et al 2005) and demonstrated a correlation between 
reduced Gstm1 expression and increased blood pressure in multiple rat strains. These 
results were also presented in McBride et al (2005). 
 
Figure 4.3 - Renal Gstm1 mRNA expression in the SHRSP, SHR, BN and WKY 
 
 
4.4.2 Gstm1 Sequencing 
Sequencing the promoter and coding regions of Gstm1 in the SHRSP, SHR, WKY strains 
and comparisons with the BN reference sequence revealed 13 promoter polymorphisms 
within 2.4 kb upstream of the translational start site in the SHRSP and SHR, the promoter 
polymorphisms were numbered sequentially (SNP1–SNP13) from the SNP closest to the 
translational start site in a 3'-5' direction. The promoter mutations included 11 
substitutions, an insertion and a deletion. A nonsynonymous mutation in the coding region 
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qRT-PCR measured by Taqman in 16 week old rats relative to β-actin and 
calibrated to expression in the SHRSP. n=3, Mean ± SE. F=119.9 ** p<0.01 vs. 
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(exon 8, nucleotide 605, H202R) was identified, and a 3'UTR polymorphism at base +29 
(Table 4.2). All Gstm1 polymorphisms were conserved between the two hypertensive 
strains. These results were also presented in McBride et al (2005). 
SNP no.  Position  SHRSP  SHR  WKY  BN 
-  +29  A  A  G  G 
-    605  G  G  A  A 
SNP1  -101  G  G  A  A 
SNP2  -103  delT  delT  T  T 
SNP3  -178  T  T  C  C 
SNP4  -255  T  T  C  C 
SNP5  -280  G  G  A  A 
SNP6  -380  C  C  G  G 
SNP7  -483  C  C  A  A 
SNP8  -1048  G  G  A  A 
SNP9  -1140  C  C  T  T 
 SNP10  -1211  insC  insC  -  - 
 SNP11  -1212  C  C  A  A 
 SNP12  -1238  C  C  T  T 
 SNP13  -2390  C  C  A  A 
Table 4.2 - Gstm1 coding and promoter SNPs in the SHRSP, SHR, WKY and BN 
 
 
4.4.3 Renal Anti-Nitrotyrosine Western Blotting 
Renal anti-nitrotyrosine western blotting revealed multiple bands in each sample, 
consistent with nitrotyrosinylated groups on multiple proteins in the cell; expected Gapdh 
bands were observed at 36 KDa (figure 4.4A). Densitometry revealed the highest level of 
nitrotyrosine relative to Gapdh in SHRSP kidneys (figure 4.4B). These results were also 
presented in McBride et al (2005) and are consistent with other data in this publication 
showing increased superoxide in kidneys and aortas of the SHRSP. 
 
 
 
A 3'UTR polymorphism was identified 29 bases downstream of the STOP codon, and 
a base change at position 605 codes for a histidine at amino acid 202 in the SHR and 
SHRSP and an arginine in the WKY and BN. 13 promoter polymorphisms were 
identified within 2.4 kb. All polymorphisms were conserved between the SHRSP and 
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Figure 4.4 – Anti-nitrotyrosine western blot in 16 week SHRSP, 2c* and WKY 
kidneys 
 
 
 
4.4.4 Rat and Mouse Gstm1 Promoter Sequence Alignments 
Given the large number of polymorphisms in the SHRSP promoter and their clustered 
distribution, it would have been impractical to clone promoter sequences isolating each 
polymorphism individually. Therefore it was decided to analyse the transcriptional effects 
of multiple SNPs in the first instance. Cross-species promoter analysis and putative ARE 
sequence searching was also carried out to aid the process of deciding where to place 
upstream primers for promoter sequence amplification. SNPs 1-12 occur in regions of high 
homology between the rat and mouse Gstm1 promoter sequences, while the sequence 
surrounding SNP13 is not conserved (figure 4.5). A core ARE sequence was identified 
1,887bp upstream of the rat Gstm1 translational initiation site. On the basis of this analysis, 
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four promoter regions were amplified for cloning, ranging in size from 0.9kb-2.5kb. The 
smallest promoter fragment was 0.9 kb in length and covered SNPs 1-7 in the SHRSP. The 
second fragment (1.6 kb) encompassed SNPs 8-12 additional to the 7 covered by the 0.9 kb 
fragment. The third fragment (2.2 kb) also encompassed the putative ARE, while the fourth 
(2.5 kb) also included SNP13 (figure 4.5).  
 
Figure 4.5 - zPicture alignment of rat and mouse Gstm1 promoters 
 
 
The precise sequences at the sites of the promoter polymorphisms and the putative ARE 
sequence in the SHRSP and WKY Gstm1 promoter were compared with the corresponding 
sequences in the mouse Gstm1 promoter (figure 4.6). The alignments between the rat and 
mouse sequences was close to 100% in most cases, the mouse sequence at the site of the 
polymorphisms was conserved with the SHRSP sequence at some SNPs and with the 
WKY sequence in others. The exceptional homology at the sites of the putative ARE 
sequences in rat and mouse lends weight to this being a functional element. 
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SNP(s)     Mouse= 
 
1+2:  WKY:   GGGAGGGACCTCATTATTTTG   
  SHRSP: GGGAGGGACC-CGTTATTTTG 
  Mouse: GGGAGGGACC-CGCTGTTTTG   SHRSP 
 
3:  WKY:   ACTTTCTGCTCTAGGGTCTGT   
  SHRSP: ACTTTCTGCTTTAGGGTCTGT 
  Mouse: GCCTTCCGCTTTAGGGTCTGC   SHRSP 
 
4:  WKY:   GTGTGTAGAACAGAATCCTGG   
  SHRSP: GTGTGTAGAATAGAATCCTGG 
  Mouse: GTGTGCAAAACAGAATCCCGG     WKY 
 
5:  WKY:   CAGGCGAGCAAATTCTGCTTT     
  SHRSP: CAGGCGAGCAGATTCTGCTTT 
  Mouse: CAGGAGAGCAGATTCTG-TTT     SHRSP 
 
6:  WKY:   TTCTTTCGCTGTCTGGCCAGT     
  SHRSP: TTCTTTCGCTCTCTGGCCAGT 
  Mouse: TTCTTTCGCTGTCTGGCCAGT     WKY 
 
7:  WKY:   GAGAGTCGAGAGCCTCCCCAC     
  SHRSP: GAGAGTCGAGCGCCTCCCCAC 
  Mouse: GAGAGTT--GAGCCTCCCCA-     WKY 
 
8:  WKY:   TGAAGGTTATACCACAGGACA     
  SHRSP: TGAAGGTTATGCCACAGGACA 
  Mouse: TGAAGGTAATACTACAGGGCA     WKY 
 
9:  WKY:   AACCACAAGCTTCTTGGTTAT       
  SHRSP: AACCACAAGCCTCTTGGTTAT 
  Mouse: -----CAAGCCTCTTGG----     SHRSP 
 
10+11:  WKY:   TCTCCTCGTCA-GTCATTTGT     
  SHRSP: TCTCCTCGTCCCGTCATTTGT 
  Mouse: TCTCCCC-------------T    No homology 
 
12:  WKY:   CCCTTTGACCTGTAAACTGTT 
  SHRSP: CCCTTTGACCCGTAAACTGTT     
  Mouse: GCCTTTGACTTGTAAACTCAT     WKY 
 
ARE:  Rat:  GAACTTGTGACAGTGCACAGA 
  Mouse: GAACTTGTGACAGTGCACAGA 
 
Figure 4.6 - Individual alignments of rat Gstm1 promoter polymorphisms with 
mouse Gstm1 promoter sequences 
 
 
 
Rat polymorphisms are shaded in red, bases in the mouse promoter that do not align 
with the rat sequence are shade in yellow. Conservation of the mouse sequence with 
either the WKY or SHRSP sequence at each individual SNP is indicated (Mouse=). The  
putative ARE in the rat Gstm1 promoter is also aligned with the equivalent sequence in 
the mouse, showing 100% homology, ARE consensus is shaded in grey.  
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4.4.5 Promoter Sequence Cloning 
PCR Script and pGL3 Basic promoter plasmids were successfully cloned, representative 
gel and sequencing images are illustrated in figure 4.7. 
 
Figure 4.7 - Agarose gel and sequencing images from Gstm1 promoter cloning 
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(A) Amplification of 2.2 kb promoter sequences from SHRSP and WKY (expected size 
2192 bp), bands were gel purified for cloning into PCR-Script. (B) PCR-screening of 
colonies after cloning 0.9 kb promoter sequences into PCR-Script (expected size 1105 
bp) (C) Undigested and double-digested (MluI and XhoI) pGL3 Basic plasmids, 2.5 kb 
and 2.2 kb promoter fragments of the expected sizes were observed following restriction-
digestion. 1  g plasmid DNA per lane. (D) Sequencing confirmed presence of promoter 
SNPs in plasmids. Sequencing from SNP 6 is shown, encoding G in the WKY and C in 
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4.4.5.1 Optimising NRK52E Transfections 
Transfection of NRK52E cells in 24-well plates with over 200 ng DNA per well was toxic 
to the cells, transfection with 200 ng pGL3 Control at DNA:FuGENE ratios of 3:1, 3:2 and 
6:1 ( l: g) resulted in high luciferase activities in cell lysates after 48 hours (figure 4.8 A), 
200ng DNA at a ratio of 3:1 was used for further transfections since it showed highest 
transfection efficiency with the least DNA. Pilot co-transfections with pGL3 Control and 
pMV10 assesd levels of β-galactosidase expression (figure 4.8 B), and β-galactosidase 
activity staining further confirmed NRK52E transfection (figure 4.8 C). 
 
Figure 4.8 - Optimisating transfection of NRK52E cells 
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(A) Transfection of 200 ng pGL3 Control DNA at DNA:FuGENE ratios of 3:1, 3:2 and 
6:1 resulted in luciferase expression, 3:1 ratio was used for experimental 
transfections. Mean ± SE, n=3 (B) Co-transfection with 50 ng pMV10 and 150 ng 
pGL3 Control resulted in significant β-galactosidase activity in NRK52E cell lysates 
compared to non-transfected cells (NT). Mean ± SE, n=3 (2 sample t test) (C) β-
galactosidase activity staining following transfection with 200 ng pGL3 Control 
showed 5-10% transfection of NRK52E cells. Scale bar =100  m James Polke, 2008    Chapter 4         144 
 
   
4.4.5.2 Comparing SHRSP and WKY Promoter Activities 
The relative promoter activities of pSP0.9, pWKY0.9, pSP1.6, pWKY1.6, pSP2.2, 
pWKY2.2, pSP2.5 and pWKY2.5 were measured in NRK52E cells (figure 4.9). pSP1.6 
had a consistent 2.2-2.6-fold lower luciferase promoter activity than pWKY1.6 across 
repeated experiments, otherwise no significant differences in promoter activities were 
observed between the promoters. This data indicated that one or more of SNPs 8-12 may 
be responsible for reduced expression of pSP1.6 compared to pWKY1.6, that the putative 
ARE sequence may have an upregulatory effect on Gstm1 expression and that SNP13 does 
not affect Gstm1 expression. 
 
Figure 4.9 - Luciferase activities of 0.9 kb -2.5 kb Gstm1 promoter sequences 
 
 
 
4.4.5.3 Luciferase Activities of Novel Subcloned SP1.6 plasmids 
Plasmids pSP1.6(1-7) and pSP1.6(8-12) were generated to test the hypothesis that one or 
more SNPs in cluster 8-12 may be responsible for reduced expression from pSP1.6. 
Promoter activities of pSP1.6(1-7) and pSP1.6(8-12) were comparable to pWKY1.6 (figure 
4.10). This indicated that an interaction between one or more SNPs in cluster 1-7 and one 
or more SNPs in cluster 8-12 is responsible for reduced expression from pSP1.6, this was 
tested by site-directed mutagenesis. 
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In comparisons between SHRSP and WKY sequences of the same length, 
significantly reduced promoter activity was observed pSP1.6 compared to pWKY 
1.6 kb. No other significant differences in promoter activities were observed. Mean 
± SE, n=3 (2 sample t test). James Polke, 2008    Chapter 4         145 
 
   
 
Figure 4.10 – Luciferase activities of subcloned 1.6 kb promoter plasmids 
 
 
4.4.5.4 Luciferase Activities of Novel SP1.6 Site-Directed 
Mutagenesis Plasmids 
SNPs 8, 9, 10+11 and 12 were introduced into pSP1.6(1-7) by site-directed mutagenesis, 
creating four further novel plasmids. Luciferase promoter activities of pSP1.6, pWKY1.6, 
pSP1.6(1.7+8), pSP1.6(1-7+9), pSP1.6(1-7+10+11) and pSP1.6(1-7+12) were compared 
by transfection into NRK52E cells, relative promoter luciferase activities were measured 
48 hours after transfection (figure 4.11). These assays failed to identify a SNP from cluster 
8-12 that interacts with SNPs 1-7, the presented data implies that SNP 8 or 9 may interact 
with SNPs 1-7, but this was not shown consistently in repeat experiments.  
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pSP1.6(1-7) and pSP1.6(8-12) promoter activities were significantly higher then 
pSP1.6 and equivalent to that of pWKY1.6, implicating an interaction between 
SNPs in cluster 1-7 and 8-12 in reduced expression from pSP1.6. Mean ± SE, 
n=3, F=26.9  **p<0.01 vs. pSP1.6 (ANOVA and Dunnett's post-test). 
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Figure 4.11 - Luciferase activities of novel site-directed mutagenesis plasmids 
 
 
 
 
4.4.6 Transfac Professional Matrix Table 
Transfac analysis identified 435 TF matrices that align to sequences surrounding each SNP 
at either SHRSP or WKY sequences with a core alignment and matrix alignment score 
over 0.75 and 0.7, respectively (table A5), these cut-offs are default settings in the Match 
module. All matrices that that uniquely bind to SHRSP or WKY sequences are included, 
and matrices for which the core alignment or matrix scores differ by more than 0.1 
between the WKY and SHRSP. The data is grouped by SNP with each row showing the 
alignment at a particular SNP site in the SHRSP or WKY with a Transfac matrix. The 
sequence shown in the 'Aligned sequence' column shows the sequence in the SHRSP or 
WKY that aligns with the matrix sequence in question, note that the +ve strand sequence is 
always shown, but the matrix may align with the –ve strand (i.e. the reverse-complement 
of the sequence shown in the 'Aligned sequence' column), in these cases, a (-) is shown in 
the 'Strand' column. Five bases in the 'Aligned sequences' are always in upper case, these 
are the bases that align with the matrix core sequence, the lower case bases align with the 
rest of the matrix. Alignment scores for core and matrix sequences are given. The 'Position' 
column refers to the base number in the inputted sequence where the matrix alignment 
starts, these are synchronous between the SHRSP and WKY inputs for most SNPs but 
where base numbering is affected by an insertion or deletion (SNPs 2 and 10), alignments 
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Compared to pWKY1.6 and pSP1.6, luciferase activities of pSP1.6(1-7+10+11) 
and pSP1.6(1-7+12) were significantly higher than pSP1.6 and equivalent to 
pWKY1.6, while activities of pSP1.6(1-7+8) and pSP1.6(1-7+9) were not 
significantly different to pSP1.6. However this pattern was not replicated in 
repeat experiments. Mean ± SE, n=3, **p<0.01 vs. pSP1.6, F=4.77, *p<0.05 vs. 
pSp1.6 (ANOVA and Dunnett's post-test). 
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may not begin at the same base number. Many transcription factors are represented by 
more than one matrix, a consequence of the fact that different evidence (gene, species etc.) 
was used to compile different matrices. The same conventions apply to the data presented 
in tables 4.3 and 4.4. 
As would be expected the largest number of matrices are listed for SNPs 1+2 and SNPs 
10+11 (93 and 101 respectively) since these affect two bases, while the fewest are listed 
for SNP 13 (8 matrices). Table A5 includes a large proportion of false-positive alignments 
for TFs unlikely to be involved in renal Gstm1 expression control, either because the TFs 
concerned are involved in other cellular processes, are not expressed in the kidney, or 
simply do not actually bind to the sequence in question, despite the alignment scores. A 
curtailed list could have been generated by increasing the cut-off values for matrix 
alignment, however it was decided to use table A5 in the first instance as an exhaustive list 
to be interrogated using the results of the experimental studies to inform specific searches. 
Table A5 could be sorted according to strain, SNP, TF, matrix identifier, or any of the 
other column headings, a number of approaches were taken to analyse the data, as 
discussed below. 
4.4.7 Transcription Factor Binding Site Analysis 
The first line of analysis of Transfac data involved searching the PubMed database for 
instances where TFs have been shown to physically associate with multiple TF sites in a 
single promoter over at least 1.1kb (SNPs 1-12 span 1,138bp). Such a precedent exists for 
a basic leucine zipper (bZIP) cap'n'collar (CNC) TF called Bach1 that can mediate 
interactions between DNA binding sites up to 4.1 kb apart (Yoshida et al. 1999). Bach1 
protein has bZIP and CNC motifs at the carboxyl terminus, and a BTB/POZ (broad 
complex-tramtrack-bric-a-brac/Pox virus and Zinc finger) domain at the amino terminus; 
the BTB/POZ domain mediates protein/protein interactions between Bach1 molecules 
bound at distant DNA binding sites. Similar to Nrf2, Bach1 dimerises with Maf TFs via the 
bZIP domain prior to DNA binding and intriguingly, Bach1 has also been demonstrated as 
a transcriptional repressor of several genes involved in oxidative-stress defence, binding to 
some of the same sites where Nrf2 upregulates expression.  
Given the ability of Bach1/Maf dimers to bind to multiple distant sites over several kb and 
the fact that Bach1/Maf binds to many of the same sequences as Nrf2/Maf dimers, table A5 
was inspected for multiple Nrf2, Bach1 and Maf TF binding sites, specifically for one or 
more sites affected by SNPs 1-7 and one or more affected by SNPs 8-12. No such pairs of James Polke, 2008    Chapter 4         148 
 
   
sites were found, but SNP10+11 does appear to affect the binding of Nrf2/Maf/Bach1 at a 
non-ARE consensus site at SNP10+11 (table 4.3). SNPs 10+11 reduce the core and matrix 
alignment scores for the Nrf2 matrix V$NRF2_Q4, while the core and matrix scores for 
alignments with Maf matrices V$TCF11MAFG_01, V$VMAF_01 and V$BACH1_01 
were only high enough for the WKY sequence to pass the criteria for inclusion in the TF 
binding site table. Note that the alignment for V$TCF11MAFG_01 and V$VMAF_01 are 
on the reverse strand. In order to assess the likelihood that Nrf2/Maf or Bach1/Maf actually 
bind to this site, the alignments were considered in more detail. V$TCF11MAFG_01 was 
constructed by assessing TCF11/MafG heterodimer binding to a random sequence library 
(Johnsen et al. 1998), while V$VMAF_01 was derived from a publication assessing vMaf, 
an avian retrovirus Maf TF (Kataoka et al. 1994), as they do not relate to Nrf2 or Bach1 
heterodimers, they were not considered further. WKY and SP sequences at SNP10+11 are 
shown below aligned with the binding sequences for Nrf2 and Bach1 from V$NRF2_Q4 
and V$BACH1_01, respectively. The V$NRF2_Q4 consensus sequence is a non-ARE 
sequence, it was constructed by aligning Nrf2 binding sequences from multiple rat, mouse 
and human genes, each of these sequences is included on the alignment. V$BACH1_01 
was constructed using a random sequence library to find recognition sequences for human 
Bach1 (Kanezaki et al. 2001), the single consensus sequence is shown. In each case the 
most conserved bases are in upper case, alignments with the WKY sequence are 
highlighted by shading in yellow, while the sites off SNPs 10+11 are shaded in red in the 
WKY and SHRSP sequences. A '-' has been inserted into the alignments in order to 
accommodate the insertion in the SHRSP sequence. Where Nrf2 binds to the reverse strand 
of the promoter, the reverse complement (RC) sequence is shown: 
V$NRF2_Q4:               Species and gene 
               gcTGA-GTCAtgaTGAGTCAtgctg      Human β-globin LCR 
      tctgttttCGCTGA-GTCATggttcccgttg         Mouse Ho-1 
           tacagagAT-GTCATAacagaa  (RC)    Mouse Gstp1 
             ctccAGA-TTCAgtaaat    (RC)     Mouse Gstp1 
             gtgtTGA-GTCAGcatcc        Mouse Gstp1 
        taaagtTGCTGA-TTCATtg        Rat Tbxas1 
       aactggcGCCACA-GTCAgccggt        Mouse Nrf2 
            ctccaTGA-CAAAgcattt        Mouse Ferritin H 
          agaaTGCTGA-GTCACggtg        Mouse Ferritin H 
TGTTTTTAGTCTCCTCGTCA-GTCATTTGTTTTTCATCTG WKY 
TGTTTTTAGTCTCCTCGTCCCGTCATTTGTTTTTCATCTG SHRSP 
  
   
 
SNP  Strain  Matrix Identifier  Position  Strand  Core 
match 
Matrix 
match 
Aligned sequence             
(+ strand) 
Factor name 
SNP11+10  WKY  V$NRF2_Q4  80  (+)  1  0.845  ctcgtcAGTCAtt  Nrf2 
SNP11+10  SHRSP  V$NRF2_Q4  81  (+)  0.873  0.742  tcgtccCGTCAtt  Nrf2 
SNP11+10  WKY  V$TCF11MAFG_01  75  (-)  1  0.747  gtctcctcgtcaGTCATttgtt  TCF11:MafG 
SNP11+10  WKY  V$VMAF_01  74  (-)  0.778  0.713  agtctcctcgTCAGTcatt  v-Maf 
SNP11+10  WKY  V$BACH1_01  80  (+)  0.8  0.821  ctcgTCAGTcatttg  Bach1 
Table 4.3 - Transfac alignment data of Nrf2, Maf and Bach1 matrices with SNP11+10
Transfac matrix alignments with WKY and SHRSP sequences at SNP11+10. V$NRF2_Q4 aligned with both SHRSP 
and WKY sequences, but the core match score differed by more than 0.1. Alignments of the other matrices in the table 
with the SHRSP sequence did not pass core and/or matrix alignment score thresholds (>0.75 core match, >0.7 matrix 
match), thus only WKY alignments are shown. 
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V$BACH1_01: 
 
             acgATGA-GTCATgct 
TGTTTTTAGTCTCCTCGTCA-GTCATTTGTTTTTCATCTG WKY 
TGTTTTTAGTCTCCTCGTCCCGTCATTTGTTTTTCATCTG SHRSP 
 
 
A second strategy to explain the interaction between SNPs 1-7 and 8-12 was employed by 
searching the matrix table for pairs of binding sites for the same TF, one in each cluster. A 
large number of TFs were considered in this analysis, though most were discounted on the 
basis of their known function and tissue expression profiles. The remaining matrices are 
listed in table 4.4. The first matrices in table 4.4 relate to the bZIP transcription factor, 
cyclic AMP response element-binding protein (CREB). CREB binds to the palindromic 
binding sequence: TGACGTCA. Table 4.4 lists a number of CREB matrix alignments that 
are affected by SNPs 1+2 and 10+11, the large number of matrices is related to the fact 
that CREB is a well studied transcription factor, that it has a palindromic binding site and 
thus aligns in both orientations, and, as seen below, it aligns twice at SNPs 10+11 in the 
SHRSP. The alignment of the canonical CREB family binding sequence with the SHRSP 
and WKY sequences at SNPs 1+2 and SNPs 10+11 is shown below, once again, SNPs are 
highlighted in red, and alignment with the WKY sequence is highlighted in yellow, 
alignment with the SHRSP sequence at SNPs 10+11 is highlighted in blue: 
SNPs 1+2: 
              TGACGTCA 
TGCAGGGCTGGGAGGGACCTCATTATTTTGTCCGGCCCACG WKY 
TGCAGGGCTGGGAGGGACC-CGTTATTTTGTCCGGCCCACG SHRSP 
 
SNPs 10+11: 
                 
            TGACGTCA 
TGTTTTTAGTCTCCTCGTCA-GTCATTTGTTTTTCATCTG WKY 
TGTTTTTAGTCTCCTCGTCCCGTCATTTGTTTTTCATCTG SHRSP 
                 TGACGTCA 
 
 
The remaining TF in table 4.4, COUP (chicken ovalbumin upstream promoter) is a 
member of the nuclear receptor (NR) superfamily of TFs. The NRs are subdivided into 
classes depending on their DNA binding specificities. COUP is a member of a subset of 
class III that also includes peroxisome proliferator-activated receptors (PPARs), retinoic 
acid receptors (RARs) and retinoid X receptor (RXR), they bind to the following 
consensus sequence, known as direct repeat 1 (DR1) as heterodimers with RXR: 
AGGTCAnAGGTCA.   
   
SNP  Strain  Matrix Identifier  Position  Strand  Core 
match 
Matrix 
match 
Aligned sequence             
(+ strand) 
Factor 
name 
SNP1+2  WKY  V$CREB_01  55  (-)  0.788  0.805  ggaCCTCA  CREB 
SNP1+2  WKY  V$CREB_02  55  (-)  0.832  0.794  ggaCCTCAttat  CREB 
SNP1+2  SHRSP  V$CREB_02  57  (-)  0.82  0.721  accCGTTAtttt  CREB 
SNP1+2  WKY  V$CREB_Q4_01  55  (-)  0.901  0.881  ggaCCTCAtta  CREB 
SNP1+2  SHRSP  V$CREB_Q4_01  57  (-)  0.789  0.715  accCGTTAttt  CREB 
SNP1+2  WKY  V$CREB_Q2  53  (-)  0.79  0.721  agggaCCTCAtt  CREB 
SNP1+2  WKY  V$CREB_Q2_01  53  (+)  0.888  0.855  agggaCCTCAttat  CREB 
SNP1+2  SHRSP  V$CREB_Q2_01  55  (+)  0.796  0.723  ggaccCGTTAtttt  CREB 
SNP1+2  WKY  V$CREB_Q4  53  (-)  0.792  0.745  agggaCCTCAtt  CREB 
SNP10+11  WKY  V$CREB_Q2  77  (-)  1  0.863  ctcctCGTCAgt  CREB 
SNP10+11  SHRSP  V$CREB_Q2  77  (-)  0.79  0.703  ctcctCGTCCcg  CREB 
SNP10+11  WKY  V$CREB_Q4  77  (-)  1  0.871  ctcctCGTCAgt  CREB 
SNP10+11  SHRSP  V$CREB_Q4  77  (-)  0.792  0.708  ctcctCGTCCcg  CREB 
SNP10+11  WKY  V$CREB_Q2_01  77  (+)  1  0.896  ctcctCGTCAgtca  CREB 
SNP10+11  SHRSP  V$CREB_Q2_01  77  (+)  0.804  0.736  ctcctCGTCCcgtc  CREB 
SNP10+11  WKY  V$CREB_Q4_01  79  (-)  1  0.906  cctCGTCAgtc  CREB 
SNP10+11  SHRSP  V$CREB_Q4_01  79  (-)  0.764  0.703  cctCGTCCcgt  CREB 
SNP10+11  WKY  V$CREB_Q4  81  (-)  0.831  0.727  tcgtcAGTCAtt  CREB 
SNP10+11  SHRSP  V$CREB_Q4  82  (-)  1  0.886  cgtccCGTCAtt  CREB 
SNP10+11  SHRSP  V$CREB_Q2  82  (-)  1  0.853  cgtccCGTCAtt  CREB 
SNP10+11  SHRSP  V$CREB_Q2_01  82  (+)  1  0.921  cgtccCGTCAtttg  CREB 
SNP10+11  WKY  V$CREB_Q4_01  83  (-)  0.789  0.723  gtcAGTCAttt  CREB 
SNP10+11  SHRSP  V$CREB_Q4_01  84  (-)  1  0.918  tccCGTCAttt  CREB 
                 
SNP3  WKY  V$COUP_DR1_Q6  56  (-)  0.917  0.702  tgctctaGGGTCt  COUP 
SNP3  WKY  V$COUPTF_Q6  51  (+)  0.848  0.726  ctttcTGCTCtagggtctgtagc  COUP 
SNP3  WKY  V$COUPTF_Q6  51  (-)  0.814  0.726  ctttctgctctagGGTCTgtagc  COUP 
SNP3  SHRSP  V$COUPTF_Q6  51  (-)  0.814  0.708  ctttctgctttagGGTCTgtagc  COUP 
SNP4  WKY  V$COUPTF_Q6  69  (-)  0.827  0.734  ttcagggtgtgtaGAACAgaatc  COUP 
SNP12  WKY  V$COUP_DR1_Q6  55  (+)  1  0.739  tGACCTgtaaact  COUP 
Table 4.4 - TF matrices that aligned with SNPs in cluster 1-7 and cluster 8-12 
Matrices aligning with one or more SNP in cluster 1-7 and one or more SNP in cluster 8-12. CREB: cyclic AMP response 
element-binding protein, COUP: chicken ovalbumin upstream promoter James Polke, 2008    Chapter 4         152 
 
   
The alignments of the sequences surrounding SNPs 3,4 and 12 in the WKY and SHRSP 
with DR1 is below. Since the sequence aligns with SNPs 4 and 12 on the reverse strand, 
the reverse complement sequence is shown: 
SNP3: 
            AGGTCAnAGGTCA 
CCCTCTACTTTCTGCTCTAGGGTCTGTAGCTCT  WKY 
CCCTCTACTTTCTGCTTTAGGGTCTGTAGCTCT  SHRSP 
 
SNP4: 
 
            TGACCTnTGACCT  (RC) 
TTCAGGGTGTGTAGAACAGAATCCTGGGGCAGA  WKY 
TTCAGGGTGTGTAGAATAGAATCCTGGGGCAGA  SHRSP 
 
SNP12: 
 
    TGACCTnTGACCT    (RC) 
GCATTGCCCTTTGACCTGTAAACTGTTTTTAGT    WKY 
GCATTGCCCTTTGACCCGTAAACTGTTTTTAGT    SHRSP 
 
 
Note the exceptionally high homology between the consensus sequence and the WKY 
sequence at SNP12, with just one mismatch. The homology is lower for SNPs 3 and 4, but 
in each case the SNP occurs at a conserved base between the consensus and WKY. The 
fact that this search only highlighted COUP and not other class III NRs is due to the low 
homology with SNP 3 and 4 sequences; PPAR and RAR matrices also aligned with 
SNP12, but not with SNPs 3 and 4, the matrix alignment of the COUP matrices at SNPs 3 
and 4 was close to the 0.7 threshold, between 0.702 and 0.734. Thus all class III TFs could 
be considered as potential regulators at SNP12 and possibly for SNPs 3 and 4 to provide an 
explanation of the interaction between SNPs in clusters 1-7 and 8-12. 
Inspections of table A5 were also performed without consideration of the in-vitro evidence 
for TF binding site interactions. The table was inspected for binding sites for TFs 
previously experimentally shown to affect GST expression (from table 4.1), and 
foreshortened by filtering out core matrix alignments of less than 0.9. These analyses also 
included SNP13. As before, literature analysis was carried out to assess the likelihood that 
candidate TFs affect Gstm1 expression, significant findings are presented.  
A nuclear factor kappa β (NFκB) binding site has been identified in the human GSTP1 
promoter (Morceau et al 2004), and NFκB is a well established redox sensitive mediator of 
expression of inflammatory and antioxidant genes. A potential site was identified by 
Transfac binding to the WKY sequence at SNPs 1+2, though a closer comparison with the 
NFκB consensus sequence (GGGRNWYYCC; R = A or G; W = A or T; Y = C or T) James Polke, 2008    Chapter 4         153 
 
   
revealed a poor alignment with both WKY and SHRSP sequences. Alignment on the 
reverse strand at SNP 7 however indicates that NFκB binding could be affected by the SNP 
in the SHRSP. The alignment of the NFκB reverse-complemented consensus sequence 
with the WKY and SHRSP sequences is shown below, the SNP is highlighted in red, 
alignment with the WKY sequence is highlighted in yellow: 
SNP7: 
                 GGRRWNYCCC     (RC)  
CTTTAAGCTGAGAGTCGAGAGCCTCCCCACCCCCCGCTGACAGATT WKY 
CTTTAAGCTGAGAGTCGAGCGCCTCCCCACCCCCCGCTGACAGATT SHRSP 
 
 
Finally, Transfac analysis revealed that SNP4 may affect an NF consensus sequence that 
binds the 'steroid receptors': androgen receptor (AR), glucocorticoid receptor (GR), 
mineralocorticoid receptor (MR) and progesterone receptor (PR). Rat Gsta2 and Gstp1 
expression have been shown to be regulated by androgen (Falkner et al 1998;Falkner et al. 
2001;Ikeda et al 2002). The consensus sequence for the steroid receptors consists of two 
'half sites' separated by three unconserved bases: AGAACAnnnTGTACC, though AR has 
also been shown to bind to sequences related to AGAACAnnnAGAACA (Claessens et al. 
2004). The WKY and SHRSP alignments with these two sequences is shown below: 
SNP4: 
               AGAACANNNAGAACA 
               AGAACANNNTGTACC 
GCTTTCAGGGTGTGTAGAACAGAATCCTGGGGCAGAGGC WKY 
GCTTTCAGGGTGTGTAGAATAGAATCCTGGGGCAGAGGC SHRSP 
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4.5  Discussion 
The experiments outlined in this chapter investigated the molecular mechanisms behind 
differential expression of Gstm1 between the WKY and SHRSP. The data presented figure 
4.3, 4.4 and table 4.2 was published in Mcbride et al 2005; qRT-PCR Gstm1 mRNA 
expression analysis confirmed renal differential gene expression previously seen in 
microarrays between SHRSP and WKY (McBride et al 2003), and demonstrated reduced 
Gstm1 expression in a second hypertensive strain, the SHR, compared to a second 
normotensive strain, the BN. Increased renal levels of nitrotyrosine in the SHRSP 
correlated with other data on renal and vascular oxidative stress that was published 
alongside the nitrotyrosine data in the same paper; superoxide levels measured by 
lucigenin-enhanced chemiluminescence in renal cortex and medulla and thoracic aortas of 
SHRSP were significantly higher than in WKY rats (McBride et al, 2005).  
Taken together, these data show that reduced renal Gstm1 expression coincides with 
increased renal oxidative stress, hypertension and the presence of 13 polymorphisms in the 
SHRSP Gstm1 promoter. These observations led to the hypothesis that one or more of the 
promoter polymorphisms are responsible for reduced renal Gstm1 expression in the 
SHRSP and that this contributes to hypertension in the SHRSP. The high number of 
polymorphisms found in the SHRSP Gstm1 promoter was initially surprising, however this 
agrees with published observations (Zimdahl et al. 2004) wherein genome-wide SNP 
analysis in the BN, WKY and SHRSP revealed an average polymorphism rate between the 
BN and the other strains as approximately 1 every 1100 base pairs, however the SNP 
distribution was non-random, with an excess of loci with no or multiple SNPs. This was 
attributed to effects of artificial selection in derivation of these closely related laboratory 
rat strains; some loci have very recent common ancestors, and hence low frequency of 
SNPs, while other loci have distant common ancestors and thus higher SNP frequency 
(Zimdahl et al 2004). The functional relevance of the H202R variant was considered in 
McBride et al, 2005. Two lines of analysis were undertaken, first, the amino acid 
sequences of 19 GSTM enzymes from rat, mouse and human were aligned, amino acid 202 
occurs in a highly conserved region; in 15 of the 19 sequences, including the consensus rat 
genome sequence, an arginine (R) residue is encoded; the histidine (H) residue is only 
present in the BN and WKY sequences indicating that Gstm1 activity is unlikely to be 
compromised by this mutation in the SHRSP and SHR. Secondly, the crystal structure of 
the rat Gstm1 protein was inspected; amino acid 202 is located on the surface of the protein 
and thus not likely to affect Gstm1 activity (Ji et al. 1992;McBride et al 2005). James Polke, 2008    Chapter 4         155 
 
   
Experiments were designed to compare the catalytic activities of WKY and SHRSP Gstm1 
protein in chapter 5, where adenoviruses were constructed to express each sequence; the 
likelihood that the 3'UTR polymorphism identified at base +29 affects Gstm1 expression 
was also addressed in this study, see sections 5.4.5 and 5.5. 
The initial experiments to compare the activities of the WKY and SHRSP promoter 
sequences indicated that SNPs 8-12 may be responsible for reduced expression in pSP1.6, 
the lack of a significant difference in promoter activities between the pSP2.2 and 
pWKY2.2 plasmids suggested that the putative ARE sequence increased promoter activity 
in pSP2.2 to a level equivalent to that of pWKY2.2 despite the effects of SNPs 8-12. The 
lack of a significant difference in activities between pSP2.5 and pWKY2.5 indicated that 
SNP13 does not affect Gstm1 promoter activity.  
The hypothesis that SNPs 8-12 may reduce expression of SP1.6 was tested by sublconing 
between pSP1.6 and pWKY1.6 to generate plasmids pSP1.6(1-7) and pSP1.6(8-12). 
Equivalent promoter activities of pSP1.6(1-7) pSP(8-12) and pWKY1.6 indicated that an 
interaction between one or more SNPs in cluster 1-7 with one or more SNPs in cluster 8-12 
was required for reduced expression from pSP1.6. In order to test this hypothesis, plasmids 
pSP1.6(1-7+8), pSP1.6(1-7+9), pSP1.6(1-7+10+11) and pSP1.6(1-7+12) were generated 
by site-directed mutagenesis of pSP1.6(1-7) and their promoter activities were assayed. 
These experiments did not conclusively identify a SNP from cluster 8-12 that individually 
interacts with SNPs in cluster 1-7 to reduce expression from the pSP1.6 promoter, SNPs 8 
and 9 were implicated in one experiment, but this result was not observed in repeat 
experiments. These results can be explained by the limitatons of luciferase activity 
measurements despite corrections for transfection efficiency and total protein, combined 
with the small difference in promoter activity observed in the original experiments (2.2-
2.6-fold difference in expression between pSP1.6 and pWKY1.6). In addition, it is possible 
that more than one of SNPs 8-12 are required for the interaction to reduce SP1.6 
expression. It was not practical to test this due to lack of time, it would have required the 
generation by site-directed mutagenesis of a further ten plasmids to analyse every possible 
combination of SNP from cluster 8-12. If continuing these experiments, transfection 
protocols could be redesigned to ensure less variability within experimental groups. Renilla 
luciferase is derived from the sea pansy (Renilla reniformis) and fluoresces at a different 
wavelength to the beetle luciferase encoded by the pGL3 plasmids used in this project; co-
transfection with renilla luciferase plasmids rather than pMV10 would allow fluorescence 
measurement of both luciferases in the same aliquot of lysate, significantly simplifying the 
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A combination of cross-species sequence comparison, literature searching and Transfac 
promoter sequence analysis was performed on SNPs 1-12 to identify the most likely SNPs 
involved in reduced expression from SP1.6. The rat and mouse Gstm1 promoter sequences 
show very high sequence homology, each of the SNPs 1-12 lie within regions of 70-90% 
identity with the mouse promoter, with no alignment at SNP13. Given the hypothesis that 
Gstm1 expression is reduced in the SHRSP due to one or more of SNPs 1-12 and accepting 
that the homology between the rat and mouse Gstm1 promoters is indicative of similar 
promoter elements controlling expression in each species, one is led to conclude that the 
SNPs where the mouse promoter has homology with the SHRSP are less likely to be 
involved in reduced Gstm1 expression (SNPs 1+2, SNP3, SNP5 and SNP9). One may also 
conclude in this analysis that the sequence surrounding SNPs 10+11 is less likely to 
regulate rat Gstm1 expression given that this is not conserved between the mouse and rat at 
all. However, these assumptions may not be correct, Gstm1 may have acquired specific 
renal function in the rat that it does not have in the mouse, its expression in this instance 
may be controlled by different elements, that being the case there may be a stronger case 
for the sequence surrounding SNPs 10+11 having specific function in the rat.  
A table of Transfac matrices was generated to list potential TF binding sites lost, created or 
affected by the polymorphisms in the SHRSP promoter. The Transfac analysis protocol 
used here has been successfully applied in published research, in the demonstration that the 
'A' variant of the -675A/T polymorphism in the human CYBA gene (encoding p22phox) 
reduces promoter activity compared to the 'T' variant by disrupting binding of the hypoxia 
inducible factor 1 alpha transcription factor (Moreno et al 2007). A number of approaches 
were taken to interrogate the matrix table to find candidate transcription factor binding 
sites to explain the reduced promoter activity of pSP1.6.  
The identification of a disrupted potential binding site for the structural TF Bach1 at 
SNP10+11, despite the fact that a similar site was not found for any of the SNPs in cluster 
1-7, was an interesting finding. Bach1, Nrf2 and Maf TFs have been shown to bind to the 
ARE and a range of promoter sequences distinct from the ARE to regulate expression of a 
number of genes involved in oxidative stress defence. For example, Bach1/Maf 
heterodimers repress human NQO-1 expression by binding to the NQO-1 ARE, this 
repression is reversed by overexpression of Nrf2 and by administration of the pro-oxidant, 
heme (Dhakshinamoorthy et al. 2005). In addition, Bach1 has also been shown to compete 
with Nrf2 at non-ARE binding sites in the promoter of the mouse heme oxygenase 1 (Ho-
1) gene, again, Bach1 represses Ho-1 expression, while Nrf2 activates expression and 
heme alleviates Bach1 binding to the Ho-1 promoter (Sun et al. 2002). Given that pSP(1-James Polke, 2008    Chapter 4         157 
 
   
7+10+11) did not show significantly reduced luciferase activity, it may not be responsible 
for reduced expression of pSP1.6, but it may be involved in reduced Gstm1 expression in-
vivo. As mentioned above, Bach1 is a heme-sensitive repressor of Ho-1 and NQO-1 
expression, and while it is yet to be shown to regulate expression of any GST genes, it has 
also shown to respond to oxidative stress induced by the sulfhydyl oxidising agent diamide 
by dissociating from the human HO-1 promoter, suggesting that it may respond to a range 
of pro-oxidant stimuli (Ishikawa et al. 2005). The evidence for a potential role of the non-
ARE Nrf2 binding sequence in the rat Gstm1 promoter is enhanced by the observation that 
such sequences have been described in the mouse Gstp1 promoter (Ikeda et al 2002). 
Interstingly, Nrf2 transcription factor has also been implicated in a rat model of 
hypertension, where it has been shown to be downregulated in DSS rats relative to 
chromosome 1 congenic rats harbouring Lewis rat Nrf2 alleles (Joe et al. 2005).  
CREB related TFs are among the most studied transcriptional regulators, they have been 
shown to affect the expression of genes involved in cellular proliferation, development and 
adaptive responses (Shaywitz et al. 1999). Transcriptional activation by CREB-related TFs 
is dependent on their phosphorylation in signalling cascades such as the MAPK pathway 
which has been shown to be involved rat Gstm1 upregulation by geniposide (Kuo et al 
2005), thus the finding of differential binding of CREB-like TFs to the WKY and SHRSP 
promoters at SNPs 1+2 and SNPs 10+11 was of interest. However, detailed analysis 
showed that while SNPs 1+2 and 10+11 do affect a potential CREB binding site in the 
WKY, SNPs 10+11 create a binding site in the SHRSP, thus disruption of interacting 
CREB family transcription factor binding sites are unlikely to affect expression in pSP1.6.  
The identification of potential disrupted binding sites for class III NR TFs COUP, RAR, 
PPAR and RXR (with which the other members of the family dimerise in DNA binding) at 
SNPs 3,4 and 12 presents the best hypothesis to explain the reduced promoter activity of 
pSP1.6. The NRs are an exceptionally diverse family of TFs with roles in development, 
reproduction, metabolism and homeostasis, they include 48 distinct members in humans 
and over 200 in C.elegans. NRs generally bind to lipophilic molecules such as steroid 
hormones, fatty acids, vitamins and prostaglandins. Structurally, the NR family are well 
conserved, with a modular structure including a C-terminal ligand-binding domain (LBD), 
a DNA binding domain (DBD) and N-terminal domain (NTD). The NTD is the most 
variable region and is responsible for the specific transactivation properties of NRs 
(McEwan 2004). Although Transfac analysis identified COUP as the binding factor at 
SNPs 3,4 and 12, each of the class III NRs could be considered candidates since they bind 
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through their role in regulation of ovalbumin expression in chickens (Sagami et al. 1986), 
and have subsequently been shown to have diverse roles in development, though their post-
developmental role is less well understood (Cooney et al. 2001). RAR TFs include a 
number of members with roles in development and as tumour suppressors (Altucci et al. 
2007). A precedent for PPAR-mediated regulation of GST expression has been 
demonstrated for the mouse Gsta2 gene, where three DR1-like sequences were shown to 
be required for induced hepatic expression of Gsta2 by PPARγ/RXR heterodimers in 
response to the RXR and PPAR activating ligands retinoic acid (RA) and 15-deoxy-δ 
(12,14)-prostaglandin J2 (PGJ2), (Park et al 2004). In a similar manner to the pattern of 
sites seen in the rat Gstm1 promoter, one of the PPARγ sites in the mouse Gsta promoter is 
highly homologous with the DR1 consensus, while the other two are poorly conserved, and 
one of the sites is in the reverse orientation. Park et al suggested that the three sites form a 
co-operative PPAR responsive enhancer module (PPARM) since deletion of any one of 
them disrupts RA and PGJ2 induced Gsta2 expression. In this model, multiple TFs bind to 
the DR1 sites and other local TF binding sites, including an Nrf2-binding ARE, in induced 
Gsta2 expression. A similar model could be proposed for the rat Gstm1 promoter, though 
the TF binding sites are distributed over 1.0 - 1.7kb (depending on the inclusion of the 
putative ARE sequence) rather than 0.5kb as in mouse Gsta2; also note that the 
experiments presented here also differ to the model used by Park et al in that no 
transcriptional activating agents were used to stimulate expression.  
PPARγ is predominantly expressed in adipose tissue, though it is expressed in the kidney 
and its expression in the rat nephron has been localised to the outer-medullary collecting 
duct, (Yang et al. 1999). Immunohistochemical studies in our laboratory have localised 
Gstm1 to the collecting duct by co-localisation with aquaporin 2 (McBride et al 2005) thus 
Gstm1 and PPARγ expression are co-localised in the rat kidney. As discussed in section 
1.1.3.5, dominant negative PPARγ mutations can cause hypertension associated with type 
2 diabetes without obesity in a mechanism thought to relate to changes in vascular tone 
(Barroso et al 1999). PPARγ agonist medications such as the thiazolinendiones (TZDs) 
have a blood pressure lowering effect, though this has predominantly been related to 
improved insulin sensitivity (Sarafidis et al. 2006). The precise role of PPARγ in the 
kidney is not well understood, though TZDs can influence renal sodium handling, 
occasionally leading to oedema via a mechanisms thought to involve upregulation of 
ENaC. This relationship has been studied in an experimental model; TZD treatment causes 
oedema in mice, but fluid retention and ENaC activation are prevented in transgenic mice 
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addition, PPARγ modulates renal oxidative stress by inhibiting expression of NAD(P)H 
oxidase subunits (Hwang et al. 2005) and may also upregulate renal NO synthesis, though 
this is disputed (Dobrian 2006). PPARy upregualtion by the TZD rosiglitazone has also 
been shown to enhance recovery of tubular epithelial cells after oxidative damage by H2O2.  
The Transfac data analysis discussed above presents hypotheses to explain the results of 
the in-vitro luciferase studies. These studies indicated that an interaction between SNPs in 
clusters 1-7 and 8-12 reduces expression in the SHRSP promoter and that this can be 
overcome by the putative ARE sequence in the 2.2kb fragment. It is interesting to consider 
how these results relate to the full promoter sequences in the SHRSP and WKY; in the 
genomic context the ARE sequence is present in the SHRSP and WKY, yet Gstm1 
expression is constitutively reduced in the SHRSP. This is a reflection of the limitations of 
in-vitro promoter analysis. Though no agents were used to stimulate promoter activity in 
these studies, the data does not necessarily represent basal promoter activity in-vivo, 
regulatory factors may be present in the rat kidney that affect constitutive expression via 
the elements proposed to interact at SNPs 1-7 and 8-12, while the ARE sequence may only 
upregulate expression in certain conditions in-vivo.  
Final analysis of the Transfac matrix table involved searching for transcription factors with 
the highest alignment scores at the SNPs, and for TFs previously shown to affect GST 
expression, without consideration of the in-vitro experimental results. This identified 
potential a potential binding site at SNP7 for NFκB at SNP 7 and a steroid receptor binding 
site at SNP4. NFκB is a well characterised mediator of inflammatory and immune 
responses, and is regulated by oxidative stress conditions (Schreck et al. 1991;Schulze-
Osthoff et al. 1993), and NFκB has been demonstrated to mediate human GSTP1 
expression in a leukemic cell line, where it is proposed to play a role in chemoresistance by 
upregulating xenobiotic metabolism (Morceau et al 2004). In addition, NFκB has been 
shown to upregulate other genes involved in oxidative stress defence such as glutamate 
cysteine ligase catalytic subunit gene, one of the mediators of glutathione synthesis 
(Morales et al. 1997). The WKY sequence at SNP4 aligns 100% with the first half of the 
steroid receptor consensus sequence, and SNP4 disrupts the alignment in the SHRSP. The 
second half of the binding sequence does not have high homology with the promoters. Like 
most NRs the steroid receptors bind to their recognition sequences as dimers, experimental 
evidence has demonstrated that the first unit in the dimer binds to the 5' conserved five 
bases of the recognition sequence, leading to conformational change of the TF that leads to 
recruitment of the second moiety (Luisi et al. 1991). It has long been recognised that the 
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1988), thus the poor alignment with the second half site does not necessarily preclude 
steroid receptor binding to the sequence above. However, it is difficult to speculate which 
of the steroid receptors may bind to this site to regulate Gstm1 expression. Several factors 
have been shown to dictate which steroid receptor binds to a particular promoter element 
including the availability of the receptor and its ligand in the cell, the availability of cell-
specific co-regulators that participate in transcriptional complexes, the local binding of 
other TFs that can potentiate binding of one steroid receptor over another, the incidence of 
other steroid receptor binding sites in the promoter, and finally, specific binding sequence 
preferences (Nelson et al. 1999). The rat Gsta2 promoter contains steroid receptor binding 
sequence that regulates Gsta2 expression in cultured liver cells in a biphasic manner. Low 
concentrations of the synthetic corticosteroid dexamethasone (10-100 nM) repress 
expression, while at high concentrations (>1 M), expression is induced (Falkner et al 
1998;Falkner et al 2001). Unpublished data from our laboratory shows that renal Gstm1 
expression is approximately 1.8-fold higher in males than females, perhaps suggesting a 
role for androgen-stimulated expression via the AR. Androgen has been implicated in 
increased expression of Gstp1 in the livers of male rats, in this case several AR response 
elements were located to the 5
th intron of the gene (Ikeda et al 2002). 
Transfac is the gold standard transcriptional regulation database, it is well curated and 
regularly updated with new additions to the database, however it is not without its 
limitations. For example, it restricts each matrix to a five-base core alignment sequence 
that is used as the first threshold in sequence alignment, this does not necessarily reflect the 
structure of the actual TF binding sequences. The ARE is a case in point, as seen above, 
the ARE consensus sequence is spread over at least 10 bases with two highly conserved 
sequences of 4 and 3 bases separated by non-conserved bases. Other TF binding sites 
consist of variable repeated elements spread over 20-30 bases or more with non-conserved 
bases between them. Thus good matrix alignments did not guarantee TF binding at that 
site, the original literature used to compile to matrices, and other published evidence, was 
also considered. These limitations highlight the challenges of in-silico promoter sequence 
analysis, understanding gene expression is probably the greatest challenge in molecular 
biology, databases must make certain assumptions in order to categorise data for searching, 
and compromises are made.  
A number of potential transcription factor binding sites affected by the SNPs in the SHRSP 
have been identified, some of which may account for the observed reduction in expression 
from the pSP1.6 promoter construct, and a putative ARE has been identified between SNPs 
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involved in Gstm1 regulation would require further laboratory investigation. A number of 
techniques are available that could be applied to SHRSP and WKY sequences to compare 
TF activity. Cells could be co-transfected with plasmids expressing a TF to compare 
luciferase activities from the promoter constructs; similarly agents could be applied to cells 
to activate the TFs in question, such as rosiglitazone or another TZD to activate PPARγ, or 
phenolic antioxidants to stimulate Nrf2. Site-directed mutagenesis could be used to disrupt 
the ARE sequence in pSP2.2 to assess its activity. Specific techniques to assess TF binding 
to WKY and SHRSP Gstm1 promoter sequences are also available such as DNaseI 
footprinting and electrophoretic mobility shift assays, which have been applied to a 
number of studies investigating the promoters of several GST genes (Kawamoto et al 
2000;Ikeda et al 2002;Bartley et al 2003).  
The above techniques can all be applied to cells transfected with promoter constructs, it 
would also be informative to study cell lines derived from the SHRSP and WKY. The most 
faithful replication of the in-vivo renal expression of Gstm1 would be from primary 
collecting duct cells. Techniques have been described to isolate inner medullary collecting 
duct cells from the rat kidney involving careful dissection followed by collagenase 
treatment and selection with high salt and urea (Maric et al. 1998) or hypotonic conditions 
(Laplace et al. 1992). Other protocols have applied immunoselective surfaces coated with 
antibodies specifically targeting collecting duct cell surface antigens in human and mouse 
(Sweeney, Jr. et al. 1998) and rabbit (Fejes-Toth et al. 1992). The Gstm1 promoter could 
be analysed in isolated SHRSP and WKY collecting duct cells using chromatin 
immunoprecipitation (ChIP), a technique that provides a precise view of the DNA 
sequences that bind to a particular TF in the cell.  
Despite the evidence that the polymorphisms differentiating the WKY and SHRSP Gstm1 
promoter may affect expression, it is important to recognise that other elements may be 
responsible for reduced SHRSP expression. For example, control elements have been 
described within the introns of genes, such as the AR sequences in intron 5 of rat Gstp1 
mentioned above (Ikeda et al 2002), and it is well documented that enhancer elements can 
also operate from several kilobases upstream or downstream of a gene. Furthermore, 
negative regulation of gene expression by microRNAs (miRNAs) has recently attracted 
much attention. The possibility that this mechanism may affect Gstm1 expression is 
considered in chapter 5. 
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5.1   Introduction 
To further assess the role of Gstm1 and its contribution to renal oxidative stress, in-vitro 
and in-vivo gene transfer approaches were taken. Recombinant adenovirus serotype 5 
(RAd5) vectors were generated to overexpress Gstm1 and to express short-hairpin RNA 
sequences designed to knock down expression of several members of the Gstm family. 
Recombinant vectors used for gene delivery were replication deficient, lacking genes (E1a 
and E1b) that mediate viral replication through transactivation of viral gene expression and 
deregulation of the host cell cycle. Adenovirus vectors are an extremely efficient means of 
gene delivery, they are popular platforms for short-term transgene expression studies for 
several reasons (Nicklin et al. 2003), for example, large DNA constructs can be cloned into 
the viral genome, up to 8 kb (though the largest fragment cloned in this experiment was 
0.74kb) and efficient cloning and amplification techniques have been perfected by many 
laboratories, high titre stocks can be generated with relative ease. In addition adenoviruses 
infect a very wide range of dividing and non-dividing cell types. They are disadvantageous 
for long-term studies since they only mediate transient gene expression. Research from the 
Glasgow laboratory has demonstrated that local adenoviral overexpression of human 
endothelial nitric oxide synthase or extracellular superoxide dismutase improves NO 
bioavailability in SHRSP carotid arteries (Alexander et al. 2000;Fennell et al 2002), many 
of the techniques developed in these studies were applied in this project. Local delivery of 
adenoviruses has also been applied in other studies examining cardiovascular phenotypes, 
for example, administration of eNOs and iNOS overexpressing adenoviruses to isolated 
rabbit carotid arteries following endothelial denudation was demonstrated to ameliorate 
intimal hyperplasia compared to uninfused vessels, while eNOS overexpression, but not 
iNOS overexpression, also promoted the regeneration of the endothelium (Cooney et al. 
2007). A similar therapeutic effect was observed by adenoviral overexpression of copper-
zinc superoxide dismutase in denuded rabbit carotid arteries, intimal hyperplasia was 
reduced compared to uninfused arteries (Kuo et al. 2004). Local delivery of adenoviruses 
overexpressing eNOS to the brain stem following experimentally-induced myocardial 
infarction in mice has been demonstrated to lessen the increase in sympathetic drive that 
accompanies the onset of heart failure, as measured by urinary noradrenalin (Sakai et al. 
2005). Tail-vein delivery of adenoviruses overexpressing human kallikrein to severely 
hypertensive uninephrectomised DOCA-salt rats reduced systolic blood pressure by up to 
32 mmHg. Blood pressure reduction lasted for at least 23 days and morphological 
examination showed that kallikrein overexpression prevented DOCA-salt mediated kidney 
damage such as glomerular sclerosis and proximal tubular dilation (Dobrzynski et al. James Polke, 2008    Chapter 5         164 
 
   
1999). Systemic injection of an adenovirus overexpressing another vasodilatory peptide, 
adrenomedullin, has also been shown to reduce blood pressure and attenuate left-
ventricular hypertrophy in DSS rats fed a 4% NaCl diet (Zhang et al. 2000).  
RNA interference (RNAi) is an endogenous mechanism of transcriptional regulation that 
has been demonstrated in mammals, plants, nematodes, Drosophila and protozoa. First 
observed in plants where overexpression of a pigment gene suppressed flower colour 
development in petunias (Napoli et al. 1990), the RNAi mechanism is thought to be an 
adaptation of defence mechanisms that target dsRNA viruses and transposons (mobile 
genetic elements that propagate via an RNA intermediary). A crucial breakthrough in the 
understanding of RNAi occurred with the demonstration that sense and anti-sense RNA 
(i.e. dsRNA) is required for RNAi (Fire et al. 1998). In the RNAi pathway, depicted in 
figure 5.1, dsRNAs are processed by the RNase III enzyme Dicer to double stranded short 
interfering RNAs (siRNAs) 21-25 base-pairs in length with a dinucleotide 3' overhang. 
siRNAs associate with the RNA-induced silencing complex (RISC) and target mRNA that 
encodes the same sequence as the siRNA. In association with siRNAs, the RISC complex 
catalyses cleavage of the target mRNA, preventing transcription, mRNA fragments are 
further processed by exonuclease enzymes. This pathway is exploited by biologists 
wishing to investigate gene function by targeted knockdown. siRNAs can be delivered to 
cells via several pathways to mediate transcriptional repression: Long dsRNAs can be 
transfected into cells for processing by Dicer to siRNAs, however dsRNAs over 30 
nucleotides in length stimulate anti-viral interferon responses in most mammalian cell lines 
leading to non-sequence specific degradation of dsRNA, therefore the preferred technique, 
particularly for in-vitro studies, is to transfect chemically synthesised siRNAs, bypassing 
the Dicer complex to interact with RISC directly (Elbashir et al. 2001a). Alternatively, 
plasmids or adenoviruses encoding shRNA sequences can be utilised, shRNA sequences 
consist of the inverted repeats of the siRNA sequence separated by a 6-9 base pair loop 
sequence. Vector-expressed shRNAs were first described by Sui et al as a tool for 
synthesis of siRNAs from a plasmid template (Sui et al. 2002) and have been extended to 
expression from a viral platform (Xia et al. 2002;Davidson et al. 2005). After transcription 
the shRNA folds back to self anneal, and is processed by Dicer to generate functional 
siRNAs (figure 5.1). Adenoviral expression of shRNAs has been applied to investigate the 
function of a number of cardiovascular and glutathione metabolism genes. For example an 
in-vivo study infected primary rat myocytes with adenoviruses expressing a shRNA 
directed against protein kinase c alpha (PKCα), resulting in increased contractility of 
myocytes compared to uninfected cells and confirming the role of PKCα in cardiac James Polke, 2008    Chapter 5         165 
 
   
 
 
Figure 5.1 - Exploitation of the endogenous RNA interference pathway in 
experimental biology 
 
 
contractility (El Armouche et al. 2007). Direct injection of adenoviruses expressing a 
shRNA targeted against AngII 1a receptors to the intracerebroventricular region of the 
brain increased water intake in mice but had no effect on blood pressure, while injection 
into the brain stem nucleus tractus solitarius reduced blood pressure but not drinking 
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activity (Chen et al. 2006). Systemic injection to rats of adenoviruses expressing anti-
glutathione synthase catalytic subunit (alternatively known as gamma glutamylcysteine 
synthase heavy chain) resulted in an 80% reduction in liver GSH levels, but not other 
organs since systemically-injected adenoviruses are delivered predominantly to the liver 
(Huard et al. 1995). GSH depletion continued for 2 weeks and hepatic acetaminophen 
toxicity was significantly potentiated in infused rats compared to controls (Akai et al. 
2007). 
The RNAi pathway overlaps with many functional elements of the microRNA (miRNA) 
transcriptional regulation pathway. miRNAs are single-stranded short (typically 21-24 bp 
long) RNA negative regulators of gene expression, they are increasingly acknowledged as 
major regulators of development and cellular homeostasis. miRNAs are encoded in the 
genome and expressed initially as pri-miRNAs, RNA templates that can encode single 
miRNAs or several tandemly aligned miRNAs. pri-miRNAs are processed by the enzyme 
complex Drosha to generate pre-miRNAs, hairpin structures that that resemble shRNA 
sequences and are processed by Dicer, producing short dsRNA molecule, similar to 
siRNAs, with a 1-4 base 3' overhang. The RISC complex mediates separation of the 
dsRNA into a single stranded molecule (this is the mature miRNA) and the association 
with the target mRNA. Unlike siRNAs, miRNAs bind exclusively to the 3'UTR of genes 
and mediate downregulation of expression by two routes: perfectly aligned miRNAs lead 
to gene silencing via the degradation of mRNAs, while imperfectly aligned miRNAs 
reduce expression by repressing translation. The overlap between the RNAi and miRNA 
pathways, and the importance of miRNAs in regulating post-developmental gene 
expression, was highlighted in research showing that systemic administration of adeno-
associated virus (AAV) vectors mediating long-term overexpression of shRNAs to mice 
caused fatality due to oversaturation of the endogenous miRNA pathways (Grimm et al. 
2006).  
Given the wide substrate specificity of the GST genes and the possibility that reducing 
Gstm1 expression alone may be compensated by upregulation of other members of the 
family, a single siRNA sequence designed to knock down expression of several Gstm 
genes is an appropriate tool. Previous experiments performed in the Glasgow laboratory by 
Dr William Miller identified the Gstmf sequence (AAGCCAGTGGCTGAATGAGAA) 
that aligns within a highly conserved region in the Gstm genes Gstm1,2,3,5 and 7 and 
effectively knocked down expression of Gstm1 protein in NRK52E cells when transfected 
as a naked chemically synthesised siRNA. James Polke, 2008    Chapter 5         167 
 
   
5.2  Aims 
·  To analyse the in-vitro and in-vivo functional effects of modulating Gstm1 and Gstm 
family  expression.  Adenoviruses  were  constructed  to  express  a  shRNA  sequence 
designed  to  reduce  expression  of  multiple  members  of  the  rat  Gstm  family,  and  to 
overexpress WKY and SHRSP Gstm1 cDNA sequences.  
·  To assess knockdown of multiple Gstm genes by the shRNA sequence at the mRNA 
and protein level in-vitro and to compare the Gstm1 expression and catalytic activity of 
the two overexpression viruses. The functional effects of modulating Gstm expression 
were  assessed  in-vitro  by  measuring  changes  in  total  GST  activity  and  cytotoxicity 
mediated by an oxidising agent, tert-butyl hydrogen peroxide (TBHP). 
·  To test the hypothesis that overexpression of Gstm1 in the carotid artery of the SHRSP 
improves endothelial NO bioavailability, measured by wire myography. James Polke, 2008    Chapter 5         168 
 
   
5.3  Methods 
5.3.1 Generating viruses by homologous recombination in 
HEK293 cells 
The overexpression and shRNAi viruses used in this project were generated in the same 
manner, (Anderson et al. 2000), relying upon homologous recombination between 
linearised plasmid shuttle and genome vectors in HEK293 cells stably transformed to 
express E1a and E1b genes (Graham et al. 1977) (figure 5.2).  
 
Figure 5.2 - Generation of recombinant adenoviruses by recombination in HEK293 
cells  
 
 
 
5.3.1.1 Anti-Gstm family shRNA sequence cloning 
shRNA sequences were cloned into the Ambion pSilencer adeno 1.0-CMV (abbreviated to 
p1.0-CMV) shuttle vector, which was supplied double digested at its multiple cloning site 
between a CMV promoter and minimal polyA sequence with XhoI and SpeI restriction 
enzymes. The Gstmf siRNA target sequence (AAGCCAGTGGCTGAATGAGAA) was 
converted to a double stranded short-hairpin sequence with overhanging ends suitable for 
cloning into the XhoI/SpeI-digested shuttle vector using and online sequence design tool on 
the Ambion website; unmodified oligonucleotides were ordered from MWG biotech. The 
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Plasmid shuttle and genome vectors encoded homologous polyA and viral genome 
sequences; cDNA or shRNA sequences were cloned into the shuttle vectors. Shuttle 
and genome vectors were linearised by digestion with PacI restriction endonuclease. 
Co-transfection into HEK293 cells followed by homologous recombination resulted in 
a linear recombinant adenoviral genome and assembly of replication deficient 
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oligonucleotides were diluted to 1  g/ l in 10mM Tris HCl, 0.5mM EDTA, pH 9.0. 2  l of 
each was mixed with 46  l Ambion 1 X DNA annealing solution and heated to 90°C for 3 
minutes, followed by 1 hour at 37°C. Annealed oligonucleotides were ligated into p1.0-
CMV as per section 2.5.6 using 100 ng p1.0-CMV with an insert:vector  molar ratio of 
100:1. Positive clones were confirmed by sequencing with pSilencer CMV1.0F and 
pSilencer CMV1.0R primers. The plasmid, named p1.0-CMV Gstmf shRNA, was 
amplified and purified as per section 2.5.3. A scrambled shRNA control plasmid, p1.0-
CMV Scr shRNA (Ambion) was transformed into JM109 cells as per section 2.5.1 and 
similarly purified. 
5.3.1.2 Cloning Gstm1 cDNA and Verifying Gstm1 Expression 
WKY and SHRSP cDNA sequences were cloned into the shuttle vector pacAd5 CMV K-
NpA (abbreviated to pK-NpA); the pK-NpA multiple cloning site resides between a CMV 
promoter and SV40 polyA sequence. Gstm1 sequences were amplified from WKY and 
SHRSP kidney cDNA by PCR using primers annealing in the 5'UTR and 3'UTR. Forward 
and reverse primers incorporated HindIII and XbaI restriction sites, respectively, preceded 
by 3 X 'C' residues, primers were named Gstm1HindIIIF and Gstm4aXbaIR. KOD 
proofreading polymerase was used as per section 2.2.3 with an annealing temperature of 
60°C. PCR product and pK-NpA were double digested with HindIII and XbaI and digests 
were electrophoresed and gel purified. Standard ligation and transformation protocols were 
performed as per section 2.5.6 with an insert:vector molar ratio of 3:1. Colonies were PCR 
screened with Gstm1HindIIIF and Gstm4aXbaIR primers, successful clones were further 
confirmed by sequencing. Plasmids, named pK-NpA WKY Gstm1 and pK-NpA SHRSP 
Gstm1 were amplified and purified . 
HeLa cells in 6-well plates were transfected at 70% confluence with 1  g of pK-NpA 
WKY Gstm1 or pK-NpA SHRSP Gstm1 in triplicate wells of 6-well plates using a 
FuGene:DNA ratio of 3:1 and 1  g DNA per well following the transfection protocol in 
section 2.3.3. A control well was transfected with pMV10 expressing β-galactosidase. Two 
days after transfection, HeLa cell protein was collected for Gstm1 western blotting and 
total GST activity assays (see below). 
5.3.1.3 Co-Transfection into HEK293 Cells  
HEK293 cells were maintained in Eagle's modified media with 10% FCS; 2mM L-
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cells were passaged using citric saline (0.13M KCl; 0.017M sodium citrate in PBS) in 
place of trypsin. Citric saline was applied to cells for 5 minutes at room temperature, 
dislodging them from the growth surface, they were then resuspended in PBS and passaged 
as per the protocol in section 2.3.1.  
The same genome vector, pacAd5 9.2-100, was used for all viruses. Genome and shuttle 
vectors were digested with PacI enzyme as per section 2.5.4. Digests were purified by 
phenol/chloroform purification and ethanol precipitation using the following method: A 
volume of 25:24:1 phenol:chloroform:iosamyl alcohol saturated with 10mM Tris pH8, 
10mM EDTA (Sigma) equal to the volume of the digestion reaction was added. Mixtures 
were vortexed for 30 seconds and centrifuged at 13000 rpm for 2 minutes. The upper 
aqueous layer was transferred to a fresh microcentrifuge tube and an equal volume of 
chloroform was added, vortexed for 30 seconds and centrifuged at 13000 rpm for 2 
minutes, the aqueous layer was removed once again. A 1/10
th volume of 3M sodium 
acetate pH5.2 and 2 volumes 100% ethanol was added, the mixtures were gently mixed by 
inverting the tubes and incubated at -70°C for 30 minutes to precipitate the DNA, then 
centrifuged at 13000 rpm at 4°C for 10 minutes. The supernatant was removed and the 
pellet was washed with 100  l 70% ethanol and centrifuged at 13000 rpm at 4°C for 2 
minutes. The supernatant was removed and the pellets were air dried for 20 minutes at 
room temperature before resuspending in H2O. 
Dual transfection of HEK293 cells was carried out in 25cm
2 flasks with the cells at 70% 
confluence using a differential pH method. This required the preparation of two specialised 
media: Media A consisted of DMEM with 1000mg/L glucose and no phenol red, with 10% 
FCS and 25mM HEPES pH 7.9. Media B consisted of DMEM with 1000mg/L glucose and 
no phenol red, and 25mM HEPES pH 7.1. Both Media A and Media B were freshly pH'd 
and filter sterilised before each use. Culture media was removed from the HEK293 cells 
and cells were washed once with PBS, 1.5ml media A was added to the flask. In a 1.5ml 
microcentrifuge tube, 320  l Media B was mixed with 16  l sterile 1M CaCl2, to which 14 
 g of linearised genome vector and 7  g shuttle vector was added. The Media B/vector 
mix was added dropwise to the flask and it was incubated overnight. The next morning the 
media was exchanged for regular culture media.  
Triplicate 25 cm
2 flasks were transfected for each virus. Formation of viruses was 
evidenced by the appearance of 'plaques', or areas of clearing in the HEK293 monolayer. 
When inspected under the microscope, cells were elongated and 'spider-web' like, over the 
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lysed cells in the monolayer. Upon the first plaques appearing the media was not replaced 
in the flasks, but 2 ml fresh media was added. 3-4 days after the plaques appeared, all the 
cells in the flask were detached, media containing cell debris was collected and centrifuged 
for 5 minutes at 2000rpm. Supernatant was poured off, resuspended in 500  l PBS, and 
crude virus stocks were made following the Arklone-P method below. Crude stocks were 
divided into 50  l aliquots and stored at -70°C. Recombinant adenoviruses were named: 
RAd WKY Gstm1  
RAd SP Gstm1  
RAd Gstmf shRNA 
RAd Scr shRNA 
5.3.2 Arklone P virus extraction 
Arklone-P (trichlorotrifluoroethane) is an industrial solvent used for virus preparations, it 
releases virus particles from unlysed cells. After centrifugation, cell pellets were 
resuspended in PBS, an equal volume of Arklone-P was added and the mixture was shaken 
following a strict protocol: 20 seconds of vigorous shaking followed by 20 seconds of slow 
shaking, repeated 3 times. The PBS/Arklone-P mixture was then centrifuged at 8,000 rpm 
for 15 minutes and the top (aqueous) layer containing the virus particles was carefully 
pipetted off, separated into 50  l or 100  l aliquots and stored at -70°C.  
5.3.3 Pure virus stock preparation 
Crude virus stocks were used to make 'seed' stocks by infecting a 150 cm
2 flask of 90% 
confluent HEK293 cells with one 50  l aliquot of crude stock. 5 ml media containing cell 
debris was added to the flask the next day. Within 3 days all cells were detached, media 
was removed, centrifuged at 2000 rpm for 10 minutes and resuspended in 2 ml PBS. The 
seed stocks were prepared by a second Arklone-P extraction, 100  l seed stock aliquots 
were stored at -70°C.  
To prepare pure viral stocks, 50  l of seed stock was added to a fresh 500 ml bottle of 
HEK293 media, this was exchanged for media on 20 X 150 cm
2 flasks of 90% confluent 
HEK293 cells. Two days after infection, 10 ml fresh media was added to each flask, within 
four to five days after infection all the cells were detached. Media containing cell debris 
was removed from each of the 20 flasks and centrifuged at 2000 rpm for 10 minutes. Cell 
debris was pooled into 8 ml PBS and viruses were extracted by Arklone-P. This extract 
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final pure stock. 1.45 and 1.32 d g/cm
3 CsCl solutions were prepared in 0.05 M Tris pH7.9. 
Plastic ultracentrifuge tubes were sterilised by rinsing with 70% ethanol followed by sterile 
H2O; 2 ml 1.45 d g/cm
3 CsCl was added to the tubes followed by slow dropwise addition 
of 3 ml 1.32 d g/cm
3 CsCl, 2 ml 40% glycerol, and then the Arklone-P virus extract. Tubes 
were topped up with PBS, and centrifuged for 1.5 hours at 25000 X g at 4°C. After 
centrifugation the virus was present in a discrete white layer between the two CsCl layers, 
it was removed with 1 ml syringe and hypodermic needle, puncturing the centrifuge tube. 
10000 KDa membrane molecular weight dialysis cassettes (Pierce) were pre-soaked in 
0.01M TE pH8 for 30 minutes before injecting the virus using a hypodermic needle. 
Excess air was removed from the cassettes and they were dialysed for 1.5 hrs in 0.01M TE 
pH8 twice, then overnight in 0.01M TE pH8, 10% glycerol. Virus stocks were separated 
into 50  l aliquots and stored at -70°C. 
5.3.4 Calculating Virus Titres 
Particle and plaque-forming unit titres were determined for all viruses. Particle titres were 
calculated with a Micro BCA Assay (Pierce). 1  l, 3  l and 5  l of virus preparations were 
diluted in duplicate wells of a 96-well plate to a total volume of 150  l with PBS. 150  l of 
0.5  g/ml – 200  g/ml albumin standards and PBS 'blanks' were also assayed in duplicate. 
150  l of 'working reagent' (25 parts Solution A, 24 parts Solution B, 1 part Solution C) 
was added to each well, and plate was incubated at 37°C for two hours protected from 
light. Absorbance at 560 nm (Abs 560nm) was measured for each standard and sample, 
duplicates were averaged and blank readings were subtracted. The Abs 560nm values of 
the standards were inspected to find the value closest to the absorbance value for each 
sample, this was used in the following formula for each volume of virus preparation 
assayed (1  l, 3  l or 5  l): 
 
The 1  l, 3  l and 5  l measurements were averaged to derive the protein concentration of 
the virus preparation and multiplied by 4x10
9 to calculate the particle titre of the virus 
preparation in particles/ml. 
Conc. of standard ( g/ l)  Abs 560nm of sample 
Abs 560nm of standard 
no. of  l of virus prep in sample 
X   1000  Protein conc. of 
sample ( g/ml) 
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Plaque forming unit (pfu) titres were calculated using a published protocol (Nicklin SA 
1999). HEK293 cells were seeded on day one to result in 60% confluence the next day in 8 
rows of 10 wells in a 96 well plate; remaining wells (columns 1 and 12) were filled with 
200  l PBS to prevent evaporation of media. On day two, media was removed from the 
cells and replaced with 100  l per well of dilutions in media of virus preparations from 10
-4 
to 10
-11: Media in all wells in row A was replaced with the 10
-4 dilution, row B with 10
-5 
and so on until row G (10
-11), media in row H was replaced with virus-free media. On day 
three, media was replaced on each well, media was changed every 48 hours on all wells 
thereafter. On day 9, all wells were inspected for plaques in the monolayer, the number of 
plaque-positive wells per row was recorded. Two adjacent rows were identified, one with 
>50% of plaque-positive wells, one with <50% plaque-positive wells. The % of plaque-
positive wells per row and dilution factor of the virus dilutions added to these rows was 
entered into the following formulae to calculate the 'tissue culture infectivity dose50' 
(TCID50) for the prep, an index of the dilution required to produce plaques in 50% of wells 
infected: 
 
Log ID50     =        log(dilution >50%) + (PD x dilution factor) 
 
TCID50 = 1 / ID50 
 
 
This was the TCID50 for the 100  l of the original dilutions added to the cells, it was 
multiplied by 10 to derive the TCID50 per ml. 1 TCID50 is approximately equal to 0.7 pfu, 
therefore pfu/ml = 0.7 X TCID50/ml. 
Genome viral titres were also calculated for Gstm1 over-expressing viruses. Serial 1/10-
fold dilutions of RAd WKY Gstm1 and RAd SP Gstm1 were made from 10
-3 to 10
-6. A 
serial 1/10-fold dilution of K-NpA WKY Gstm1 cDNA was made from 5 ng/ l to 0.05 
pg/ l to generate a standard curve. Triplicate 20  l simplex Taqman RT-PCR was 
performed using the Applied Biosystems Taqman probe for rat Gstm1 (part no. 
Rn00755117_m1) as per section 2.7 with 2 l of template per reaction. Ct values of 
triplicates were averaged, the standard curve was plotted as log (concentration plasmid 
(ng/ l)) vs. Ct and the equation of the line was derived. Ct values of virus dilutions were 
used to interpolate the equivalent concentration of template in each, giving a virus genome 
titre in units of: ng of plasmid DNA. 
% positive > 50%  -  50% 
% positive > 50%  -  % positive < 50% 
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5.3.5 In-vitro Virus Infections 
Standard in-vitro virus infections followed a similar protocol for all cell types. Cells were 
infected at 90% confluence. Prior to infection the precise number of cells per well was 
calculated in a control well by trypsinisation and counting with a haemocytomoter as per 
section 2.3.2. Appropriate dilutions of virus stocks were made in PBS and added to cell 
culture. The next day, media was replaced. Three different cell culture strains were used in 
in-vitro experiments: HeLa, NRK52E and RGE (rat glomerular endothelial) cells. 
Optimisation of infection was performed in 6-well plates using RAd35, a recombinant 
adenovirus encoding LacZ with a CMV promoter at various multiplicities of infection 
(MOI). 48 hours after infection, cells were stained and fixed for β-galactosidase activity as 
per section 2.3.4. 
NRK52E infection was further optimised using a modified protocol incorporating CaCl2 to 
enhance viral infection (Fasbender et al. 1998). RAd35 dilutions were made in culture 
media plus 0.025 M CaCl2. Media was exchanged and 24 hours after infection and 48 
hours post infection, cells were fixed and stained for β-galactosidase activity. The CaCl2 
protocol was used for all NRK52E infections thereafter. 
5.3.6 Gstm1 Western Blotting 
Standard western blots were performed for Gstm1 in cell lysates as detailed in section 2.6, 
The primary polyclonal anti Gstm1 antibody, named, 'Alexis' was obtained from the 
laboratory of Professor John Hayes, Dundee University and used at 1/2000 dilution in TBS 
tween 5% milk. The secondary antibody, DAKO 3099 swine anti-rabbit HRP-conjugated, 
was also diluted 1/2000 in TBS Tween 5% milk. Following development of Gstm1 bands 
the blot was stripped as per section 2.6.5 and re-probed with anti β-actin primary antibody 
(Abcam 8226) at 1/1000 dilution in TBS Tween 5% milk, secondary antibody (DAKO 
P0260 rabbit anti-mouse HRP-conjugated) was used at 1/2000 dilution. 
5.3.7 GST Activity Assays 
Sigma total GST Assay Kit was used to measure total GST activity in cultured cell lysates. 
Assays were performed in 96-well plates. 1  l or 2  l of PBS/0.2% Triton lysates were 
diluted in a total volume of 20  l sample buffer in duplicate wells. A standard curve was 
generated by assaying duplicate wells of a serial dilution of GST standard from 5  g/ml to 
0.31  g/ml. substrate solution was made fresh for each assay, consisting of 19.6 ml PBS, James Polke, 2008    Chapter 5         175 
 
   
200  l 200 mM GSH, 100mM CDNB. Substrate solution was added to all wells to a total 
volume of 200  l. Absorbance at 340 nm (Abs 340nm) was measured in each well once a 
minute for 10 minutes to measure the accumulation of GS-DNB conjugate. Duplicates 
were averaged. Abs 340nm per minute was plotted for each sample and the linear portion 
of the curve (R
2 ≥0.95 over at least three points) was used to derive the GST activity. GST 
concentrations of samples were interpolated from the standard curve and corrected for 
concentration of protein in the original sample to give GST a reading of  g GST protein/ 
 g total protein. 
5.3.8 Taqman RT-PCR of Gstm Isoforms 
Taqman RT-PCR was performed on the following Gstm isoforms using Applied 
Biosystems Taqman Gene Expression Assays: Gstm1 (part no. Rn00755117_m1) Gstm2 
(Rn00598597_m1) Gstm3 (Rn00579867_m1), and Gstm5 (Rn00597012_m1). A Gene 
Expression Assay was not available for rat Gstm7, a custom Applied Biosystems assay was 
designed by a colleague, Dr Caline Tan, to anneal to unique sequences spanning exons 6 
and 7 to ensure gene and cDNA-specific amplification. The expression levels of Gstm 
isoforms was measured relative to β-actin by multiplex PCR in all samples as per section 
2.7, equivalent amplification efficiencies of Gstm and β-actin probes in all sample types 
were verified. 5  l reactions were performed in 384-well reaction plates using 2  l 
template per reaction. 
5.3.9 Sequencing of RNAi Target Sequences 
The Gstmf target sequence in Gstm1, Gstm2, Gstm3, Gstm5 and Gstm7 was sequenced in 
DNA extracted from NRK52E cells. DNA was extracted using a Qiagen QIAmp DNA 
Mini Kit. 5x10
6 cells were collected by trypsinisation and centrifugation and resuspended 
in 200  l PBS. 200  l buffer AL was added, the mixture was vortexed for 15 seconds and 
incubated at 56°C for 10 minutes. 200  l 100% ethanol was added, the mixture was 
vortexed, applied to a QIAmp spin column and washed through the membrane by 
centrifugation at 6000 x g for 1 minute. 500 l AW1 buffer was applied to the column and 
it was centrifuged at 6000 x g for 1 minute. This was repeated with buffer AW2, 
centrifuging for 3 minutes. The column was dried completely by a further centrifugation at 
full speed for 1 minute and DNA was eluted in 200  l H2O. 
Forward and reverse primers binding to unique sequences of exon 3 in Gstm1, 2,3,5 and 7 
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temperature of 60°C (primers were named Gstm1 Ex3F+R, Gstm2 Ex3F+R, Gstm3 
Ex3F+R, Gstm5 Ex3F+R, Gstm7 Ex3F+R). PCR clean-up, sequencing reaction, 
sequencing clean-up and electrophoresis were performed as per section 2.4. 
5.3.10 Cytotoxicity Assays 
Cytotoxicity of tert-butyl hydrogen peroxide (TBHP) to RGE cells was measured with the 
Promega CytoTox 96 Non-Radioactive Cytotoxicity Assay kit, which measures lactate 
dehydrogenase activity released from cells. For assays involving infected cells, RGE cells 
were infected 48 hours prior to cytotoxicity assays. TBHP was applied 24 hours prior to 
cytotoxicity assays in all experiments. Media was removed from experimental wells, 
Triton was added to three control 'max cytotoxicity' wells to a final concentration of 0.1% 
and they were freeze-thawed to -20°C to lyse cells. Media from experimental and control 
wells was centrifuged at full speed at 4°C for 5 minutes. 50 l of supernatant was aliquoted 
into duplicate wells of a clear 96-well assay plate, cell-free media was aliquoted into three 
control wells. 50 l of substrate mix was added to each well and the plate was incubated at 
room temperature for 30 minutes, protected from light. 50 l Stop solution was added to 
wells and absorbance at 490nm (Abs 490nm) was measured. Absorbance levels from 
triplicates were averaged, background absorbance from cell-free media was subtracted 
from all other wells. Abs 490nm of experimental wells were expressed as a percentage of 
the Abs 490nm of the max cytotoxicity wells.  
5.3.11 Local Delivery of RAd WKY Gstm1 to SHRSP Carotid 
Arteries 
5.3.11.1 Surgical Procedure and Viral Delivery 
Surgical procedures were performed by Elizabeth Beattie. Rats were anaesthetised with 
halothane and the skin covering the left side of the neck was incised. The left common 
carotid artery was exposed by blunt dissection at the base of the neck and surgical thread 
was looped under the artery. The upper section of the common carotid was then exposed at 
the level of the bifurcation into the internal and external carotid. An artery clip was applied 
to the internal carotid and the external carotid was tied off approximately 0.5 cm anterior to 
the bifurcation. A hole was punctured in the external carotid posterior to the tie using a 
hypodermic needle. A teased 0.28 mm bore catheter connected to a 0.5 ml syringe 
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inserted as far as the bifurcation. The section of the external carotid containing the catheter 
was tied to prevent backflow and 2.4x10
8 or 6x10
8 pfu of virus in  30  l PBS was injected 
into the vessel. Immediately after the injection, the lower loop of surgical thread below the 
common carotid was lifted to close off the artery and an artery clip was applied. The 
section of the common carotid containing the virus was kept isolated for twenty minutes, 
after which the catheter was removed and both ties on the external carotid secured, artery 
clips were removed and the rat was sutured. Rats were administered 0.05 ml veturgesic 
after surgery. Twenty-four or 48 hours after surgery, rats were euthanized under 
anaesthetic, left and right carotid arteries were removed and placed in physiological saline, 
RNA-later or β-galactosidase activity assay fixative. In the finalised experimental protocol 
6x10
8 pfu virus was infused and animals were sacrificed 48 hours later. 
5.3.11.2 Carotid Artery Wire Myography 
Wire myography protocols were performed by Angela Spiers according to published 
protocols (Spiers et al. 2005). Excised carotid arteries were placed in physiological saline 
solution (PSS) (118.4 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4H2O, 24.9 mM NaHCO3, 
2.5 mM CaCl2, 11.1 mM glucose, 0.023 mM EDTA) and dissected into 2 mm rings under 
a dissection microscope. Two rings were cut per vessel. Rings were mounted on two 40 
µm stainless steel wires on the stage of a four channel small vessel myograph (Danish 
MyoTechnologies 610M), one wire was attached to a force transducer and the other to a 
micrometer. Vessels were maintained at 37°C in PSS, pH7.4, gassed with 95% O2, 5% 
CO2 for the duration of experiments. After mounting, vessels were equilibrated under 1 g 
tension for 30 minutes, then a 'wake-up' protocol was followed to ensure contractility: 
Vessel rings were maximally contracted twice by depolarisation with 125 mM potassium 
physiological saline solution (KPSS), washing with PSS and relaxing to baseline after 
contractions. To check endothelial integrity, rings were contracted with 1x10
-5M PE then 
relaxed with 3x10
-6M carbechol, rings that did not respond to these protocols were 
discarded from the study. Vessel rings were re-equilibrated for 30 minutes before 
recording a cumulative concentration response curve to phenylephrine (PE) from 1x10
-9M 
to 3x10
-5M. 10
-4M N-Nitro-L-Arginine Methyl Ester (L-NAME) was applied to the vessel 
rings for 40 minutes and a second contractile response curve to 1x10
-9M – 3x10
-5M PE was 
recorded. Contraction to PE in the presence of L-NAME was expressed as a percentage of 
the maximal contraction in the first PE response curve as a measure of NO bioavailability 
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5.3.11.3 RNA Extraction from Carotid Arteries and cDNA 
Sequencing 
RAd WKY Gstm1-infused and uninfused carotid arteries were dissected from freshly 
euthanized SHRSP rats and placed directly into RNA-Later stabilisation solution 
(Ambion). Carotids were also obtained from 2c* and WKY rats. Vessels were dissected 
under RNA-Later using a dissection microscope, removing nervous and connective tissue. 
RNA extraction was performed using a modified protocol for Qiagen RNEasy Mini 
columns for fibrous tissue. Vessels were homogenised with a 13 mm ball bearing in 400  l 
RLT buffer (10  l/ml β-mercaptoethanol) using a Qiagen Tissuelyser set at 25 Hz for 4 
minutes. The homogenate was diluted with 786  l H2O, 13  l proteinase K (600 mU/ml) 
was added and tubes were incubated at 55°C for 10 minutes. Lysates were centrifuged for 
3 minutes at 10000 x g, supernatant was removed to a fresh tube, 0.5 volume of 100% 
ethanol was added and mixed by pipetting. Samples were applied to RNeasy Mini columns 
and centrifuged for 15s at 8000 x g. 350  l RW1 buffer was applied and columns were 
centrifuged for 15s at 8000 x g. 10  l Qiagen DNAse I (3 U/ l) was diluted in 70 l RDD 
buffer and applied to each column for 15 minutes at room temperature. Columns were 
washed with 350  l RW1, followed by two washes with 500  l RPE buffer, centrifuging 
for 15s at 8000 x g after each addition, then dried by centrifugation for 1 minute at full 
speed. DNase-free RNA was eluted in 40  l RNase-free H2O. cDNA was generated using 
Applied Biosystems TaqMan Reverse Transcription Reagents as per section 2.7.1, the 
lowest RNA concentration among the samples dictated 210.2 ng RNA template per reverse 
transcription. 
Carotid artery cDNAs were PCRd using Roche FastStart taq with an annealing temperature 
of 61°C using Gstm1HindIII and Gstm4aXbaI primers as per section 2.2.3. PCR products 
were electrophoresed (2% agarose) and gel purified as per section 2.5.5, eluting in 40  l 
H2O. 10  l of gel purified PCR product of the expected size (759 bp) was amplified in 
sequencing reactions as per section 2.4.2 and standard sequencing clean-up and 
electrophoresis protocols were performed as per sections 2.4.3-4. 
5.3.11.4 Carotid Artery Gstm1 Immunohistochemistry 
RAd WKY Gstm1-infused and uninfused carotid arteries were dissected in PSS under a 
dissection microscope to remove blood, connective and nervous tissue. Tissues were fixed 
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blocks by Andrew Carswell. 6  m sections were cut onto silanised microscope using a 
Shandon Finesse 3 microtome and baked overnight at 60°C. Immunohistochemistry was 
performed by Andrew Carswell. Tissue sections were de-paraffinised and hydrated by 
washing twice in Histoclear for 7 minutes, 100% ethanol for 7 minutes, 70% ethanol for 7 
minutes, and H2O for 7 minutes. Endogenous peroxidase activity was quenched by 
incubation in 0.3% H2O2 in methanol for 30 minutes, followed by two washes in H2O for 
10 minutes. Sections were blocked with 0.01% horse serum for 1 hour. 'Alexis' rabbit anti-
Gstm1 antibody was applied at a 1/6000 dilution in blocking solution; negative control 
sections were treated with rabbit serum at the same total protein concentration as the 
positive slides. Slides were left in humidified trays at room temperature overnight then 
washed three times in PBS for five minutes. Vectastain Elite ABC Universal kit was used 
for secondary antibody application; horse anti-rabbit secondary antibody was diluted in 
blocking reagent and applied to the slides for 30 minutes, slides were washed three times in 
PBS for five minutes. Vectastain ABC reagent was prepared and pre-incubated for 30 
minutes, then applied to the slides for 30 minutes, slides were washed three times in PBS. 
Vector Lab DAB (3,3'-diaminobenzidine) substrate kit was used for colour development; 
DAB substrate reagent was added, incubated for 5 minutes and washed in H2O for five 
minutes. Nuclei were counterstained with Harris's modified haematoxylin for 2 minutes, 
then rinsed in running water for 5 minutes. Finally, sections were dehydrated by 10 minute 
washes in 70% ethanol, 95% ethanol, 100% ethanol and two washes in Histoclear. Cover 
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5.4  Results 
5.4.1 Recombinant Virus Construction and Titring 
The Gstmf shRNA oligonucleotides were annealed and cloned into the pSilencer adeno 
1.0-CMV backbone. Co-transfection of PacI-linearised 1.0-CMV Gstmf shRNA or 1.0-
CMV Scrambled shRNA with PacI-linearised pacAd5 9.2-100 into HEK293 cells resulted 
in the generation of recombinant adenoviruses, confirmed by sequencing. 
PCR primers Gstm1F and Gstm4R that anneal within the Gstm1 5'UTR and 3'UTR, 
respectively, and had already been applied for Gstm1 cDNA sequencing (See section 
4.3.2) were to be used for cloning, however, while planning the cDNA PCR procedure it 
was noticed that there is an ambiguous base in the 3'UTR (position +35) between different 
Gstm1 reference sequences: NM_017014 and X04229 sequences code for a 'G' at this 
residue, while Ensembl reference sequence ENSRNOT00000041192 denotes an 'A'. This 
residue lies within 3 bases of the 5' end of the primer binding site for primer Gstm4R, 
therefore the primer was redesigned to anneal 4 bases upstream, avoiding the ambiguous 
base, the new primer (synthesised to also encode a HindIII restriction site) was designated 
Gstm4aXbaIR. Cloning of digested PCR products from amplification of Gstm1 cDNAs in 
WKY and SHRSP kidney cDNA into the K-NpA backbone was confirmed by PCR (figure 
5.3). Sequencing confirmed correct insertion of the WKY and SHRSP cDNA sequences 
into K-NpA and the presence of the known coding variant at base 605 (WKY = A; SHRSP 
= G), it also identified the previously noted 3'UTR SNP at base +29, and the sequence at 
base +35 also differed between the two strains: WKY = A, SHRSP = G. Particle and pfu 
titres were ascertained for all recombinant viruses, genome titres were also ascertained for 
RAd WKY Gstm1 and RAd SP Gstm1 (table 5.1). 
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Figure 5.3 - PCR screen following Gstm1 cDNA cloning 
 
 
Virus  Particle titre 
(particles/ml)  pfu titre (pfu/ml)  Genome titre (ng 
plasmid DNA) 
RAd WKY Gstm1  3.25x10
11  6.90x10
12  0.082 
RAd SP Gstm1  2.21x10
11  5.22x10
12  0.063 
RAd Gstmf shRNA  2.21x10
11  3.29x10
12  ND 
RAd Scr shRNA  4.417x10
11  4.30x10
12  ND 
Table 5.1 - Recombinant adenovirus particle, pfu and genome titres 
 
5.4.2 K-NpA Gstm1 Plasmid Transfections in HeLa cells 
HeLa cells were transfected with pK-NpA WKY Gstm1 cDNA and pK-NpA SHRSP 
Gstm1 cDNA to confirm Gstm1 expression from the shuttle vectors prior to adenovirus 
construction. Control transfection with pMV10 verified transfection of HeLa cells (figure 
5.4 A). Gstm1 protein levels were equivalent in HeLa cells transfected with pK-NpA 
WKY Gstm1 cDNA and pK-NpA SHRSP Gstm1, measured by densitometry relative to β-
actin protein (figure 5.4 B and C). There was no significant difference between total GST 
activities in the same cell lysates (figure 5.4 D). 
H2O 
WKY  SHRSP 
WKY 
750bp 
1 kb 
500 bp 
750bp 
1 kb 
500 bp 
SHRSP and WKY Gstm1 cDNA sequences were ligated into pK-NpA, colonies were 
screened with Gstm1HindIIIF and Gstm4aXbaIR primers. All clones screened were 
positive. Expected product size = 759 bp. 
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Figure 5.4 - Transfection of K-NpA Gstm1 cDNA plasmids into HeLa cells 
 
 
 
 
 
5.4.3 Optimising In-vitro Viral Infections 
In experiments to optimise viral infection protocols, low transduction levels were observed 
in NRK52E cells following infection with RAd35 from 10-300 pfu/cell and infection with 
MOIs above 300 was toxic to the cells. The CaCl2-enhanced infection method (25-100 
pfu/cell) was not toxic, increasing transduction was observed with increasing MOI, 100 
pfu/cell resulted in the highest level of viral transduction (figure 5.5A). 48 hours following 
infection of HeLa cells with RAd35 from 10-100 pfu/cell, increasing transduction levels 
were observed with increasing MOI (figure 5.5B). Very efficient transgene expression was 
observed in RGE cells at low MOIs (figure 5.5C). 
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(A) Control well transfected with pMV10 expressing β-galactosidase demonstrated 
efficient transfection of HeLa cells. (B) Western blotting confirmed expression of Gstm1 
protein (26 KDa) in transfected wells. β-actin expression (42 KDa) was verified in all 
wells. 20  g protein loaded in all wells except kidney control, 30  g loaded. (C) Gstm1 
densitometry, corrected for β-actin, showed equivalent levels of Gstm1 expression from 
each plasmid. Mean ± SE (D) Total GST activity measurements were not significantly 
different between cells transfected with K-NpA WKY and SHRSP Gstm1 cDNA 
plasmids. Mean ± SE. Scale bar = 100  m. NT = non-transfected (2 sample t test). 
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Figure 5.5 - Optimisation of in-vitro virus infections with RAd35 
 
 
5.4.4 Gstm Knockdown by RAd Gstmf shRNA in NRK52E Cells 
NRK52E cells were infected at 25, 50 and 100 pfu/cell with RAd Gstmf shRNA and 
control viruses. qRT-PCR for Gstm isoforms was performed to measure knockdown of 
Gstm1,2,3,5 and 7. Expression of Gstm3 was significantly reduced compared to all controls 
at 50 and 100 pfu/cell, while Gstm1 and 2 expression were reduced compared to all 
controls at 100 pfu/cell. Expression of Gstm5 and Gstm7 was not significantly reduced 
(figure 5.6). 
A: NRK52E 
100 pfu/cell  NI  50 pfu/cell  25 pfu/cell 
B: HeLa 
10 pfu/cell  NI  50 pfu/cell  100 pfu/cell 
C: RGE 
10 pfu/cell  NI  5 pfu/cell  50 pfu/cell 
β-galactosidase staining 48 hours post infection at indicated MOIs. (A) NRK52E infections 
with modified CaCl2 protocol. (B) HeLa infections. (C) RGE infections. Scale bar = 100  m. 
NI: non-infected.  
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Figure 5.6 – Continued overleaf  
   
 
Figure 5.6 - Anti-Gstm family shRNA-mediated mRNA knockdown of Gstm isoforms 
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NRK52E cells were infected in triplicate wells at 25, 50 and  100 pfu/cell with RAd Gstmf shRNA, RAd Scr shRNA and RAd60 using a  
modified CaCl2 protocol. RNA was extracted 48-hours post infection for gene expression measurements of Gstm1, Gstm2, Gstm3, Gstm5 
and Gstm7 by Taqman RT-PCR. Gene expression is expressed relative to β-actin in each case and normalised to non-infected wells 
(NI). n=3, mean ± SE * p<0.05 vs. Gstmf, ** p<0.01 vs. Gstmf (ANOVA and Dunnett's post-test). James Polke, 2008    Chapter 5         186 
 
   
RAd Gstmf shRNA was infected into NRK52E cells at an MOI of 100 pfu/cell and western 
blotting confirmed Gstm1 knockdown compared to RAd Scr shRNA and NI controls 
(figure 5.7 A and B). GST activities were assayed on the same lysates, reduction in Gstm 
expression mediated by Gstmf did not reduce total GST activity (figure 5.7 C). 
 
Figure 5.7 - Anti-Gstm family shRNA-mediated knockdown of Gstm1 protein 
 
 
 
 
 
5.4.5 Gstmf Target Site Sequencing in Gstm1,2,3,5 and 7 
Given the variable capacity for RAd Gstmf shRNA to mediate knockdown of Gstm genes 
at the mRNA level in NRK52E cells (figure 5.6), the target sites for Gstmf in Gstm1,2,3,5 
and 7 were sequenced from NRK52E genomic DNA. During this process it was observed 
that the published reference sequences for these genes have changed since Gstmf was 
originally designed (in 2004), Gstmf does not align 100% with all of the sequences. Exon 3 
sequences surrounding the Gstmf target were sequenced in each gene and aligned with 
Gstmf, homology between the genes and Gstmf is shaded: 
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NRK52E cells were infected in triplicate wells at 100 pfu/cell  with RAd Gstmf shRNA, 
RAd Scr shRNA and RAd60 using a  modified CaCl2 protocol. Protein was extracted 
48-hours post infection for Gstm1 Western blotting and total GST activity assays (A) 
Immunoreactive Gstm1 protein (26 kDa) and β-actin (42 kDa) was observed in all wells. 
40  g NRK protein per lane, 30  g kidney protein. (B) Densitometry measuring Gstm1 
protein relative to β-actin in infected cells showed reduced Gstm1 protein in RAd Gstmf 
shRNA-infected cells relative to RAd Scr shRNA infected and non-infected cells (NI). F 
= 10.2 * p<0.05 vs. Gstmf, **p<0.01 vs. Gstmf (ANOVA and Dunnett's post-test). (C) No 
differences in total GST activity in cells lysates was measured.  
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Gstmf:       AAGCCAGTGGCTGAATGAGAA 
Gstm1: TGACAGAAGCCAGTGGCTGAATGAGAAGTTCAA  
Gstm2: TGACAGAAGCCAGTGGCTGAGTGAGAAGTTCAA  
Gstm3: TGACAGAAGCCAGTGGCTGAATGAGAAGTTCAA  
Gstm5: TGATAGAAGCCAATGGCTGGACGTGAAATTCAA  
Gstm7: TGACAGAAGCCAGTGGCTGAGTGAGAAGTTCAA  
 
 
The sequences above agree with the current consensus sequences for the Gstms from 
Ensembl. The homology of Gstmf with Gstm1 and Gstm3 is 100%, while there are 
mismatches between Gstmf and Gstm2,5 and 7 sequences.  
5.4.6 Gstm1 Expression from Crude Viral Stocks 
Serial dilutions of crude stocks of RAd WKY Gstm1 and RAd SP Gstm1 were used to 
infect HeLa cells. No viral plaques were seen in any wells confirming the absence of wild-
type virus was present in the preparations. 8 days following infection, cells were recovered 
and Gstm1 protein levels were assessed by western blot. Increasing dose of virus resulted 
in increasing Gstm1 staining in cell lysates, confirming viral transgene expression (figure 
5.8).  
 
Figure 5.8 - Verification of Gstm1 overexpression viruses 
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Crude stocks of RAd WKY Gstm1 and RAd SHRSP Gstm1 were serially diluted 
from 10
-3 to 10
-6 and 10
-2 to 10
-6, respectively and used to infect HeLa cells in 
duplicate wells. Gstm1 western blotting was performed directly on cell debris with 
10  g rat kidney control protein. Gstm1 protein (26 kDa) was present at highest 
concentrations after infection with lowest dilutions of crude extracts. NI: non-
infected, K: kidney. 
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5.4.7 Comparing WKY and SHRSP Gstm1 Overexpression Viruses 
RAd WKY Gstm1 and RAd SP Gstm1 were infected into HeLa cells at MOIs of 10, 50 
and 100 pfu/cell in experiments designed to compare the transcriptional and catalytic 
activities of the WKY and SHRSP Gstm1 sequences, control wells were infected with 
RAd60 or were uninfected. After 48 hours cells were lysed and a western blotting was 
performed to compare Gstm1 expression; rat Gstm1 immunoreactivity was observed in 
cells infected with Gstm1 overexpression viruses at all MOIs but not RAd60 or non-
infected cells (figure 5.9 A). Densitometry showed higher Gstm1 expression level in cells 
infected with RAd SP Gstm1 compared to RAd WKY Gstm1 at 10, 50 and 100pfu/cell 
(figure 5.9 B). GST activity assays on cell lysates showed increased total GST activity in 
cell lysates infected with RAd SP Gstm1 compared to RAd WKY Gstm1 at each MOI, no 
increase in GST activity was seen in RAd60-infected cells compared to non-infected cells 
(figure 5.9 C).  
5.4.8 miRNA Alignments in the WKY and SHRSP Gstm1 3'UTR 
The Wellcome Trust Sanger Institute in Cambridge, UK, maintains an online database of 
verified functional miRNAs, called miRBase (http://microrna.sanger.ac.uk); release 10.0 
(August 2007) was interrogated to find miRNAs that bind to the SNPs between the 3'UTR 
of WKY and SHRSP Gstm1. One miRNA was identified, rno-miR-10b, that aligns at its 
extreme 3' end with the SNP at base +35, base-paring is indicated by a vertical line: 
rno-miR-10b:       3' UGUGUUUAAGCCAAGAUGUCCC 5' 
         |  || ||| | | || |||| 
WKY:   5' GGACCTATCCACATTGGATCCTGCAGGCCACCCT 3' 
SHRSP:  5' GGACCTGTCCACATTGGATCCTGCAGGCCACCCT 3' 
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Figure 5.9 - Adenovirus-mediated WKY and SHRSP Gstm1 expression in HeLa cells 
 
 
 
0
0.01
0.02
0.03
0.04
0.05
SHRSP
Gstm1
10
SHRSP
Gstm1
50
SHRSP
Gstm1
100
WKY
Gstm1
10
WKY
Gstm1
50
WKY
Gstm1
100
Rad60 
10
Rad60 
50
Rad60 
100
NI
u
g
 
G
S
T
 
/
 
u
g
 
T
o
t
a
l
 
P
r
o
t
e
i
n
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
SHRSP WKY
G
s
t
m
1
/
B
-
A
c
t
i
n
 
(
O
D
U
/
m
m
2
)
0
0.2
0.4
0.6
0.8
1
1.2
SHRSP WKY
0
0.5
1
1.5
2
2.5
3
SHRSP WKY
50 pfu/cell: 
SHRSP   WKY  K 
B 
10 pfu/cell: 
SHRSP   WKY  K 
Gstm1 
B-Actin 
100 pfu/cell: 
SHRSP   WKY  K 
A 
Gstm1 
B-Actin 
SHRSP   WKY  Rad 60  NI  K 
C 
p<0.01  p<0.01  p<0.05 
**  ** 
** 
HeLa cells were infected with RAd WKY Gstm1, RAd SP Gstm1 and RAd60 at 10, 50 
and 100 pfu/cell in triplicate wells. 48 hours post infection, protein was harvested. (A) 
Gstm1 expression (26kDa) in cells infected at 100 pfu/cell, no Gstm1 expression in 
RAd60-infected or non-infected (NI) cells.  β-actin (42kDa) immunoreactivity in all wells. 
(B) Western blotting and densitometry relative to β-actin showing higher Gstm1 
expression from RAd SP Gstm1 than RAd WKY Gstm1 at all titres. (C) Total GST 
activity was higher in cells infected with RAd SP GStm1 than RAd WKY Gstm1. 10  g 
NRK52E protein per lane, 30  g kidney (K) protein. ** p<0.01 vs. SHRSP at equivalent 
pfu (2 sample t test). 
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5.4.9 Gstm1 expression in RGE Cells and Cytotoxicity Assays 
Experiments performed in 96-well plates showed increasing cytotoxicity of 0-0.1mM 
TBHP to RGE cells (figure 5.10 A). Concentrations of 0.07 mM, 0.08 mM and 0.09 mM 
TBHP were used in an experiment to assess the protective effects of Gstm1 expression 
from TBHP cytotoxicity in RGE cells. Infection of RGE cells with RAd WKY Gstm1 at 10 
pfu/cell resulted in Gstm1 expression (figure 5.10 B) but did not protect against 
cytotoxicity mediated by TBHP (figure 5.10 C).  
 
Figure 5.10 - Cytotoxicity assays in RGE cells treated with TBHP 
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(A) Treatment of RGE cells with 0-0.1mM TBHP in 96-well paltes mediated 
increasing cytotoxicity after 24 hours. (B) Gstm1 Western blot in RGE cells 48 hours 
post-infection with 10 pfu/cell RAd WKY Gstm1 and RAd60. Gstm1 protein observes 
at 26 kDa, β-actin at 42 kDa. (C) RGE cells were infected with RAd WKY Gstm1 or 
RAd60 24 hours prior to treatment with 0.07, 0.08 and 0.09 mM TBHP in 6-well 
plates. Overexpression of Gstm1 did not protect cells against TBHP cytotoxicty. NI: 
non-infected, n=3, mean ± SE * p<0.05 NI vs. Gstm1, # p<0.01 NI vs. Rad60 
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5.4.10 Local Delivery of RAd WKY Gstm1 to SHRSP Carotid 
Arteries 
5.4.10.1 Optimising Viral Dose and Expression Time 
SHRSP carotids were infused with 2.4x10
8 or 6x10
8 pfu of RAd WKY Gstm1 and 
sacrificed after 24 or 48 hours. Left and right carotid arteries were fixed and stained for β-
galactosidase activity. Only vessels infused with 6x10
8 virus for 48 hours showed 
significant levels of β-galactosidase staining, β-galactosidase activity was evident in the 
endothelium and interstitial tissue (figure 5.11); consequently this protocol was used for 
experimental infusions with RAd WKY Gstm1.  
 
Figure 5.11 - β-galactosidase expression in RAd35-infected SHRSP carotid arteries 
 
 
 
 
Infused: 
Uninfused: 
48 hours after infection with 6x10
8 pfu of RAd35, carotids were fixed and stained for 
b-galctosidase activity. Transgene expression was observed in endothelial (short 
arrows) and adventitial (long arrows) tissue layers. Scale bar  = 100  m. James Polke, 2008    Chapter 5         192 
 
   
5.4.10.2 Gstm1 Expression in Carotid Arteries 
Expression of Gstm1 mRNA was significantly lower, by approximately 2-fold, in the 
carotid arteries of SHRSP rats compared to 2c* and WKY (figure 5.12A). Infusion of RAd 
WKY Gstm1 into SHRSP carotid arteries increased Gstm1 expression by 1.1-3.6 fold 
compared to contra-lateral controls (figure 5.12B). PCR of Gstm1 cDNA from infused and 
uninfused SHRSP carotid arteries produced two PCR products, of approximately 690 bp 
and 640 bp, in addition to the expected 759 bp product (figure 5.12C), indicating either 
amplification of non-specific templates or the expression of alternatively spliced Gstm1 
isoforms in the rat carotid artery. Sequencing of the 759 bp product revealed clear 
heterozygosity at the polymorphic bases between the WKY and SHRSP Gstm1 cDNA 
sequences (figure 5.12D), indicating expression of WKY Gstm1 sequence in infused 
vessels. Immunohistochemistry for Gstm1 protein demonstrated Gstm1 expression in 
infused and uninfused vessels, Gstm1 protein levels were higher in infused vessels in 
endothelial, smooth muscle and adventitial layers (figure 5.13). 
 
5.4.10.3 Wire Myography to Assess NO Bioavailability 
Wire myography was performed on vessel rings from infused and uninfused carotid 
arteries to assess changes in NO bioavailability following overexpression of Gstm1. There 
was no increase in NO bioavailability in infused vessels compared to uninfused vessels 
(figure 5.14). James Polke, 2008    Chapter 5         193 
 
   
 
Figure 5.12 - Gstm1 expression in infused and uninfused carotid arteries 
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(A) Gstm1 mRNA expression in uninfused WKY and 2c* carotid arteries measured by 
Taqman qRT-PCR was approximately 2-fold higher than in the SHRSP. n=4, mean ± 
SE, F=7.7 * p<0.05, ** p<0.01 vs. SHRSP (ANOVA and Dunnett's post-test). (B) 
Infusion with RAd WKY Gstm1 increased SHRSP carotid artery Gstm1 expression 1.1-
3.6 fold compared to contra-lateral control vessels. (C) Gstm1 PCR from carotid cDNA 
resulted in multiple bands in infused and uninfused arteries, the expected 759 bp band 
was gel-purified for cDNA sequencing, (D) which revealed heterozygous base-calls at 
sites of coding and 3'UTR polymorphisms between the SHRSP and WKY bases in 
SHRSP vessels infused with RAd WKY Gstm1, confirming transgene expression.  
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Figure 5.13 - Gstm1 immunohistochemistry in SHRSP carotid arteries 
 
 
 
 
 
Figure 5.14 - NO bioavailability in SHRSP carotid arteries 
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PE concentration response curves of SHRSP carotid artery rings, uninfused vs. infused 
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-4M L-NAME 
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5.5  Discussion 
Recombinant adenoviruses have been applied to assess the functional effects of modulating 
expression of Gstm genes in-vitro and in-vivo. RAd Gstmf shRNA mediated consistent in-
vitro knockdown of Gstm1,2 and 3 mRNA in NRK52E cells. mRNA expression 
measurements for Gstm5  and 7 were more variable and no consistent knockdown was 
observed.  This led to the sequencing of the Gstmf target sequence in each of the genes. 
Four mismatches were identified between the Gstmf sequence and the target sequence in 
Gstm5, this is likely to explain the lack of significant knockdown of Gstm5 observed in 
these experiments and is consistent with published research that any more than 3 
mismatches in a target alignment is not compatible with knockdown (Saxena et al. 2003).  
A single base mismatch was identified at the same base in the target sequences of Gstm2 
and 7, knockdown of Gstm2 but not Gstm7 may be explained by low absolute levels of 
Gstm7 expression in NRK52E cells, the lower the expression level the more sensitive the 
technique required to measure changes in expression. Unpublished results from our 
laboratory show that Gstm7 is expressed to a low level in the rat kidney, and the raw data 
from these experiments corroborated this, Ct values for Gstm7 were the highest among all 
the genes analysed, indicating low template abundance. The mis-matched base in the 
Gstm2 target sequence is likely to be responsible for the lower knockdown of Gstm2 (32% 
at 100 pfu/cell) compared to that of Gstm1 and 3 (56% and 58%, respectively), this is 
consistent with published studies that have shown reduced knockdown from single base 
mismatches between siRNAs and target sites. For example, Du et al (2005) analysed the 
effect of systematically mutating every base in the target site of a well-characterised 
siRNA of the human CD46 gene, covering every possible permutation of base pair 
mismatches. They found that the siRNA reduced expression of the wild-type CD46 by 
92% and that the position and base composition of a mismatch influenced the effect on 
RNAi efficacy. Mismatches were well tolerated at either of the two 5'-most or 3'-most 
bases of the alignments, having little or no effect on silencing, mismatches in bases 7-11 
had the greatest effect on silencing, while mismatches at bases 12-17 (corresponding to the 
mismatch between Gstmf and Gstm2 and 7) had variable effects, knockdown varied for 
these targets from 55%-92% (Du et al. 2005). Du et al showed that alignment of the central 
region of an RNAi sequence is the most critical for effective knockdown, this has been 
confirmed by other publications (Yuan et al. 2005;Dykxhoorn et al. 2006). Furthermore, 
they confirmed other reports that the specific mismatch between Gstmf and Gstm2 and 7 
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(Saxena et al 2003;Holen et al. 2005), consistent with the preserved knock-down of Gstm2 
in this study. 
Given the 100% homology between Gstmf and Gstm1 and 3 target sequences, greater 
knockdown of Gstm1 and 3 may have been expected, shRNA-expressing adenoviruses 
have been shown to mediate 90% mRNA and 50% protein knockdown in-vitro (El 
Armouche et al 2007), and Ambion currently guarantee that at least a third of their 
chemically-synthesised siRNAs mediate at least 70% knockdown in-vitro. That this level 
of gene silencing was not achieved in these experiments could be related to many factors. 
First, NRK52E cells have low transduction efficiency, even with CaCl2-enhanced infection 
they showed the lowest infectivity at 100 pfu/cell of all the cells used in this study, and 
infection with MOIs above 100 pfu/cell were toxic. Secondly, the choice of the Gstmf 
sequence, in 2004, was limited not only by finding homologous sequences in all 5 Gstms, 
but also the accepted conventions applied to RNAi design at that time. These conventions 
included a recommendation from a published protocol to locate the siRNA target sequence 
at an AA  dinucleotide at its 5' end (Elbashir et al. 2001b), and to ensure <50% GC content 
in the 21-base sequence, as recommended by Ambion and other published work e.g. 
(Holen et al. 2002). These criteria have subsequently been superseded by more 
sophisticated algorithms to design siRNA sequences that are based on extensive 
experimental evidence, Ambion now use a proprietary algorithm, and there are numerous 
published algorithms publicly available via the internet. These algorithms are not limited to 
AA dinucleotide 5' anchor sites, they consider sequence-dependent factors that dictate, for 
example, the entry of the RNAi sequence into the RISC complex, the likelihood of 
secondary structure formation in mRNA targets and other less well understood factors 
whereby specific bases at specific positions influence RNAi (Matveeva et al. 2007). If this 
study were to be extended, other cell types would be infected and additional RNAi 
sequences would be screened for RNAi efficacy against the Gstm family using newer 
algorithms. It may be necessary to consider using more than one shRNA sequence, though 
this may not necessarily require more than one recombinant adenovirus to be made, several 
publications have described expression cassettes that express multiple shRNA sequences 
simultaneously, for example, a bispecific lentiviral vector has been engineered to express 
two shRNAs targeted against cellular receptors for HIV (Anderson et al. 2005), and 
retroviral vectors have been developed to express 3 shRNAs (Wang et al. 2006b).  
The relatively modest knockdown of Gstm genes in NRK cells partially explains the lack 
of reduced GST activity in RAd Gstmf shRNA-infected cell lysates, though the non-
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contributory factors. Given the demonstrated relative specificity of mouse Gstm1 as a 
metaboliser of the alternative substrate, DCNB (Fujimoto et al. 2006), future experiments 
could assess reduced DCNB metabolism as a functional measure of Gstm1 knockdown. 
RAd WKY Gstm1 and RAd SP Gstm1 both expressed functional Gstm1 protein that dose-
dependently increased total GST activity in HeLa cells. However, despite titring the 
overexpression viruses as accurately as possible by three methods (particle, pfu and 
genome titring), RAd SP Gstm1 consistently expressed more protein and increased total 
GST activity in to a greater degree than RAd WKY Gstm1. This, coupled with the intrinsic 
insensitivity of western blot densitometry and the fact that the enzymatic activity assay 
measured total GST activity prevented an accurate comparisons of catalytic activities of 
the adenovirally-expressed WKY and SHRSP Gstm1 proteins. In order to compare the 
catalytic activity of the two enzymes they should be purified by a method such as high-
pressure liquid chromatography, which has been applied for the purification of GST 
enzymes in the past, for example, see Rouimi et al (1996). 
The higher expression from RAd SP Gstm1 was surprising given the lower expression of 
Gstm1 in the SHRSP in-vivo and in the light of equal protein expression and GST activity 
after transfection of HeLa cells with pK-NpA WKY Gstm1 and pK-NpA SHRSP Gstm1, 
though no corrections for transfection efficiency were made in this experiment. Possible 
explanations could include a virus preparation-specific effect not related to the viral titres, 
or a spontaneous mutation in the promoter sequence of either virus: upregulating SHRSP 
Gstm1 cDNA expression or downregulating WKY Gstm1 cDNA expression. In order to 
test these hypotheses further viral preparations could be made and the existing preparations 
could be sequenced. An alternative explanation is a cell-specific sequence dependent effect 
in HeLa cells whereby one of the polymorphisms between the WKY and SHRSP Gstm1 
cDNA sequences affects transcriptional or translational efficiency in HeLa cells. For 
example, the 3'UTR SNP at base +35 potentially affects binding of rno-miR-10b, base-
pairing with the WKY 3'UTR but not the SHRSP 3'UTR. That the miRNA aligns to the 
polymorphic base at its very 3' end may reduce the likelihood that the polymorphism 
would direct differential knockdown of Gstm1, it has been shown that miRNA target 
binding is mediated primarily at the 5' end of the miRNA, high complementarity from 
bases 2-8 (5'-3' in the miRNA) are required for miRNA binding, with less stringency 
required at the 3' end of the miRNA; if there is low complementarity at the 5' end then the 
3' end becomes critical (Brennecke et al. 2005), however this is not the case in this 
alignment. Furthermore there are conflicts between the published mature miRNA sequence 
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identical to that of the mouse and human, while published mouse and human sequences 
differ. Some cloned sequences encompass the 3' base that aligns with the Gstm1 3'UTR 
SNP (Lagos-Quintana et al. 2003;Kajimoto et al. 2006), while in other publications the 
miRNA sequence is shifted by 2 bases 5' at its 5' end and by one or two bases at its 3' end, 
so that it no longer aligns with the polymorphism (Landgraf et al. 2007;Ma et al. 2007), as 
illustrated below: 
                 3'   UGUUUAAGCCAAGAUGUCCCAU 5' 
                 3'  GUGUUUAAGCCAAGAUGUCCCAU 5' 
               3' UGUGUUUAAGCCAAGAUGUCCC   5' 
         |  || ||| | | || |||| 
WKY:   5' GGACCTATCCACATTGGATCCTGCAGGCCACCCT 3' 
SHRSP:  5' GGACCTGTCCACATTGGATCCTGCAGGCCACCCT 3' 
 
 
Thus the involvement of miR-10b in RAd WKY Gstm1 expression would depend on the 
exact sequence expressed in the HeLa cells. Given that HeLa cells are cancerous in origin 
it is interesting to note that miR-10b has recently been demonstrated to have a role in 
tumourigenesis, being highly expressed in breast cancer cells (Ma et al 2007). A precedent 
for a single SNP affecting gene expression via disruption of miRNA-binding was recently 
published, showing that the +1166A/C polymorphism in the human AngII type 1 receptor 
gene (AT1R) 3'UTR dictates the binding of miR-155, the 'A' allele pairs with the miRNA, 
while the C allele does not, leading to increased AT1R expression (Martin et al. 2007), in 
this instance the mismatch was 5 bases from the 5' end of the miRNA. 
Increasing concentration of TBHP mediated increasing cytotoxicity in RGE cells cultured 
in 96-well plates, however lower cytotoxicity was observed for the same concentrations of 
TBHP when the experiments were performed in 6-well plates. This was attributed to 
greater evaporation from 96-well plates, effectively increasing the concentration of TBHP 
in each well. Infection of RGE cells with RAd Gstm1 viruses did not protect them from 
TBHP-mediated cell death, indeed lower toxicity was observed in the non-infected cells. 
This result is likely to be due to variability of LDH assay rather than virus-mediated 
toxicity, only 10 pfu/cell was used in these experiments, the cytotoxicity plateaued in the 
non-infected cells between 0.08M TBHP and 0.09M TBHP, which was not observed in 
preliminary experiments in 96 well plates. The lack of a cytoprotective effect of Gstm1 
overexpression in these experiments has a number of possible explanations. For example, 
the administration of TBHP over 24 hours represents acute oxidative attack, which Gstm1 
does not defend against directly. Cytotoxicity over 24 hours is an end-point far removed 
from the specific cellular role of Gstm1, which operates as part of a large battery of cellular 
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assay may be to measure the effect of Gstm1 overexpression or knockdown on an 
intermediate marker of cellular oxidative stress, such as lipid peroxidation, since it is well 
documented that GST enzymes directly metabolise lipid peroxides (Hiratsuka et al 
1997;Hayes et al 1999). Other studies have shown increases in lipid peroxides in renal 
cells following short-term treatment with TBHP at higher doses (0.25mM – 2mM) for 
much shorter time periods (30 minutes to 4 hours)  (Schnellmann 1988;Martin et al. 2001). 
Such protocols could be applied to cells previously infected with viruses overexpressing 
Gstm1. 
The distribution of transgene expression from RAd35 and RAd WKY Gstm1 in infused 
carotids showed predominantly endothelial and adventitial expression and increased 
medial expression, consistent with previous studies using this protocol of adenoviral 
delivery to carotid arteries in rats (Alexander et al 2000;Fennell et al 2002) and rabbits 
(Cooney et al 2007). Gstm1 cDNA sequencing of RAd WKY Gstm1 infused and uninfused 
vessels confirmed transgene expression and also highlighted the possibility that alternative 
transcripts of Gstm1 may be expressed in the rat carotid artery; the additional bands in the 
carotid artery cDNA PCR were not observed when amplifying from rat kidney cDNA 
during the construction of the virus shuttle vector. An alternative explanation is non-
specific PCR amplification from other transcripts unique to the carotid artery 
transcriptome. There are no published rat Gstm1 splice variants, though exon-skipping has 
been observed in a human testes-specific transcript of human GSTM1 (Ross et al. 1993). 
The additional bands could be analysed by DNA sequencing in future analysis. 
Overexpression of WKY Gstm1 cDNA did not improve NO bioavailability in isolated 
SHRSP carotid arteries, there are a number of possible explanations for this. For example, 
inconsistent increases in Gstm1 mRNA expression were observed in infused arteries, 
increasing the number of vessels used in each group in the study may have revealed 
differences in NO bioavailability not apparent in the small study presented here. In 
addition, published studies from the Glasgow laboratory using the same local delivery 
protocol showed that overexpression of eNOS (Alexander et al. 1999;Alexander et al 
2000) and extracellular superoxide dismutase (ecSOD) (Fennell et al 2002) improved NO 
bioavailability, while copper/zinc superoxide dismutase (Cu/Zn SOD) (Alexander et al 
2000) and mitochondrial manganese SOD (MnSOD) (Fennell et al 2002) overexpression 
did not have an effect in this model. This was explained by the physical range of effects of 
the specific candidates in the endothelium (Fennell et al 2002); eNOS generates NO that is 
able to diffuse freely from the cell, while ecSOD is membrane-bound on either the 
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beyond the cell they are expressed from. Meanwhile, Cu/Zn SOD and MnSOD are 
intracellular, as is Gstm1, which furthermore is not involved directly in ROS metabolism 
itself, but metabolises the by-products of oxidative damage. Overexpression of Gstm1 may 
have a positive effect if extended over a longer period of time than 48 hours, increased 
capacity to metabolise reactive lipids, proteins and nucleic acids would reduce the total 
oxidative load on the cell, over time this may improve vascular oxidative balance. The 2-
fold constitutively increased in-vivo expression levels of Gstm1 in the WKY, coupled with 
lower vascular O2
-· levels than in the SHRSP (Alexander et al 2000;McBride et al 2005), 
support this analysis. Had the in-vivo studies demonstrated that overexpression of Gstm1 
improved endothelial NO bioavailability in the SHRSP carotid artery, similar studies 
would have been performed with the anti-Gstmf shRNA virus in the WKY. However, 
given that the anti-Gstmf sequence did not knock down all the Gstms tested and did not 
reduce total GST activity in cultured cells, these experiments were not justified. Note also 
that any extended in-vivo study would have included further control groups of rats infused 
with Rad60 and mock-infused with PBS. 
The experiments presented in this chapter applied recombinant adenoviruses designed to 
assess the functional consequences of modulating Gstm1 expression in-vitro and in-vivo. 
Recombinant adenoviruses have been generated that express catalytically active Gstm1, 
and successfully knock down the expression of several Gstm family members. They have 
also identified a novel 3'UTR polymorphism that potentially affects WKY Gstm1 
expression in-vitro, and found that several Gstm1 transcripts may be expressed in the rat 
carotid artery. Overexpression of Gstm1 in the SHRSP carotid artery did not improve 
endothelial NO bioavailability, however, this does not rule out a role for Gstm1 in vascular 
oxidative stress defence, future studies with transgenic SHRSP rats expressing multiple 
copies of WKY Gstm1 will provide a better model of  long-term Gstm1 expression. 
Chapter 6 outlines the work performed towards generating a transgenic Gstm1 rat. The 
adenoviral studies will be taken forward using recombinant targeted viruses. When 
administered intravenously, Ad5 gene delivery is restricted almost exclusively to the liver 
(Huard et al 1995), while the Ad19p virus, an Ad5 serotype subgroup virus expressing a 
different fibre protein, shows markedly reduced liver tropism in the rat (Denby et al. 2004). 
Research in the Glasgow laboratory has developed recombinant Ad19p vectors expressing 
adenoviral fibre peptides that specifically target gene delivery to kidney tubules (Denby et 
al. 2007), sequences encoding Gstm1 cDNA and anti-Gstm shRNAs will be cloned into 
this platform to assess the functional consequences of modulating Gstm1 expression at the 
site of its renal expression in-vivo.   James Polke, 2008    Chapter 6         201 
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6.1  Introduction 
Our understanding of hypertension genetics has been advanced by QTL analysis and 
congenic breeding strategies in the rat, identifying numerous candidate genes. However, 
establishing definitive proof that a gene affects blood pressure control requires evidence 
that changing the expression of the candidate in isolation alters blood pressure from a 
knockout or transgenic strain. It is not currently possible to generate gene-targetted 
knockout rats, this technique depends on genetic modification of embryonic stem cell lines, 
which can only be generated for the mouse at present. One of the first transgenic rat lines 
developed overexpressed the mouse renin (Ren-2) gene and displayed severe hypertension 
that was remediable by the ACE inhibitor captopril (Mullins et al. 1990). Over 100 
transgenic rat lines have subsequently been generated including some that express 
antisense sequences to reduce expression of target genes (Tesson et al. 2005), a number of 
these transgenic strains have been designed for cardiovascular disease research (table 6.1).  
The experiments that led to the derivation of the Cd36 transgenic rat, discussed in section 
1.2.3.3, exemplify the progression from identification of a QTL, construction of congenic 
strains and an identification of a positional and functional candidate gene to confirmation 
of its functional effect (Aitman et al 1997;Aitman et al 1999;Pravenec et al 2001b). Similar 
experiments were recently performed to investigate the functional effects of reduced 
expression of sterol regulatory element binding transcription factor 1 (Sreb1f) in the SHR 
(Pravenec et al. 2008). A chromosome 10 QTL for hepatic steatosis in the BN after feeding 
with a high cholesterol diet was identified in a panel of recombinant inbred strains between 
the BN-Lx/Cub and SHR/Ola (Bottger et al. 1998), and a unique coding mutation was 
subsequently identified in the SHR Srebf1 gene that underlies the QTL (Pravenec et al. 
2001a). Congenic and subcongenic strains were generated by substituting the BN 
chromosome 10 QTL onto the SHR, the BN allele corresponded to approximately 2.5-fold 
higher SrebfI expression, and 2-fold increased liver cholesterol levels (Pravenec et al 
2008). An SHR transgenic rat was generated to overexpress SrebfI, which showed 
equivalent liver cholesterol levels to the SHR congenic rat harbouring the BN SrebfI allele, 
further verifying the functional role of SrebfI, despite the counter-intuitive incidence of the 
allele conferring hepatic steatosis in the BN (Pravenec et al 2008). 
 
  
   
Transgene  Construct  Phenotype  Reference 
Mouse renin  17.6 kb linear genomic construct, 
including promoter 
Severe hypertension  (Mullins et al 1990) 
Human renin and 
angiotensinogen 
(double transgenic) 
17.6 and 16.3 kb linear genomic 
constructs, including promoters 
Moderately severe hypertension, 
death by renal and cardiac damage 
by week 7. 
(Ganten et al. 1992) 
Rat prorenin  3.5 kb linear, liver specific promoter  Normotensive, severe renal and 
cardiac damage in males 
(Veniant et al. 1996) 
Rat vasopressin  12 kb linear hypothalamus-specific 
promoter. 
Exaggerated responses to osmotic 
challenge 
(Waller et al. 1996) 
Human endothelin 2  9.4 kb linear genomic construct, 
including promoter 
Normotensive  (Liefeldt et al. 1999) 
Angiotensinogen 
antisense 
3 kb linear, brain specific promoter  Reduced BP in normotensive rats  (Schinke et al. 1999) 
Rat Cd36  4.8 kb linear construct, human EF1-
alpha promoter 
Amelioration of metabolic syndrome 
phenotype in SHR 
(Pravenec et al 2001b) 
Human Arginine 
vasopressin 
3 kb linear, CNS-specific promoter  Hyponatraemia  (Nagasaki et al. 2002) 
Ang-(1-7) fusion 
protein 
Linear construct, CMV promoter   Improved cardiac contractility, 
protection from cardiac hypertrophy  
(Santos et al. 2004)  
Rat SrebfI  4 kb linear construct, Pepck 
promoter 
Increased liver cholesterol in 
transgenic SHR 
(Pravenec et al 2008) 
Table 6.1 - Transgenic rat strains for the study of cardiovascular diseases
Unless otherwise stated, recipient strains were normotensive. Srebf1: sterol regulatory element binding transcription factor 1. 
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Traditional techniques to generate transgenic rats are fundamentally the same as those used 
for mice, involving the microinjection of the transgenic construct into the pronucleus of 
single-cell embryos, followed by implantation into recipient females. Resultant pups are 
screened for insertion of the transgene by PCR or southern blot and used as founders for 
homozygous transgenic lines. These techniques are more successful in mice, typically 
generating 3%-5% transgene-positive offspring per injected embryo (Brinster et al. 1985), 
compared to 0.2%-2% in rats (Charreau et al. 1996;Popova et al. 2002). The lower success 
in rats is in part due to the physical characteristics of the embryo pronucleus, which tend to 
be harder to microinject; the cytoplasmic membrane of the rat is more resistant to injection 
and the pronucleus is very sticky; up to 10-50% of embryos may be lost during 
microinjection (Popova et al. 2005).  
Different DNA constructs can be used for microinjection, common techniques include 
small linear (up to 40 kb) constructs artificially constructed to overexpress the transgene 
from a constitutive or tissue-specific promoter, or large circular or linearised plasmids can 
be used such as bacterial, bacteriophage P1 or yeast artificial chromosomes (BAC, PAC or 
YAC) accommodating up to 300 kb, 100 kb and 2 Mb genomic DNA sequences including 
the gene of interest (Giraldo et al. 2001). Insertion into the genome is a random process 
and may occur more than once in a single embryo, every transgenic line is unique and may 
have different transgene expression patterns and levels to others. Insertion into a non-
transcriptionally active region of the genome may silence expression of the transgene, 
while insertion adjacent to tissue specific enhancers may influence expression patterns, this 
is known as the 'position-effect' (Wilson et al. 1990;al Shawi et al. 1990). Integration of the 
transgene into a coding sequence will usually ablate endogenous gene expression, with 
potentially lethal consequences for the embryo (Mullins et al. 2006). BAC, PAC and YAC 
transgenic lines are less susceptible to transcriptional effects from the genome since the 
gene is insulated by large flanking sequences; in addition, large genomic clones are likely 
to include short-range and long-range control elements, increasing the likelihood of 
physiologically faithful gene expression patterns in the transgenic (Giraldo et al 2001). 
Large inserts can also encode multiple genes in addition to the gene of interest, which may 
also be expressed in the transgenic animal (Nistala et al. 2004). Short expression constructs 
in contrast are easier to amplify and prepare, express only the gene of interest and are less 
likely to shear or recombine before microinjection (Giraldo et al 2001). 
Given the low efficiency of microinjection protocols, successful transgenesis depends on a 
large supply of recipient embryos. This is achieved by administering hormones to stimulate 
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microinjected and implanted into recipient females. Recipient females are made 
psuedopregnant by mating with vasectomised males on the day prior to implantation. This 
chapter outlines experimental work performed to prepare BAC and linear expression 
constructs for the generation of transgenic SHRSP rats overexpressing Gstm1. James Polke, 2008    Chapter 6         206 
 
   
6.2  Aims 
·  To amplify and purify a bacterial artificial chromosome encoding Gstm1 in preparation 
for direct micronuclear injection. 
·  To verify the integrity and purity of BAC preparations by restriction digestion, linear 
and pulse-field gel electrophoresis and direct BAC sequencing. 
·  To clone the WKY Gstm1 cDNA sequence into an expression vector  to generate  a 
linear  expression  construct  for  Gstm1  transgenesis  and  to  prepare  linear  fragment 
microinjection solutions. 
·  Following  microinjection  and  birth  of  pups,  to  screen  prospective  transgenics  for 
integration of BAC and linear transgenic constructs. James Polke, 2008    Chapter 6         207 
 
   
6.3  Methods 
6.3.1 BAC Microinjection Construct Preparation 
6.3.1.1 BAC Selection and Purification 
The CHORI-230 BAC library was in initially constructed as part of the rat genome project; 
it contains approximately 200000 clones of 200 kb average size on the pTARBAC2.1 
plasmid backbone, which encodes chloramphenicol resistance for clone selection 
(Osoegawa et al. 2004). Clones encompassing Gstm1 were identified by mapping BAC 
alignments in the University of California Santa Clara (UCSC) Genome Browser. The 
Gstm gene family is aligned in a cluster on chromosome 2, at the time of selecting the 
BAC for the transgenic study (2004), the rat genome annotation was less complete and 
Gstm1 was the most distal of the Gstm genes aligned in the assembly. The 234 kb clone, 
CH230-90M3 was selected since it encompassed Gstm1 but no other Gstm genes, the gene 
encoding guanine nucleotide binding protein (Gnai3) was annotated at that time. Since 
2004 more genes have been mapped to this region of the genome and CH230-90M3 is now 
known to cover 9 transcripts, including Gstm1, Gstm7, and 7 other transcripts, including 4 
predicted genes (figure 6.1).  
CH230-90M3-containing bacterial cultures was purchased from the BACPAC Resource 
Centre, Children's Hospital Oakland Research Institute, Oakland, California. Cultures were 
streaked for single colonies overnight on LB agar (12.5  g/ml chloramphenicol). The BAC 
purification was performed using modifications of a published protocol (Gama et al. 2002). 
A single colony was picked into 10 ml LB culture media (30  g/ml chloramphenicol) and 
incubated at 30°C in a shaking incubator (180 oscillations per minute) overnight. One litre 
of LB culture media (30  g/ml chloramphenicol) was inoculated with 2 ml overnight 
starter culture was incubated at 30°C in for approximately 11.5 hours, following bacterial 
growth until culture optical density at 600 nm (OD600) reached 1.0. Cultures were grown at 
30°C rather than 37°C because large DNA constructs can adopt sequence-dependent 
secondary structures at 37°C that can lead to deletion of insert sequences (Gama Sosa et al. 
1988). Optical density was measured using a Pharmacia Biotech Ultraspec 2000 
spectrophotometer in a quartz cuvette with a sterile culture media blank. The culture was 
centrifuged for 5 minutes at 5000 g, culture media was poured off and pellets were stored 
at -20°C. Column-based Nucleobond BAC Maxi kits were used for BAC purification 
following the manufacturer's instructions. The 1 litre culture was split over 2 columns,   
   
 
Figure 6.1 - Linear depiction of transcripts encoded by the circular CH230-90M3 BAC 
 
 
 
pTARBAC2.1 Backbone 
Amigo  Gstm1  Gnai3  Gstm7 
20kb 
Ampd2  Gnat2 
(pred) 
Gpr61 
(pred) 
Cyb561d1 
(pred) 
Mg29 
(pred) 
Exons are shaded blue, UTR sequences are shaded green, the direction of transcription is indicated under each transcript. Only 
the 3'-most exons of the Mg29 transcript is covered by the BAC. pred: predicted, Mg29: mitsugumin 29, Cyb561d1: cytochrome b-
561 domain containing 1, Amigo: amphoretin-induced gene and open-reading frame, Gpr61: G-protein coupled receptor 61, 
Gnat2: guanine nucleotide binding protein alpha 2, Ampd2: adenosine monophosphate deaminase 2 
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producing 2 preparations, 90M3A and 90M3B. Pellets from each 500 ml was resuspended 
in 24 ml Buffer S1 + RNase A and 24 ml buffer S2 was added, mixed and left for 3 
minutes at room temperature. 24 ml Buffer S3 was added, mixed and left for 5 minutes on 
ice. Precipitates were filtered through a Nucleobond Folded Filter paper, flow through was 
collected and applied to pre-wet (buffer N2) BAC Maxi columns. Flow-through was re-
loaded to ensure maximum DNA binding. Columns were washed with 2 x 18 ml buffer N3 
and eluted with 15 ml buffer N5, preheated to 50°C. 11 ml isopropanol was added to 
precipitate BAC DNA and samples were centrifuged at 15000 g for 30 minutes at 4°C. 
Supernatant was replaced with 5 ml ice-cold 70% ethanol, samples were centrifuged at 
15000 g for 10 minutes at 4°C, ethanol was removed, pellets were air-dried and DNA was 
resuspended in 320  l RNase-free H2O using wide-bore pipette tips to minimise shearing 
of BAC DNA.  
For microinjection, prep 90M3B was diluted to 3 ng/ l in 0.2 lm sterile-filtered BAC 
microinjection buffer: 10 mM Tris; 0.1 mM EDTA; 0.1 M NaCl, 7 mM Spermidine; 3 mM 
Spermine. The inclusion of polyamine spermine and spermidine in BAC microinjection 
buffer helps to stabilise BAC DNA and protect it from shearing during microinjection 
(Schedl et al. 1993;Montoliu et al. 1995). BAC microinjection buffer was made with fresh 
sterile solutions and filter-sterilised, microinjection solutions were made fresh on the day 
of injection.  
6.3.1.2 BAC Restriction Digestion and Electrophoresis 
BAC sample integrity and purity were assessed by restriction digestion followed by 
standard or pulse-field gel electrophoresis. Three  g of 90M3A and 90M3B DNA 
preparations were digested with HindIII or NotI restriction enzymes following the protocol 
in section 2.5.4. HindIII digests were electrophoresed for 8 hours at 90 V through a 25 cm 
0.8% agarose gel in 1 x TAE at 4°C. 1  g of uncut BAC preparations were also 
electrophoresed. After electrophoresis the gel was stained with 0.5  g/ml ethidium 
bromide for 30 minutes and destained in 1 mM MgSO4 for 25 minutes before visualisation 
under UV light. 
Pulse-field gel electrophoresis (PFGE) was performed on NotI digested BAC DNA at the 
laboratory of Professor John Mullins at the Centre for Cardiovascular Science, University 
of Edinburgh. Digested DNA was electrophoresed alongside 1  g undigested BAC 
preparations, λ HindIII DNA size markers and New England Biolabs Mid Range I and Mid 
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electrophoresis by mixing with molten low-melting point agarose and pipetting into wells. 
Electrophoresis was performed at 10°C through 0.8% agarose gel in 0.5 x TAE using 
BioRad Chef DR2 apparatus. DNA was electrophoresed for 24 hours at 6 V/cm with 
current orientation switching every 1-20 seconds. After electrophoresis gels were stained 
with ethidium bromide, destained and visualised exactly as linear gels. 
6.3.1.3 Direct BAC Sequencing 
BAC preparation purity was assessed by direct sequencing. 1  g BAC DNA template was 
used in modified sequencing reactions with 30 pmol primer and temperature cycling as 
suggested by Applied Biosystems: 
Sequencing reaction        Heat cycling: 
 
BAC DNA (200 ng/ l)  5  l     95°C   
5 X Sequencing buffer  4  l     95°C 
Ready Reaction    8  l     50°C 
Primer (15pmol/ l)    2  l    60°C 
H2O        1  l      
Primers pBACSp6F and Gstm13F were used for sequencing. Sequencing reaction clean up 
and analysis protocols were otherwise followed exactly as described in section 2.4. 
6.3.2 Linear Microinjection Fragment Preparation 
A 2.7 kb linear microinjection construct was cloned for Gstm1 transgenesis using the same 
expression platform and microinjection fragment purification protocol employed in Cd36 
rat transgenesis (Pravenec et al 2001b). The WKY Gstm1 cDNA sequence was cloned into 
pEF1/Myc-HisA (Invitrogen), an expression construct including the constitutive human 
elongation factor 1 α subunit (EF1α) promoter and bovine growth hormone (BGH) 
polyadenylation signal separated by a multiple cloning site. A linear expression construct 
was subsequently cleaved from the plasmid by restriction digestion and purified for 
microinjection. 
6.3.2.1 pEF1 WKY Gstm1 Cloning 
pEF1/Myc-HisA plasmid was double-digested with KpnI and XbaI restriction enzymes 
following the protocol in section 2.5.4. WKY Gstm1 cDNA sequence was similarly 
double-digested from pK-NpA WKY Gstm1 plasmid (previously used in construction of 
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Gstm1 overexpression virus – see section 5.3.1.2) and cloning protocols from section 2.5 
were followed, confirming insert ligation in positive clones by sequencing with pEF1 T7F 
and BGH PolyAR primers. The resultant expression plasmid, named pEF1 WKY Gstm1, 
was amplified and purified using the Qiagen Maxi kit as outlined in section 2.5.3.  
6.3.2.2 Restriction Digestion of pEF1 WKY Gstm1 to Generate 
Linear Fragment 
The linear microinjection fragment was produced by sequential digestion of pEF1 WKY 
Gstm1 with PvuII and AatII enzymes (figure 6.2). A total of 20  g plasmid was digested 
with PvuII in 10 x 20  l digests following the protocol in section 2.5.4. Restriction digests 
were pooled and electrophoresed on 1% agarose gel for 3 hours. The 4705 bp fragment 
was gel purified using the Qiagen QIAquick protocol in section 2.5.5. The DNA was 
concentrated by ethanol precipitation: A 1/10
 volume of 3 M sodium acetate (pH 5.2) and 2 
volumes of 100% ethanol were added, the mixture was vortexed and placed at -80°C for an 
hour before centrifuging at 13000 rpm for 2 minutes. Supernatant was removed and the 
pellet air-dried before resuspending in H2O to give a final concentration of approximately 
200 ng/ l. The DNA was digested with AatII following the standard protocol and 
electrophoresed on 1% agarose for 3 hours. The 2725 bp fragment was purified for 
microinjection using the Qiagen QIAEX II kit. The band was excised from the gel and 300 
 l of QX1 buffer was added per 100 mg of gel; QIAEXII beads were resuspend by 
vortexing and 10  l was added before incubating the mix for 10 minutes at 50°C, vortexing 
every 2 minutes to dissolve the gel. The mixture was centrifuged for 30 seconds at 13000 
rpm and supernatant was removed, the pellet was washed by resuspending in 500  l buffer 
QX1 and centrifuged for 30 seconds at 13000 rpm. The pellet was washed twice more with 
500  l buffer RPE and supernatant was removed. The pellet was air-dried for 15 minutes 
before resuspending in 0.2 lm sterile-filtered linear fragment microinjection buffer (10mM 
Tris pH 7.4, 0.1 mM EDTA), vortexing, centrifuging at 13000 rpm for 1 minute and 
transferring the DNA solution to a fresh tube. For microinjection DNA solutions, linear 
fragment DNA was diluted to 10 ng/ l in linear fragment microinjection buffer.  James Polke, 2008    Chapter 6         212 
 
   
 
Figure 6.2 - pEF1 WKY Gstm1 plasmid 
 
 
 
6.3.2.3 Gstm1 Expression from pEF1 WKY Gstm1 
Gstm1 protein expression from pEF1 WKY Gstm1 was confirmed by transfection into 
HeLa cells and western blotting. HeLa cells were transfected in 6 well plates with 1  g 
DNA per well at 3:1 FuGene:DNA ratio ( g: l), control wells were untransfected or 
transfected with pMV10. After 48 hours HeLa cells were harvested in PBS/0.2% Triton 
and 20  g protein was used for Gstm1 and β-actin western blotting following the protocol 
in section 5.3.6, 30  g control rat kidney protein was also loaded.  
6.3.3  Superovulation, Microinjection and Implantation 
Initial microinjections of CH230-90M3 BAC DNA were performed by technical staff at 
the University of Glasgow Central Research Facility. Subsequently, BAC and linear 
fragment microinjection solutions and SHRSP male and female rats were sent to the 
laboratory of Dr Michal Pravenec, Institute of Physiology, Academy of Sciences of the 
Czech Republic, Prague. Animal procedures are briefly outlined below. 
Superovulation in six-week old SHRSP females was initiated by intraperitoneal (IP) 
injection of 15 U of pregnant mare's serum gonadotrophin (PMSG), followed 48 hour later 
by IP injection with 20 U human chorionic gonadotrophin (HCG). Immediately after HCG 
6872 bp
WKY Gstm1 cDNA 
BGH PolyA signal 
EF-1 α promoter
AatII (122) 
PvuII (2847)  PvuII (3943) 
PvuII (5014) 
pEF1 WKY Gstm1 
The restriction sites for PvuII and AatII enzymes are indicated in red, coordinates in 
brackets. Digestion with PvuII resulted in the generation of 4705 bp, 1096 bp and 
1071 bp fragments, the 4705 bp fragment was gel-purified and digested with AatII to 
produce a 1980 bp fragment and the 2725 bp microinjection fragment encompassing 
the EF-1α promter, Gstm1 cDNA and BGH polyadenylation sequences. James Polke, 2008    Chapter 6         213 
 
   
injection females were placed with mature male stud SHRSPs for fertilisation. The next 
morning, females with cervical plugs (an indication that they have mated) were sacrificed 
and fertilised embryos were harvested for microinjection. Four days prior to 
microinjection, oestrus was synchronised in recipient SHR (Glasgow laboratory) or 
Sprague Dawley (Prague laboratory) rats with donor SHRSPs by injection with 20 U 
leutenising hormone releasing hormone (LHRH). On the day prior to microinjection 
recipient rats were placed with vasectomised male rats to induce pseudopregnancy.  
Microinjections were performed on single cell embryos immobilised by gentle suction with 
a holding pipette. The microinjection needle, with an internal tip diameter of less than 1 
 m, was filled with microinjection solution and manipulated to inject the egg. In order to 
ensure pronuclear injection, the needle tip was injected though both membranes of one of 
the pronuclei and then drawn back in to the pronucleus before injecting; successful 
injection was observed by swelling of the pronucleus. Embryos were incubated overnight 
and pseudopregnant females were surgically implanted with viable one or two cell 
embryos on the following day, surgery involved making an incision in the back of the 
anaesthetised rat just below the ribs, locating the oviducts and making a small incision to 
inject the embryos. An average of 12 microinjected embryos were implanted into each 
recipient female. 
6.3.4 Transgenic Screening 
Genomic DNA from potential transgenic rats was extracted from tail tips and screened for 
transgene sequences by PCR. Potential BAC transgenics were screened with 5 PCRs, 
amplifying the regions across each 'BAC-end' with 2 primer pairs (pBACSp6F + 90M3-1R 
and pBACT7R + 90M3-3F), amplifying two regions of the pTARBAC2.1 backbone 
(pBAC1F + pBAC2R and pBAC3F + pBAC4R) and with one primer pair that amplified a 
region of the Gstm1 promoter (Gstm10F and Gstm13R). Gstm10R/Gstm13F PCR products 
were also sequenced in all animals, incorporation of WKY sequence would have been 
revealed by heterozygosity at several SNPs in the Gstm1 promoter. Potential linear-
fragment transgenics were screened with three PCRs, amplifying across the EF1α promoter 
sequence (primers pEF1F + pEF1R), and with two primer pairs that spanned EF1α 
promoter and Gstm1 cDNA sequence (pEF2F + pEF2R and pEF3F + pEF3R). All PCRs 
were performed following protocols as described in section 2.2.3 using an annealing 
temperature of 58°C. Positive control plasmid DNA (20 ng CH230-90M3 or 5 ng pEF1 
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6.4  Results 
6.4.1 BAC Restriction Digestion and Electrophoresis 
HindIII digestion of 90M3A and 90M3B BAC preparations resulted in multiple well-
resolved bands upon electrophoresis, digested and uncut lanes were clean, indicating 
undamaged DNA (figure 6.3 A). The expected banding pattern for HindIII digestion of 
CH230-90M3 was retrieved from Internet Contig Explorer (iCE) database, an internet-
based library of 'fingerprint maps' for BAC digests that was designed to aid in sequence 
alignments for the rat genome sequencing project (Fjell et al. 2003); alignment of the iCE 
HindIII digest of CH230-90M3 showed an identical band pattern to the digests performed 
in these experiments, confirming the identity and integrity of the BAC preps (figure 6. 3 
B).  
NotI digests of 90M3A and 90M3B were electrophoresed by PFGE, generating the 
expected band pattern and uncut DNA resolved to approximately 234kb (figure 6.4). 
90M3B was chosen for microinjections because when uncut it resolved better than 90M3A 
in both gels with slightly less smearing of at the top of the lanes, though 90M3A integrity 
was also confirmed and could be used in future microinjections. James Polke, 2008    Chapter 6         215 
 
   
 
Figure 6.3 - Agarose electrophoresis of HindIII-digested CH230-90M3 BAC  
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HindIII  Uncut  A  B 
A  B  A  B 
1 
(A) HindIII-digested and undigested BAC preparations 90M3A and 90M3B resolved to 
produce consistent banding pattern with little evidence of smearing in uncut lanes. (B) 
Alignment of HindIII-digested BAC DNA with expected band pattern from Internet 
Contig Explorer revealed the expected band pattern, confirming intact BAC DNA. 
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Figure 6.4 - PFGE of NotI-digested CH230-90M3 BAC 
 
242kb 
209kb 
97kb 
15kb 
9.4kb 
194 kb 
218kb 
NotI  Uncut 
A  B  A  B 
1 
242.5kb 
NotI digestion produced fragments at the expected sizes of 204 kb, 18.4 kb and 
10.6 kb. The major band in uncut lanes corresponded to the intact 234kb plasmid. 
There was minimal smearing in digested or undigested lanes indicating intact BAC 
preparations.  
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6.4.2 Direct BAC Sequencing 
Direct sequencing from CH230-90M3 BAC template was performed with pBAC SP6F and 
Gstm10F primers. Sequencing read lengths of 400-550 bp were achieved with clean 
backgrounds, confirming BAC preparation purity and confirming BAC expected sequences 
(figure 6.5).  
 
Figure 6.5 - Electropherogram from direct sequencing of 90M3 
 
 
 
6.4.3 Gstm1 Expression from pEF1 WKY Gstm1 
Transfection of HeLa cells with pEF1 WKY Gstm1 resulted in expression of 
immunoreactive Gstm1 protein in cell lysates 48 hour later, indicating effective Gstm1 
expression from the plasmid construct (figure 6.6). 
 
Figure 6.6 - Gstm1 protein expression from pEF1 WKY Gstm1 
 
 
6.4.4 Transgenic Screening 
Five BAC construct implantations were carried out in Glasgow, generating a total of 18 
potential transgenic pups, though 2 from one litter were consumed by the mother within 48 
hours of being born. Six recipient females were implanted on each occasion (table 6.2). 
This represents a live birth rate per implantation of 5%; none of the pups were positive in 
B-Actin 
Gstm1 
pEF1 WKY Gstm1  NT  K 
Ref Sequence 
90M3A 
Sequencing of 90M3 with pBACSp6F was of high quality, traces showed low 
background and aligned 100% with expected (Ref) sequences. 
 
HeLa cells were lysed 48 hours post-transfection. 20  g protein was loaded in each 
lane. Expected 26 kDa Gstm1 protein bands were observed transfected wells, but not 
in non-transfected (NT) cells. β-actin immunoreactivity (42 kDa) was observed in all 
cells. K = control rat kidney protein (30  g). James Polke, 2008    Chapter 6         218 
 
   
BAC-specific PCR screens (figure 6.7A). Microinjection and implantation was performed 
three times in Prague, once with the BAC construct only and twice with both constructs; a 
total of 35 potential BAC transgenic and 25 potential linear fragment transgenic pups were 
born (table 6.3), a live birth rate per implantation of 9.7% and 14.8 %, respectively. PCR 
screening was negative in all cases (figure 6.7B). Data supplied by the Prague laboratory 
showed that approximately 65% of microinjected embryos were viable the following day. 
 
Microinjection  No. of Recipients  No. of Pups 
1  6  0 
2  6  7 
3  6    2* 
4  6  9 
5  6  0 
Table 6.2 - Microinjected embryos implanted at Glasgow University 
 
 
 
 
 
Microinjection  BAC 
Recipients 
BAC Pups  Linear Fragment 
Recipients 
Linear Fragment 
Pups 
1  10  13  -  - 
2  12  5  6  6 
3  8  17  8  19 
Table 6.3 - Microinjected embryos implanted at Academy of Sciences of the Czech 
Republic 
 
 
 
 
 
 
Implantations of microinjected embryos performed with the BAC transgenic 
construct at the Central Research Facility, University of Glasgow. An average of 12 
microinjected embryos was implanted on each occasion, a total of 18 pups were 
born, 2 (*) were cannibalised.  
 
Implantations of microinjected embryos performed with BAC and linear fragment 
transgenic constructs at the Institute of Physiology, Academy of Sciences of the 
Czech Republic, Prague. An average of 12 microinjected embryos were implanted 
on each occasion, generating a total of 60 potential transgenic rats. 
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Figure 6.7 - PCR Screening for BAC and linear fragment transgenic rats 
 
 
T1  T2  WKY 
BAC  H2O 
750 bp 
500 bp 
250 bp 
pEF1F+R 
Gstm10/13 
pEF2F+R 
pEF3F+R 
A 
B 
* 
PCR Screening for BAC and linear fragment transgenic rats. (A) BAC Transgenic 
screening in two potential transgenics (T1 ans T2). Control WKY and CH230-90M3 
BAC DNA also PCRd. Loading order and expected band size: Gstm10+Gstm13 
(738 bp), pBACSp6F + 90M3-1R (442 bp), pBACT7R + 90M3-3F (380 bp), 
pBAC1F + pBAC2R,(371 bp) and pBAC3F + pBAC4R (387 bp). (B) Linear 
fragment transgenic screening in 17 potential transgenic rats. Loading order in 
pEF1F+R, pEF2F+R, pEF3F+R PCRs: Potential transgenics 1-17, pEF1 WKY 
Gstm1 +ve control, H2O. Gstm10+Gstm13 positive control PCRs also performed on 
all rats, 19 potential BAC transgenics were included in the same PCR. Expected 
product sizes: pEF1F+R: 381 bp, pEF2F+R: 380, pEF3F+R: 838 bp.  * double band 
in +ve control lane for pEF1 F+R due to split well. 
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6.5  Discussion 
This chapter has outlined the work performed to date in the ongoing project to develop a 
transgenic SHRSP rat overexpressing Gstm1. A genomic BAC clone encompassing Gstm1 
and a linear construct encoding Gstm1 have been cloned and purified using published 
protocols and several techniques have been applied to verify the purity, integrity and 
transcriptional activity of the constructs. To date approximately 720 microinjected 
embryos have been implanted but no transgenic pups have been born, despite 78 live 
births.  
The lack of transgenic rats produced so far could have many possible explanations. For 
example, scientists at Glasgow University have no experience in rat transgenesis, all 
previous microinjections having been performed on mouse embryos; as noted above, 
microinjection is the limiting factor in rat transgenics due to the physical properties of the 
rat embryo and pronucleus. The Prague laboratory however have extensive practical 
experience in rat transgenesis (Pravenec et al 2001b;Pravenec et al. 2003;Pravenec et al 
2008), and it is expected that collaboration with this laboratory will result in a transgenic 
Gstm1 rat presently. The lack of a transgenic rats from microinjections performed to date 
in Prague may simply be due to chance and further microinjections are ongoing. It is also 
possible that either of the transgenic constructs have integrated on several occasions but in 
each case have disrupted the expression of vital genes. There is also the possibility that 
overexpression of transgenes in the constructs was lethal to the developing embryo; this is 
more likely for the BAC transgenics since CH230-90M3 encodes a number of transcripts 
in addition to Gstm1 (figure 6.1), though there is no published evidence that any of these 
genes may be toxic if overexpressed. There are several published reports of transgenic 
overexpression causing embryonic lethality in mice, including the membrane protein 
neurophilin that is involved in cell-cell interactions (Kitsukawa et al. 1995), the cardiac 
developmental transcription factor Nkx2.5 (Wakimoto et al. 2003) and the vascular 
endothelial growth factor (Vegf-A) gene (Miquerol et al. 2000), note however that these are 
all genes with established roles in development or transcriptional control, which does not 
apply to Gstm1.  
BAC-mediated transgenesis has been attempted in this study in an effort to ensure a 
physiological Gstm1 expression pattern, however there are drawbacks to this procedure, 
for example, it has recently been learnt that CH230-90M3 encodes Gstm7 in addition to 
Gstm1, and though circular BAC microinjection has been used to successfully derive 
transgenic animals in numerous studies (Antoch et al. 1997;Kaufman et al. 1999;Duff et al. James Polke, 2008    Chapter 6         221 
 
   
2000), BAC growth and purification are challenging procedures and other researchers have 
used linearised BAC molecules that have undergone more rigorous purification protocols 
such as caesium chloride gradient centrifugation or dialysis (Antoch et al 1997;Probst et al. 
1998). Given these factors, future microinjections will concentrate on the linear expression 
construct. However it must be recognised that kidney Gstm1 expression will not be 
guaranteed in all transgenic rats; tissue-specific expression pattern and consequent 
phenotype of transgenics is dependent on the 'position effect' of random insertion into the 
genome (Wilson et al 1990;al Shawi et al 1990). The Cd36 transgenesis experiments, 
which used exactly the same expression construct as employed in these experiments, 
exemplify this phenomenon: Two transgenic lines were generated, SHR-TG10, which 
carried 6-8 transgenic copies of Cd36 but did not show kidney transgene expression, and 
SHR-TG19, which carried a single transgene which was expressed at low levels in the 
kidney (Pravenec et al 2001b). Thus more than one Gstm1 transgenic rat line may need to 
be generated before renal transgene expression is shown. 
Alternative strategies to DNA pronuclear microinjection are also being considered for 
Gstm1 transgenesis, a particularly promising technique is lentiviral vector transgenesis. 
Lentivirus vectors are engineered replication-deficient virus particles designed to deliver 
transgenes to replicating cells or embryos. They are well suited to transgenesis due to their 
ability cross cell and nuclear membranes and to integrate sequences into the host genome, 
they have been employed for transgenesis in several species including mice, rats, chickens, 
pigs, quail and cows (Park 2007). A particular advantage with respect to rat transgenesis is 
that lentiviruses are not injected into the embryo itself, rather they are introduced under the 
zona pelucida and mediate their own passage across the cell membrane and to the 
pronucleus, thus avoiding the problems associated with rat pronuclear injection. An 
alternative to microinjection in lentiviral transgenesis has also been employed whereby 
mice embryos were denuded of the zona pelucida and incubated in medium containing 
lentiviruses (Pfeifer et al. 2002). Transgenesis with lentiviral vectors has been 
demonstrated to be far more efficient than by DNA microinjection, in a recent study to 
generate transgenic rats expressing green fluorescent protein (GFP), 49.6% of 
microinjected embryos generated live births, of which 22% born to Sprague Dawley 
mothers and 14% born to Dahl S rats were transgenic (Michalkiewicz et al. 2007). The 
main disadvantages of lentiviral vectors are the size of transgenic insert that can be 
packaged by the virus, which is limited to approximately 10 kb, and the laboratory 
expertise required to grow and purify the vectors, though the Glasgow laboratory has 
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also concerns that the efficiency of transgene insertion may slow the creation of fixed 
transgenic lines; multiple insertions throughout the genome resulted in variable copy 
numbers being transmitted to subsequent generations (Lois et al. 2002). However it has 
been shown that viral titres used for injections correlate with the number of genomic 
insertions in transgenic pups, reducing viral titres reduces the number of insertions 
(Michalkiewicz et al 2007). 
Given the proposed kidney-specific effects of reduced Gstm1 expression on hypertension 
in the SHRSP, it is worth considering a renal-specific promoter in Gstm1 transgenesis. 
Gstm1 protein has been specifically located to the principal cells of the collecting duct by 
immunohistochemical colocalisation with aquaporin-2 (Aqp2) (McBride et al 2005), a 9.5 
kb Aqp2 promoter sequence has been used in mouse transgenesis to specifically direct GFP 
expression to principal cells of the collecting ducts in the cortex, outer and inner medulla 
(Zharkikh et al. 2002). In this study, GFP expression was upregulated by dehydration of 
the mice and no expression was observed in the adjacent intercalated cells in the collecting 
duct. An alternative kidney tubule-specific promoter has also been described, constituting 
3.3 kb of the kidney-specific cadherin gene (Ksp-cadherin) upstream regulatory region. 
Transgenic mice expressing LacZ driven by the Ksp-cadherin promoter showed β-
galactosidase expression exclusively in the kidney, specifically in the tubular epithelium of 
the inner medulla, the renal papilla and pelvis, and weakly in the cortex and outer medulla 
(Yang et al. 2006). 
Once Gstm1 transgenic SHRSP rats have been derived and confirmed by PCR, they will be 
subject to a number of experiments. Blood pressure will be measured by radiotelemetry 
and kidney GSH levels will be measured. The tissue-specific expression pattern of the 
transgene will be established by qRT-PCR or northern blotting and germline transmission 
of the transgene will be confirmed in future generations. Genomic copy number of the 
transgene will be assessed by southern blotting. Primary cell lines could also be derived 
from transgenic rats to assess Gstm1 catalytic activity by total GST activity assays and 
with the proposed Gstm1-specific substrate 1,2-dichloro-4-nitrobenzene (DCNB) 
(Fujimoto et al 2006). Changes in renal and vascular oxidative stress levels will also be 
measured. Generation of a transgenic animal with altered expression of a candidate gene 
for a complex physiological trait is a critical test of its contribution to a disease phenotype; 
increased expression of Gstm1 alone may not affect blood pressure in the SHRSP to a great 
extent, however as detailed above, numerous secondary phenotypes can also be measured. 
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The experiments performed in this project applied a wide range of functional genomic 
techniques in the investigation of hypertension in the SHRSP. The hypertension candidate 
gene Gstm1 has been extensively examined with genome-wide expression profiling (which 
also implicated other GSH metabolism-related genes), promoter sequence analysis, and 
adenoviral in-vitro and in-vivo overexpression and knock-down experiments. Functional 
studies examined the effects of modulating Gstm1 expression on in-vitro enzyme activities 
and in-vivo oxidative stress and NO bioavailability. Significant steps have also been taken 
towards the production of a transgenic SHRSP rat overexpressing Gstm1. Together, the 
strategies developed in these experiments represent a thorough approach to the assessment 
of a hypertension candidate gene. 
Blood pressure QTL analysis by congenic breeding in rats has been established for many 
years (Rapp 2000), however, the success of this strategy alone for positive identification of 
blood pressure genes is probably limited to confirmation that Cyp11b1 accounts for 
increased blood pressure in the DSS compared to the DSR under salt loading (Cicila et al 
2001;Garrett et al 2003). This approach has otherwise been hampered by difficulties 
including the large numbers of genes under QTL peaks, epistatic interactions between 
QTLs and loss of phenotype in small congenic intervals (Rapp 2000;Saad et al. 2001;Dutil 
et al 2005). Combining congenic breeding with microarray expression profiling in the 
manner that led to the identification of Gstm1 was therefore an important advance, and this 
approach was further extended by the data analysis techniques applied in this project. The 
finding presented here, that Gstm1 expression is reduced in the SHRSP prior to the 
development of severe hypertension, was significant in determining that the reduced 
expression observed at 16 weeks of age (McBride et al 2003) was not secondary to high 
blood pressure and likely to be a causative factor in increased blood pressure. This 
observation is also corroborated by published data comparing gene expression between 3 
week old SHR and WKY rats that showed reduced Gstm1 expression in the SHR at this 
earlier timepoint (Seubert et al 2005). Though the differentially expressed GSH 
metabolism genes identified in microarray mRNA expression data were not confirmed by 
qRT-PCR, the finding that GSH levels may be affected by genetic elements from the 2c* 
congenic interval was also significant and demonstrates the value of metabolic pathway 
analysis by IPA. It is predicted that this type of analysis, where candidate genes are not 
necessarily considered in isolation, but as part of interacting pathways will become 
increasingly important in complex genetic research (Dominiczak et al 2005). Indeed, IPA 
software has been applied in published hypertension research in rat inbred models. For 
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and Vcam1 in salt-sensitive hypertension in the SHRSP, and IPA software provided a 
functional transcriptional network that implicated activation of Edg1 in the expression of 
Vcam1 via numerous cell signalling molecules and transcription factors (Graham et al 
2007). The pathways, including elements such as platelet-derived growth factor-β 
(PDGFRB), protein kinase B (Akt1), PI3 kinase regulatory subunit 1 (PIK3R1), mitogen-
activated protein kinase kinase kinase 8 (MAP3K8) and transcription factors such as 
NFκB1, MYC and CCAAT/enhancer binding protein-β (CEBPB) will be the subject of 
further research and are hoped to lead to the identification of novel biomarkers for salt 
sensitive hypertension (Graham et al 2007). In addition, IPA has also been applied in 
conjunction with Transfac promoter sequence analysis in the identification of functional 
networks of genes whose expression may be affected by the differential expression of 
transcription factors from hypertension QTLs (Joe et al 2005;Lee et al 2007). 
Having established Gstm1 as a robust hypertension candidate gene, the subsequent 
experiments were designed to analyse the molecular mechanisms behind its reduced 
expression in the SHRSP and its relation to oxidative stress. The co-incidence of reduced 
renal Gstm1 expression and increased renal oxidative stress was an important result that, 
along with the identification of a coding mutation and 13 promoter polymorphisms in the 
SHRSP and SHR Gstm1 promoter, contributed to a recent publication (McBride et al 
2005). Significantly, reduced Gstm1 expression was also demonstrated in SHRSP carotid 
arteries, which is also consistent with increased vascular oxidative stress in the SHRSP 
(McBride et al 2005).  
Transfac promoter analysis was an invaluable tool in the identification of candidate 
transcription factors that may influence Gstm1 expression. Of the potential transcription 
factors who's binding may be affected by SHRSP Gstm1 promoter polymorphisms, PPARγ 
represents the strongest candidate since binding sites in both implicated clusters may be 
affected, and a precedent for PPARγ-mediated GST expression exists (Park et al 2004). If 
confirmed, this finding would increase the many roles for PPARγ in transcription 
regulation already proposed, including those in adipocyte differentiation (Tontonoz et al 
1994), lipid metabolism (Motojima et al. 1998;Tordjman et al. 2003), renal sodium 
homeostasis (Guan et al 2005) and reduced renal NADPH oxidase activity (Hwang et al 
2005). That PPARγ has a proven role in oxidative stress defence is significant in the light 
of the results presented here and is also corroborated by recent studies demonstrating that 
increased PPARγ expression facilitates recovery of cultured renal tubular epithelial cells 
after H2O2-induced injury (Sommer et al. 2007), and inhibits AngII synthesis in mesangial 
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complicated by the recent publication that PPARγ upregulates renin expression via binding 
to a novel response element in the renin promoter (Todorov et al. 2007). Overall, the 
analysis of the Gstm1 promoter warrants further study, it would be particularly informative 
to confirm the role of the putative ARE sequence, especially given that a functional ARE 
has not been described for the rat or mouse Gstm1 promoter, despite the fact that the Nrf2-
null mouse exhibits reduced Gstm1 expression (Chanas et al 2002). It may be interesting to 
consider an electrophoretic mobility shift assay (EMSA)-led approach to promoter analysis 
in future studies. Such a methodology was applied in the investigation of reduced 
expression of Anpep in the kidneys of the DSS rat compared to the DSR (Farjah et al 
2004), leading to the identification of a disrupted CEBPB motif in the DSR Anpep 
promoter (Kotlo et al. 2007a). 
The adenoviral overexpression platform applied in this project proved extremely flexible 
for the cloning and construction of several viruses to modulate Gstm expression. The anti-
Gstm family shRNA sequence was effective in the knockdown of genes against which it 
was fully aligned, the finding that target sequences differed from published gene sequences 
should be borne in mind in any future RNAi experiments. The hypothesis that reduced 
expression from the WKY Gstm1 virus in HeLa cells is due to differential binding of miR-
10b is interesting but does not relate to the in-vivo differential expression of Gstm1, unless 
it is hypothesised that miR-10b is overexpressed in the SHRSP and that the 3'UTR SNP at 
+35 has no effect, in this case, any other miRNA that putatively aligns with the Gstm1 
3'UTR is equally a candidate. The lack of increased NO bioavailability following Gstm1 
overexpression in the SHRSP carotid artery does not exclude a role for it in oxidative-
stress defence or hypertension and further experiments to develop targeting gene 
expression vectors are underway.  
The functional studies discussed above evaluated the effects of modulating Gstm1 
expression on in-vitro or intermediate phenotypes, these experiments could lend weight to 
the association of reduced Gstm1 expression to hypertension. In contrast, the blood 
pressure of a transgenic SHRSP overexpressing Gstm1 in the kidney would provide clearer 
evidence of the direct role played by this gene in hypertension. As discussed in chapter 6, 
these efforts are ongoing and may be extended to include lentiviral transgenesis.  
Collectively, these expression, functional and transgenic approaches were applied to the 
investigation of a candidate gene identified via a QTL, congenic and mRNA expression 
profiling strategy. While this approach has yielded successes in the identification of genes 
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2001b;Yagil et al 2005), several other studies have identified differentially expressed genes 
that on further analysis do not locate to minimal congenic intervals (Frantz et al. 
2001;Moujahidine et al 2004;Garrett et al 2005). Hence there is considerable interest in a 
number of other high-throughput functional genomic techniques that are likely to play an 
important role in the continued search for genes, proteins and pathways affecting complex 
polygenic traits (Dominiczak et al 2005;McBride et al. 2006).  
Our increasing understanding of the complexities of gene expression control and the 
improved cost-effectiveness of genetic and expression analysis has led to the advent of 
techniques such as genetical genomics, or expression genetics, where mRNA expression is 
treated as a phenotype in linkage analysis to locate eQTLs. As discussed in section 1.2.3.4, 
this technique has been applied in a panel of recombinant inbred strains to study a rat 
model of metabolic syndrome, identifying several cis- and trans- acting eQTLs and 
potential candidate genes (Hubner et al 2005). While cis-acting eQTLs are intrinsically 
easier to investigate since the elements that control their expression are likely to be within 
the gene itself or in nearby regulatory regions, trans-acting eQTLs often cluster to the 
same genetic location and point to potential major effect loci with central roles in 
metabolic pathways (Petretto et al. 2006). Thus this technique is potentially tremendously 
powerful provided experiments are appropriately designed and data is analysed correctly; 
the expression genetics field is in its early stages and tools for statistical data analysis and 
for translating findings into testable hypotheses in implicated pathways are still under 
development (Drake et al. 2006). Many of the concepts and approaches developed for 
linkage of gene expression to quantitative trait loci also applicable to analysis of the 
genetics of proteomic and metabolomic traits, as discussed below. 
Proteomics, which involves the identification of polymorphic protein expression and 
isoforms between samples, is being increasingly applied in complex disease genetics 
research. Proteomic strategies are particularly useful because they allow researchers to 
assess the distribution and relative concentrations of proteins, which are the functional 
units of the organism that have the greatest direct effect on phenotype. A common strategy 
in proteomic experiments is to locate polymorphic protein spots following separation of 
proteins electrophoretically in 2 dimensions (by size and by isoelectric point) and to 
identify the proteins concerned by mass spectrometry and mass fingerprint analysis. One of 
the limitations of proteomic strategies in the past has been the reproducibility of techniques 
used to separate protein samples (McBride et al 2006), however advances such as 2 
dimensional difference in gel electrophoresis (2D-DIGE), where samples to be compared 
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a technique has examined the specific proteins expressed within inner-medullary collecting 
duct (IMCD) cells compared to inner-medullary non-collecting duct cells (Hoffert et al. 
2004), and was also used to examine the regulation of proteins in IMCD cells following 
long-term administration of vasopressin (van Balkom et al. 2004). Proteomic strategies 
have also been combined with linkage analysis in some models, for example, Klose et al 
(2002) performed genetic analysis of the mouse brain proteome by comparing protein 
composition and genetic linkage data on a panel of mice from a backcross between two 
genetically divergent mouse species, Mus musculus and Mus spretus. They found that 
polymorphic proteins showed a high degree of allele-specific transmission, which was 
particularly evident in heterozygotes, and that variations in protein quantities and isoforms 
often mapped distant to their genomic coding location, an illustration of the many post-
transcriptional and post-translational events that occur to a protein that are mediated by 
proteins encoded elsewhere in the genome (Klose et al. 2002).  
Proteomic approaches have also been applied by colleagues in Glasgow examining human 
cardiovascular disease; urinary protein biomarkers were assayed in healthy individuals and 
patients with coronary artery disease (CAD) to distinguish a signature polypeptide pattern 
specific to CAD patients (Zimmerli et al. 2007). In this instance capillary electrophoresis 
and mass-spectrometry was applied to search for metabolomic markers of disease with 
potential clinical application, rather than to assay for genetically mediated differences in 
protein expression. However, metabolomic analysis has also been combined with genetic 
analysis to map the genetic determinants of different metabolite profiles in disease states. 
For example, proton nuclear magnetic resonance (
1H NMR) was recently applied in a study 
to compare the metabolite profile of an inbred rat model of diabetes, the Goto-Kakizaki 
(GK) rat, with the normoglycaemic BN (Dumas et al. 2007). Genotyping data was 
available on F2 rats from a GKxBN cross (Gauguier et al. 1996); 
1H NMR spectra were 
obtained for plasma samples of a subset of these animals and linked to their genotype data 
to examine the genetic influence of metabolite levels. Metabotypic QTLs for proline and 
tyrosine on Chromosome1 and glucose on chromosomes 5 were validated by the 
examination of the plasma metabolite profiles of congenic strains harbouring the 
appropriate alleles at each locus. The metabotypic QTL with the highest LOD score (13.7) 
was examined in greater detail, revealing that increased plasma benzoate concentration was 
associated with GK alleles at a locus encoding several uridine diphosphate-glucuronosyl-
transferase (UGT) enzymes, the expression of one of which (Ugt2b) was found to be 
reduced 78-fold in the GK compared to the BN. Benzoate is a gut microbial degradation 
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while the significance of this finding to diabetes is unclear (indeed, the same allele at this 
locus in the GK rat is shared by the WKY). This emphasizes the utility of genetic analysis 
of metabolomic data by uncovering a genetic polymorphism affecting a 
mammalian/bacterial symbiotic relationship (Dumas et al 2007).  
Traditional QTL mapping typically identifies large genomic regions encompassing several 
potential candidate genes, and strategies such as congenic and subcongenic breeding 
followed by substitution mapping can reduce the implicated region but are laborious. 
Increasing marker density for genetic mapping only moderately improves QTL resolution 
(Rapp 2000), the main limitation being the limited opportunity for recombination by the F2 
generation, when most genome-wide scans are performed. This experimental design is 
typically necessitated by the cost of breeding and housing large numbers of animals 
(particularly for rats), and the expense and poor coverage of traditional genotyping 
methods; this subsequently leads to the situation where only large-effect QTLs reach 
statistical significance. A recent landmark study addressed these issues by breeding a 
population of 'heterogeneous stock' mice in 50 generations from 8 inbred progenitor strains 
(Valdar et al. 2006). Over 2000 mice were genotyped at 13549 SNPs and phenotyped for 
101 phenotypes varying from body weight, immunological marker antibody staining, 
glucose tolerance testing, blood count to behavioural traits such as startle response, anxiety 
measurements and activity. Using bespoke statistical analysis techniques they identified 
843 QTL peaks that exceeded the significance threshold for 97 of the phenotypes, only 1% 
of which individually accounted for more than 5% of phenotypic trait variance. Thus each 
of the traits examined appear to be under the influence of a large number of small effect 
QTLs, and the analysis accounted for an average of 73% QTL-based additive variance in 
phenotype for all traits (as a percentage of the pedigree-based variance), leaving 
considerable scope for epistatic and environmental factors to affect phenotype. Of 40 
previously described QTLs from traditional QTL mapping in the parental strains, between 
a third and half mapped to the same location in this study. The challenge of gene 
identification at the QTLs identified remains, there were an average of 27 genes within the 
95% confidence interval of the QTLs identified (Valdar et al 2006), however this study is 
particularly significant for the possible implications on the analysis of human complex 
genetic diseases. As with any novel analytical technique, the robustness of the statistical 
methods applied by Valdar et al remains to be proven (Darvasi 2006), however it is 
important to reemphasize that the population used in this study was derived from 8 founder 
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QTLs may exhibit even smaller effects on complex traits, requiring extremely large 
experimental groups to identify all but the largest effect alleles.  
The last year has seen the publication of risk loci for a number of human complex diseases 
following genome wide association studies in large populations. Risk loci have been 
identified for six of the 7 diseases studied by the Wellcome Trust Case Control Consortium 
(WTCCC), including bipolar disorder, coronary artery disease, Crohn's disease, 
rheumatoid arthritis and type 1 and 2 diabetes (The Wellcome Trust Case Control 
Consortium 2007), and further loci have been identified for obesity (Frayling et al. 2007), 
prostate cancer (Gudmundsson et al. 2007) and others. However, the odds ratios associated 
with the risk alleles at these loci are modest, (between 1.2 and 1.7). While disease risk odds 
ratios and trait variance are not directly comparable, the low odds ratios associated with the 
disease risk loci mirror the low phenotypic variance explained by a majority of the QTLs 
identified by Valdar et al, leading to the conclusion that in animals and humans any given 
continuous trait is likely to be governed by allelic variants at very few (if any) large effect 
loci, some with intermediate effect, and many with small effects.  
An example of a complex trait for which large-effect alleles have been identified is high-
density lipoprotein cholesterol (HDL-C) levels in humans; candidate gene investigations 
have demonstrated that small number of rare SNPs contribute to low HDL-C levels and 
multiple mildy-penetrant alleles are concluded to account for a remainder of the phenotype 
(Cohen et al. 2004). Hypertension was the only condition for which a risk locus was not 
identified above the significance threshold in the WTCCC study. As discussed in section 
1.1.4.3 there are a number of plausible explanations for this, not least the likely incidence 
of hypertension in the unphenotyped control population (The Wellcome Trust Case 
Control Consortium 2007). With this in mind, the discussion above points to the possibility 
that essential hypertension too is caused by the cumulative effects of many small-effect 
loci in most cases. This is not to detract from the importance of genetic studies in models 
of complex disease, identification of robust candidate genes and pathways will shed light 
on the physiological pathways of blood pressure control that are applicable to humans.  
In addition to the recent methodological advances that have contributed to our 
understanding of complex genetic traits, a number of important findings regarding the 
fundamental mechanisms of genomic organisation, gene expression and inheritance are 
also likely to have an impact on genetic hypertension research in the near future. Data from 
phase I of the HapMap project (The International HapMap consortium 2005) has already 
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information it provides on the haplotypes associated with alleles at tagging SNPs. The 
recent release of phase II of HapMap, with a SNP density of approximately one per 
kilobase, allows for improved haplotype tagging and has also revealed insights into 
genome-wide recombination rates. For example, the locations of several recombination 
hotspots have been confirmed and it is estimated that they account for approximately 60% 
of all recombination, despite covering just 6% of the genome. Furthermore, recombination 
rates were shown to be lower in transcribed regions overall, while rates varied by gene 
class, with defence and immunity genes showing the highest recombination rates (The 
International HapMap consortium 2007). Another international collaborative project has 
recently provided fascinating insights into the regulation and extent of transcription in 
humans. The pilot phase of the encyclopaedia of DNA elements (ENCODE) project 
analysed 1% of the human genome, assessing transcription and chromatin structure and 
applying comparative sequence analysis to gauge the extent to which transcriptionally 
functional sequences are conserved across evolution (Birney et al. 2007). Unexpectedly, 
they showed that 80% of the analysed sequence is transcribed, despite the fact that only 2% 
encodes protein. Even after accounting for known functional non-coding RNAs such as 
siRNAs and miRNAs, vastly more of the genome appears to be transcribed than previously 
thought. It is possible that RNA polymerase 'reads through' the template during 
transcription, but the ENCODE investigators also showed that many of the unexpected 
transcripts are derived from regions of the genome previously thought to be 
transcriptionally silent. In another surprising finding, they showed that approximately 50% 
of functional sequences (i.e. those directing transcription) were not well conserved in 
comparisons with 20 other mammalian species, while approximately 40% of well 
conserved sequences did not appear to be functional in humans. The latter observation may 
be explained by the limited cell types used in the ENCODE study, expression analysis in 
different cell types may yield many more functional sequences. But the non-conservation 
of functional sequence is intriguing; ENCODE authors and commentators have speculated 
that the a more detailed examination of such divergent sequences may be necessary to 
locate the critical, well conserved bases that are presumably central to transcription factor 
binding at these locations (Birney et al 2007;Greally 2007;Henikoff 2007).  
The preliminary results of the ENCODE project therefore confirm the complexity of 
genomic organisation and highlight our incomplete understanding of the mechanisms that 
underlie expression and phenotypic variance. A number of other studies have also recently 
shed light on mechanisms affecting gene expression and expression of complex traits, 
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expression, and the influence of the mitochondrial genome. Duplications and deletions 
arising commonly through unequal crossover during cell replication give rise to copy 
number variations (CNVs) in genes and genomic regions. Though the focus of genetic 
research has concentrated on SNP variation, there is increasing recognition that CNV also 
affects phenotype. Genome-wide studies have demonstrated that up to 12% of the human 
genome is affected by copy-number variation in genetic segments down to 1 kb in size 
(Redon et al. 2006), while larger rearrangements (from 40 kb) affect approximately 3% of 
the genome (Wong et al. 2007), several hundred genes and disease loci are therefore 
potentially affected by CNV. Variation in gene copy number may affect phenotype by 
causing a direct relative change in protein levels, or by affecting regulatory regions. 
Despite widespread deletion and duplication, it is interesting to note that single-nucleotide 
variations have been shown to account for over 80% of variation in gene expression, with 
CNVs accounting for less than 20% (Stranger et al. 2007). Nevertheless, CNV has been 
shown to affect disease phenotype in numerous monogenic diseases (reviewed by Inoue et 
al. 2002), and low copy number polymorphisms in the constant fragment (Fc) receptor 
γR3-related sequence (Fcgr3-rs) in rats and the orthologous FCGR3B gene in humans have 
been shown to cause predisposition to macrophage-dependent autoimmune 
glomerulonephritis (Aitman et al. 2006).  
The role of miRNA in the regulation of gene expression has attracted considerable research 
interest, revealing insights into developmental processes (Zhao et al. 2007), tumour 
classification in cancer research (Lu et al. 2005), and stem cell division (Hatfield et al. 
2005). The ability of miRNAs to affect the expression of complex traits is considered all 
the more likely since they are known to target multiple mRNAs (Lim et al. 2005), indeed 
genome-wide expression profiling of miRNAs in patients with heart disease (ischaemic 
cardiomyopathy, dilated cardiomyopathy and aortic stenosis) revealed disease-specific 
miRNA expression patterns particular to each condition compared to healthy controls 
(Ikeda et al. 2007). The impact of non-coding RNAs on gene expression has also been 
demonstrated in epigenetic research. Epigenetics is the study of chromatin modifications 
that affect gene expression. Classically, the inheritance of epigenetic modifications was 
thought to be restricted to somatic cell divisions, though transgenerational epigenetic 
modifications are known to occur in plants (Chandler et al. 2000), a recent study showed 
that RNA-mediated epigenetic changes can also be transmitted to offspring in mice 
(Rassoulzadegan et al. 2006), thus adding to the list of functions ascribed to non-coding 
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Several studies have examined the relative paternal or maternal contributions to the 
heritability of blood pressure, some showing a bias towards paternal transmission (Uehara 
et al. 1998) while others suggests a maternal bias that could implicate variants in the 
mitochondrial genome (Destefano et al. 2001;Sun et al. 2003;Yang et al. 2007). However, 
it is acknowledged that exclusive maternal influences also include the in-utero 
environment which has been shown to affect other complex traits such as diabetes (Fetita 
et al. 2006) and lipoprotein levels (Bansal et al. 2005), making the direct influence of the 
mitochondrial genome difficult to quantify. Examples of rare mitochondrial mutations that 
cause hypertension (Wilson et al 2004) and diabetes (Maassen et al. 2005) have provided 
indirect evidence of a role for the mitochondrial genome in complex diseases, but 
variations in copy number and tissue distribution of mitochondrial mutations make 
experimental investigations extremely challenging. Thus the recent development of 
conplastic rat strains that are of identical nuclear genotype but carry mitochondria from 
different strains (Pravenec et al. 2007), is extremely valuable. Pravenec et al developed rat 
strains carrying the SHR nuclear genome and mitochondria derived either from the SHR or 
BN and showed significant differences between the two strains in glucose tolerance, 
muscle glycogen levels and muscle ATP levels. Sequence differences between the two 
mitochondrial genomes were also detected in several genes, providing candidates for 
further investigation (Pravenec et al 2007). 
This discussion has outlined many recent methodological developments and advances in 
our understanding of gene expression and inheritance that are likely to impact the search 
for causative loci (genes and expressed non-coding sequences) in complex diseases such as 
essential hypertension. The utility of advanced strategies such as IPA and shRNA-
expressing adenoviruses has been demonstrated by work performed in this project which 
has used a range of techniques to examine a robust hypertension candidate gene. While the 
role of reduced Gstm1 expression in hypertension in the SHRSP is still to be fully 
elucidated, significant progress has been made in the development of many tools to study 
its function. These approaches can also be applied in the analysis of other candidate genes 
in the future.  The advances discussed above can be applied in conjunction with inbred 
models of disease such as the SHRSP and congenic strains; candidate genes and pathways 
identified by such studies can be investigated using many of the techniques applied in this 
work; in this manner we are very likely to make considerable strides in our understanding 
of conditions such as hypertension that will aid in the development of new therapies and 
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Appendix 
Primer Name  Sequence 
    Anpep coding sequence primers 
Anpep1F  CTCCCTGCCCACCAGCATCA 
Anpep2R  CCATTGATGAGGGCCATGGT 
Anpep3F  GACCCTTCAGGAAGATCCTT 
Anpep4R  TTGAGATACGGAATGGGCAC 
Anpep5F  AGTGAGCACCATCATGGACC 
Anpep6R  TCACCACAGTTGCTTTCCGG 
Anpep7F  AGTGGTCTCGAAGAGTGTAG 
Anpep8R  GATAGTCATAGGCGTCACGC 
ANPEPcDNA1F  GTTAGGTGTGGCAGCCGTAT 
ANPEPcDNA1R  GATGTTAGGTGCCGGAGTGT 
ANPEPcDNA2F  TACCCGACTCCTACCAGGTG 
ANPEPcDNA2R  CTCATCAAGCAAGGAAAGG 
ANPEPcDNA3F  ACACTCCGGCACCTAACATC 
ANPEPcDNA3R  CTTGCAGAGCGTAATCACCA 
    Anpep promoter sequence primers 
ANPEPup1F  CAGGGTGACAGGAACCCTAA 
ANPEPup1R  GTTCCCCAGCCTTTATCTCC 
ANPEPup2F  GAAGAATCAGATGGGCTGGA 
ANPEPup2R  TTGCCCTCTGCTCTCTATCC 
ANPEPup3F  CCCGAGTTCTATGGAGCAAA 
ANPEPup3R  GCACGGGATAGATGACTGCT 
ANPEPup4F  GGTGGAGCCAGTGTGCTTAT 
ANPEPup4R  CACCTGGTAGGAGTCGGGTA 
ANPEPup5F  CATCAGCCCAGACCTGATAG 
ANPEPup5R  GTCGGGATGGACTGGACATA 
ANPEPup6F  TTCTCAAAGGCCCAGAGGTA 
ANPEPup6R  CAGGACCTTTTCCTCTCACG 
ANPEPup7F  GGCTCATGTGTTTCCCCTTA 
ANPEPup7R  GCACGGGATAGATGACTGCT 
    Gclm Coding sequence primers 
GCLM1F  CAGCGGTCTTCCCGCCTGCC 
GCLM2R  ACATTCACGCCTCAGTGACG 
GCLMcDNA3F  AAAGTGTCCGTCCACGCACA 
GCLMcDNA3R  CTGTTTAGCAAATGCAGTCA 
GCLMcDNA4F  TTGCTATAGGCACCTCGGAT 
GCLMcDNA4R  ATTCACGCCTCAGTGACGCT 
GCLMcDNA5F  CACTGTGGCTGCTGAGGTAC 
GCLMcDNA5R  CTCTTCCAGTATGTCTTAAC 
    Gclm Promoter sequence primers 
GCLMup1F  CGGCCAAGTGAGAGGAATAG 
GCLMup1R  GAGGCCACAGGACATGAGAT 
GCLMup2F  TTTGAGGGCTGGAGATGTTC 
GCLMup2R  AGGTATGTCGGAGCCAGATG 
GCLMup3F  CTTCTGGGAAACCTTTGCTC 
GCLMup3R  CAAAAGGACAGCCAGAGGTC 
GCLMup4F  AAGCAAAGCAAAGCAAAGGA 
GCLMup4R  CGTGGACGGACACTTTTTC 
GCLMup5F  GCATTCCTGATAGGAGTTTG 
GCLMup5R  CATTTGGGAGGCAGAGCTGT 
GCLMup6F  CACCACTGCCTGGAGGCTAAACT 
GCLMup6R  AAAGGCCTAAGCCCATGAAT 
GCLMup7F  GGGCTGTGCACAACAAATAC 
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GCLMup7R  CGCTTGCCTGCTTCTATTTC 
GCLMup8F  GAAATCAACACGCTGGGAGA 
GCLMup8R  GTCGCTGCGGTTTTTGAGGC 
GCLMup9F  AGGCCTTTCTCTCGAAGGAT 
GCLMup9R  ACCCGAGAAAGTGCTTCGTA 
GCLMup10F  CGCCGTCAGCTCTTACCAG 
GCLMup10R  AGCTCACCGCGGTATCTCTA 
GCLMup11F  CGGGAACCTGCTCAACTG 
GCLMup11R  TTGTCCCGAATCCAATTCA 
    Ggt1 coding sequence primers 
GGT1AF  CAGCCTAGCTGGACCTCTTG 
GGT1AR  ACGTGGGCATTAATGAGTCC 
GGT1BF  AAGCGTTGCTCAGAGATTGG 
GGT1BR  GGCCAACTTCGGCATAGTTA 
GGT1CF  GCAAGAGCCTTGGACAAAAA 
GGT1CR  TTGGGTGAGTGGTTTCATCA 
GGT1DF  TCCGCAACATGAGTTCTGAG 
GGT1DR  GTATGGTGGTGCCGAGTCTT 
    Them4 coding sequence primers 
THEM4cDNA1F  TGGTTGAGAGGACATTGCAG 
THEM4cDNA1R  GTGATGTCGATGATGGTTGC 
THEM4cDNA2F  AGGCTTTGAGTACGCGATGT 
THEM4cDNA2R  TCAGCAGCTGTGACAGGAGT 
THEM4cDNA3F  GGTGAGTTCCACACCGTTCT 
THEM4cDNA3R  GCAATGAGCTGTGTTCCTGA 
THEM4cDNA4F  TCCACAGAGCGTTGAGTGAC 
THEM4cDNA4R  GAAAGCTGGATGCTTCCTTG 
    Them4 promoter sequence primers 
THEM4upAF  GCCTCCAACGAAAGAGAAAA 
THEM4upAR  TCAGGGCTTCAGGGATATTG 
THEM4upBF  CAATATCCCTGAAGCCCTGA 
THEM4upBR  GTACATGGGTTCGTGTGTGG 
THEM4upCF  TGTCTCCTAGTCCCCAATGC 
THEM4upCR  TCTCTAGGCTGGCATGGTCT 
THEM4upDF  TGGAACTGGAATTGCAAACA 
THEM4upDR  TAAAGGGAGCCTGTTTCACG 
THEM4upEF  GTGCACCCTTCGACAGAAAT 
THEM4upER  CTGCAATGTCCTCTCAACCA 
THEM4upFF  TGATGATGTCTTGACTGCTCCT 
THEM4upFR  CTGCAGAAGGCCAGAGTTTT 
THEM4upGF  TGCCATGGAAAAGGGAGTTA 
THEM4upGR  GTACATGGGTTCGTGTGTGG 
THEM4upHF  TGTCTCCTAGTCCCCAATGC 
THEM4upHR  GCTGGAGAGATGGTTCACAAG 
THEM4upIF  TGGAACTGGAATTGCAAACA 
THEM4upIR  TCTCTAGGCTGGCATGGTCT 
    Slc7a12 coding sequence primers 
Slc7a12AF  ACACAAATTGACAGAGAAGC 
Slc7a12BR  AGGAAAGACTCTGTTCATCC 
Slc7a12CF  GAAATAAAAAGGCCAGCTGA 
Slc7a12DR  TGTAGGACCAACGGCTTCCC 
Slc_1F  CACCATTGGTACAGGGATTT 
Slc_1R  AAAAAGGAGAACGTGTCCAG 
Slc_2F  CTAACTGGAATTGTGGTGC 
Slc_2R  CAGTAGTAGCTGACTTACAGGC 
Slc_3F  AGTAGTAGCTGACTTACAGGCT 
Slc_3R  CGTTGGTCCTACAAAGGT 
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Slc7a12 promoter sequence primers 
slc7a12_UP_1F  CAGTTGAAATGCATGGCTGA 
slc7a12_UP_1R  GCATCTCATCTTGATGTCCTGA 
slc7a12_UP_2F  TTTGGCAGAAGCCAGAACAT 
slc7a12_UP_2R  TGCTGGGCAATACATGTCAG 
slc7a12_UP_3F  GCGTGTGTGTGTGTGTGTGT 
slc7a12_UP_3R  TTCTCCCTCCCTTTTTCACC 
slc7a12_UP_4F  GGCTCTTCTGCTCTGCTTGT 
slc7a12_UP_4R  TTGGAGCCTCCCATAAAATG 
slc7a12_UP_5F  AGTGGGGAGAGGGAACTTGT 
slc7a12_UP_5R  TCTGCTGGCTCTTGTCTTCA 
slc7a12_UP_6F  TCTTGGACACTGAACCACCA 
slc7a12_UP_6R  TGCATGGTTATGCCTTTTTG 
    Gstm1 promoter sequence primers 
Gstm10R  CCGCGGACGTTCCAGTATCC 
Gstm11F  AGTCTCCAGGGAAAGTGCTAG 
Gstm12R  CTGTTCTACACACCCTGAAAGC 
Gstm13F  ACAGAAGGACTGAGTTCCCAA 
Gstm14R  CAGGAACAGTTGGCGACATGG 
Gstm15F  CCCAGGATAACCTGAATTTGAG 
Gstm16R  AGGACACAAGGAGCCCAAAGC 
Gstm17F  GGTGACACACTGGCTTCATAC 
Gstm18R  CAAATGACTGACGAGGAGACT 
Gstm19F  CTCTGGCTCCCTTCCAGGCCC 
Gstm20R  CGCATCAGCACATTTTCATGC 
Gstm21F  GATTATTCCTGCACAGTGTCC 
Gstm22R  TGTCCTGGAGAATTCAATCCC 
Gstm23F  GGTTCAGCACAACACAACACG 
Gstm24R  CTCTGCCCCATTGAGGCTCTC 
Gstm25F  CCTTCTCCTTCCCCTTTATCC 
    Gstm1 coding sequence primers 
Gstm1F  CAAATTGAGAAGACCACAGC 
Gstm2R  AAGAGGGAGTATCGAACTCAG 
Gstm3F  TTTGAGCCCAAGTGCCTGGA 
Gstm4R  GCAGGATCCAATGTGGATAG 
    Gstm1 promoter sequence cloning primers 
Gstm1-1R  CCCCTCGAGGGTTCTGGCGCTGTGGTC     
Gstm1-0.9F  CCCACGCGTTTGTGTCCTGTGCAGAGTGTT 
Gstm1-1.6F  CCCACGCGTCTCTGAGCCCTTTGTTCTGG 
Gstm1-2.2F  CCCACGCGTGGAAGGTTGGAAACCACTGA 
Gstm1-2.5F  CCCACGCGTGTGAGCTGGCCACGTCTTAG 
RV3F  CTAGCAAAATAGGCTGTCCC 
GL2R  CTTTATGTTTTTGGCGTCTTCC 
T7F  GTAATACGACTCACTATAGGGC  
T3R  AATTAACCCTCACTAAAGGG 
    Site directed mutagenesis primers 
SNP8F  CCTTGTGAAGGTTATGCCACAGGACATATATCC 
SNP8R  GGATATATGTCCTGTGGCATAACCTTCACAAG
G 
SNP9F  CAATTAACCACAAGCCTCTTGGTTATGGAAG 
SNP9R  CTTCCATAACCAAGAGGCTTGTGGTTAATTG 
SNP10+11F  TTTAGTCTCCTCGTCCCGTCATTTGTTTTTCA 
SNP10+11R  TGAAAAACAAATGACGGGACGAGGAGACTAAA 
SNP12F  TGCCCTTTGACCCGTAAACTGTTTTTAGTC 
SNP12R  GACTAAAAACAGTTTACGGGTCAAAGGGCA 
    Adenoviral shuttle plasmid cloning and sequencing primers 
Gstm1HindIIIF  CCCAAGCTTCAAATTGAGAAGACCACAGC 
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Primer Name  Sequence 
Gstm4aXbaI  CCCTCTAGACCTGCAGGATCCAATGTGG 
mCMVpF   GTGGGAGGTCTATATAAGCAGAGCTCG 
polyAR  TTAAAAAACCTCCCACACCTCCCCC 
pSilencer CMV1.0F  GGATTTCCAAGTCTCCAC 
pSilencer CMV1.0R  AGCACCTTCCAGATCTGC 
    shRNA target sequence primers 
Gstm1 Ex3F  TGCTGGTCTCCCTCTAGCTG 
Gstm1 Ex3R  ACAGCCCATCACAGAAACAC 
Gstm2 Ex3F  TTGAATTTTGGAGGGCTGAC 
Gstm2 Ex3R  CTGGGTGAGGATAGACATGG 
Gstm3 Ex3F  AACCCTTGATGGTGTGGTGT 
Gstm3 Ex3R  AGCCCATCACAGAAAGATGG 
Gstm5 Ex3F  TCTCCAGTCAGCTGGGAACT 
Gstm5 Ex3R  TCAGAGACCTGGCTAGCAACT 
Gstm7 Ex3F  GGTCCCCTTCCTGTTGAAAT 
Gstm7 Ex3R  CATTCATCGTGGCTAGCATG 
    pEF1/Myc-HisA sequencing primers 
pEF1 T7F  TAATACGACTCACTATAGGG 
BGH PolyAR  TAGAAGGCACAGTCGAGG 
    BAC transgenic screening primers 
pBACT7R  CGCTAATACGACTCACTATA 
90M3-3F  TTACCATTAGCATGATACAAG 
pBACSp6F  GACATTTAGGTGACACTATA 
90M3-1R  GCCTTGAGTTGCGTCATTAAG 
pBAC-1R  CCGCTGCTTCACCTATTCTC 
pBAC-2F  TTCTTCTTTGCTTCCTCGCC 
pBAC-3R  CCAACCAGAACACGATAATCAC 
pBAC-4F  ACATACGCTCAATACTCAACC 
Gstm10  CCGCGGACGTTCCAGTATCC 
Gstm1  ACAGAAGGACTGAGTTCCCAA 
    Linear fragment transgenic screening primers 
pEF1_Gstm1cDNA_1F   GCCAGATATACGCGTTGACA 
pEF1_Gstm1cDNA_1R  ACCACACACGGCACTTACCT 
pEF1_Gstm1cDNA_2F  TTTGCCCTTTTTGAGTTTGG 
pEF1_Gstm1cDNA_2R  GGCCCAGTTTGAACTTCTCA 
pEF1_Gstm1cDNA_3F  GACCCAAGCTGGCTAGGTAA 
pEF1_Gstm1cDNA_3R  TGAGATGAGTTTTTGTTCGAAGG 
 
Table A1 – Primer sequences 
  
   
Probe Set ID  GeneChip 
Array 
Gene Title  Location 
L07281_at  U34A   carboxypeptidase E  16p13 
rc_AA799448_g_at  U34A   Transcribed locus, strongly similar to NP_084275.3 limb-
bud and heart [Mus musculus] 
--- 
rc_AI014135_g_at  U34A   Mss4 protein  13q13 
rc_AI232192_s_at  U34C   gamma-glutamyltransferase 1  --- 
rc_AI232402_at  U34C   ---  --- 
rc_AI233164_i_at  U34C   ---  --- 
rc_AI180260_at  U34C   synaptic vesicle glycoprotein 2b  1q31 
rc_AA875269_at  U34A   stearoyl-Coenzyme A desaturase 2  1q54 
rc_AI043990_at  U34B   Transcribed locus  --- 
rc_AI236231_at  U34C   NAD(P)H:quinone oxidoreductase type 3, polypeptide A2 
(predicted) 
13q13 
rc_AI044292_s_at  U34B   ---  --- 
rc_AI233127_at  U34C   Similar to CDNA sequence BC036333 (predicted)  16q12.4 
rc_AI071578_g_at  U34C   Neuronal regeneration related protein  18p12 
L46791_at  U34A   carboxylesterase 3  19p11 
rc_AI111561_at  U34C   Transcribed locus  --- 
rc_AA997142_at  U34B   Them4  2q34 
J02810mRNA_s_at  U34A   glutathione S-transferase, mu 1  2q34 
X04229cds_s_at  U34A   glutathione S-transferase, mu 1  2q34 
H32189_s_at  U34A   glutathione S-transferase, mu 1  2q34 
AA801165_at  U34C   histone 2, H2aa (predicted)  2q34 
rc_AI060176_at  U34B   Similar to solute carrier family 7 (cationic amino acid 
transporter, y+ system), member 12 
2q23 
rc_AA924865_at  U34B   similar to RIKEN cDNA 2900010J23  3p11 
AF007758_g_at  U34A   synuclein, alpha  4q24 
rc_AI009183_s_at  U34B   alkaline phosphatase, tissue-nonspecific  5q36 
rc_AI073168_at  U34C   ---  --- 
Table A2 – Continued overleaf  
   
Probe Set ID  GeneChip 
Array 
Gene Title  Location 
rc_AI070350_at  U34C   deleted in polyposis 1-like 1 (predicted)  7q11 
rc_AI235320_at  U34C   aconitase 2, mitochondrial  1q13 or 
20q11 
rc_AA893148_at  U34A   solute carrier family 22 (organic cation transporter), 
member 13 (predicted) 
8q32 
S56937_s_at  U34A   UDP glycosyltransferase 1 family, polypeptide A1, A6, A7, 
A8, A2, A4, A11, A5 
9q35-q36 
/// 9q35 
D38065exon_s_at  U34A   UDP glycosyltransferase 1 family, polypeptide A1  9q35-q36 
 
Table A2 – Differentially expressed probesets implicating the 2c* congenic interval at 5 weeks of age 
 
 
Probe Set ID  GeneChip Array  Gene Title  Location 
H32189_s_at  U34A   glutathione S-transferase, mu 1  2q34 
J02810mRNA_s_at  U34A   glutathione S-transferase, mu 1  2q34 
rc_AA894148_s_at  U34A   ---  --- 
X04229cds_s_at  U34A   glutathione S-transferase, mu 1  2q34 
 
Table A3 – Differentially expressed probesets implicating the 2c* congenic interval at 16 weeks of age 
 
Probesests consistently differentially expressed in renal gene expression microarrays in comparisons between the WKY and SHRSP 
and between the 2c* and SHRSP at five weeks of age. 
 
Probesests consistently differentially expressed in renal gene expression microarrays in comparisons between the WKY and SHRSP 
and between the 2c* and SHRSP at five weeks of age. 
  
   
 
Probe Set ID  GeneChip 
Array 
Gene Title  Location 
AF004017_at  U34A   solute carrier family 4, member 4  14p22 
D28557_s_at  U34A   cold shock domain protein A  4q42 
J02585_at  U34A   stearoyl-Coenzyme A desaturase 1  1q54 
J04035_at  U34A   elastin  12q12 
L19998_at  U34A   sulfotransferase family 1A, phenol-preferring, member 1  --- 
rc_AA892750_at  U34A   regulator of G-protein signaling 1  13q21 
rc_AA945611_at  U34A   ribosomal protein L10  Xq37 
rc_AI029920_s_at  U34A   insulin-like growth factor binding protein 5  9q33 
rc_AI231472_s_at  U34A   collagen, type 1, alpha 1  10q31 
S60054_s_at  U34A   renin 1  13q13 
S77528cds_s_at  U34A   CCAAT/enhancer binding protein (C/EBP), beta  3q42 
X05834_at  U34A   fibronectin 1  9q33 
X55183_at  U34A   amphiregulin  14p22 
X56325mRNA_s_at  U34A   hemoglobin alpha, adult chain 1 /// hemoglobin alpha 2   10q12 
X76489cds_g_at  U34A   CD9 antigen  4q42 
X81449cds_g_at  U34A   keratin complex 1, acidic, gene 19  10q32.1 
AFFX-BioDn-5_at  U34B   dethiobiotin synthetase  --- 
rc_AA849965_at  U34B   calcium binding protein 39 (predicted)  9q35 
rc_AA850038_at  U34B   Nuclear receptor subfamily 2, group F, member 2  1q31 
rc_AA851497_f_at  U34B   hemoglobin alpha, adult chain 1 /// hemoglobin alpha 2 
chain 
10q12 
rc_AA899197_at  U34B   poly(A) binding protein, cytoplasmic 1  7q22 
rc_AA899590_at  U34B   ribonucleotide reductase M2  6q16 
rc_AA901342_at  U34B   claudin 11  2q24 
rc_AA925340_at  U34B   ubiquitin-conjugating enzyme E2N  4q12 
rc_AA925364_i_at  U34B   ---  --- 
rc_AA943281_at  U34B   Transcribed locus  --- 
Table A4 – Continued overleaf 
  
   
Probe Set ID  GeneChip 
Array 
Gene Title  Location 
rc_AA944180_at  U34B   similar to Cyclin-dependent kinases regulatory subunit 2 
(CKS-2) 
17p14 
rc_AA955914_i_at  U34B   fibrillarin (predicted)  1q21 
rc_AA957296_at  U34B   CTD (carboxy-terminal domain, RNA polymerase II, 
polypeptide A) small phosphatase-like (predicted) 
8q32 
rc_AA996628_at  U34B   papillary renal cell carcinoma (translocation-associated) 
(predicted) 
2q34 
rc_AA996710_at  U34B   zinc finger, BED domain containing 3 (predicted)  2q12 
rc_AA997684_at  U34B   Procollagen, type VIII, alpha 2 (predicted)  5q36 
rc_AI013050_at  U34B   SRY-box containing gene 4 (predicted)  17p12 
rc_AI044100_at  U34B   ---  --- 
AFFX-BioDn-5_at  U34C   dethiobiotin synthetase  --- 
rc_AA818949_at  U34C   similar to DnaJ (Hsp40) homolog, subfamily B, member 12   20q11 
rc_AA859323_at  U34C   similar to spinster-like protein (predicted)  10q24 
rc_AI071738_at  U34C   Transcribed locus  --- 
rc_AI071887_at  U34C   Transcribed locus  --- 
rc_AI072107_at  U34C   ---  --- 
rc_AI072144_at  U34C   A kinase (PRKA) anchor protein 2 (predicted)  5q24 
rc_AI073081_at  U34C   low density lipoprotein receptor-related protein 6 
(predicted) 
4q43 
rc_AI104996_at  U34C   LOC499304  --- 
rc_AI176294_at  U34C   small nuclear ribonucleoprotein D2 (predicted)  1q21 
rc_AI177902_s_at  U34C   polymerase (DNA-directed), delta interacting protein 2  10q25 
rc_AI178901_at  U34C   Transcribed locus  --- 
rc_AI178966_at  U34C   delta sleep inducing peptide, immunoreactor  Xq35 
rc_AI180353_at  U34C   lysyl oxidase-like 2 (predicted)  15p11 
rc_AI180373_at  U34C   mitogen activated protein kinase kinase kinase 1  2q14 
rc_AI227643_at  U34C   similar to olfactomedin-like 1 /// olfactomedin-like 1 
(predicted) 
1q33 
Table A4 – Continued overleaf  
   
Probe Set ID  GeneChip 
Array 
Gene Title  Location 
rc_AI228159_at  U34C   similar to HECT domain containing 1  6q22 
rc_AI229785_at  U34C   keratin complex 1, acidic, gene 19  10q32.1 
rc_AI231339_at  U34C   6-phosphogluconolactonase (predicted)  16p14 
rc_AI231350_at  U34C   Dual specificity phosphatase 6  7q13 
rc_AI233200_at  U34C   Synaptonemal complex protein 3  7q13 
rc_AI235186_i_at  U34C   ---  --- 
rc_AI235284_at  U34C   CD99  --- 
rc_AI235749_at  U34C   similar to tensin  9q33 
rc_AI236668_at  U34C   ectonucleoside triphosphate diphosphohydrolase 5  6q31 
rc_AI237606_at  U34C   B-cell leukemia/lymphoma 6 (predicted)  11q23 
 
 
 
Table A4 – Differentially expressed probesets implicating the 2c* congenic interval between 5 and 16 weeks of age 
 
 
 
 
 
 
 
 
 
Probesests consistently differentially expressed in renal gene expression microarrays in comparisons between 5 week old and 16 week 
old 2c* rats and between 5 week old and 16 week old WKY rats 
  
   
SNP  Strain  Matrix Identifier  Position  Strand  Matrix 
match 
Core 
match 
Matrix sequence (+ strand)  Factor name 
SNP1+2  WKY  V$HOX13_01  49  (+)  1  0.9  tgggagggacctCATTAttttgtccggccc  Hox-1.3 
SNP1+2  SHRSP  V$HTF_01  49  (+)  0.849  0.804  tgggagggaCCCGTtattttgtcc  HTF 
SNP1+2  SHRSP  V$NFKB_C  50  (-)  0.76  0.714  gggaggGACCCg  NF-kappaB 
SNP1+2  WKY  V$T3R_01  50  (-)  0.8  0.839  gggagGGACCtcatta  v-ErbA 
SNP1+2  SHRSP  V$CMYB_01  51  (+)  0.895  0.817  ggagggacccGTTATttt  c-Myb 
SNP1+2  SHRSP  V$GFI1_01  51  (-)  0.765  0.761  ggagggacccgTTATTttgtccgg  Gfi-1 
SNP1+2  SHRSP  V$NFKAPPAB_01  51  (-)  0.877  0.795  ggaggGACCC  NF-kappaB 
SNP1+2  WKY  V$VJUN_01  51  (-)  0.8  0.72  ggagggaCCTCAttat  v-Jun 
SNP1+2  WKY  V$ATF_B  52  (-)  0.8  0.785  gagggaCCTCAt  ATF 
SNP1+2  WKY  V$ATF3_Q6  52  (-)  0.877  0.79  gagggaCCTCAtta  ATF3 
SNP1+2  WKY  V$GFI1_01  52  (-)  0.765  0.701  gagggacctcaTTATTttgtccgg  Gfi-1 
SNP1+2  WKY  V$MINI20_B  52  (+)  0.968  0.711  gagggaCCTCAttattttgtc  Muscle 
SNP1+2  SHRSP  V$XBP1_01  52  (-)  0.779  0.744  gagggaCCCGTtatttt  XBP-1 
SNP1+2  WKY  V$AML_Q6  53  (-)  0.874  0.817  agggaCCTCAttatt  AML 
SNP1+2  WKY  V$AREB6_02  53  (+)  0.8  0.77  aggGACCTcatt  AREB6 
SNP1+2  SHRSP  V$ARNT_01  53  (-)  0.792  0.737  agggaCCCGTtatttt  Arnt 
SNP1+2  WKY  V$CREB_Q2  53  (-)  0.79  0.721  agggaCCTCAtt  CREB 
SNP1+2  WKY  V$CREB_Q2_01  53  (+)  0.888  0.855  agggaCCTCAttat  CREB 
SNP1+2  WKY  V$CREB_Q4  53  (-)  0.792  0.745  agggaCCTCAtt  CREB 
SNP1+2  WKY  V$CREBP1_Q2  53  (-)  0.8  0.762  agggaCCTCAtt  CRE-BP1 
SNP1+2  WKY  V$PEBP_Q6  53  (+)  0.881  0.803  agggACCTCattatt  PEBP 
SNP1+2  SHRSP  V$WHN_B  53  (+)  0.761  0.759  aggGACCCgtt  Whn 
SNP1+2  WKY  V$AP1_Q2  54  (-)  0.773  0.738  gggaCCTCAtt  AP-1 
SNP1+2  WKY  V$E4F1_Q6  54  (+)  0.8  0.713  gggaCCTCAt  E4F1 
SNP1+2  WKY  V$NFKAPPAB_01  54  (+)  0.986  0.71  GGGACctcat  NF-kappaB 
SNP1+2  WKY  V$PADS_C  54  (-)  0.772  0.721  gggACCTCa  Poly 
SNP1+2  SHRSP  V$RORA1_01  54  (-)  0.8  0.717  gGGACCcgttatt  RORalpha1 
SNP1+2  WKY  V$RORA1_01  54  (-)  0.8  0.808  gGGACCtcattat  RORalpha1 
SNP1+2  WKY  V$RORA2_01  54  (-)  0.8  0.749  gGGACCtcattat  RORalpha2 
SNP1+2  WKY  V$S8_01  54  (+)  0.865  0.861  gggacctCATTAtttt  S8 
SNP1+2  WKY  V$CHX10_01  55  (-)  0.784  0.773  ggacctCATTAttt  CHX10 
SNP1+2  WKY  V$COREBINDINGFACTOR_Q6  55  (-)  0.846  0.809  ggaCCTCA  core-binding 
Table A5 – Continued overleaf  
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SNP1+2  WKY  V$CREB_01  55  (-)  0.788  0.805  ggaCCTCA  CREB 
SNP1+2  WKY  V$CREB_02  55  (-)  0.832  0.794  ggaCCTCAttat  CREB 
SNP1+2  SHRSP  V$CREB_Q2_01  55  (+)  0.796  0.723  ggaccCGTTAtttt  CREB 
SNP1+2  WKY  V$CREB_Q4_01  55  (-)  0.901  0.881  ggaCCTCAtta  CREB 
SNP1+2  WKY  V$CREBATF_Q6  55  (-)  0.873  0.867  ggaCCTCAt  CREBATF 
SNP1+2  WKY  V$CREBP1CJUN_01  55  (+)  0.844  0.746  gGACCTca  CRE-BP1 
SNP1+2  WKY  V$CREBP1CJUN_01  55  (-)  0.78  0.73  ggACCTCa  CRE-BP 
SNP1+2  WKY  V$FOXJ2_02  56  (-)  1  0.701  gacctcATTATttt  FOXJ2 
SNP1+2  WKY  V$FREAC7_01  56  (-)  0.766  0.739  gacctcATTATtttgt  Freac-7 
SNP1+2  WKY  V$GATA1_03  56  (+)  0.766  0.73  gacctCATTAtttt  GATA-1 
SNP1+2  SHRSP  V$GATA4_Q3  56  (-)  0.907  0.756  gacccgtTATTT  GATA-4 
SNP1+2  WKY  V$IPF1_Q4_01  56  (+)  1  0.933  gacctCATTAttttg  IPF1 
SNP1+2  WKY  V$S8_01  56  (-)  0.785  0.783  gaccTCATTattttgt  S8 
SNP1+2  WKY  V$XFD2_01  56  (-)  0.781  0.713  gacctcATTATttt  XFD-2 
SNP1+2  SHRSP  V$CREB_02  57  (-)  0.82  0.721  accCGTTAtttt  CREB 
SNP1+2  SHRSP  V$CREB_Q4_01  57  (-)  0.789  0.715  accCGTTAttt  CREB 
SNP1+2  SHRSP  V$CREBATF_Q6  57  (-)  0.773  0.725  accCGTTAt  CREBATF 
SNP1+2  SHRSP  V$GFI1B_01  57  (-)  0.792  0.753  acccgTTATTtt  GFI1B 
SNP1+2  SHRSP  V$VMYB_01  57  (-)  1  0.985  acCCGTTatt  v-Myb 
SNP1+2  SHRSP  V$FOXJ2_01  58  (-)  0.96  0.754  cccgtTATTTtgtccggc  FOXJ2 
SNP1+2  SHRSP  V$FOXJ2_02  58  (-)  0.897  0.709  cccgttATTTTgtc  FOXJ2 
SNP1+2  SHRSP  V$GATA1_02  58  (-)  0.754  0.737  cccgtTATTTtgtc  GATA-1 
SNP1+2  SHRSP  V$HNF3B_01  58  (+)  1  0.821  cccgtTATTTtgtcc  HNF-3beta 
SNP1+2  WKY  V$IPF1_Q4  58  (-)  1  0.898  cctCATTAtttt  IPF1 
SNP1+2  WKY  V$NKX25_02  58  (+)  0.778  0.74  ccTCATTa  Nkx2-5 
SNP1+2  SHRSP  V$PTF1BETA_Q6  58  (-)  0.795  0.827  cccgttattTTGTC  PTF1-beta 
SNP1+2  SHRSP  V$S8_01  58  (-)  0.785  0.741  cccgTTATTttgtccg  S8 
SNP1+2  WKY  V$SOX9_B1  58  (-)  0.758  0.757  cctcATTATtttgt  SOX-9 
SNP1+2  SHRSP  V$VMYB_02  58  (-)  1  0.973  cCCGTTatt  v-Myb 
SNP1+2  WKY  V$FOXJ2_01  59  (-)  0.96  0.76  ctcatTATTTtgtccggc  FOXJ2 
SNP1+2  WKY  V$FOXJ2_02  59  (-)  0.897  0.775  ctcattATTTTgtc  FOXJ2 
SNP1+2  WKY  V$GATA1_02  59  (-)  0.754  0.739  ctcatTATTTtgtc  GATA-1 
Table A5 – Continued overleaf  
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SNP1+2  WKY  V$HNF3B_01  59  (+)  1  0.863  ctcatTATTTtgtcc  HNF-3beta 
SNP1+2  WKY  V$LHX3_01  59  (-)  0.85  0.783  ctcATTATtt  Lhx3 
SNP1+2  SHRSP  V$LMO2COM_02  59  (+)  0.751  0.709  cCGTTAttt  Lmo2 
SNP1+2  SHRSP  V$S8_01  59  (-)  0.785  0.748  ccgtTATTTtgtccgg  S8 
SNP1+2  WKY  V$S8_01  59  (-)  0.785  0.743  ctcaTTATTttgtccg  S8 
SNP1+2  SHRSP  V$GATA1_05  60  (-)  0.8  0.781  cgTTATTttg  GATA-1 
SNP1+2  SHRSP  V$GATA1_06  60  (-)  0.79  0.789  cgTTATTttg  GATA-1 
SNP1+2  SHRSP  V$GATA2_02  60  (-)  0.785  0.772  cgTTATTttg  GATA-2 
SNP1+2  SHRSP  V$HFH3_01  60  (+)  0.981  0.769  cgtTATTTtgtcc  HFH-3 
SNP1+2  SHRSP  V$HNF4_01_B  60  (-)  0.8  0.706  cgttaTTTTGtccgg  HNF-4alpha1 
SNP1+2  SHRSP  V$LMO2COM_02  60  (-)  0.757  0.762  cgtTATTTt  Lmo2 
SNP1+2  SHRSP  V$MEF2_Q6_01  60  (+)  1  0.766  cgtTATTTtgtc  MEF-2 
SNP1+2  WKY  V$NKX25_02  60  (-)  0.887  0.773  tCATTAtt  Nkx2-5 
SNP1+2  SHRSP  V$NKX25_02  60  (+)  0.778  0.729  cgTTATTt  Nkx2-5 
SNP1+2  WKY  V$S8_01  60  (-)  0.785  0.746  tcatTATTTtgtccgg  S8 
SNP1+2  WKY  V$SOX5_01  60  (-)  0.823  0.842  tcATTATttt  Sox-5 
SNP1+2  WKY  V$FOX_Q2  61  (+)  0.934  0.733  catTATTTtgtcc  FOX 
SNP1+2  WKY  V$GATA1_05  61  (-)  0.8  0.747  caTTATTttg  GATA-1 
SNP1+2  WKY  V$GATA1_06  61  (-)  0.79  0.784  caTTATTttg  GATA-1 
SNP1+2  WKY  V$GATA2_02  61  (-)  0.785  0.76  caTTATTttg  GATA-2 
SNP1+2  WKY  V$HFH3_01  61  (+)  0.981  0.767  catTATTTtgtcc  HFH-3 
SNP1+2  WKY  V$HNF4_01_B  61  (-)  0.8  0.706  cattaTTTTGtccgg  HNF-4alpha1 
SNP1+2  WKY  V$LHX3_01  61  (+)  0.782  0.701  caTTATTttg  Lhx3 
SNP1+2  WKY  V$LMO2COM_02  61  (-)  0.757  0.751  catTATTTt  Lmo2 
SNP1+2  WKY  V$NKX25_02  61  (+)  0.778  0.766  caTTATTt  Nkx2-5 
SNP3  WKY  V$AR_02  41  (+)  0.8  0.74  tggccctctactttcTGCTCtagggtc  AR 
SNP3  WKY  V$AR_03  41  (+)  0.8  0.756  tggccctctactttcTGCTCtagggtc  AR 
SNP3  WKY  V$GR_01  41  (+)  0.8  0.806  tggccctctactttcTGCTCtagggtc  GR 
SNP3  WKY  V$PR_01  41  (+)  0.8  0.782  tggccctctactttcTGCTCtagggtc  PR 
SNP3  WKY  V$PR_02  41  (+)  0.8  0.81  tggccctctactttcTGCTCtagggtc  PR 
SNP3  WKY  V$DR3_Q4  45  (+)  0.804  0.76  cctctactttcTGCTCtaggg  VDR, 
SNP3  SHRSP  V$GFI1_01  45  (-)  0.765  0.719  cctctactttcTGCTTtagggtct  Gfi-1 
Table A5 – Continued overleaf  
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SNP3  SHRSP  V$PLZF_02  46  (-)  1  0.714  ctctactttctgCTTTAgggtctgtagct  PLZF 
SNP3  WKY  V$GRE_C  47  (+)  0.762  0.716  tctactttctGCTCTa  GR 
SNP3  SHRSP  V$HNF1_Q6  49  (+)  0.809  0.732  tacTTTCTgctttagggt  HNF-1 
SNP3  SHRSP  V$BARBIE_01  51  (-)  1  0.904  ctttctGCTTTaggg  Barbie Box 
SNP3  WKY  V$BARBIE_01  51  (-)  0.759  0.715  ctttctGCTCTaggg  Barbie Box 
SNP3  WKY  V$COUPTF_Q6  51  (+)  0.848  0.726  ctttcTGCTCtagggtctgtagc  COUPTF 
SNP3  SHRSP  V$COUPTF_Q6  51  (-)  0.814  0.708  ctttctgctttagGGTCTgtagc  COUPTF 
SNP3  WKY  V$COUPTF_Q6  51  (-)  0.814  0.726  ctttctgctctagGGTCTgtagc  COUPTF 
SNP3  SHRSP  V$GFI1B_01  51  (-)  0.792  0.718  ctttcTGCTTta  GFI1B 
SNP3  SHRSP  V$MTATA_B  51  (-)  0.901  0.767  ctttctgcTTTAGggtc  Muscle 
SNP3  SHRSP  V$LDSPOLYA_B  52  (+)  0.886  0.774  tttcTGCTTtagggtc  Poly A 
SNP3  SHRSP  V$MMEF2_Q6  52  (-)  0.9  0.737  tttctgCTTTAgggtc  MEF-2 
SNP3  WKY  V$MTF1_Q4  54  (+)  0.9  0.733  tcTGCTCtagggtc  MTF-1 
SNP3  SHRSP  V$PIT1_Q6  54  (+)  0.837  0.736  tcTGCTTtagggtctgta  Pit-1 
SNP3  WKY  V$COUP_01  55  (-)  0.825  0.72  ctgctctagGGTCT  COUP-TF, 
SNP3  SHRSP  V$POU1F1_Q6  55  (+)  0.868  0.712  cTGCTTtagg  POU1F1 
SNP3  SHRSP  V$TITF1_Q3  55  (-)  0.857  0.738  ctgCTTTAgg  TTF1 
SNP3  WKY  V$ZID_01  55  (+)  0.888  0.842  cTGCTCtagggtc  ZID 
SNP3  WKY  V$COUP_DR1_Q6  56  (-)  0.917  0.702  tgctctaGGGTCt  COUP 
SNP3  WKY  V$GATA4_Q3  57  (-)  0.752  0.701  gctctagGGTCT  GATA-4 
SNP3  WKY  V$HNF4ALPHA_Q6  57  (-)  0.79  0.776  gctCTAGGgtctg  HNF-4alpha 
SNP3  SHRSP  V$LEF1TCF1_Q4  57  (+)  0.822  0.712  gCTTTAgggtc  LEF1TCF1 
SNP3  SHRSP  V$RORA1_01  57  (+)  0.8  0.73  gctttagGGTCTg  RORalpha1 
SNP3  SHRSP  V$TATA_C  57  (-)  0.79  0.715  gCTTTAgggt  TATA 
SNP3  WKY  V$MINI20_B  58  (-)  0.929  0.712  ctctagggtcTGTAGctctgg  Muscle 
SNP3  SHRSP  V$E2F_Q4  59  (+)  0.773  0.798  tTTAGGgt  E2F 
SNP4  WKY  V$COUPTF_Q6  69  (-)  0.827  0.734  ttcagggtgtgtaGAACAgaatc  COUPTF 
SNP4  SHRSP  V$BRN2_01  74  (+)  0.917  0.721  ggtgtgtAGAATagaa  Brn-2 
SNP4  WKY  V$AR_02  75  (-)  1  0.713  gtgtgtaGAACAgaatcctggggcaga  AR 
SNP4  WKY  V$AR_03  75  (-)  1  0.757  gtgtgtaGAACAgaatcctggggcaga  AR 
SNP4  WKY  V$GR_01  75  (-)  1  0.917  gtgtgtaGAACAgaatcctggggcaga  GR 
SNP4  SHRSP  V$GR_01  75  (-)  0.8  0.768  gtgtgtaGAATAgaatcctggggcaga  GR 
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SNP4  SHRSP  V$OCT1_06  75  (+)  0.829  0.726  gtgtgTAGAAtaga  Oct-01 
SNP4  WKY  V$PR_01  75  (-)  1  0.897  gtgtgtaGAACAgaatcctggggcaga  PR 
SNP4  SHRSP  V$PR_01  75  (-)  0.8  0.753  gtgtgtaGAATAgaatcctggggcaga  PR 
SNP4  WKY  V$PR_02  75  (-)  1  0.843  gtgtgtaGAACAgaatcctggggcaga  PR 
SNP4  SHRSP  V$PR_02  75  (-)  0.8  0.705  gtgtgtaGAATAgaatcctggggcaga  PR 
SNP4  SHRSP  V$SOX9_B1  76  (+)  0.758  0.724  tgtgtAGAATagaa  SOX-9 
SNP4  SHRSP  V$GATA1_03  77  (+)  0.766  0.756  gtgtaGAATAgaat  GATA-1 
SNP4  SHRSP  V$MRF2_01  77  (+)  0.914  0.814  gtgtagAATAGaat  MRF-2 
SNP4  WKY  V$MRF2_01  77  (+)  0.773  0.704  gtgtagAACAGaat  MRF-2 
SNP4  SHRSP  V$OCT1_02  77  (-)  0.992  0.766  gtgtaGAATAgaatc  Oct-01 
SNP4  WKY  V$CMYB_01  78  (-)  0.869  0.797  tgtAGAACagaatcctgg  c-Myb 
SNP4  SHRSP  V$PITX2_Q2  78  (-)  0.834  0.705  tgtaGAATAga  PITX2 
SNP4  SHRSP  V$SOX5_01  78  (+)  0.815  0.715  tgtAGAATag  Sox-5 
SNP4  WKY  V$GRE_C  80  (-)  1  0.713  tAGAACagaatcctgg  GR 
SNP4  WKY  V$HAND1E47_01  80  (-)  0.859  0.794  tagaACAGAatcctgg  Hand1:E47 
SNP4  SHRSP  V$MTATA_B  80  (+)  0.846  0.706  tagaATAGAatcctggg  Muscle 
SNP4  SHRSP  V$OCT1_06  80  (+)  0.829  0.825  tagaaTAGAAtcct  Oct-01 
SNP4  WKY  V$VMYB_01  80  (+)  0.904  0.861  tagAACAGaa  v-Myb 
SNP4  WKY  V$VMYB_02  80  (+)  0.889  0.831  tagAACAGa  v-Myb 
SNP4  WKY  V$AR_Q2  81  (-)  1  0.744  AGAACagaatcctgg  AR 
SNP4  SHRSP  V$OCT1_06  81  (-)  0.893  0.868  agaaTAGAAtcctg  Oct-01 
SNP4  SHRSP  V$TATA_C  81  (+)  0.841  0.758  agaaTAGAAt  TATA 
SNP4  SHRSP  V$HNF6_Q6  82  (-)  0.843  0.752  gaATAGAatcct  HNF-6 
SNP4  SHRSP  V$LPOLYA_B  82  (+)  0.8  0.778  gAATAGaa  Lentiviral 
SNP4  WKY  V$FOXJ2_02  83  (+)  0.897  0.718  aacAGAATcctggg  FOXJ2 
SNP4  SHRSP  V$GATA2_03  85  (-)  0.802  0.783  taGAATCctg  GATA-2 
SNP5  WKY  V$AIRE_01  37  (+)  0.891  0.703  gtgttttgGGGAGcaggcgagcaaat  AIRE 
SNP5  SHRSP  V$GFI1_01  48  (-)  0.96  0.847  agcaggcgagcAGATTctgctttc  Gfi-1 
SNP5  WKY  V$E2F_01  50  (+)  0.8  0.753  caggcgaGCAAAttc  E2F 
SNP5  WKY  V$CEBPDELTA_Q6  51  (-)  0.846  0.772  aggcgaGCAAAt  C/EBPdelta 
SNP5  WKY  V$ELF1_Q6  51  (+)  0.784  0.76  aggcgAGCAAat  ELF-1 
SNP5  WKY  V$E2F_Q3_01  52  (-)  0.788  0.751  gGCGAGcaa  E2F 
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SNP5  SHRSP  V$HSF_Q6  52  (+)  0.928  0.714  ggcgagcaGATTC  HSF 
SNP5  WKY  V$NFY_Q6_01  52  (+)  0.814  0.773  ggcgagCAAATtc  NF-Y 
SNP5  SHRSP  V$HAND1E47_01  53  (-)  0.871  0.803  gcgaGCAGAttctgct  Hand1:E47 
SNP5  WKY  V$LEF1TCF1_Q4  53  (-)  0.81  0.763  gcgagCAAATt  LEF1TCF1 
SNP5  WKY  V$NFY_01  53  (+)  0.812  0.753  gcgagCAAATtctgct  NF-Y 
SNP5  WKY  V$S8_01  53  (+)  0.785  0.751  gcgagcaAATTCtgct  S8 
SNP5  SHRSP  V$TAL1ALPHAE47_01  53  (+)  1  0.778  gcgagCAGATtctgct  Tal-1alpha 
SNP5  SHRSP  V$TAL1BETAE47_01  53  (+)  1  0.781  gcgagCAGATtctgct  Tal-1beta:E47 
SNP5  SHRSP  V$TAL1BETAITF2_01  53  (+)  1  0.777  gcgagCAGATtctgct  Tal-1beta 
SNP5  WKY  V$CHX10_01  54  (-)  0.824  0.767  cgagcaAATTCtgc  CHX10 
SNP5  SHRSP  V$E47_01  54  (+)  0.934  0.737  cgagCAGATtctgct  E47 
SNP5  WKY  V$ETS1_B  54  (+)  0.773  0.715  cgAGCAAattctgct  c-Ets-1 
SNP5  WKY  V$HNF3B_01  54  (-)  0.767  0.728  cgagcAAATTctgct  HNF-3beta 
SNP5  SHRSP  V$AREB6_01  55  (-)  0.8  0.71  gagCAGATtctgc  AREB6 
SNP5  WKY  V$E2F_Q3  55  (-)  0.917  0.728  gaGCAAAt  E2F 
SNP5  SHRSP  V$GATA1_02  55  (+)  0.754  0.738  gagcAGATTctgct  GATA-1 
SNP5  SHRSP  V$GATA1_03  55  (+)  0.945  0.909  gagcaGATTCtgct  GATA-1 
SNP5  SHRSP  V$MYOD_01  55  (+)  0.873  0.719  gagCAGATtctg  MyoD 
SNP5  WKY  V$NFY_Q6  55  (+)  0.779  0.734  gagCAAATtct  NF-Y 
SNP5  WKY  V$S8_01  55  (-)  0.785  0.742  gagcAAATTctgcttt  S8 
SNP5  SHRSP  V$E12_Q6  56  (+)  0.943  0.772  agCAGATtctg  E12 
SNP5  SHRSP  V$IRF_Q6  56  (+)  0.781  0.705  agcagATTCTgcttt  IRF 
SNP5  SHRSP  V$ICSBP_Q6  58  (-)  0.783  0.757  caGATTCtgctt  ICSBP 
SNP5  SHRSP  V$ISRE_01  58  (+)  0.8  0.759  caGATTCtgctttca  ISRE 
SNP5  SHRSP  V$LMO2COM_02  58  (+)  0.757  0.755  cAGATTctg  Lmo2 
SNP5  WKY  V$NKX25_02  59  (-)  0.778  0.766  aAATTCtg  Nkx2-5 
SNP5  WKY  V$GFI1B_01  60  (-)  0.792  0.7  aattcTGCTTtc  GFI1B 
SNP6  WKY  V$AP4_01  48  (-)  0.915  0.712  tgttctttCGCTGtctgg  AP-4 
SNP6  SHRSP  V$PBX_Q3  49  (-)  0.8  0.792  gttctttCGCTC  PBX 
SNP6  SHRSP  V$CEBPDELTA_Q6  51  (+)  0.807  0.718  tCTTTCgctctc  C/EBPdelta 
SNP6  SHRSP  V$DR3_Q4  52  (+)  0.881  0.706  ctttcgctctcTGGCCagtct  VDR, 
SNP6  WKY  V$MINI20_B  53  (-)  0.813  0.722  tttcgctgtcTGGCCagtctc  Muscle 
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SNP6  SHRSP  V$AP2ALPHA_02  55  (-)  0.898  0.737  tcgctctcTGGCCag  AP-2alphaA 
SNP6  SHRSP  V$HNF4_01_B  55  (-)  0.8  0.774  tcgctCTCTGgccag  HNF-4alpha1 
SNP6  SHRSP  V$HNF4_Q6_01  55  (-)  0.888  0.803  tcgctCTCTGgcca  HNF4 
SNP6  WKY  V$LDSPOLYA_B  55  (+)  0.966  0.846  tcgcTGTCTggccagt  Poly A 
SNP6  WKY  V$MEIS1_01  55  (-)  0.833  0.845  tcgcTGTCTggc  MEIS1 
SNP6  WKY  V$SRF_C  55  (+)  0.836  0.7  tcgctgTCTGGccag  SRF 
SNP6  SHRSP  V$ZID_01  55  (+)  0.908  0.768  tCGCTCtctggcc  ZID 
SNP6  SHRSP  V$HNF4_DR1_Q3  56  (+)  0.846  0.748  cgctCTCTGgcca  HNF-4 
SNP6  SHRSP  V$MAZ_Q6  56  (-)  0.819  0.785  cgCTCTCt  MAZ 
SNP6  WKY  V$SMAD4_Q6  56  (-)  0.99  0.83  cgcTGTCTggccagt  SMAD-4 
SNP6  WKY  V$TGIF_01  56  (+)  0.85  0.786  cgcTGTCTggc  TGIF 
SNP6  WKY  V$SMAD4_Q6  57  (+)  0.878  0.736  gctgtctGGCCAgtc  SMAD-4 
SNP6  WKY  V$SMAD3_Q6  59  (+)  1  0.912  tGTCTGgcc  SMAD-3 
SNP6  SHRSP  V$SMAD3_Q6  59  (+)  0.825  0.794  tCTCTGgcc  SMAD-3 
SNP6  WKY  V$SMAD4_Q6  60  (-)  0.878  0.717  gtcTGGCCagtctcc  SMAD-4 
SNP7  SHRSP  V$E2F1_Q3_01  50  (-)  0.936  0.726  gagagtcgAGCGCctc  E2F-1 
SNP7  WKY  V$GATA4_Q3  51  (+)  0.752  0.708  AGAGTcgagagc  GATA-4 
SNP7  WKY  V$ZID_01  52  (-)  1  0.785  gagtcgaGAGCCt  ZID 
SNP7  WKY  V$SMAD4_Q6  53  (+)  0.876  0.7  agtcgagAGCCTccc  SMAD-4 
SNP7  SHRSP  V$E2F1_Q6_01  54  (+)  0.88  0.735  gtcgAGCGCc  E2F-1 
SNP7  SHRSP  V$E2F_Q3_01  55  (+)  0.903  0.701  tcgAGCGCc  E2F 
SNP7  WKY  V$LMO2COM_02  55  (+)  0.751  0.733  tCGAGAgcc  Lmo2 
SNP7  WKY  V$PPARA_02  56  (-)  0.81  0.718  cgagagcctccCCACCccc  PPARalpha 
SNP7  SHRSP  V$WHN_B  56  (-)  0.761  0.74  cgaGCGCCtcc  Whn 
SNP7  SHRSP  V$AREB6_02  57  (+)  0.8  0.763  gagCGCCTcccc  AREB6 
SNP7  WKY  V$NFKB_C  57  (-)  0.96  0.714  gagagcCTCCCc  NF-kappaB 
SNP7  SHRSP  V$E2F_Q3_01  58  (-)  1  0.707  aGCGCCtcc  E2F 
SNP7  SHRSP  V$E2F1_Q6_01  58  (-)  0.935  0.702  aGCGCCtccc  E2F-1 
SNP7  SHRSP  V$GABP_B  58  (-)  0.8  0.74  agcgCCTCCcca  GABP 
SNP7  WKY  V$NFKAPPAB_01  58  (-)  0.965  0.717  agagcCTCCC  NF-kappaB 
SNP7  SHRSP  V$EGR1_01  59  (-)  0.83  0.749  gcgCCTCCccac  Egr-1 
SNP7  SHRSP  V$NGFIC_01  59  (-)  0.773  0.716  gcgCCTCCccac  NGFI-C 
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SNP7  SHRSP  V$UF1H3BETA_Q6  59  (-)  0.8  0.784  gcgcctCCCCAccc  UF1H3BETA 
SNP7  SHRSP  V$KROX_Q6  60  (+)  0.75  0.709  cgccTCCCCacccc  KROX 
SNP8  WKY  V$MTATA_B  47  (-)  0.819  0.75  ttgtgaagGTTATacca  Muscle 
SNP8  SHRSP  V$HNF4ALPHA_Q6  48  (-)  0.816  0.703  tgtGAAGGttatg  HNF-4alpha 
SNP8  SHRSP  V$RFX1_02  49  (+)  0.804  0.706  gtgaaggttatGCCACag  RFX1 
SNP8  SHRSP  V$CDX2_Q5  50  (+)  0.854  0.703  tgaagGTTATgcca  Cdx-2 
SNP8  SHRSP  V$IPF1_Q4_01  51  (-)  0.802  0.778  gaaggTTATGccaca  IPF1 
SNP8  SHRSP  V$IPF1_Q4  52  (+)  0.783  0.708  aaggTTATGcca  IPF1 
SNP8  SHRSP  V$OCT1_01  52  (+)  1  0.717  aaggtTATGCcacaggaca  Oct-01 
SNP8  SHRSP  V$OCT1_02  52  (+)  1  0.809  aaggtTATGCcacag  Oct-01 
SNP8  WKY  V$OCT1_02  52  (+)  0.94  0.763  aaggtTATACcacag  Oct-01 
SNP8  WKY  V$TBX5_01  54  (-)  0.781  0.701  ggttATACCaca  TBX5 
SNP8  SHRSP  V$CEBPGAMMA_Q6  55  (+)  0.752  0.762  gttATGCCacagg  C/EBPgamma 
SNP8  SHRSP  V$MEIS1_01  55  (-)  0.868  0.792  gttaTGCCAcag  MEIS1 
SNP8  SHRSP  V$AML_Q6  56  (-)  1  0.843  ttatgCCACAggaca  AML 
SNP8  WKY  V$AML_Q6  56  (-)  1  0.945  ttataCCACAggaca  AML 
SNP8  SHRSP  V$MEIS1_01  56  (+)  0.863  0.797  ttaTGCCAcagg  MEIS1 
SNP8  WKY  V$PEBP_Q6  56  (+)  1  0.91  ttatACCACaggaca  PEBP 
SNP8  SHRSP  V$PEBP_Q6  56  (+)  0.82  0.772  ttatGCCACaggaca  PEBP 
SNP8  SHRSP  V$TGIF_01  56  (-)  0.79  0.704  ttaTGCCAcag  TGIF 
SNP8  SHRSP  V$AP2ALPHA_02  57  (+)  0.911  0.884  taTGCCAcaggacat  AP-2alphaA 
SNP8  SHRSP  V$AP2ALPHA_03  57  (+)  0.855  0.755  taTGCCAcaggacat  AP-2alphaA 
SNP8  SHRSP  V$E2F1DP1_01  57  (+)  0.771  0.715  taTGCCAc  E2F-1:DP-1 
SNP8  SHRSP  V$HNF4_01_B  57  (+)  0.8  0.736  tatgcCACAGgacat  HNF-4alpha1 
SNP8  WKY  V$LEF1TCF1_Q4  57  (-)  0.763  0.715  tatacCACAGg  LEF1TCF1 
SNP8  WKY  V$PADS_C  57  (-)  1  0.903  tatACCACa  Poly 
SNP8  SHRSP  V$PADS_C  57  (-)  0.772  0.728  tatGCCACa  Poly 
SNP8  SHRSP  V$COREBINDINGFACTOR_Q6  58  (-)  1  0.876  atgCCACA  core-binding 
SNP8  WKY  V$COREBINDINGFACTOR_Q6  58  (-)  1  0.983  ataCCACA  core-binding 
SNP9  SHRSP  V$MINI20_B  46  (+)  0.937  0.706  aattaaCCACAagcctcttgg  Muscle 
SNP9  WKY  V$RORA1_01  48  (-)  0.8  0.701  tTAACCacaagct  RORalpha1 
SNP9  WKY  V$NERF_Q2  51  (-)  0.8  0.808  accacaagctTCTTGgtt  NERF1a 
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SNP9  WKY  V$BARBIE_01  52  (-)  0.759  0.727  ccacaaGCTTCttgg  Barbie Box 
SNP9  WKY  V$ETS1_B  52  (-)  0.773  0.762  ccacaagcTTCTTgg  c-Ets-1 
SNP9  WKY  V$ETS2_B  54  (-)  0.785  0.768  acaagcTTCTTggt  c-Ets-2 
SNP9  WKY  V$EVI1_06  54  (+)  1  0.739  ACAAGcttc  Evi-1 
SNP9  SHRSP  V$AP2ALPHA_02  55  (+)  0.989  0.811  caAGCCTcttggtta  AP-2alphaA 
SNP9  WKY  V$SF1_Q6  55  (-)  0.8  0.734  CAAGCttc  SF-1 
SNP9  WKY  V$HNF1_Q6  57  (+)  0.787  0.722  agcTTCTTggttatggaa  HNF-1 
SNP9  SHRSP  V$NKX25_Q5  57  (+)  0.8  0.766  agcCTCTTgg  NKX25 
SNP9  WKY  V$NRF2_01  57  (-)  0.8  0.703  agCTTCTtgg  NRF-2 
SNP9  WKY  V$PEBP_Q6  57  (-)  0.766  0.707  agcttcTTGGTtatg  PEBP 
SNP9  WKY  V$ELF1_Q6  58  (-)  0.784  0.722  gcTTCTTggtta  ELF-1 
SNP9  WKY  V$PIT1_Q6  58  (+)  0.932  0.857  gcTTCTTggttatggaag  Pit-1 
SNP9  SHRSP  V$PIT1_Q6  58  (-)  0.886  0.727  gcctcttggttATGGAag  Pit-1 
SNP9  WKY  V$PIT1_Q6  58  (-)  0.886  0.737  gcttcttggttATGGAag  Pit-1 
SNP9  WKY  V$ALPHACP1_01  59  (-)  0.8  0.763  cttCTTGGtta  alpha-CP1 
SNP9  SHRSP  V$NKX25_01  60  (-)  0.783  0.749  CTCTTgg  Nkx2-5 
SNP11+10  WKY  V$COMP1_01  72  (-)  0.786  0.78  ttagtctcctcgtCAGTCatttgt  COMP1 
SNP11+10  WKY  V$VMAF_01  74  (-)  0.778  0.713  agtctcctcgTCAGTcatt  v-Maf 
SNP11+10  WKY  V$RORA1_01  75  (+)  0.8  0.706  gtctcctCGTCAg  RORalpha1 
SNP11+10  WKY  V$TCF11MAFG_01  75  (-)  1  0.747  gtctcctcgtcaGTCATttgtt  TCF11:MafG 
SNP11+10  WKY  V$ATF_01  76  (-)  1  0.917  tctcctCGTCAgtc  ATF 
SNP11+10  SHRSP  V$ATF_01  76  (-)  0.8  0.744  tctcctCGTCCcgt  ATF 
SNP11+10  WKY  V$ATF_B  76  (-)  1  0.793  tctcctCGTCAg  ATF 
SNP11+10  SHRSP  V$HTF_01  76  (+)  0.849  0.8  tctcctcgtCCCGTcatttgtttt  HTF 
SNP11+10  WKY  V$MINI20_B  76  (+)  0.96  0.741  tctcctCGTCAgtcatttgtt  Muscle 
SNP11+10  SHRSP  V$PAX3_B  76  (+)  0.818  0.721  tctcctcgTCCCGtcatttgt  Pax-3 
SNP11+10  WKY  V$ATF4_Q2  77  (-)  1  0.765  ctcctCGTCAgt  ATF4 
SNP11+10  SHRSP  V$CETS1P54_03  77  (-)  0.812  0.8  ctcctcGTCCCgtcat  c-Ets-1 
SNP11+10  WKY  V$CREB_Q2  77  (-)  1  0.863  ctcctCGTCAgt  CREB 
SNP11+10  SHRSP  V$CREB_Q2  77  (-)  0.79  0.703  ctcctCGTCCcg  CREB 
SNP11+10  WKY  V$CREB_Q2_01  77  (+)  1  0.896  ctcctCGTCAgtca  CREB 
SNP11+10  SHRSP  V$CREB_Q2_01  77  (+)  0.804  0.736  ctcctCGTCCcgtc  CREB 
Table A5 – Continued overleaf  
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SNP11+10  WKY  V$CREB_Q4  77  (-)  1  0.871  ctcctCGTCAgt  CREB 
SNP11+10  SHRSP  V$CREB_Q4  77  (-)  0.792  0.708  ctcctCGTCCcg  CREB 
SNP11+10  WKY  V$CREBP1_Q2  77  (-)  1  0.788  ctcctCGTCAgt  CRE-BP1 
SNP11+10  SHRSP  V$ELK1_01  77  (-)  0.9  0.728  ctcctCGTCCcgtcat  Elk-1 
SNP11+10  WKY  V$AP1_Q2  78  (-)  0.967  0.932  tcctCGTCAgt  AP-1 
SNP11+10  WKY  V$E4F1_Q6  78  (+)  1  0.771  tcctCGTCAg  E4F1 
SNP11+10  SHRSP  V$E4F1_Q6  78  (+)  0.8  0.701  tcctCGTCCc  E4F1 
SNP11+10  SHRSP  V$GABP_B  78  (-)  0.8  0.791  tcctCGTCCcgt  GABP 
SNP11+10  SHRSP  V$HOX13_01  78  (+)  0.767  0.749  tcctcgtcccgtCATTTgtttttcatctga  Hox-1.3 
SNP11+10  WKY  V$MEIS1_01  78  (-)  0.77  0.702  tcctCGTCAgtc  MEIS1 
SNP11+10  WKY  V$PBX_Q3  78  (-)  0.887  0.814  tcctcgtCAGTC  PBX 
SNP11+10  WKY  V$TAXCREB_01  78  (-)  1  0.755  tcctCGTCAgtcatt  Tax/CREB 
SNP11+10  WKY  V$ATF6_01  79  (-)  1  0.864  cctCGTCA  ATF6 
SNP11+10  SHRSP  V$ATF6_01  79  (-)  0.8  0.729  cctCGTCC  ATF6 
SNP11+10  WKY  V$CREB_01  79  (-)  1  0.819  cctCGTCA  CREB 
SNP11+10  WKY  V$CREB_02  79  (-)  1  0.883  cctCGTCAgtca  CREB 
SNP11+10  WKY  V$CREB_Q4_01  79  (-)  1  0.906  cctCGTCAgtc  CREB 
SNP11+10  SHRSP  V$CREB_Q4_01  79  (-)  0.764  0.703  cctCGTCCcgt  CREB 
SNP11+10  WKY  V$CREBATF_Q6  79  (-)  1  0.937  cctCGTCAg  CREBATF 
SNP11+10  SHRSP  V$CREBATF_Q6  79  (-)  0.794  0.749  cctCGTCCc  CREBATF 
SNP11+10  SHRSP  V$ELK1_02  79  (-)  0.767  0.765  cctcGTCCCgtcat  Elk-1 
SNP11+10  WKY  V$ER_Q6  79  (-)  0.846  0.768  cctCGTCAgtcatttgttt  ER 
SNP11+10  SHRSP  V$IK1_01  79  (-)  0.837  0.755  cctcGTCCCgtca  Ik-1 
SNP11+10  WKY  V$LDSPOLYA_B  79  (-)  0.896  0.748  cctcgtcAGTCAtttg  Poly A 
SNP11+10  WKY  V$SMAD4_Q6  79  (+)  0.959  0.777  cctcgtcAGTCAttt  SMAD-4 
SNP11+10  SHRSP  V$ARNT_01  80  (-)  0.792  0.709  ctcgtCCCGTcatttg  Arnt 
SNP11+10  WKY  V$ATF_01  80  (-)  0.8  0.724  ctcgtcAGTCAttt  ATF 
SNP11+10  WKY  V$BACH1_01  80  (+)  0.8  0.821  ctcgTCAGTcatttg  Bach1 
SNP11+10  SHRSP  V$HIF1_Q3  80  (-)  0.793  0.719  ctcgtCCCGTcatt  HIF-1 
SNP11+10  SHRSP  V$MYC_Q2  80  (+)  0.814  0.709  CTCGTcc  Myc 
SNP11+10  SHRSP  V$NRF2_01  80  (-)  0.8  0.75  ctCGTCCcgt  NRF-2 
SNP11+10  WKY  V$NRF2_Q4  80  (+)  1  0.845  ctcgtcAGTCAtt  Nrf2 
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SNP11+10  WKY  V$PBX1_02  80  (+)  0.789  0.722  ctcgtCAGTCatttg  Pbx1b 
SNP11+10  SHRSP  V$SMAD4_Q6  80  (+)  0.837  0.775  ctcgtccCGTCAttt  SMAD-4 
SNP11+10  SHRSP  V$ATF_01  81  (-)  1  0.907  tcgtccCGTCAttt  ATF 
SNP11+10  SHRSP  V$ATF_B  81  (-)  1  0.832  tcgtccCGTCAt  ATF 
SNP11+10  WKY  V$ATF4_Q2  81  (-)  0.933  0.732  tcgtcAGTCAtt  ATF4 
SNP11+10  WKY  V$BEL1_B  81  (-)  0.782  0.733  tcgtcagtcatttgttttTCATCtgata  Bel-1 
SNP11+10  WKY  V$CREB_Q2  81  (-)  0.839  0.756  tcgtcAGTCAtt  CREB 
SNP11+10  WKY  V$CREB_Q4  81  (-)  0.831  0.727  tcgtcAGTCAtt  CREB 
SNP11+10  SHRSP  V$E2F1_Q6_01  81  (+)  0.815  0.73  tcgtCCCGTc  E2F-1 
SNP11+10  SHRSP  V$HIF1_Q5  81  (-)  0.788  0.73  tcgtCCCGTcat  HIF-1 
SNP11+10  WKY  V$HNF1_Q6  81  (+)  0.802  0.806  tcgTCAGTcatttgtttt  HNF-1 
SNP11+10  SHRSP  V$NRF2_Q4  81  (+)  0.873  0.742  tcgtccCGTCAtt  Nrf2 
SNP11+10  SHRSP  V$STRA13_01  81  (+)  0.793  0.703  tcgtCCCGTcattt  Stra13 
SNP11+10  WKY  V$AP1_Q2  82  (-)  1  0.953  cgtcAGTCAtt  AP-1 
SNP11+10  SHRSP  V$ATF4_Q2  82  (-)  1  0.818  cgtccCGTCAtt  ATF4 
SNP11+10  SHRSP  V$CEBPDELTA_Q6  82  (-)  0.772  0.742  cgtcccGTCATt  C/EBPdelta 
SNP11+10  SHRSP  V$CREB_Q2  82  (-)  1  0.853  cgtccCGTCAtt  CREB 
SNP11+10  SHRSP  V$CREB_Q2_01  82  (+)  1  0.921  cgtccCGTCAtttg  CREB 
SNP11+10  SHRSP  V$CREB_Q4  82  (-)  1  0.886  cgtccCGTCAtt  CREB 
SNP11+10  SHRSP  V$CREBP1_Q2  82  (-)  1  0.831  cgtccCGTCAtt  CRE-BP1 
SNP11+10  SHRSP  V$E2F1DP1_01  82  (+)  1  0.729  cgTCCCGt  E2F-1:DP-1 
SNP11+10  SHRSP  V$GCM_Q2  82  (+)  0.783  0.833  cgtcCCGTCatt  GCM 
SNP11+10  WKY  V$MEIS1_01  82  (-)  0.77  0.789  cgtcAGTCAttt  MEIS1 
SNP11+10  WKY  V$POU1F1_Q6  82  (-)  0.848  0.753  cgtcAGTCAt  POU1F1 
SNP11+10  WKY  V$SMAD3_Q6  82  (-)  0.874  0.828  cgtCAGTCa  SMAD-3 
SNP11+10  WKY  V$SMAD3_Q6  82  (+)  0.825  0.791  cGTCAGtca  SMAD-3 
SNP11+10  WKY  V$AP1_C  83  (+)  1  0.885  gtcAGTCAt  AP-1 
SNP11+10  WKY  V$AP1_C  83  (-)  0.808  0.853  gTCAGTcat  AP-1 
SNP11+10  SHRSP  V$AP1_Q2  83  (-)  0.967  0.896  gtccCGTCAtt  AP-1 
SNP11+10  WKY  V$CREB_02  83  (-)  0.832  0.736  gtcAGTCAtttg  CREB 
SNP11+10  WKY  V$CREB_Q4_01  83  (-)  0.789  0.723  gtcAGTCAttt  CREB 
SNP11+10  WKY  V$CREBATF_Q6  83  (-)  0.773  0.726  gtcAGTCAt  CREBATF 
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SNP11+10  SHRSP  V$E4F1_Q6  83  (+)  1  0.816  gtccCGTCAt  E4F1 
SNP11+10  WKY  V$ER_Q6  83  (-)  0.837  0.769  gtcAGTCAtttgtttttca  ER 
SNP11+10  SHRSP  V$GATA4_Q3  83  (-)  0.791  0.706  gtcccgtCATTT  GATA-4 
SNP11+10  WKY  V$HNF6_Q6  83  (+)  0.789  0.726  gtcagTCATTtg  HNF-6 
SNP11+10  SHRSP  V$MEIS1_01  83  (-)  0.77  0.79  gtccCGTCAttt  MEIS1 
SNP11+10  WKY  V$NFE2_01  83  (-)  0.777  0.726  gtcagTCATTt  NF-E2 
SNP11+10  WKY  V$NKX22_01  83  (+)  0.762  0.744  gTCAGTcatt  Nkx2-2 
SNP11+10  SHRSP  V$WHN_B  83  (-)  0.761  0.755  gtcCCGTCatt  Whn 
SNP11+10  SHRSP  V$ATF6_01  84  (-)  1  0.781  tccCGTCA  ATF6 
SNP11+10  SHRSP  V$CREB_01  84  (-)  1  0.842  tccCGTCA  CREB 
SNP11+10  SHRSP  V$CREB_02  84  (-)  1  0.878  tccCGTCAtttg  CREB 
SNP11+10  SHRSP  V$CREB_Q4_01  84  (-)  1  0.918  tccCGTCAttt  CREB 
SNP11+10  SHRSP  V$CREBATF_Q6  84  (-)  1  0.946  tccCGTCAt  CREBATF 
SNP11+10  SHRSP  V$CREBP1_01  84  (-)  0.897  0.704  tccCGTCA  CRE-BP1 
SNP11+10  SHRSP  V$ER_Q6  84  (-)  0.846  0.78  tccCGTCAtttgtttttca  ER 
SNP11+10  SHRSP  V$VMYB_01  84  (-)  0.763  0.781  tcCCGTCatt  v-Myb 
SNP11+10  WKY  V$HNF1_Q6  85  (+)  0.809  0.786  cagTCATTtgtttttcat  HNF-1 
SNP11+10  SHRSP  V$SP3_Q3  85  (-)  0.925  0.786  cCCGTCatttgttt  Sp3 
SNP11+10  SHRSP  V$VMYB_02  85  (-)  0.778  0.77  cCCGTCatt  v-Myb 
SNP11+10  SHRSP  V$HNF1_Q6  86  (+)  0.809  0.776  ccgTCATTtgtttttcat  HNF-1 
SNP11+10  SHRSP  V$NKX25_02  87  (+)  0.778  0.729  cgTCATTt  Nkx2-5 
SNP12  SHRSP  V$AIRE_01  44  (-)  0.886  0.854  gcattgccctttgACCCGtaaactgt  AIRE 
SNP12  WKY  V$HTF_01  47  (-)  0.756  0.72  ttgccctttgACCTGtaaactgtt  HTF 
SNP12  SHRSP  V$HTF_01  49  (+)  0.849  0.788  gccctttgaCCCGTaaactgtttt  HTF 
SNP12  SHRSP  V$PAX6_01  49  (-)  0.96  0.8  gccctttgaccCGTAAactgt  Pax-6 
SNP12  WKY  V$CEBPGAMMA_Q6  51  (-)  0.752  0.724  cctttGACCTgta  C/EBPgamma 
SNP12  WKY  V$E47_02  51  (-)  1  0.752  cctttgACCTGtaaac  E47 
SNP12  WKY  V$XBP1_01  51  (+)  0.779  0.737  cctttgACCTGtaaact  XBP-1 
SNP12  WKY  V$AREB6_01  52  (+)  1  0.926  ctttgACCTGtaa  AREB6 
SNP12  SHRSP  V$AREB6_01  52  (+)  0.8  0.753  ctttgACCCGtaa  AREB6 
SNP12  WKY  V$DEC_Q1  52  (-)  0.973  0.716  ctttgACCTGtaa  DEC 
SNP12  WKY  V$MTATA_B  52  (-)  0.797  0.749  ctttgaccTGTAAactg  Muscle 
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SNP12  SHRSP  V$XBP1_01  52  (-)  0.779  0.767  ctttgaCCCGTaaactg  XBP-1 
SNP12  SHRSP  V$ARNT_01  53  (-)  0.792  0.701  tttgaCCCGTaaactg  Arnt 
SNP12  WKY  V$CREBP1_Q2  53  (+)  0.8  0.713  ttTGACCtgtaa  CRE-BP1 
SNP12  WKY  V$E12_Q6  53  (-)  1  0.778  tttgACCTGta  E12 
SNP12  SHRSP  V$E2F_02  53  (+)  0.852  0.761  TTTGAccc  E2F 
SNP12  SHRSP  V$E2F_Q4  53  (+)  0.813  0.741  tTTGACcc  E2F 
SNP12  SHRSP  V$HIF1_Q3  53  (-)  0.793  0.725  tttgaCCCGTaaac  HIF-1 
SNP12  WKY  V$MYOD_01  53  (-)  1  0.713  tttgACCTGtaa  MyoD 
SNP12  SHRSP  V$NRF2_Q4  53  (-)  0.873  0.702  ttTGACCcgtaaa  Nrf2 
SNP12  SHRSP  V$WHN_B  53  (+)  0.761  0.732  tttGACCCgta  Whn 
SNP12  SHRSP  V$ATF_01  54  (-)  0.8  0.726  ttgaccCGTAAact  ATF 
SNP12  WKY  V$ATF_B  54  (+)  0.8  0.771  tTGACCtgtaaa  ATF 
SNP12  SHRSP  V$E2F_01  54  (+)  0.8  0.734  ttgacccGTAAActg  E2F 
SNP12  WKY  V$PAX6_Q2  54  (+)  0.821  0.753  ttgaccTGTAAact  PAX6 
SNP12  WKY  V$RORA2_01  54  (-)  1  0.728  tTGACCtgtaaac  RORalpha2 
SNP12  WKY  V$ATF6_01  55  (+)  0.8  0.771  TGACCtgt  ATF6 
SNP12  SHRSP  V$CEBPDELTA_Q6  55  (-)  0.823  0.702  tgacccGTAAAc  C/EBPdelta 
SNP12  WKY  V$COUP_DR1_Q6  55  (+)  1  0.739  tGACCTgtaaact  COUP 
SNP12  WKY  V$CREB_01  55  (+)  0.824  0.806  TGACCtgt  CREB 
SNP12  SHRSP  V$CREB_Q2_01  55  (+)  0.796  0.716  tgaccCGTAAactg  CREB 
SNP12  WKY  V$CREBP1CJUN_01  55  (+)  0.844  0.756  tGACCTgt  CRE-BP1 
SNP12  WKY  V$PPARG_03  55  (-)  0.9  0.802  tgaCCTGTaaactgttt  PPAR 
SNP12  WKY  V$TFE_Q6  55  (-)  0.932  0.742  tgACCTGt  TFE 
SNP12  WKY  V$MEIS1_01  56  (-)  0.77  0.788  gaccTGTAAact  MEIS1 
SNP12  SHRSP  V$TAXCREB_01  56  (-)  0.906  0.72  gaccCGTAAactgtt  Tax/CREB 
SNP12  SHRSP  V$CREB_02  57  (-)  0.832  0.787  accCGTAAactg  CREB 
SNP12  SHRSP  V$CREB_Q4_01  57  (-)  0.789  0.709  accCGTAAact  CREB 
SNP12  SHRSP  V$CREBATF_Q6  57  (-)  0.773  0.722  accCGTAAa  CREBATF 
SNP12  SHRSP  V$E2F_Q4_01  57  (+)  0.75  0.736  accCGTAAact  E2F 
SNP12  WKY  V$TGIF_01  57  (+)  0.79  0.786  accTGTAAact  TGIF 
SNP12  SHRSP  V$VMYB_01  57  (-)  0.773  0.741  acCCGTAaac  v-Myb 
SNP12  SHRSP  V$E2F1_Q4_01  58  (-)  0.75  0.745  ccCGTAAac  E2F-1 
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SNP12  SHRSP  V$VMYB_02  58  (-)  0.778  0.77  cCCGTAaac  v-Myb 
SNP12  WKY  V$XFD2_01  58  (+)  0.901  0.749  cctGTAAActgttt  XFD-2 
SNP12  SHRSP  V$E2F1_Q4  59  (-)  0.785  0.845  ccGTAAAc  E2F-1 
SNP12  SHRSP  V$E2F1DP1_01  59  (-)  0.802  0.743  cCGTAAac  E2F-1:DP-1 
SNP12  SHRSP  V$E2F4DP2_01  59  (-)  0.821  0.737  cCGTAAac  E2F-4:DP-2 
SNP12  WKY  V$HP1SITEFACTOR_Q6  59  (-)  0.941  0.831  CTGTAaactgtt  HP1 
SNP12  SHRSP  V$MYOD_01  60  (-)  0.873  0.707  cgtaAACTGttt  MyoD 
SNP13  SHRSP  V$E2_Q6_01  22  (+)  0.917  0.705  ccTACCTtctcctatt  E2 
SNP13  SHRSP  V$ETS1_B  22  (-)  0.907  0.771  cctaccttCTCCTat  c-Ets-1 
SNP13  WKY  V$AIRE_01  24  (-)  0.987  0.701  taccttctactatTACCActtctacc  AIRE 
SNP13  SHRSP  V$CETS1P54_03  24  (-)  0.855  0.774  taccttCTCCTattac  c-Ets-1 
SNP13  SHRSP  V$ETS2_B  24  (-)  0.861  0.708  taccttCTCCTatt  c-Ets-2 
SNP13  SHRSP  V$CETS1P54_02  26  (-)  0.907  0.872  ccttCTCCTatta  c-Ets-1(p54) 
SNP13  SHRSP  V$CETS1P54_01  27  (-)  0.782  0.706  cttcTCCTAt  c-Ets-1(p54) 
SNP13  SHRSP  V$WT1_Q6  28  (+)  0.972  0.824  tTCTCCtat  WT1 
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